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Summary 
Nucleic acids are the fundamental molecules of life. Although both DNA and RNA are generally seen 
as composed of four canonical bases, they instead include a range of modified nucleosides which are 
involved in key epigenetic processes and in modulation of protein translation.  
Analysis of modified tRNA nucleosides 
The greatest variety of modified nucleosides is found in tRNA, where modifications can range from 
simple methylations to complex hypermodified nucleosides such as wybutosine. To date, a large 
number of studies have led to structural elucidation and identification of the biosynthetic pathways for 
a number of these modifications. However, there is still little information concerning the systemic 
behaviour of modified tRNA nucleosides, largely due to the fact that for a long time there was no 
method available for a parallel quantification of tRNA modification sets.  
To this end, the Carell group recently developed an LC-MS based quantification method using 
synthetic isotope standards which provided us with an effective tool for the investigation of tRNA 
modifications in a system-based manner. We were interested in investigating the tissue-specific 
distribution of modified tRNA nucleosides and therefore quantified 11 representative RNA 
modifications in 8 different tissues from mouse and pig. Interestingly, tRNA populations were found 
to be differently modified depending on the tissue, with some tissues having overall highly modified 
tRNA and others displaying less modified tRNA pools, suggesting that different modification levels 
are required to satisfy different translational needs (Summary Figure 1). In support of this hypothesis, 
we obtained a positive correlation between modification levels and in vitro protein translation rates for 
cytosolic tRNA samples. 
 
Summary Figure 1 A) Quantification of modified tRNA nucleosides in mouse and pig organs; B) Correlation analysis of 
tRNA modification content and in vitro translation activity. 
In a related project, we were interested in elucidating the regulation of tRNA modification levels in 
yeast cells entering stationary phase. In a previous study done in the Carell group, yeast was found to 
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display an increasingly modified tRNA population when grown to quiescence. We therefore decided 
to monitor the fate of tRNA modifications by pulse-chase labelling using labelled methionine during 
initial growth, followed by growth in unlabelled medium over 7 days (Summary Figure 2). Monitoring 
of the heavy (labelled) modification content over time revealed low modification turnover rates. 
Furthermore, analysis of the light to heavy ratios of the methylated tRNA nucleosides revealed a 
higher proportion than expected of the light (unlabelled) modification compared to the corresponding 
heavy (labelled) modification starting from day 1. This suggests that the observed increase in 
modification content per tRNA might result from increased modification activity over time, possibly 
linked to low tRNA turnover rates. Although we cannot exclude that there might be some extent of 
tRNA degradation, this process seems to preferentially target hypomodified tRNA species. We suggest 
that the increase in modification content observed during entry into stationary phase might be 
necessary for effective protein synthesis during stress response and it might additionally ensure a rapid 
start of translation upon exit from quiescence. 
 
Summary Figure 2 Experimental procedure for monitoring tRNA modifications during yeast growth. 
In addition, we were interested in investigating the molecular features which ensure the selective 
modification of uridine at the wobble position 34 of E.coli tRNA
Glu
, tRNA
Lys
 and tRNA
Arg
. More 
specifically, we focused on the last two biosynthetic steps leading to the 
5-methylaminomethyl-2-thiouridine (mnm
5
s
2
U) base, both of which are performed by the bifunctional 
enzyme MnmC. With the final goal of elucidating the biochemical and structural features of this 
enzyme in complex with substrate tRNAs for both the first and second modification steps, we 
identified the key residues involved in the first modification step and further characterized the binding 
affinity of MnmC to both substrate RNA molecules (Summary Figure 3). 
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Summary Figure 3 A) Activity assay of wild type and mutant MnmC with cmnm5s2U-containing substrate tRNA; B) 
Investigation of binding affinity of MnmC for substrate tRNA for both the first and second modification steps. 
Analysis of modified DNA nucleosides 
DNA also comprises a number of modified nucleosides. Most importantly, methylcytosine (mC) is a 
key player in epigenetic regulation of gene expression. Since 2009, additional modified cytosine 
derivatives have been discovered: these are hydroxymethylcytosine (hmC), formylcytosine (fC) and 
carboxycytosine (caC), all found to be generated by the Tet protein family. In the course of this study 
we were interested in elucidating whether hmC, fC and/or caC are involved in a pathway of active 
demethylation by C-C bond cleavage. In order to selectively monitor putative demethylation reactions, 
heavy atom-isotopologues of these cytosine derivatives were used in this work to generate DNA 
strands by Polymerase Chain Reaction (Summary Figure 4). These strands, containing the isotopically 
labelled cytosine derivatives, were subsequently used as substrates for in vitro assays performed using 
stem cell nuclear extracts. Up to now the protein or complex involved in this putative pathway of 
demethylation remains elusive and further experiments are ongoing. 
 
Summary Figure 4 A) PCR products analyzed by gel electrophoresis; B) UV and mass trace of digested fC-containing PCR 
product. 
The purification of a recombinant mouse Dnmt1 protein fragment enabled to assess the in vitro 
methylation activity of Dnmt1 in the presence of fC and caC in a hemi-modified CpG context. This 
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assay revealed that maintenance methylation cannot take place in the presence of fC and caC, 
supporting a role for these modifications in removal of the methylation pattern via replication-
dependent dilution (Summary Figure 5). 
 
Summary Figure 5 A) Summary of demethylation pathways; B) Methylation activity of a recombinant mouse Dnmt1 
fragment in the presence of a hemi-modified CpG (plotted as mC/XG (%), XG = modified CpG site, X = mC, hmC, fC or 
caC). 
Finally, we were interested in investigating the deamination of hmC to hmU as an alternative pathway 
of active demethylation where deamination is coupled to base excision repair (BER). In the course of 
this study however, we observed that hmU is generated by enzymatic activity of Tet1 on T 
nucleobases. In fact, overexpression of the catalytic domain of Tet1 and its inactive equivalent in 
HEK-293T cells revealed that the generation of hmU is dependent on Tet1 activity (Summary Figure 
6). The same experiment was repeated in the presence of labelled methionine: labelling was detected 
in the case of mC and hmC, as expected, but was not observed in the case of hmU. This confirms that 
hmU is not generated by deamination of hmC, but rather by oxidation of T. We further observed a 
Vitamin C-dependent increase of hmU production by Tet1 in HEK-293T cells and confirmed the 
removal of hmU in an A:T context by SMUG1. These results reveal that hmU is an additional 
nucleobase generated by Tet1 and suggest that hmU, up to now regarded only as an oxidative damage, 
might instead have a broader function. 
 
Summary Figure 6 A) hmU generation in HEK-293T cells upon overexpression of Tet1 catalytic domain and inactive 
mutant; B) Effect of SMUG1 knock down on DNA modification levels. 
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Zusammenfassung 
Nukleinsäuren sind die zentralen Moleküle des Lebens. Obwohl sowohl DNA als auch RNA 
gemeinhin als aus vier kanonischen Basen bestehend betrachtet werden, enthalten sie tatsächlich 
zusätzlich eine Vielzahl von modifizierten Nukleosiden, die entscheidend an epigenetischen Prozessen 
und der Modulation der Proteintranslation beteiligt sind. 
Analyse modifizierter tRNA-Nukleoside 
Die größte Vielfalt an modifizierten Nukleosiden findet man in der tRNA, wo neben einfachen 
Methylierungen auch komplexere hypermodifizierte Nukleoside wie z.B. Wybutosin vorkommen. 
Mittlerweile sind viele dieser Modifikationen sowohl im Hinblick auf ihre strukturellen Eigenschaften 
als auch bezüglich ihrer Biosynthese gut charakterisiert. Trotzdem gibt es nur wenige Informationen 
über das systemische Verhalten der modifizierten tRNA-Nukleoside als Gesamtheit, hauptsächlich 
weil bisher eine effektive Methode für die parallele Quantifizierung von tRNA-Modifikationssets 
fehlte. Aus diesem Grunde wurde kürzlich von Carell und Mitarbeitern eine LC-MS-basierte 
Quantifizierungsmethode für RNA-Modifikationen entwickelt, die auf der Verwendung von 
synthetischen Isotopologen als Massenstandards beruht und eine systembasierte Untersuchung von 
tRNA-Modifikationen erlaubt. 
Mit dieser Methode sollte zunächst die Verteilung von modifizierten tRNA-Nukleosiden in Geweben 
unterschiedlicher Organe untersucht werden. Dazu haben wir 11 repräsentative RNA-Modifikationen 
ausgewählt und diese in 8 verschiedenen Gewebetypen, jeweils von Maus und Schwein, quantifiziert. 
Interessanterweise zeigte sich dabei, dass die tRNA-Populationen der verschiedenen Gewebetypen 
unterschiedlich stark modifiziert sind. Z.B. enthalten die tRNA-Sets von Leber und Kleinhirn alle 
untersuchten Nukleosidmodifikationen in großer Menge, andere Gewebe haben dagegen ein generell 
niedriges tRNA-Modifikationsniveau (Abbildung 1). Dies deutet darauf hin, dass unterschiedliche 
tRNA-Modifikationsgrade notwendig sind, um die speziellen Anforderungen bezüglich der 
Translation in den verschiedenen Geweben zu befriedigen. In Übereinstimmung mit dieser Hypothese 
konnten wir durch in-vitro-Experimente zeigen, dass eine positive Korrelation zwischen dem 
Modifikationsgrad cytosolischer tRNA-Sets und den entsprechenden Proteintranslationsraten besteht. 
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Abbildung 1 A) Quantifizierung modifizierter tRNA-Nukleoside in Mäuse- und Schweineorganen; B) Korrelationsanalyse 
zwischen tRNA-Modifikationsgehalt und in-vitro-Translationsaktivität. 
In einem ähnlichen Projekt haben wir die Regulation des tRNA-Modifikationsniveaus in Hefezellen 
beim Erreichen der stationären Wachstumsphase untersucht. In einer früheren Arbeit von Carell und 
Mitarbeitern wurde gezeigt, dass das tRNA-Modifikationsniveau ansteigt, sobald sich die Hefezellen 
dem stationären Zustand nähern. Wir wollten daher das Schicksal der einzelnen tRNA-Modifikationen 
durch Pulse-Chase-Labelling-Experimente verfolgen. Dazu wurde dem Nährmedium während der 
ersten Wachstumsphase Methyl-D3-markiertes Methionin zugesetzt, was zu einer CD3-
Isotopenmarkierung der neugebildeten methylierten tRNA-Nukleoside führte. Dann wurden die 
Hefezellen sieben Tage lang in unmarkiertem Medium weiterkultiviert (Abbildung 2). Zu 
verschiedenen Zeitpunkten wurden Proben entnommen und das Verhältnis von leichtem 
(unmarkiertem) zu schwerem (markiertem) Isotopolog bei den methylierten tRNA-Nukleosiden 
analysiert. Eine Bestimmung der Absolutmengen der markierten Modifikationen zu verschiedenen 
Zeitpunkten ergab geringe Umsatzraten für die verschiedenen Modifikationen. Zusätzlich war ab 
Tag 1 bei allen untersuchten Modifikationen der Anteil an unmarkierten Nukleosiden im Vergleich 
zum Anteil an markierten Nukleosiden größer als erwartet. Diese Ergebnisse deuten darauf hin, dass 
der beobachtete Anstieg der Modifikationsdichte wahrscheinlich aus einer gesteigerten 
Modifikationsaktivität resultiert, eventuell in Verbindung mit niedrigen tRNA-Umsatzraten. Obwohl 
wir nicht ausschließen können, dass es bei einem Teil der tRNAs zu einer Degradation kommt, scheint 
dieser Prozess selektiv die hypomodifizierten tRNA-Spezies zu betreffen. Wir vermuten, dass die 
beobachtete Zunahme der Modifikationsdichte beim Eintritt der Hefezellen in die stationäre Phase 
notwendig ist, um eine effektive Proteinsynthese auch bei ungünstigen Wachstumsbedingungen zu 
gewährleisten. Zusätzlich könnte die hohe tRNA-Modifikationsdichte auch einen schnellen Neustart 
der Translation beim Ausgang aus dem Ruhezustand ermöglichen. 
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Abbildung 2 Experiment zur Untersuchung der modifizierten tRNA-Nukleoside von Hefe in verschiedenen 
Wachstumsphasen.  
In einem weiteren Projekt wollten wir die molekularen Prozesse aufklären, die eine selektive 
Modifikation des Uridins an der Wobble-Position (Position 34) in den E. coli-tRNAs tRNA
Glu
, 
tRNA
Lys
 und tRNA
Arg
 ermöglichen. Dabei haben wir uns auf die letzten beiden Stufen der mnm
5
s
2
U- 
(5-Methylaminomethyl-2-thiouridin)-Biosynthese konzentriert, die beide von dem bifunktionellen 
Enzym MnmC katalysiert werden. Das Ziel dabei war, die biochemischen und strukturellen 
Eigenschaften von MnmC aufzuklären, auch im Komplex mit den Substrat-tRNAs sowohl des ersten 
als auch des zweiten Modifikationsschrittes. Im Rahmen dieses Projektes konnten wir die 
Bindungsaffinität von MnmC zu beiden Substrat-tRNAs bestimmen und die für den ersten 
Modifikationsschritt entscheidenden Aminosäuren identifizieren (Abbildung 3). 
 
Abbildung 3 A) Aktivitätsassay von Wildtyp- und mutiertem MnmC mit cmnm5s2U-enthaltender Substrat-tRNA; 
B) Untersuchung der Bindungsaffinität von MnmC zu den Substrat-tRNAs für den ersten und den zweiten 
Modifikationsschritt. 
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Analyse modifizierter DNA-Nukleoside 
Auch die DNA enthält mehrere modifizierte Nukleoside; sehr wichtig ist z.B. das Methylcytosin (mC) 
als Hauptakteur in der epigenetischen Regulation der Genexpression. Seit 2009 wurden weitere 
Cytosinderivate als Bestandteil der DNA entdeckt. Es handelt sich hierbei um Hydroxymethylcytosin 
(hmC), Formylcytosin (fC) und Carboxycytosin (caC), die alle von den Tet-Enzymen generiert 
werden. 
Während der Prozess der Methylierung von Cytosin detailliert untersucht ist, gibt es praktisch nur 
wenige Erkenntnisse darüber, wie diese Methylierung wieder rückgängig gemacht werden kann. Wir 
wollten daher zunächst untersuchen, ob hmC, fC und / oder caC als Zwischenstufen an einer aktiven 
Demethylierung durch Spaltung der C-C-Bindung zwischen der substituierten Methylgruppe und dem 
C5-Atom des Cytosins in Frage kommen. Um mögliche Demethylierungsreaktionen selektiv verfolgen 
zu können, wurden im Rahmen dieser Studie synthetische Isotopologe dieser Cytosinderivate durch 
eine Polymerase-Kettenreaktion (PCR) in DNA-Stränge eingebaut (Abbildung 4). Diese DNA-Stränge 
wurden dann für in-vitro-Assays verwendet, bei denen sie mit Zellkernextrakten von Stammzellen 
inkubiert wurden. In diesen Experimenten konnte jedoch bis jetzt keine aktive Demethylierung 
nachgewiesen werden, und auch ein für die postulierte aktive Demethylierung verantwortliches Enzym 
oder Komplex konnte noch nicht identifiziert werden. 
 
Abbildung 4 A) Analyse der PCR-Produkte durch Gelelektrophorese; B) UV- und Massenspur des verdauten, fC-
enthaltenden PCR-Produktes. 
Das Enzym Dnmt1 ist bei der DNA-Replikation zuständig für das Übertragen des 
Methylierungsmusters auf den neugebildeten Strang. Die Methylierungsaktivität von Dnmt1 beim 
Vorhandensein von fC oder caC in der hemimethylierten DNA konnte von uns in-vitro durch die 
erfolgreiche Reindarstellung eines rekombinanten Dnmt1-Proteinfragments der Maus untersucht 
werden. Befindet sich fC oder caC im DNA-Strang, so findet keine Methylierung des 
gegenüberliegenden DNA-Abschnittes durch Dnmt1 statt, auch wenn es sich dabei um einen CpG-
Abschnitt handelt (Abbildung 5). Dies deutet auf eine mögliche Rolle von fC und caC im Rahmen 
einer passiven DNA-Demethylierung durch replikationsgekoppelte Verdünnung hin. 
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Abbildung 5 A) Übersicht über mögliche Demethylierungswege; B) Methylierungsaktivität eines rekombinanten Dnmt1-
Proteinfragments der Maus bezüglich halbmodifiziertem CpG (Dargestellt als mC/XG (%), XG = modifiziertes CpG, 
X = mC, hmC, fC oder caC). 
Eine alternative Hypothese über den Ablauf der aktiven DNA-Demethylierung beinhaltet die 
Deaminierung von hmC zu Hydroxymethyluracil (hmU), gefolgt von einer Basen-Exzisionsreparatur 
(base excision repair, BER), bei der hmU durch C ersetzt wird. Unsere Untersuchungen zur 
Deaminierung von hmC ergaben jedoch, dass diese Reaktion praktisch nicht stattfindet. Stattdessen 
konnten wir zeigen, dass auch hmU durch die enzymatische Aktivität von Tet1 gebildet wird, wobei 
Thymin (T) dem Enzym als Substrat dient. Dazu haben wir sowohl die katalytische Domäne (Tet1cd) 
als auch eine inaktive Variante von Tet1 (Tet1cm) in HEK-293T-Zellen überexprimiert und die 
modifizierten DNA-Nukleoside via LC-MS/MS quantifiziert. Dabei war das hmU-Level bei 
Überexpression von Tet1cd um den Faktor 60 größer als bei einer Expression von Tet1cm 
(Abbildung 6). Bei einer Wiederholung dieses Experiments in Gegenwart von markiertem Methionin 
konnten wir zeigen, dass sich die Markierung wie erwartet zwar bei mC und hmC, nicht aber bei hmU 
findet, d.h. hmU wird nicht durch Deaminierung von hmC, sondern durch Oxidation von T gebildet. 
Wir konnten weiterhin einen Vitamin C-abhängigen Anstieg der hmU-Produktion durch Tet1 
nachweisen und bestätigen, dass hmU durch die Glycosylase SMUG1 in einem A:T- bzw. A:hmU-
Kontext aus der DNA entfernt wird. Unsere Resultate zeigen, dass hmU eine weitere durch Tet1 
gebildete Nukleobase ist und nicht nur, wie bisher vermutet, ein oxidativer DNA-Schaden. 
 
Abbildung 6 A) hmU-Level in HEK-293T-Zellen bei Überexpression der katalytischen Domäne von Tet1 (Tet1cd) bzw. 
einer katalytisch inaktiven Variante (Tet1cm); B) Effekt eines SMUG1-Knockdowns auf die DNA-Modifikationslevel. 
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1 Introduction 
Nucleosides are fundamental molecules of life which constitute the building blocks of 
deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). DNA is responsible for storage of the 
genetic information, while RNA, transcribed from DNA, performs a wide range of functions, from 
transport and translation of the genetic information to catalysis and modulation of gene expression.  
The four canonical DNA nucleosides are deoxyadenosine (dA), deoxycytosine (dC), deoxyguanosine 
(dG) and deoxythymidine (dT), while RNA is composed of the corresponding canonical 
ribonucleosides A, C, G and U. However, in both cases there are additional non-canonical nucleosides. 
In the case of RNA these range from simple methylations to highly complex modifications and they 
play a role in fine-tuning of the RNA structure and its catalytic properties. In the case of DNA, the 
structural complexity of the modified nucleosides is reduced compared to RNA, but, nevertheless, 
modified DNA nucleosides play an essential function in mammalian epigenetic gene regulation.   
1.1 RNA modifications 
So far, more than 100 RNA modifications have been identified. Modifications have been found for all 
four canonical nucleosides and can range from simple methylations, such as for N
1
-methylguanosine 
(m
1
G), to more complex hypermodified nucleosides, such as wybutosine (yW) or queuosine (Q).
[1]
 
The majority of RNA modifications are found in tRNA, where modifications also display the largest 
diversity and complexity of structures. However, modified RNA nucleosides have also been found in 
rRNA and mRNA, as well as in small non-coding RNA species. Recently, the development of more 
sensitive detection methods, as well as the improvement of the RNA isolation protocols, have allowed 
the detection of 14 new RNA modifications, including agmatidine (C
+
) and 8-methyladenosine (m
8
A). 
Further technological advances will most likely lead to the discovery of new modified nucleosides in 
the coming years.
[2] 
 
Figure 1 Examples of naturally occurring RNA modifications.   
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1.1.1 Transfer RNA 
Transfer RNA (tRNA) is an adapter molecule that links each mRNA codon triplet to the 
corresponding amino acid during protein translation in the ribosome. tRNA molecules are composed 
of three main loops, an amino acid acceptor stem and a variable loop. All tRNAs adopt a characteristic 
L-shaped tri-dimensional structure which allows for optimal fitting in the ribosomal active site (see 
Figure 2). The CCA tail, located at the 3´-end of the tRNA molecule, is crucial for amino acid loading, 
while the dihydrouridine stem and loop (DSL) and the thymidine stem and loop (TSL) contribute to 
the 3D structure.
[3]
 The anticodon stem and loop (ASL) is found at the end of the L-shaped structure 
and it contains the three-nucleotide sequence which is required for codon recognition and protein 
synthesis. 
Modifications are found in various positions of the tRNA molecule, with an average of 10-15% of the 
tRNA nucleosides being modified, and they are essential for correct tRNA folding and maturation.
[4]
 
Most modifications outside of the anticodon loop are simple modifications such as methylated 
nucleosides or pseudouridines (). On the contrary, the anticodon loop (position 32 to 38) displays the 
largest variety of modifications, in particular at position 34, known as the wobble position, and at 
position 37, directly adjacent to the anticodon triplet (Figure 2).
[5]
 These two positions are crucial for 
modulation of codon-anticodon interactions at the ribosome A- and P-sites.
[6]
 Position 32 is a 
conserved pyrimidine position, generally unmodified or containing simple modifications (e.g. 
methylations or ), while position 33 is almost exclusively occupied by a uridine.[5] 
 
Figure 2 Schematic representation of tRNA cloverleaf structure and 3D structure of yeast tRNAPhe.[7] In both 
representations characteristic features of the tRNA molecule are highlighted: DSL (violet), TSL (blue), CCA-tail (green), 
anticodon (red). Structural data for yeast tRNAPhe was derived from the crystal structure 1EHZ.[7] 
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1.1.2 Functions of tRNA modifications 
RNA modifications, depending on their nature and location in the tRNA molecules, have three main 
functions: modulation of the codon-anticodon interaction, folding and structural stabilization and, 
finally, recognition of the specific tRNA molecule. 
1.1.2.1 Modulation of codon-anticodon interaction 
The fast rate of protein synthesis (20-40 peptide bonds per second
[8]
) and the high fidelity of mRNA 
translation (1 error per 1x10
3‒1x104 amino acids[9]) requires precise and efficient cognate tRNA 
selection. Binding of the correct tRNA at the ribosome A-site is verified by kinetic and induced-fit 
proofreading mechanisms. Upon entering of the aminoacyl-tRNA, elongation factor and GTP in the 
ribosome A-site, the anticodon forms a minihelix with the codon triplet. The minihelix is evaluated by 
formation of specific H-bonds between ribosomal A1492, A1493 and G530 and the backbones of the 
codon and anticodon RNA strands. Incorrect H-bond formation arising from non-cognate tRNA 
results in release of the tRNA molecule, while correct codon-anticodon pairing (or pairing to near-
cognate tRNA) leads to GTP hydrolysis, release of the elongation factor and translocation of the tRNA 
from the A- to the P-site of the ribosome.
[10]
 
Modifications involved in codon-anticodon interaction contribute to cognate-codon selection in the 
A-site, as well as to stabilization of the codon-anticodon binding and frameshift prevention.
[11]
 These 
modifications are generally located in the anticodon loop, and the major contributions are given by the 
modifications at position 34 and position 37. 
Position 34, known as the wobble position, is involved in decoding of degenerate codons which 
correspond to a single amino acid. In fact, some amino acids are coded for by as many as six codon 
triplets, while others are coded by only one or two triplets. Translation is performed by a limited set of 
tRNAs, which in some cases recognize more than one codon sequence by wobbling of the third 
codon-anticodon base pair. Wobble base-pairing accounts for up to 30-40 % of all codon 
recognition.
[12]
 The wobble position often consists of a large variety of uridine derivatives, inosine (I), 
2´-O-methylated nucleosides and hypermodified nucleosides belonging to the queuosine family.
[5, 13]
 
Depending on the nature of the modification, wobble base pairing can be extended to all four 
nucleobases or restricted to only two. An interesting example is provided by the uridine derivatives. In 
fact, while s
2
U34 enhances base pairing to A and xm
5
U34 (such as mnm
5
U34) allows for efficient 
pairing to codons ending in A and G, xo
5
U34 (e.g. cmo
5
U34) enables a single tRNA isoacceptor to 
read three or four synonymous codons, i.e. NNX (X = A/C/G/U).
[12, 14]
 The different wobbling 
properties have been explained in terms of dynamic conformations of the modified nucleotides, where 
in this case the 2-thio group limits the uridine to anti, 3´-endo, gauche
+
 conformation, promoting 
binding to adenosine, while 5-oxy derivatives can adopt both the C2´-endo as well as the C3´-endo 
conformation, allowing a wider pairing ability.
[15]
 In support of the major role played by wobble base 
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modifications, lack of modification at the U34 position of ASLs of glutamine, lysine, arginine and 
cysteine results in impaired codon binding.
[11a, 16]
  
Purines found at position 37 of the ASL are generally modified and play a key role in codon-anticodon 
interaction.
[6]
 Prominent modifications are N
6
-threonylcarbanyladenosine (t
6
A), N
2
-methylguanosine 
and 2-methylthio-N
6
-isopentenyladenosine (ms
2
i
6
A).
[1, 5]
 Upon codon-binding in the A-site of the 
ribosome, purine 37 stacks on top of the first codon-anticodon base pair, as shown for t
6
A in Figure 3, 
where the modified nucleoside stacks both with the base at position 38 as well as with the first base of 
the mRNA codon.
[17]
 This stabilisation effect is particularly important for U/A-rich codon-anticodon 
pairs, and t
6
A37 in the ASL of tRNA
Lys(UUU)
 is an essential requirement for codon-binding in the A-
site.
[16b, 17]
  
The enhanced stability of the codon-anticodon interaction afforded by modifications at position 37 
(and/or at the wobble position) also prevents +1 frameshift events by favouring cognate tRNA 
selection. Furthermore, it  reduces pausing in the A-site and prevents slippage of the peptidyl-tRNA in 
the P-site of the ribosome.
[18]
 For example, unmodified A37 in tRNA
Tyr(QUA)
 resulted in up to 9-fold 
increase in frameshifting compared to tRNA containing the modification ms
2
io
6
A37. Similarly, lack of 
the mnm
5
 modification at U34 in tRNA
Lys(UUU)
 resulted in nearly three-fold increase in +1 
frameshifting when paired with codon AAA, and almost six-fold increase in frameshifting when 
paired with the synonymous codon AAG.
[18a] 
 
Figure 3 Modulation of codon-anticodon interaction. Modification t6A at position 37 of tRNALys(UUU) enhances interaction 
with codon AAA in the A site of the ribosome. Stacking of the purine moiety of A37 with neighbouring bases is shown by a 
wide dotted line. Data was derived from crystal structure 1XMQ.[17] 
Another important function of modified purine 37 nucleosides is to structure the anticodon loop for 
optimal fitting in the ribosomal A- and P-sites. In fact, as shown in Figure 4, modification at position 
37 prevents intra-loop H-bonding, ensuring an ´open loop´ conformation of the ASL.
[19]
 The absence 
of intra-loop base pairing leads to a reduction of the melting temperature of the ASL compared to that 
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of unmodified RNA. However, as evident from solution-structure analyses and X-ray crystallographic 
structures of tRNAs,
[11b]
 it also results in a constrained architecture which is optimal for fitting in the 
ribosomal A-site, therefore reducing the entropic penalty upon binding of the tRNA. This, in turn, 
leads to enhanced accuracy and faster rates of cognate tRNA selection, given that the optimal ASL as 
well as the stabilising effect of modified nucleosides in the extended anticodon domain ensure more 
efficient selection of the tRNA molecules.
[11b] 
 
Figure 4 Structural role of modifications at position 37. A) E.coli tRNAPhe anticodon loop conformation in the presence of 
ms2i6A modification at position 37 (PDB 318G).[20] B) E.coli tRNAPhe unmodified ASL showing intraloop Watson-Crick 
bases between unmodified A37 and U33, resulting in a compact three nucleotide loop (PDB 1J4Y).[21] 
1.1.2.2 Folding and structural stabilisation 
tRNA modifications also contribute to folding and stabilisation of the tRNA molecule in various ways. 
As mentioned in the previous chapter, an important contribution to conformational stability is 
introduced by modifications at purine 37, which prearrange the ASL for optimal fitting in the A 
site.
[11b]
 Modifications located in the core of the tRNA, especially 2´-O-methylations, 
pseudouridinylations or thiolations, further stabilise the tRNA molecule by favouring the 3´-endo 
conformation of the ribose, which is the preferred conformation adopted upon hybridization to A-form 
helices.
[4b, 22]
 The additional stabilisation afforded by modifications also results in an increase of the 
melting temperature (Tm),
[23]
 as exemplified by studies with yeast tRNA
Phe
, where modifications led to 
a Tm of 6 °C higher compared to unmodified tRNA.
[24]
 In some cases, modifications contribute to 
larger structural effects, as in the case of mitochondrial tRNA
Lys
, where m
1
A at position 9 is essential 
for correct folding of the tRNA molecule.
[25]
 
Presence of specific modifications is also necessary for maturation of tRNA molecules, and absence of 
these can lead to rapid degradation of the tRNA. This is the case for m
1
A at position 58 of tRNAi
Met
, 
where this modification is required for maturation and stability of the corresponding pre-tRNA, which 
is otherwise rapidly degraded by a TRF4/RRP6-dependent nuclear surveillance pathway.
[26]
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Furthermore, absence of certain modification pairs in yeast tRNA, such as m
7
G46 and m
5
C,
[4a]
 results 
in temperature-sensitive growth and degradation of tRNA
Val(AAC)
 by a rapid tRNA degradation (RTD) 
pathway, again suggesting a key role for specific modification networks in maturation and stabilisation 
of the tRNA.
[4a, 27]
 
1.1.2.3 tRNA recognition 
Modifications also contribute in defining the identity of tRNA molecules in order to ensure selective 
interaction with enzymes involved in tRNA processing and recruitment to the translational 
machinery.
[28]
 In particular, various modifications have been implicated in the selective recognition by 
amino acyl synthetases. For examples, m
1
G strongly reduces misacylation of tRNA
Asp
 with an Arg by 
arginyl-tRNA synthetase (ArgRS).
[29]
 Another interesting example is that of lysidine k
2
C34 of E.coli 
tRNA
Ile(CAU)
. Selective interaction of IleRS with the lysidine modification at the anticodon ensures 
correct charging with isoleucine, while the unmodified tRNA would be mischarged with methionine 
by MetRS.
[30]
 
Modifications also play a role in discrimination between initiator and elongator tRNA
Met
 in fungi and 
plants. The steric bulk resulting from the modification 2´-O-ribosyladenosine Ar (p) or 
2´-O-ribosylguanosine Gr(p) located at position 64 of initiator tRNAi
Met
 prevents ternary complex 
formation with elongator factor eEF-1 and GTP, therefore preventing tRNAi
Met
 from contributing to 
the elongation process.
[31]
  
1.1.3 Biogenesis of tRNAs and tRNA modifications 
tRNAs and their modifications have a complex, stepwise biosynthetic pathway. In yeast, pre-tRNAs 
are transcribed in the nucleolus,
[32]
 where they also undergo 5´-processing.
[33]
 The 3´ trailer sequence is 
subsequently cleaved, most likely in the nucleoplasm, followed by addition of the CCA sequence at 
the 3´-end of the molecule.
[34]
 Furthermore, intron-containing tRNAs undergo splicing either in the 
nucleus or in the cytoplasm depending on the organism.
[34a]
 
Modification of tRNA molecules occurs in a stepwise manner following a strict order.
[35]
 The main 
factors governing the tRNA modification process are substrate specificity as well as subcellular 
localization of the modification enzymes.
[34a]
  
Substrate specificity dictates the timing of the modification process depending on the extent of 5´- and 
3´-end processing and on the presence or absence of an intron. Certain modifying enzymes depend 
specifically on the local architecture of intron-containing tRNAs, as in the case of pseudouridines at 
positions 34, 35 and 36 as well as m
5
C34 of various eukaryotic tRNAs.
[36]
 Similarly, studies performed 
with yeast tRNA
Phe
 revealed the intron-dependent formation of m
5
C40. The same study also identified 
a subset of modifications which requires prior intron splicing, specifically the anticodon modifications 
Cm32, Gm34 and m
1
G37, and another subset which is introduced independently of the presence of an 
intron, which includes a number of modifications outside of the anticodon stem-loop.
[37]
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Timing of tRNA modification is also affected by the cellular distribution of modifying enzymes, as in 
the case of yeast tRNA
Phe
 (Figure 5).
[28]
 In this case, after initial processing and modification in the 
nucleus, the intron-containing tRNA is exported to the cytoplasm, where splicing takes place at the 
mitochondrial outer membrane.
[38]
 Modifications m
2
G10, Cm32 and Gm34 are subsequently 
introduced in the cytoplasm, prior to import of the tRNA into the nucleus, where m
1
G37 is generated. 
tRNA
Phe
 is then re-exported to the cytoplasm where biosynthesis of yW at position 37 takes place and 
the mature tRNA can be amino acylated and recruited to the translational machinery.
[34b]
 In relation to 
tRNA transport, it should be noted that retrograde transport of tRNA molecules into the nucleus is not 
only occurring during tRNA maturation, but it has also been observed to involve mature tRNAs, 
particularly in response to nutrient deprivation.
[39]
 Retrograde transport of mature tRNAs is reversible 
and it is suggested to play a role in proofreading of tRNAs or in downregulation of protein 
translation.
[39-40]
 
 
Figure 5 Biosynthesis of yeast tRNAPhe. Maturation of tRNAPhe in S.cerevisiae depicting transport between the nucleus and 
the cytosol, alongside the various processing steps (5´ and 3´ end processing, splicing, modifications).[28] 
However, tRNA modifications can also be governed by subtle architectural aspects, such as the 
presence of other specific modifications in the tRNA molecule.
[4c]
 One such example is found in 
Trypanosoma brucei, where C to U editing at the first position of the anticodon of tRNA
Trp
 was found 
to be negatively regulated by the presence of s
2
U33, suggesting that both the CCA and the edited UCA 
anticodons might have a distinct biological role.
[41]
 
Incorrect processing and maturation of tRNA molecules results in degradation of the tRNA. Various 
degradation pathways have been described,
[34a]
 one involving the TRAMP complex, which functions 
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in nuclear surveillance, and one being the Rapid tRNA Decay (RTD), which specifically targets 
certain hypomodified tRNAs.
[4a, 34a]
 Furthermore, cells have been found to respond to various stress 
conditions by inducing endonucleolytic cleavage of tRNAs at the anticodon loop.
[42]
 The resulting 
tRNA halves have been suggested to play a role in modulation of protein synthesis, either by blocking 
the translational machinery, or by acting as siRNA- or miRNA-like templates for selective mRNA 
degradation. Yet, the exact role of tRNA endonucleolytic cleavage and of the resulting tRNA 
fragments is still unclear.
[43]
 
1.1.4 Regulation of tRNA modifications 
Emerging evidence suggests a role for tRNAs and tRNA modifications in cellular response to 
stress.
[43-44]
 A study performed by Chan et al. revealed a highly dynamic reprogramming of tRNA 
modifications in response to various stresses, with some modifications increasing and other being 
depleted.
[44a]
 In a subsequent report, further investigation of the response of yeast cells to H2O2 
exposure highlighted the crucial role of Trm4 and the resulting m
5
C34 modification for modulation of 
the response mechanism.
[45]
 In fact, oxidative stress triggers expression of a subset of genes enriched 
in TTG codons. The selective increase in m
5
C modification at the wobble position of tRNA
Leu(CAA)
 
ensures efficient translation of this gene pool. Loss of Trm4 resulted in hypersensitivity to oxidative 
stress, confirming the essential role of the modification m
5
C34 in modulating stress response.
[45]
 
Similarly, Trm9, which catalyses the methylation of uridine derivative mcm
5
U34 and mcm
5
s
2
U34, was 
found to contribute to stress response against methyl methanesulfonate (MMS).
[46]
 Here again, Trm9-
dependent modifications were observed to modulate efficient translation of arginine and glutamic acid 
codons which are selectively enriched in genes actively transcribed during the response process.
[46]
 In 
line with these findings, recent studies highlighted that specific non-optimal codon compositions are 
enriched in subsets of genes involved in the same pathway, as an optimization strategy to enhance 
coordinate protein synthesis for these genes. Such variations in codon content are suggested to be 
involved in modulation of cell-cycle dependent fluctuations in protein levels
[47]
 as well as in the 
specific transcription of genes involved in stress response.
[46]
 Modulation of tRNA modifications to 
selectively favour translation of certain codons might therefore provide an avenue for efficient 
translation of these subsets of genes.
[48]
 
Specific tRNA modifications are also enhanced for structural stabilization in response to heat stress in 
thermophiles.
[4b, 49]
 Examples include the modifications Gm, m
2
2Gm, ac
4
Cm, s
2
T and m
1
A. The 
enhanced thermal stabilization conferred by these modifications allows growth at elevated 
temperatures, which is otherwise impaired in null mutants.
[50]
 
1.1.5 tRNA modifications in evolution 
tRNAs from different organisms contain a variety of different RNA modifications at different 
positions, suggesting that the nature of transfer RNA modifications as well as their patterns in the 
tRNA molecule might depend on the origin of the tRNA. However, certain modifications are found 
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across all three domains, Eukarya, Bacteria and Archaea,
[5]
 suggesting a very early function of these 
modifications in evolution.
[51]
 Efficient modulation of protein translation and maintenance of the 
reading frame is an essential feature for survival of the organism, and must have therefore exerted a 
strong selective pressure in optimization of the tRNA molecules.
[52]
 Indeed, modification m
1
G37, 
which is found across all three kingdoms, was identified as an essential feature for cellular life 
throughout evolution and was suggested to have evolved prior to divergence of the kingdoms.
[52]
 
m
1
G37 was in fact shown to play a major role in maintaining the reading frame and lack of this 
modification is known to result in severe growth impairment in both bacteria and eukaryotes.
[18a, 52]
 A 
similar scenario was proposed by Urbonavicius et al., which suggested that modifications involved in 
preventing +1 frameshifting must have played a crucial role throughout evolution.
[18a]
 However, while 
specific modifications involved in modulation of translation might have indeed evolved for optimized 
protein synthesis, Phizicky et al. have pointed out that other modifications, particularly those outside 
of the anticodon loop, might have arisen from overlapping reactivity and poor substrate specificity of 
the modification enzymes rather than as an evolutionary demand.
[4c]
 This might also explain the lack 
of phenotype observed in mutant strains lacking certain modifications in the tRNA core structure.
[4a, 4c]
 
Interestingly, a recent study further elucidated the role of two tRNA-modifying enzymes in the 
evolution of tRNA isoacceptor populations across the three kingdoms. According to this report, 
appearance of eukaryotic tRNA-dependent adenosine deaminases (hetADAT), which catalyse 
conversion of adenosine 34 to inosine 34, and of bacterial uridine methyltransferases (UMs) which 
modify xo
5
U34 derivatives, was found to have contributed to divergence of the tRNA populations of 
Eukarya and Bacteria with respect to the genome of Archaea. In fact, the improved decoding ability of 
specific tRNA isoacceptors enabled by these modifications led to an enrichment of these isoacceptors, 
therefore contributing to the evolution of genomic codon composition and to differences in tRNA gene 
populations.
[53]
 
1.2 DNA modifications 
Modified DNA nucleosides display a lower degree of structural complexity compared to RNA 
nucleosides. Of crucial importance are the modified cytosine derivatives found in eukaryotic genomic 
DNA, which include methylcytosine (mC), hydroxymethylcytosine (hmC), formylcytosine (fC) and 
carboxycytosine (caC). In particular, mC is known to be a key modification involved in epigenetic 
regulation of gene expression, while the growing number of studies focusing on hmC, fC and caC are 
slowly uncovering their roles as potential epigenetic markers and/or intermediates in various pathways 
of demethylation. 
1.2.1 Epigenetic modulation of gene expression 
Multicellular organisms are composed of different cell types with vastly different characteristics 
despite all cells sharing the same genetic information. These characteristics are defined by different 
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sets of proteins expressed and therefore by different sets of genes activated depending on the cell type. 
A crucial step in the regulation of gene expression is transcription, which is generally regulated by 
sequence-specific transcription factors as well as by cis-acting regulatory elements such as promoters 
and enhancers. Nevertheless, given the complexity of the mammalian gene expression system, there is 
need for an extra layer of regulation which ensures durable gene expression patterns and cellular 
identity, while at the same time allowing for cells to respond to environmental and developmental 
stimuli. This additional level of regulation is introduced by histone modifications, which are 
responsible for short-term modulation of gene-expression, while DNA methylation confers long-term 
gene silencing.
[54]
 These regulatory features, histone and DNA modifications, are by definition 
epigenetic, given that they alter gene expression without changing the DNA sequence. 
1.2.2 Chromatin structure and histone modifications 
Eukaryotic DNA is organized in a hierarchy of structural levels closely associated with specific DNA 
binding proteins. This combination of DNA and proteins is known as chromatin and it is essential for 
packaging of the DNA as well as for modulation of gene expression. The smallest packaging unit is 
known as nucleosome, where a 147-bp DNA segment is coiled in 1.65 turns around a histone octamer, 
composed by two H2A-H2B heterodimers and by a H3-H4 tetramer.
[55]
 Core histones are globular 
proteins with an unstructured N-terminal tail which can be covalently modified. Nucleosomes are 
separated by about 50-bp-long DNA segments. This loosely packed chromatin form is known as 
´beads on a string´ and it is generally associated with active transcription. Further packaging is 
introduced by the linker histone H1, which binds between nucleosomes generating the so called 
´30-nm fiber´, and nucleosomes are finally organized in various higher order chromatin 
architectures.
[56]
 According to its structure, chromatin is divided into heterochromatin, which is more 
densely packed and generally (but not exclusively) transcriptionally inactive, and euchromatin, more 
dispersed and commonly regarded as transcriptionally active.
[57]
 Most importantly, chromatin 
packaging is a highly dynamic process, with profound implications for gene expression. 
 
Figure 6 Structural organization of eukaryotic DNA. (Adapted from Felsenfeld and Groundine, 2003[56b])  
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Histones play a crucial role in modulation of the dynamics of chromatin accessibility. Histones can in 
fact be dynamically functionalized with a variety of post-translational modifications. These include 
acetylation, methylation, phosphorylation as well as more complex modifications such as 
SUMOylation or ADP-ribosylation. These modifications have important roles in gene expression, 
replication and DNA repair and they collectively contribute to defining the ´histone code´.
[58]
 Histone 
modifications affect chromatin packaging by two main mechanisms: they can either disrupt 
nucleosome interactions, or they can mediate the recruitment of specific non-histone proteins.
[59]
 For 
example, acetylation of lysine residues leads to charge neutralization, therefore weakening the charge-
dependent nucleosome-DNA interactions and increasing chromatin accessibility. Charge-effects are 
also suggested to take place upon phosphorylation.
[58a]
 On the other hand, various proteins have been 
found to interact with or to be affected by specific histone modifications, contributing to modulation of 
downstream events.
[60]
 For example, DNMT3L-dependent targeting of de novo DNA methylation by 
interaction with H3 tails is inhibited by H3K4me.
[61]
 In addition, specific histone methyltransferases 
were found to target DNA methylation to defined genomic sections by recruitment of DNA 
methyltransferases
[62]
 while, on the other hand, DNA methylation was similarly observed to direct 
histone modifications.
[63]
  
In general, transcriptionally active chromatin is associated with acetylation of histones H3 and H4 and 
trimethylation of H3K4, H3K36 and H3K79, while heterochromatin generally correlates with low 
levels of acetylation and high content of methylated H3K9, H3K27 and H4K20.
[64]
 Bivalent domains 
have also been found, possessing both activating and repressive modifications.
[65]
 In fact, histones can 
be modified at multiple sites simultaneously, contributing to a complex crosstalk between different 
epigenetic marks. 
1.2.3 DNA methylation 
1.2.3.1 Distribution of DNA methylation 
In the genome, cytosine methylation takes place predominantly in a CpG dinucleotide context. CpG 
dinucleotides are underrepresented in the genome, possibly because they constitute mutation hot 
spots,
[66]
 and they tend to cluster in regions known as CpG islands (CGIs). GCIs are defined as DNA 
segments of at least 200 bp with a high C/G content (minimum 50 %) and a ratio of observed to 
statistically predicted CpG frequency of at least 0.6.
[67]
 CGIs are associated with about 60-70 % of 
human gene promoters. Of these, the majority is usually unmethylated,
[68]
 while about 6 % of them is 
methylated in a tissue-specific manner at early stages of development or in differentiated tissues.
[69]
 
In general, promoter CGIs methylation inversely correlates with gene expression. Methylation-
dependent transcriptional repression can be induced by two main mechanism: methylation can lead to 
the recruitment of proteins which specifically bind methylated CpG sites, therefore preventing binding 
of transcription factors at these sites;
[70]
 alternatively, methyl-CpG-binding proteins can themselves 
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recruit chromatin remodelling factors and histone modifiers which lead to repression of 
transcription.
[71]
 Methylation of promoter CGIs is generally associated with long-term silencing
[72]
 and 
it plays an essential role in genomic imprinting
[73]
 and X-chromosome inactivation.
[74]
 
However, DNA methylation does not only occur at CGIs and it does not exclusively correlate with 
transcriptional silencing. In fact, sparsely distributed CpGs found in gene bodies are generally highly 
methylated
[72]
 and methylation at these sites was found to positively correlate with active 
transcription.
[75]
 DNA methylation can also occur in regions in close proximity to CGIs, known as 
CpG island shores, and in this case it is closely associated with transcriptional repression.
[76]
 
Furthermore, DNA methylation has also been observed in a CHH and CHG context, where H is A, C 
or T.
[77]
 In fact, about one quarter of the methylated cytosines present is embryonic stem cells is found 
in a non-CpG context, with enrichment of these methylated cytosines at gene bodies, showing a 
positive correlation with gene expression, and depletion at protein binding sites and enhancers.
[77b]
 
Interestingly, levels of non-CpG methylcytosine were found to decrease during differentiation and to 
be restored in induced pluripotent stem cells, suggesting that stem cells might rely on a different 
mechanism for modulation of gene expression.
[77b]
 Finally, methylation is not only involved in 
regulation of gene transcription, but also in genome stabilization. In particular, high methylation levels 
found at repetitive elements are thought to prevent reactivation of endoparasitic sequences that would 
otherwise result in translocations and chromosomal instability.
[78]
 
DNA methylation plays a key role in mammalian development and large changes in methylation 
patterns are observed throughout differentiation.
[79]
 A first wave of genome-wide epigenetic 
reprogramming is observed after fertilization, when the genome of the male pronucleus undergoes 
rapid demethylation (as a result of genome-wide oxidation of mC), followed by passive demethylation 
of the maternal genome. A similar wave of demethylation is observed during specification of 
primordial germ cells.
[79b]
 Subsequently, during development, establishment of methylation patterns by 
de novo methyltransferases is essential for correct differentiation, contributing to the long-term 
repression of key pluripotency genes Oct4 and Nanog and to tissue-specific modulation of gene 
expression.
[79a]
 
Importantly, misregulation of methylation patterns is strongly linked to diseases.
[80]
 Cancer cells 
feature genome-wide hypomethylation, which promotes chromosomal instability,
[81]
 as well as local 
hypermethylation at CpG islands, which often leads to inactivation of genes involved in a variety of 
essential pathways, such as DNA repair, cell cycle control and apoptosis.
[82]
 Misregulation of DNA 
methylation has also been implicated in a variety of other diseases, including ICF (Immune deficiency, 
centromeric instability and facial abnormalities) and Rett syndrome.
[80]
 Interestingly, inhibitors of 
DNA methyltransferases, such as azacytidine, have been approved as drugs for cancer treatment, once 
again highlighting the essential role of correct methylation in maintenance of the normal cell 
functioning.
[83]
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1.2.3.2 DNA Methyltransferases 
Methylation of cytosine is performed by DNA methyltransferases (Dnmts) in the presence of cofactor 
S-adenosylmethionine (SAM). In mammals, three Dnmts display DNA methyltransferase activity, 
namely Dnmt1, Dnmt3a and Dnm3b (Figure 7). A fourth member, Dnmt3L, lacks catalytic activity, 
although it was shown to interact and stimulate activity of Dnmt3a and Dnmt3b.
[84]
 Finally, Dnmt2, 
despite sharing all the conserved catalytic motifs, has only limited activity as DNA 
methyltransferase
[85]
 and was instead reported to act as a tRNA methyltransferase.
[86]
  
 
Figure 7 A) Schematic representation of domain structure of mammalian DNA methyltransferases and B) their 
catalytic mechanism. Mechanism of methyl transfer reaction is based on that of the bacterial methyltransferase M.Hha1.[87] 
SAM: S-adenosylmethionine; SAH: S-adenosylhomocystein. 
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Dnmt3a and Dnmt3b are known as de novo methyltransferases and are responsible for the 
establishment of the DNA methylation pattern during embryogenesis and development of germ 
cells.
[88]
 Expression levels of the de novo methyltransferases are elevated in embryonic stem cells, 
while differentiation leads to their down-regulation and only low expression levels are observed in 
somatic tissues.
[88]
 Both Dnmt3a and Dnmt3b are essential for mammalian development. Dnmt3b null 
mouse embryos show developmental defects after E 9.5 and no viable embryo can develop to term.
[88a]
 
On the contrary, Dnmt3a null embryos are able to develop to term, but show significant growth defects 
and generally die four weeks after birth.
[88a]
 The different phenotypes observed for the two de novo 
methyltransferases are suggestive of different roles for these two Dnmts. Dnmt3b plays a major role 
during early development, while Dnmt3a appears to be crucial at later developmental stages.
[88a]
 
Similarly, Dnmt3a conditional mutant mice show imprinting defects in the germline, while no 
apparent phenotype is observed for Dnmt3b conditional mutants, suggesting that Dnmt3a is crucial for 
the establishment of maternal and paternal imprints.
[89]
  
After establishment of DNA methylation by de novo methyltransferases, maintenance of this pattern is 
performed by Dnmt1.
[90]
 Dnmt1 has a higher affinity for hemimethylated DNA
[91]
 and is associated 
with the replication machinery to ensure efficient maintenance of methylation.
[90, 92]
 Furthermore, the 
CXXC domain of Dnmt1 is reported to selectively bind to unmethylated CpG sites
[93]
 and to result in a 
conformation which prevents catalysis on unmethylated DNA, thus providing an autoinhibitory 
mechanism that ensures methylation only in the presence of hemimethylated CpGs.
[94]
 While Dnmt1 
null mutant stem cells are viable, with low but stable levels of methylation, loss of Dnmt1 in mice 
results in embryonic lethality, highlighting the importance of maintenance of methylation for normal 
development.
[95]
  
DNA methyltransferases are characterized by a large multidomain N-terminus, which is responsible 
for nuclear localization and modulation of protein-protein and protein-DNA interactions, and by a 
highly conserved C-terminus which harbours the catalytic methyltransferase domain and which is 
responsible for cofactor and substrate DNA binding and catalysis (Figure 7A).
[96]
 All active 
methyltransferases share a common catalytic mechanism (Figure 7B):
[97]
 initially, a conserved cysteine 
residue performs a nucleophilic attack at the C6 position of the cytosine (which is flipped out of the 
DNA double helix and buried into the hydrophobic pocket of the active site);
[87]
 this reaction, which is 
facilitated by protonation at N3 by a conserved glutamate residue, is followed by attack at the methyl 
group of the SAM cofactor and by final re-aromatization of the methylated cytosine nucleobase via a 
syn-elimination of the enzyme cysteine.
[87, 97]
  
1.2.4 Oxidized cytosine derivatives 
In 2009 two groups independently reported the detection in mammalian genomic DNA of a further 
modified cytosine species, 5-hydroxymethylcytosine (hmC), which is now widely accepted as the 
sixth genomic nucleoside in higher eukaryotes.
[98]
 A previous report had also documented the 
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detection of hmC in mammalian DNA, although the levels of hmC documented were substantially 
higher compared to more recent studies.
[99]
 Recent reports additionally identified formylcytosine (fC) 
and carboxycytosine (caC) in genomic DNA of higher eukaryotes, bringing the total number of 
modified cytosines to four.
[100]
 
A computational search to identify homologues of the trypanosome thymine hydroxylases JBP1 and 
JBP2 led to the discovery of the ten-eleven translocation (Tet) protein family,
[98b]
 whose members 
were shown to catalyze the conversion of methylcytosine (mC) to hmC,
[98b, 101]
 as well as the 
sequential oxidation of hmC to generate fC and caC.
[100a, 100b]
  
The discovery of the Tet protein family and of the oxidized cytosine derivatives highlighted the 
possibility for a dynamic, Tet-mediated regulation of methylcytosine levels in genomic DNA and, 
since the first report by Tahiliani et al., it has been the focus of intensive research worldwide.
[102]
 
1.2.4.1 Tet family proteins 
In jawed vertebrates the Tet protein family is composed of Tet1, Tet2 and Tet3.
[98b, 101]
 In all three 
proteins, the catalytic domain, composed of a Cys-rich region followed by a double-stranded -helix 
(DSBH) domain, is located at the C-terminus and it displays 2-oxoglutarate (2-OG)- and iron (II)-
dependent dioxygenase activity (Figure 8).
[98b, 101]
 Additionally, Tet1 and Tet3 posses a CXXC domain 
at their N-terminus, while in the case of Tet2 a chromosomal inversion event led to the detachment of 
the CXXC domain.
[103]
. The CXXC domain of Tet1 has been reported to bind CpG-containing DNA in 
the presence of unmodified cytosine as well as of mC and hmC, a feature which might explain the 
enrichment of Tet1 at CpG-dense genomic regions,
[104]
 while the CXXC domain of Tet3 is able to bind 
unmodified cytosine regardless of whether it is followed by a guanine.
[105]
 
Tet1 is highly expressed in mouse ES cells and downregulated during differentiation and it is 
suggested to play a role in regulation of pluripotency and differentiation. In fact, a report by Ito et al. 
showed that shRNA-mediated knockdown of Tet1 in mouse ES cells results in downregulated 
expression of the pluripotency factor Nanog by increased methylation at the Nanog-proximal 
promoter,
[101]
 and similar observations were made for other pluripotency-related genes,
[106]
 although 
there are still discrepancies concerning these results.
[107]
 Furthermore, Tet1 was suggested to be 
important for inner cell mass specification, as depletion of Tet1 levels in pre-implantation embryos 
leads to biased differentiation towards trophectoderm and mesoendoderm lineage.
[101, 106-107]
 Tet1-null 
mice are viable and fertile, but tend to display smaller body size, suggesting a role of Tet1 in 
regulation of development.
[108]
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Figure 8 A) Summary of domain structure of mammalian Tet proteins and B) their catalytic mechanism.[109] DSBH: 
dioxygenase activity, metal binding domain. 
Genome-wide mapping of Tet1 in ES cells highlighted a dual role of this protein in the regulation of 
transcription. Tet1 is enriched at gene promoters and exons,
[106, 110]
 and it has been suggested to 
contribute to maintenance of a hypomethylated state for CpG-rich promoters.
[104a, 106]
 However, 
although Tet1-dependent promoter hypomethylation is necessary for expression of a subset of 
transcriptionally active genes, Tet1 also plays a repressive role, especially for genes involved in the 
differentiation process.
[110b, 111]
 In fact, Tet1 contributes to gene silencing by favouring recruitment of 
the Polycomp Repressive Complex 2 (PRC2) through maintenance of a hypomethylated state at the 
target genes (since binding of PRC2 is inhibited by the presence of mC).
[111]
 Similarly, Tet1 was found 
to display a significant overlap of target genes with the SIN3A co-repressor complex, further 
supporting a role of Tet1 in transcriptional repression.
[110b]
 The dual role of Tet1 highlighted by these 
studies is thought to be essential for correct maintenance of pluripotency and timely coordination of 
the differentiation process. 
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Tet2 is also expressed in ES cells, although its depletion results in milder effects compared to Tet1
[101, 
107]
 and it was not found to associate with SIN3A.
[110b]
 Interestingly, Tet2 is also expressed in 
hematopoietic stem cells (HSCs) and it is suggested to play a crucial role in regulation of 
hematopoietic differentiation.
[112]
 In fact, although Tet2-null mice are viable, they display a lower 
genomic hmC content and an enlarged HSCs pool, with a tendency to develop hematopoietic 
malignancies.
[112a]
 Furthermore, mutations in Tet2, both leading to catalytic inactivation or unrelated to 
enzymatic activity, are amongst the most frequently encountered mutations in myeloid 
malignancies.
[113]
 
In contrast to Tet1 and Tet2, Tet3 is poorly expressed in ES cells but is instead enriched in oocytes and 
zygotes. Here, Tet3 was shown to be responsible for the genome-wide oxidation of mC to hmC, fC 
and caC in the male pronucleus after fertilization.
[114]
 Tet3-deficient zygotes fail to reduce global levels 
of mC in the paternal genome and depletion of Tet3 in the female germ line results in reduced 
fecundity and increased probability of developmental failure of embryos.
[114a]
 Studies performed in 
Xenopus laevis also highlighted a role of Tet3 in early eye and neural development,
[105]
 while depletion 
of Tet2 and Tet3 in developing mouse cortex resulted in impaired differentiation of neural progenitor 
cells.
[115]
 
Tet proteins have also been reported to interact with the enzyme OGT (O-linked 
-D-N-acetylglucosamine (O-GlcNAc) transferase), responsible for the in vivo addition of O-GlcNAc 
to serine and threonine residues. OGT, which is known to modify a variety of proteins including 
chromatin interactors and modifiers, was shown to be enriched at promoters in a Tet-dependent 
manner and to specifically trigger O-GlcNAcylation of histones and histone modifiers, therefore 
contributing to modulation of transcriptional activity.
[116]
 
1.2.4.2 Distribution of DNA oxidized cytosine derivatives 
Hydroxymethylcytosine has been detected in a variety of cell types, ranging from ES cells
[98b]
 to 
Purkinje neurons
[98a]
, as well as in mammalian tissues where hmC levels are found to be highest in the 
brain.
[117]
 Formylcytosine and carboxycytosine have also been found in a range of mammalian cells, 
but while hmC levels are around 5-10 % of the mC content in ES cells, fC and caC are found in much 
lower amounts, about 0.1 and 0.01 % of the mC content, respectively.
[100]
 Since 2009, the development 
of genome-wide mapping of hmC, fC and caC, both using precipitation-based and single-base 
resolution methods, has provided invaluable tools for the study of the distribution of modified 
cytosines in genomic DNA.
[118]
 
Mapping of hmC revealed that it is mostly associated with euchromatic regions. Enrichment was 
detected at gene bodies, where gene expression is generally found to positively correlate with hmC 
levels, as well as at enhancers and at promoter regions with intermediate CpG content,
[106, 110a, 119]
 
Furthermore, base-resolution mapping showed that hmC is asymmetrically distributed at CpG 
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sites.
[118b]
 Mapping of fC in ES cells revealed enrichment mostly at the same set of promoters as 
hmC,
[120]
 while depletion of TDG in ES cells showed increased presence of fC and caC at these 
promoters and at enhancers regions, suggesting the possible occurrence of Tet-mediated demethylation 
at these sites.
[118d, 121]
 
1.2.4.3 Putative roles of oxidized cytosine derivatives 
Interest in the Tet proteins and in the oxidized cytosine derivatives has mostly focused on the 
possibility that these nucleosides could serve as intermediates in a pathway of DNA demethylation. In 
fact, methylation patterns have been found to display a dynamic nature, with both genome-wide and 
gene-specific changes being observed. To date, several mechanisms have been proposed, involving 
both passive and active demethylation.
[102a, 122]
 
Passive demethylation, which is up to now the most widely accepted mechanism in mammals, 
involves erasure of the methylation pattern by preventing maintenance methylation by Dnmt1 and its 
partner Uhrf1. Dnmt1 was in fact found to have reduced methylation activity at hemi-hmC CpG sites, 
therefore suggesting a role for hmC in supporting passive demethylation (although coupled to 
oxidation) during transcription.
[123]
 Passive demethylation is thought to take place during the two 
waves of genome-wide demethylation observed in the paternal pronucleus after fertilization and 
during specification of primordial germ cells. Rapid demethylation of the male pronucleus has in fact 
been found to correspond to genome-wide oxidation of mC to hmC, fC and caC by Tet3, and current 
evidence suggests that the modified cytosine patterns are subsequently lost through replication.
[114]
 A 
similar phenomenon is thought to take place in primordial germ cells, where the drop in methylation 
levels observed between E9.5 and E10.5 was in fact found to coincide with massive oxidation of mC 
to hmC, in this case performed by Tet1 and Tet2, followed by replication-dependent dilution of 
hmC.
[124]
 
Various mechanisms of active demethylation have been suggested and can mostly be classified as 
involving the DNA repair machinery, namely base excision repair (BER), or direct C-C bond cleavage 
at the C5 position of the modified cytosine (Figure 9). 
Demethylation involving BER is well established in plants, where the Demeter family of glycosylases 
is responsible for direct excision of mC in Arabidopsis thaliana.
[125]
 In mammals, BER is thought to 
either involve direct removal of the oxidizes cytosine derivatives, or to be coupled to deamination. The 
former mechanism was shown to take place in the case of fC and caC, which can both be excised by 
Thymine DNA glycosylase (TDG).
[100a, 126]
 The latter pathway was proposed to involve deamination of 
hmC by activation-induced cytidine deaminase (AID)/apolipoprotein B mRNA editing enzyme, 
catalytic polypeptide (APOBEC) family enzymes, followed by excision of the deamination product, 
hmU, by the glycosylases TDG and single-strand-selective monofunctional uracil-DNA glycosylase 1 
(SMUG1).
[127]
 In support of this pathway, TDG was shown to interact with AID and with the damage 
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response protein Gadd45,
[127a]
 and previous findings have reported the coupling of deamination and 
BER in the removal of mC via conversion to T followed by base excision.
[128]
 However, this pathway 
remains controversial, since studies investigating the activity of AID and APOBEC family proteins 
reported a reduced activity in the presence of increasingly C5-modified cytosine derivatives.
[129]
 
 
Figure 9 Summary of active demethylation pathways involving hmC, fC and caC. 
On the other hand, active demethylation is proposed to take place via direct C-C bond cleavage at the 
C5 position of the modified cytosine.
[122b]
 Hints for this mechanism come from the E. coli 
2-oxoglutarate (2OG)-dependent dioxygenase AlkB, known to carry out the oxidative demethylation 
of 1-methyladenine and 3-methylcytosine by initial oxidation followed by release of formaldehyde.
[130]
 
Similarly, enzymes involved in the thymidine salvage pathway were shown to perform three 
consecutive oxidation steps to generate iso-orotate from T, followed by decarboxylation. However, the 
thymine 7-hydroxylase and the iso-orotate decarboxylase involved in this pathway were only isolated 
from fungi, and no homologue has yet been found in mammals.
[131]
 Up to now, evidence for such a 
pathway was provided by a report published by Schiesser et al., who documented the presence of a 
decarboxylation activity in the ES nuclear extracts,
[132]
 while Dnmt3a and Dnmt3b were shown to 
catalyze the removal of the hydroxymethyl group from hmC in vitro.
[133]
 Nevertheless, the identity of 
the enzyme or complex involved in active demethylation via C-C bond cleavage in vivo remains 
elusive. 
Apart from a possible role as intermediates in various pathways of DNA demethylation, oxidized 
cytosine derivatives might also act as specific DNA markers which can influence transcription and 
chromatin structure. Mass spectrometry analysis of modified cytosine interactors reveals that mC and 
its oxidized derivatives bind distinct subsets of proteins, suggesting specific biological roles 
particularly in the case of mC and hmC, while fC and caC largely recruit proteins involved in DNA 
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repair.
[134]
 Most importantly, oxidized cytosines might be involved in antagonizing the mC-dependent 
silencing effect. For example, methyl CpG-binding protein 1 (MBD1), MBD2 and Kaiso, which are 
responsible for recruitment of repressive histone modifying enzymes, specifically interact with mC but 
not with hmC, suggesting that Tet-mediated oxidation to hmC might result in chromatin remodelling 
and in transcriptional activation.
[123, 135]
 On the other hand, oxidized cytosine can affect the 
processivity of Pol II, and especially fC and caC were reported to stall the polymerase in vitro,
[136]
 
while hmC was reported to lower the melting temperature of the double helix compared to mC, 
therefore possibly promoting transcriptional elongation.
[137]
 
In summary, since the discovery of the Tet proteins and of the oxidised methylcytosine derivatives 
hmC, fC and caC there has been great interest in these novel modified DNA nucleosides. While the 
large number of studies already publish has helped to shed light on aspects related to these 
nucleosides, many fundamental questions regarding their role and removal remain unanswered.  
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2 Aims of the Project 
The distribution and dynamic regulation of tRNA modifications in eukaryotic systems is essential for 
the modulation of protein translation. Most of the studies on this topic reported to date have 
investigated the role and biosynthesis of individual tRNA modifications, while there is little 
information available concerning their systemic behaviour. We were therefore interested in 
investigating the global tRNA modification levels both in higher eukaryotes as well as in the 
unicellular organism S. cerevisiae, using an LC-MS-based quantification method. On the one hand we 
wanted to quantify the tRNA modification levels in various mammalian tissues in order to evaluate 
their tissue-dependent distribution (Chapter 3). On the other hand, we were interested in elucidating 
the nature of the variation in modification content in yeast cells during growth into stationary phase, 
with the aim of distinguishing between active increase of modification content versus passive 
enrichment of modified tRNA molecules. (Chapter 4). 
Additionally, we wanted to elucidate the biochemical and structural features which enable the 
selective modification of U34 in some E.coli tRNAs. Biochemical studies were therefore planned to 
characterize the bifunctional enzyme MnmC, responsible for the two final modification steps leading 
to mnm
5
s
2
U34, and to analyze its interaction with substrate tRNA (Chapter 5). 
In a second part of this work we focused on the analysis of modified DNA nucleosides and more 
specifically on the investigation of pathways involved in the removal of methylcytosine (mC). Since 
2009, the number of modified cytosine derivatives has expanded to include hydroxymethylcytosine 
(hmC), formylcytosine (fC) and carboxycytosine (caC). These cytosine derivatives are suggested to be 
involved in pathways of active demethylation, but despite the growing number of studies on this 
subject there is still controversy concerning the mechanism of mC removal. We therefore wanted to 
investigate putative demethylation pathways by C-C bond cleavage between the hydroxymethyl-
/formyl-/carboxy- group and the C5 atom on the cytosine base, using selectively labelled heavy atom-
isotopologues of hmC, fC and caC (Chapter 6). For this purpose, DNA strands containing modified 
cytosine derivatives had to be generated by Polymerase Chain Reaction (Chapter 7), and subsequently 
implemented as substrates for in vitro activity assays. Additionally, we were interested in determining 
whether maintenance methylation is possible in the presence of hemi-modified fC- and caC-containing 
strands, and we therefore planned to investigate the methylation activity of mouse Dnmt1 in the 
presence of these cytosine derivatives (Chapter 6). 
In a related project, we wanted to investigate an alternative pathway of active demethylation involving 
the putative deamination of hmC to yield hydroxymethyluracil (hmU). Deamination of hmC is in fact 
highly contested and our aim was to determine whether this process is indeed involved in the removal 
of mC. Interestingly, in the course of this study we observed that hmU generation is largely dependent 
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on oxidation of T by Tet1, rather than on deamination of hmC. We subsequently focused on 
confirming this finding (Chapter 8). 
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Transfer RNAs (tRNAs) are adapter molecules needed to
translate genetic information into a peptide sequence.[1] At
the ribosome, the anticodon of each tRNA reads the
corresponding codon of the messenger RNA. This antico-
don–codon interaction allows the ribosomes large subunit to
catalyze amide-bond formation between the cognate amino
acids present at the 3’ terminus of aminoacyl-tRNAs and the
growing peptide chain.[2] The tRNA adapters required for this
process display a surprisingly large chemical diversity.[3] Aside
from the four canonical nucleosides A, C, G, andU, more than
100 modified nucleosides are key constituents (Figure 1).[4]
The most diverse and complex chemical structures are found
in the anticodon stem-loop either in the anticodon at the
wobble position or directly adjacent to the 3’ position of the
anticodon,[5] suggesting that here the chemical complexity is
necessary to establish translational fidelity.[6] The ribosome
seems to need the modified anticodon region to better
distinguish correctly base-paired tRNA from mispaired
interactions in order to prohibit, for example, codon-slippage
processes that would lead to frameshifts.[7]
In order to investigate how the set of nucleoside
modifications influences the translational efficiency we quan-
tified the tRNA modifications individually in various tissues
by an isotope-dilution-based LC–MS method. (Details on the
materials and methods are given in the Supporting Informa-
tion, Table S1, and Figure S1). The quantified modification
levels were correlated with the translational efficiency by
means of an in vitro translation system. For the experiments,
11 representative tRNAmodifications (Figure 1) were chemi-
cally synthesized as isotope-labeled derivatives.[8] A majority
of the investigated nucleosides are located inside the
extended anticodon,[9] the other synthesized modified nucleo-
sides are found at various other positions.[10]
As biological material for the analysis we chose a range of
different organ tissues from mouse and pig. Porcine tissues
were used because they are available in large amounts, while
murine tissues were analyzed at a later stage to confirm the
results in a genetically more defined organism. For pig, 5–10 g
of tissue from two animals was sampled from each organ,
while murine samples were obtained from two sets of five
animals of which whole organs were analyzed. After total
tRNA extraction and complete enzymatic hydrolysis to
nucleosides, a mixture of the isotope-labeled tRNA modifi-
cations was added and the solution was subjected to LC–MS
analysis. The ratios of the mass peak integrals from natural to
isotope-labeled nucleosides were determined and calibration
curves, which were previously measured for each investigated
modified nucleoside, then allowed exact parallel quantifica-
tion of the respective modifications (see Figure S2 in the
Supporting Information).[8a] LC–MS quantification was per-
formed at least in triplicate and results were averaged for each
tissue. The error margin of the experiment was in this way
limited to around 5%.
The obtained quantitative values for mouse and pig
samples are shown color coded in Figure 2A and B, respec-
tively, together with the approximate positions of the
measured modifications in the tRNA sequence. The values
represent the measured number of each modification per
1000 tRNA molecules (%) (exact values are listed in
Tables S2–7 in the Supporting Information). Therefore,
rather than yielding the absolute concentration of a modifica-
tion in a given tissue, the data show directly the extent to
which the analyzed tRNA set is modified. For representative
murine and porcine tissues, an additional quantification of the
ubiquitous tRNA modifications m5C and Y was performed
(see Figure S4).
The data show that each tissue type incorporates different
amounts of a specific modified nucleoside into the respective
tRNA ensemble. While the tRNAs in liver tissue contain
large numbers of modified nucleosides (colored red), those
isolated from lung and kidney tissue feature far fewer
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modifications (colored yellow and green). It is known that the
amounts of individual tRNA species vary between tissues,[11]
but these variations are small in comparison to the detected
changes in modification levels, arguing that tissues modify
their tRNA to different extents (for a detailed discussion
about the influence of codon bias see the Supporting
Information). Most important in this respect is the observa-
tion that the levels of the m1A, m2G, m5C, and Y modifica-
tions (Figure 2 and Figure S4) follow the overall trend. These
modifications are present in almost all tRNA species, and
hence if tRNA composition would bias the quantitative data
then the levels of these modifications would be expected to
stay constant (or at least not follow the trend strongly).
Consistently, murine and porcine tissues
show similar trends with liver, characterized by
a high metabolic activity, having tRNA in both
cases highly modified, while the tRNA from
muscle tissue such as heart shows a rather low
modification content.[12] Divergence between
the two organisms is observed for some tissues
such as cerebrum and spleen. This might be due
to species-specific variation in tissue metabo-
lism, or it might arise from genetic variation
between species, as previously observed for
bacteria.[13] Surprising is the observation that
the data for Am follow a different trend, with
higher Am levels found in tissues with largely
unmodified tRNA (see Figure 2 and Table S8 in
the Supporting Information). Because 2’-O-
methylation stabilizes RNA,[4,14] the observed
pattern could reflect the role of this modification
in stabilizing hypomodified tRNA. Furthermore,
while levels of queuosine (Q) generally fit the
overall trend, this nucleoside has unexpectedly
high levels in brain tissue both in mouse and pig,
suggesting a more complex specialized role in
those tissues.[15]
In order to confirm the results, we next
measured themodification content in a sequence
context. To this end we carried out a parallel
LC–MS analysis of partial tRNA digests
(RNase A) from two representative porcine
tissues, liver and heart. From the digests we
obtained a number of defined tRNA fragments
(small oligomers) resulting from selective cleav-
age after C andU. Out of the obtained fragments
we determined 10 for which we were able to
detect the unmodified and modified sequences
using mammalian tRNA sequences from the
Sprinzl tRNA database.[3b] We then determined
the relative amounts of the modified versus the
unmodified tRNA fragments. The extent of
modification of the respective tRNA sequence
was calculated directly from the ratio between
the areas of the specific mass peaks for the
modified and the unmodified fragments (see
Figure 3 and Table S9 in the Supporting Infor-
mation).[16] The results show that the represen-
tative modified nucleosides m1G, m1A, m2G, i6A, and t6A are
indeed more abundant in tRNA fragments derived from liver,
supporting the data from the isotope-dilution-based direct
nucleoside quantification.
Based on the data we concluded that tissues mature their
tRNA differently to satisfy individual translational needs. In
support of this hypothesis we observed that published data for
the rates of protein synthesis in vivo in different mammalian
organs show a good level of correlation with our quantitative
data for pig tissues (Figure S5 in the Supporting Informa-
tion),[12,17] suggesting that higher overall tRNA modification
content might be linked to faster rates of protein translation
in a certain tissue. In order to test this hypothesis directly, we
analyzed the translational efficiency of tissue-specific tRNA
Figure 1. Isotope-labeled tRNA nucleosides present in eukaryotic tRNA and positions
where these modifications are typically found. The introduced isotope labels are
marked in color: D in a blue box: deuterium; * in a red box: 13C; * in a green box: 15N.
The anticodon is highlighted in red, the remainder of the anticodon stem-loop is in
yellow, and positions of Y are marked in orange. Abbreviations are explained in
Table S1 in the Supporting Information.
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ensembles using an in vitro cou-
pled transcription/translation
reticulocyte lysate system.[18] The
original tRNAs present in the
system were removed chromato-
graphically using an ethanola-
mine–Sepharose column.[18] Subse-
quently, the tissue-extracted tRNA
ensembles were added. Transla-
tional efficiency was measured by
observing the increase in lumines-
cence linked to the production of
the protein luciferase (see Fig-
ure S7). The slopes of the plotted
curves from at least three repeated
experiments were normalized to
the most efficient ensemble.
In a first set of experiments,
total tRNA ensembles from por-
cine tissues were used. Figure 4
plots the measured rates against
the corresponding normalized
modification levels calculated
based on LC–MS data presented
in Figure 2B (exact values are
listed in Figure S8 in the Support-
ing Information). From Figure 4 it
can be seen that the overall modi-
fication content correlates with the
translational efficiency of the iso-
lated tRNA ensemble, but the
correlation is far from optimal.
We noted that specifically the
values obtained from tissues
known to be rich in mitochondria
(heart in particular) deviate from
the expected trend.[19] Since mito-
chondrial tRNA features its own
set of modifications,[13] we there-
fore removed in a second experi-
ment the mitochondria from the
porcine tissues before the tRNA
extraction (Figure S6 in the Sup-
porting Information).[20] The
obtained data for cytosolic tRNA
show indeed a higher degree of
correlation between the transla-
tional activity and the modification
content (black squares in Figure 4;
r= 0.861, P= 0.028), indicating
that the modification level of cyto-
solic tRNAs is one factor that
influences the efficiency of trans-
lation. This correlation was further
confirmed for mouse using total
tRNA ensembles extracted from
tissues known to have relatively
low mitochondrial tRNA content
(see Figure S9). Our results are
Figure 2. Quantitative data for the investigated tRNA modifications in various murine (A) and porcine
(B) tissues. All tRNA nucleoside values are given per 1000 tRNA molecules (%). These data reveal
a similar, tissue-dependent extent of modification for all investigated modified nucleosides except
Am. Color codes in (A) and (B) are based on quantile calculations; red: highest value, yellow: 50%
quantile, green: lowest value. For intermediate values appropriate intermediate shades were
calculated. Despite the slight variation in the absolute quantification values, trends in modification
content were conserved across different biological samples (both in mouse and pig, see Tables S2–S5
in the Supporting Information).
Figure 3. Representative qualitative comparison of amounts of unmodified RNA fragments AAC and
the corresponding modified t6AAC in the RNase A digests of liver and heart tRNA. Overlayed LC–MS
chromatograms showing ions detected at the calculated masses of the AAC (m/z=489.5682–
489.5742) and t6AAC (m/z=562.0863–562.0933) fragments (z=2) and the corresponding struc-
tures. The ratio of the peak areas of modified to unmodified fragments for liver can be seen to be
higher than that for heart. Further identified fragment ratios are listed in Table S9 in the Supporting
Information.
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consequently in good agreement with the common idea that
specific noncanonical bases fine-tune the binding of tRNAs to
the ribosome. As the translation rate is determined by the
competition between near-cognate and cognate aminoacyl-
tRNAs,[21] a high modification level increases the affinity of
the correct tRNA to the ribosome, which may allow faster
discrimination.[22] This reduces the ribosome step time, which
in turn may increase protein synthesis rates.
In summary, we have reported the parallel quantification
of 12 modified nucleosides in tRNA ensembles from various
porcine and murine tissues and showed that the overall
modification content varies substantially. Furthermore, we
provide evidence that the modification level correlates with
the in vitro protein synthesis capacity, suggesting that the
extent to which the tRNA ensemble is chemically modified
modulates the translational efficiency. Our data show that the
tRNA modification level is another layer of information that
programs cells in terms of their translational potency.
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4.1 Introduction 
tRNA modifications are known to play a crucial role during protein translation by affecting the tRNA 
binding affinity to the ribosome and by reducing frame-shifting and misincorporation.
[11a, 11b, 18a]
 
Furthermore, recent studies have revealed that modified tRNA nucleosides are also involved in 
cellular stress response mechanisms by altering the translational efficiency of specific protein subsets 
and by influencing tRNA stability.
[4a, 44a, 46]
 Previous studies performed by Dr. Antje Hienzsch, which 
focused on variations in tRNA modification content in S. cerevisiae in response to a variety of stress 
conditions,
[138]
 revealed that yeast cells grown into stationary phase display an increasingly modified 
tRNA population. A similar observation was made by Preston et al.,
[139]
 who documented an increase 
in m
5
C during entry of S. cerevisiae into stationary phase. However, there are yet no data available 
concerning how this increase in tRNA modifications is afforded, and whether it is a regulated response 
to nutrient depletion.  
4.2 Results 
The study presented in this chapter aims at investigating the origin of the observed modification 
increase during entry of yeast cells into stationary phase. According to our hypothesis, three main 
scenarios could explain the change in modification content: on the one hand, fast turnover of tRNA 
species would imply that the increase in modification is due to new, more modified tRNAs which are 
generated during entry into stationary phase, implying a regulation of tRNA modifications in response 
to the stress conditions; on the other hand, slow tRNA turnover would link modification increase to a 
longer RNA half-life, suggesting that tRNA species present in the cell can be increasingly modified 
over time. Finally, a third possibility is that, regardless of the turnover rate, hypomodified tRNAs 
might be selectively degraded leading to an enrichment of the modified tRNA pool.  
In order to distinguishing between these possible scenarios we decided to monitor tRNA modification 
turnover during entry into stationary phase by pulse-chase labelling. The approach relied on initial 
labelling of the tRNA modifications during exponential growth and subsequent monitoring of these 
modifications during growth into stationary phase to evaluate their turnover and to assess the timing 
and regulation of RNA modification. 
In order to label the tRNA modifications, yeast S. cerevisiae was grown in medium containing 
[methyl-D3]-L-methionine. The labelled methionine is then converted into [methyl-D3]-S-adenosyl 
methionine ([methyl-D3]-SAM), which serves as a common methyl donor, leading to labelling of 
methylated RNA nucleosides. In order to monitor the fate of RNA modifications throughout different 
growth phases, yeast was initially grown in labelled complete minimal medium to an optical density of 
OD600 = 1, at which point cells were gently pelleted and resuspended in rich YPD medium (non-
labelled) and allowed to grow for 7 days in the same medium (see Figure 10). Samples were removed 
prior to medium exchange (time point 0 h), and at time points 1, 2, 4, 20, 24, 48, 72, 96, 120, 144, 
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168 h after exchange to non-labelled medium. At each collection point the optical density was 
measured and tRNA was extracted using the procedure detailed in section 4.4.2. tRNA samples were 
subsequently digested to nucleosides, spiked with labelled samples to quantify non-methylated RNA 
modifications and subjected to LC-MS analysis. 
 
Figure 10 Overview of the experimental procedure. 
The analysis of samples collected at time points 0‒168 h proceeded in three steps: first, evaluation of 
the tRNA and tRNA modification content, in order to confirm the increase in modification levels 
during entry into stationary phase;
[138]
 second, evaluation of the ratio of light to heavy modification 
content over time and comparison with expected ratios based on cell growth; third, evaluation of 
heavy labelled modification content and its variation over time. 
4.2.1 Variation in tRNA content per cell during growth 
Analysis of the tRNA content throughout the 7 days revealed that the overall tRNA population 
changes over time. As shown in Figure 11 (Panel A), upon exchange to unlabelled YPD medium, 
optical density followed the expected growth profile: initially, we observe a rapid increase in cell 
density, corresponding to log-phase (first 24 h), where cell growth is based on fermentation of 
glucose; this stage is followed by a more moderate growth phase known as post-diauxic phase (day 
1-5), where metabolism shifts from fermentation to respiration, mostly based on ethanol and other 
non-fermentable carbon sources. Once all carbon sources have been depleted from the medium, cells 
reach saturation and cease proliferation at about day 5.  
Interestingly, tRNA content per OD unit increases during the first four time points, reaching a 
maximum at time point 4 h, and it then slowly decreases starting from day 1 until day 7 (see Figure 11, 
Panel B). Note that in the absence of further time points between time 4 h and 20 h we cannot exclude 
that during this time the tRNA content per OD unit might further increase. The observed decrease in 
tRNA content starting from day 1 is in line with previous findings published by Sethy et al.,
[140]
 which 
showed that tRNA transcription is down-regulated during transition from exponential to postdiauxic 
phase. In their study, the growth-dependent change in transcription was attributed to depletion of 
TFIIIB70 and possibly also affected by TFIIIC, though to a lesser extent. TFIIIB70 is a subunit of 
transcription factor TFIIIB which is stoichiometrically limiting for Pol III transcription. Later findings 
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also documented Maf1 negative regulation of Pol III transcription levels during shift from 
fermentation to respiration.
[141]
 
 
Figure 11 Yeast growth profile and tRNA content/OD unit after transfer to unlabelled YPD medium. A) Variation in 
optical density (OD600) during growth in YPD over 7 days. B) Normalized tRNA content per OD unit (%). Time points 
1-168 h refer to sampling time after medium exchange to unlabelled YPD (note that the Time axis in plot B is not linear). 
(exact values listed in Table 2). 
4.2.2 Quantification of tRNA modifications during growth into stationary phase 
In order to monitor the extent of tRNA modification and to confirm that it increases during growth 
into stationary phase after initial growth in labelled medium, quantification of the modified 
nucleosides was carried out using two different methods depending on the nature of the modification. 
In the case of methylated modifications (m
1
A, m
1
G, m
2
G, m
2
2G, m
5
C, Am), quantification was 
performed by UV absorbance, since the endogenous labelled nucleosides did not permit quantification 
using synthetic standards. In the case of non-methylated modifications (Ar, i
6
A, t
6
A), isotope standards 
were added to the nucleoside mixture for LC-MS quantification.
[142]
 Therefore, accurate quantification 
could be obtained for the modifications m
1
G, m
2
G, m
1
A, m
5
C, Am, Ar, i
6
A, t
6
A and m
2
2G. In the case 
of Cm, m
7
G and Gm, as well as the initial 4 time points of m
2
2G, the modified nucleosides could not 
be quantified by UV absorbance due to poor resolution by column chromatography, and only 
approximate quantification was obtained from comparison of the ion count signals as detailed below. 
yW could not be quantified due to low abundance and poor absorbance of the hypermodified 
nucleoside. Most importantly, in all cases quantification of the modified nucleosides was normalized 
with respect to the content of A nucleoside (quantified by UV absorbance). Therefore, changes in 
modification levels reflect changes in the proportion of modified nucleosides in the overall tRNA 
population. 
As an example, Figure 12B shows the normalized variation in m
1
G content over 7 days, a trend which 
could be observed for most other modifications as well. Exceptions were observed in the case of i
6
A, 
t
6
A and Am, and they will be discussed separately. 
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Figure 12 A) Variation in optical density (see Figure 11) and B) Relative change in m1G content during 7 days. 
Quantification of m1G was performed by means of UV absorbance. Values were normalizes to time point 1 h. Time points 
1-168 h refer to sampling time after medium exchange to unlabelled YPD. Note that in B) the Time axis is not linear. For 
further details, see Table 3. 
As shown in the plot, variation in modification content can be divided in two phases: an initial phase, 
during the first 24 h, and a subsequent phase starting from day 2. Throughout day 1, modifications 
vary only very slightly, but there is a distinctive trend showing an initial decrease in modification 
content which reaches a minimum at 4 h (for individual modifications, see Figure 13). This feature is 
observed for m
1
G, m
2
G, m
1
A, m
5
C and Ar. Interestingly, this minimum correlates with a maximum in 
tRNA content as highlighted in Figure 11B. This correlation could be explained in terms of a fast 
tRNA production required to sustain log phase exponential growth, which cannot be matched by a 
sufficiently fast tRNA modification rate, therefore yielding a partially undermodified tRNA population 
at time point 4 h. 
In the case of Am, modification content follows exactly the opposite trend, reaching a maximum at 
time 4 h. Methylation at the 2´-O- position is known to stabilize RNA
[4b, 50a]
 and, in the case of 
mammalian tissues, higher overall tRNA modification content correlates with a lower Am content (see 
Chapter 3), suggesting that this modification is introduced to stabilize less modified tRNA samples. 
Therefore, at time point 4 h (as shown is Figure 13), a higher content of Am modification might be 
present in order to compensate for the lower extent of modification. In the case of i
6
A, no distinctive 
trend is observed, while t
6
A shows a decreasing trend during the first 24 h (except for time point 0 h).  
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Figure 13 Percental change in modification content during day 1. Plots show the variation percent in modification content 
for the nucleosides m1A, m1G, m2G, m5C and Am quantified by UV absorbance, and for Ar, i6A and t6A quantified by 
LC-MS using labelled isotope standards (in all cases quantification was normalized to A nucleoside content). Values were 
normalized to time point 1 h (see Table 4). 
After the first 24 h, in agreement with results previously described by Dr. Antje Hienzsch, most 
modifications increase during growth towards saturation.
[138]
 As shown in Figure 14 (Panels A and B), 
which details the percental change for each modification with respect to day 1, m
1
A, m
1
G, m
2
G, m
5
C, 
Ar and m
2
2G all increase from day 2 to day 7. In some cases the increase is very marked, such as for 
m
5
C and Ar, while in other cases only mild increase is observed, such as in the case of m
2
2G. Once 
again, the 2´-O-methylated nucleoside Am behaves differently, showing a rather constant or slightly 
decreasing trend with respect to the first 24 h. As previously discussed, this might be explained in 
terms of stabilization of the tRNA species, which for the increasingly modified tRNA samples 
observed over time results therefore in reduced Am content. In the case of i
6
A, modification content 
remains constant over time, which is to some extent in disagreement with previous findings described 
by Dr. Antje Hienzsch, who instead observed an increase of this modification. A possible reason for 
such discrepancy might arise from the different initial samples, since in the original study by Dr. Antje 
Hienzsch yeast samples at time 0 were collected at a cell density of OD600 = 0.6, while in this case the 
density at time 0 h was OD600 = 1. Alternatively, it might be due to the different starting conditions of 
yeast cells in minimal labelled medium with respect to cells grown only in rich YPD medium (as 
performed by Dr. Antje Hienzsch). Finally, t
6
A modification content remains relatively constant 
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during the first 4 days, followed by a dramatic increase starting from day 5. This could either result 
from a larger availability of L-threonine (required for the biosynthesis) at later growth stages, or might 
instead be linked to a higher activity or expression of the biosynthetic enzyme Sua5. Dependence of 
the t
6
A modification content on L-threonine availability might also explain the low t
6
A content at time 
point 0 h (see Figure 13), since at this time point yeast is grown in minimal medium where we expect 
a lower availability of amino acids. 
 
Figure 14 Percental change in modification content with respect to day 1. A) Plots show the variation percent in 
modification content during days 2 to 7 with respect to day 1. Average values for day 1 were calculated by averaging the first 
six time points (from 0 to 24 h). B) Summary color-coded table displaying the percental change for each modification 
depending on the position in the tRNA molecule. Color code: red = highest value; yellow = 0 % change; green = lowest value 
(see Table 5). 
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In the case of Gm, Cm and m
7
G, an approximate quantification of the relative change was performed 
by comparison of the integral of the ion count signals of light and heavy modification with respect to 
either m
1
G, in the case of Gm, or with respect to m
5
C, for Cm and m
7
G. m
1
G and m
5
C were selected 
for comparison because they elute at similar retention times. These ratios were normalized with 
respect to the UV absorbance of the reference nucleosides and of the nucleoside A (for details, see 
Table 1). The resulting change in modification content is displayed in Figure 15. Approximate 
quantification reveals that, especially in the case of Gm, there is a large increase in modification 
content stating from day 2, in agreement with other modifications (Figure 14). 
 
Figure 15 Percental change in Gm, Cm and m7G. Plots show the percental change of Gm (based on m1G), Cm and m7G 
(based on m5C) with respect to the modification content at time point 1 h. Changes in modification content were estimated 
from comparison of the ion count integrals and normalized to A nucleoside content (see Table 6). 
In summary, yeast tRNAs show a slight decrease in the extent of modification during the first 24 h, 
followed by an overall increase in modification content during entry into stationary phase, in line with 
previous findings.
[138]
 Exceptions are observed particularly for Am, which shows the opposite trend. 
This modification is generally thought to stabilize poorly modified tRNA molecules. Variations in Am 
modification content might therefore reflect a different need for stabilization which inversely 
correlates with the overall extent of modification of the tRNA species. 
4.2.3 Quantification of light and heavy labelled modifications during growth 
In order to monitor the fate of heavy (CD3)-labelled modifications, ratios of light (CH3)- to heavy 
(CD3)-labelled modifications was evaluated over time. The first sample (time 0 h) was collected prior 
to exchanging the medium to rich YPD medium (non-labelled) and was used to evaluate the maximal 
extent of labelling. Subsequent samples collected after medium exchange displayed gradually 
decreasing labelling, as expected in response to culture growth in non-labelled medium. Note that even 
in labelled medium, the extent of heavy modification did not reach 100 %, due to endogenous 
methionine biosynthesis. Endogenous methionine is non-labelled because it is generated from 
homocysteine and 5-methyltetrahydropteroyltri-L-glutamate. The result is a mixed SAM pool which is 
only partially labelled and which results therefore in a partial labelling of methylated nucleosides.
[143]
 
Upon changing of the medium, the mixed SAM pool containing [methyl-D3]-SAM is expected to 
convert to fully unlabelled SAM within few minutes (labelled SAM expected to drop to half within 
20 s).
[144]
 Therefore the extent of heavy (CD3)-labelling detected in tRNA species during growth is 
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only due to modifications introduced during growth in labelled medium, and can be used to assess 
turnover of tRNAs generated prior to medium exchange. 
CH3/CD3 ratios were quantified by comparison of the integrals of light and heavy modifications by 
LC-MS analysis. Analysis of CH3/CD3 ratios was performed for the modifications m
1
A, Am, m
7
G, 
Gm, m
1
G, m
2
G, m
2
2G, m
5
C and Cm. In labelled medium, the proportion of light modification content 
was on average about twice as abundant as the heavy modification. Upon exchanging of the medium, 
the CH3/CD3 ratio increased over the first five days until it stabilized at a ratio of about 70-80 between 
day 5 and day 7. Most modifications followed a similar pattern, with the exception of Am which on 
average showed lower ratios. 
Having quantified the CH3/CD3 ratios for the aforementioned modifications, the variation in ratios 
over time was evaluated using two different models. In the first model, expected ratios over time were 
estimated based purely on changes in optical density. In the second, more complex model, the 
variation in tRNA content per OD unit (see Figure 11) was also taken into account. In both cases, 
measured ratios of all modifications (except for Am) were averaged and their average ratio at time 1 h 
was used to construct the models. Comparison was then done between the average measured ratios 
over the 7 days and the expected ones. Am was analyzed separately. Both models rely on the 
assumption that the heavy-labelled tRNA content present at time point 1 h is not degraded over time 
and that it can therefore be used to calculate the expected ratios assuming that there is a linear increase 
in modification content with increasing OD.  
In the first model, we assume that tRNA content per OD unit is constant over time, and that the 
CH3/CD3 modification ratio can be estimated exclusively from the increase in optical density, i.e. the 
increasing CH3/CD3 ratio reflects the increasing dilution in labelled tRNA modification during cell 
division (with tRNA content proportionally increasing with OD). Therefore, starting from an OD600 of 
1.32 (time 1 h) with an average CH3/CD3 ratio of 2.24 ± 0.12, we can assume that about one third of 
the tRNA modifications are labelled. This number is assumed to remain constant over the 7 days, and 
therefore the expected CH3/CD3 ratio can simply be estimated by calculating the proportion of non-
labelled tRNAs from the measured OD600 at each time point (for details, see Table 1). 
Figure 16A shows the comparison of the average measured CH3/CD3 ratios (for all modifications but 
Am) with respect to the expected ratios calculated based on optical density. As it can be seen, expected 
ratios accurately predicted measured values up to time point 24 h. However, starting from day 2 the 
measured CH3/CD3 ratios are higher than expected, suggesting that there is a greater proportion of 
light (CH3)-modification than expected. This can result from two different scenarios: it can either be 
due to an increase in the number of modifications introduced starting from day 2, meaning that tRNA 
samples are more extensively modified with non-labelled SAM, or it could arise from turnover of 
labelled tRNA, which would lead to a gradual loss of heavy modifications and therefore to higher 
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CH3/CD3 ratios. Interestingly, Am follows the opposite trend: as shown in Figure 16B, starting from 
time point 20 h the average measured CH3/CD3 ratio for Am is lower than the ratio expected based on 
optical density, implying that this modification is introduced to a lesser extent than expected during 
growth into stationary phase. This would again support the hypothesis that Am might be introduced 
preferentially for low modified tRNA samples (first 24 h), later becoming less essential upon 
increasing extent of tRNA modification (day 2‒7). 
 
Figure 16 Comparison of measured and expected CH3/CD3 ratios based on optical density. A) Comparison of measured 
and expected ratios for all modifications except Am. Measured ratios were averaged for m1A, m1G, m2G, m7G, Gm, m22G 
(CD3-, CH3-labelled only), m
5C and Cm. Expected ratios were calculated assuming that light (CD3)-modification content 
increased linearly with optical density, starting from time point 0 h, with an initial CH3/CD3 ratio of 2.24 and OD600 = 1.32. 
B) Comparison of average measured Am ratios and expected ratios. Expected ratios were calculated as in A).(see Table 7) 
In the second model, expected CH3/CD3 ratios are calculated based on varying tRNA content per OD 
unit as well as optical density. This model accounts for the fact that the tRNA pool per cell is not 
constant over time. In fact, given that the tRNA per OD unit gradually decrease after the first 24 h (see 
Figure 11), a model assuming a constant tRNA content per OD unit (first model) would overestimate 
the amount of non-labelled tRNA produced during days 2 to 7. 
Once again, the model is constructed from knowledge of the initial OD600 (1.32), CH3/CD3 ratio 
(2.24 ± 0.12) and normalized tRNA content per OD unit (68.4 % ± 3.1 %). The labelled tRNA pool is 
assumed to remain constant over the 7 days (i.e. no turnover), and the expected ratios are calculated as 
described above (see also Table 1). Figure 17A shows the comparison of the measured and expected 
CH3/CD3 ratios for all modifications except Am. As in the previous model, the expected ratios closely 
model the measured ones up to time point 24 h, after which the expected ratios largely underestimate 
the real CH3/CD3 values. As in the previous case, this might arise from increased modification extent 
starting from day 2, or it could be due to degradation of labelled tRNA. Interestingly, the expected 
ratio at time point 4 h overestimates the CH3/CD3 ratio. This, knowing that at this time point we 
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observe the largest proportion of tRNA content per OD unit (Figure 11B), could be explained in terms 
of an overestimation of the extent of tRNA modification at 4 h. In fact, as discussed in Section 4.2.2, 
Figure 13, the extent of modification at this time point reaches a minimum, implying that the tRNA 
sample is less modified. The model used to calculate the CH3/CD3 ratios shown in Figure 17 assumes 
instead that the proportion of tRNA modification is uniform at all time points, and is therefore not 
surprising that it might overestimate the ratio at time point 4 h. 
Once again, Am shows a different pattern, with ratios which are generally fitting with the modelled 
ratios, suggesting that the Am content in tRNA is not increasing over time, but that it is rather more 
closely correlating with the increase in tRNA during growth. 
 
Figure 17 Comparison of measured and expected CH3/CD3 ratios based on tRNA content per OD unit. A) Comparison 
of measured and expected ratios for all modifications except Am. Measured ratios were averaged for m1A, m1G, m2G, m7G, 
Gm, m22G (CD3-, CH3-labelled only), m
5C and Cm. Expected ratios were calculated assuming that light (CH3)-modification 
content increased linearly with tRNA content, starting from time point 0 h, with an initial CH3/CD3 ratio of 2.24, 
OD600 = 1.32 and tRNA content per OD unit of 68.38 %. B) Comparison of average measured Am ratios and expected ratios. 
Expected ratios were calculated as in A). (see Table 8) 
In summary, evaluation of the CH3/CD3 ratios over time suggests that for all modifications but Am 
there is a greater proportion of light (CH3)-modification than expected starting from day 2. This might 
either be due to the production of more highly modified tRNAs starting from this time point, or it 
might result from degradation of labelled tRNA, yielding a reduced heavy (CD3)-modification content 
and higher CH3/CD3 ratios. Once again, Am shows a different trend, with ratios largely fitting with a 
linear increase in modification content following optical density and variation in tRNA content, again 
suggesting a different role of this modification compared to other modified nucleosides investigated in 
this study. 
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4.2.4 Evaluation of CH3- and CD3-modification content over time 
We next calculated the content of heavy and light nucleoside for the modifications for which 
quantification by UV absorbance could be obtained in order to evaluate the variation in CD3-labelled 
modification over time. Based on a simple model which only accounts for variations in cell number, 
the proportion of (CH3)- and (CD3)-modification for each point was estimated from the experimental 
CH3/CD3 ratio and the modification content quantified by UV absorbance, and subsequently 
multiplied by the optical density to account for cell growth over time (see Table 1). Data for m
1
A, 
m
1
G, m
2
G, m
5
C and Am are shown in Figure 18. 
 
Figure 18 Evaluation of (CD3)- and (CH3)-modification content over time. Heavy and light modification content for m
1A, 
m1G, m2G, m5C and Am was evaluated based on average ratios and normalized modification content as estimated from UV 
absorbance, and finally multiplied by the optical density to account for increasing cell amount (see Table 9).  
Surprisingly, as it is evident from Figure 18, the (CD3)-modification content of all modified 
nucleosides analyzed remains largely constant over the seven days. If turnover of labelled tRNA was 
taking place, we would expect the signal for (CD3)-modification to gradually decrease, while this is 
not observed, implying that the labelled tRNA generated in the initial medium is present until the end 
of the experiment. This suggests that, based on a simplified model which only accounts for increasing 
cell number, the modified (labelled) tRNA samples are subject to very slow or no turnover under these 
experimental conditions. 
The heavy and light modification content was also assessed using a more complex model which 
additionally accounts for the varying tRNA content per OD unit (see Table 1). As an example, 
comparison of the two different approaches in the quantification of the (CD3)- and (CH3)-content for 
m
1
A is shown in Figure 19. 
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Figure 19 Comparison of (CD3)- and (CH3)-content evaluation based on A) OD and B) OD and tRNA content per OD 
unit. Heavy and light modification content for m1A was evaluated based on average ratios and normalized modification 
content as estimated from UV absorbance. The two different models estimate the absolute (CH3)- and (CD3)-modification 
content over time by taking into account the optical density (plot A) versus optical density and variable tRNA content (plot 
B). Note that modification content is depicted in a.u. and units are not comparable between the different models (see Table 
10). 
As evident from Figure 19B, a model which accounts for variations in tRNA content suggests that 
there might be indeed some extent of turnover of labelled tRNA modifications. However, the current 
experimental set up does not allow to decouple the turnover of modified tRNA nucleosides from 
overall tRNA turnover (including un-/hypomodified tRNAs). This issue could be addressed by double 
labelling of the tRNA modifications and of the tRNA molecule, therefore allowing to accurately 
account for tRNA turnover with respect to modification content. 
In conclusion, evaluation of the overall (CH3)- and (CD3)-modification content over time, using a 
simplified model which only accounts for changes in cell number, suggests that the turnover of 
modified (labelled) tRNA is slow or absent under these experimental conditions. 
4.3 Discussion 
The observed increase in tRNA modification reported in this chapter and in previous studies done by 
Dr. Antje Hienzsch,
[138]
 raises a few interesting questions. How is the increase in modifications 
afforded by yeast cells? Are modifications the result of an enhanced modification of the tRNA 
population, or are they rather the result of passive enrichment of modified tRNAs? What is the benefit 
of a more modified tRNA pool? 
tRNA molecules are known to be very stable,
[145]
 and previous studies have reported half lives of 50 h 
in chicken muscle,
[146]
 44 h in Euglena gracilis
[147]
 and 3 to 5 days in Physcomitrella patens,
[148]
 while, 
to the best of our knowledge, no data is available concerning the turnover rates of tRNA in 
S. cerevisiae. One key finding presented in this chapter is the fact that modifications introduced in 
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tRNA molecules during exponential growth in labelled medium are detected throughout the entire 
duration of the study. Absence of a recycling pathway has allowed to use detection of modified tRNA 
nucleosides in urine as a reliable measure of tRNA turnover in higher eukaryotes
[149]
. Given that no 
recycling pathway is known for yeast, we deduce that labelled tRNA is being degraded only very 
slowly, and that, more generally, turnover of (modified) tRNA is rather slow in yeast cultures entering 
stationary phase. It should be noted, however, that a model which accounts for changes in tRNA 
content over time does suggest some turnover of modified tRNA nucleosides (Section 4.2.4), and this 
aspect should be further investigated by double-labelling of the tRNA molecule and tRNA 
modifications to highlight whether the respective turnover rates are coupled or not. 
In fact, one possible reason for the low turnover rates observed in this study might be that, contrary to 
the experimental approach used for evaluation of the turnover in P. patens or in E. gracilis,
[147-148]
 
which relied on labelling of uracil or adenine, our method allows for the selective monitoring of the 
tRNA modified nucleosides. The longer turnover rates might in this case reflect the enhanced stability 
of highly modified tRNA molecules compared to unmodified tRNA (which could show higher 
turnover rates). In fact, tRNA modifications are known to play a crucial role in stabilization of tRNA 
molecules,
[4a, 4b]
 and lack of specific tRNA modifications was shown to lead to rapid degradation.
[4a]
 
The observed stability of modified tRNA suggests two possible scenarios: on the one hand, we can 
postulate that there is no tRNA turnover taking place and that tRNA modifications are gradually being 
introduced in tRNAs; on the other hand there might be some extent of turnover or degradation, but this 
might be selective for unmodified or hypomodified tRNA, leading to a gradual enrichment of the 
modified tRNA pool.  
From analysis of the CH3/CD3 ratios presented in section 4.2.3, our model suggests that starting from 
day 1 there is not only an increase in modification content (which could arise purely from enrichment 
of the modified tRNA population), but that, additionally, there is a higher ratio of light to heavy 
modification content than expected. Given that we observe little or no turnover of labelled 
modifications (using a simplified model), the higher CH3/CD3 ratio observed might reflect a higher 
degree of modification content which is actively introduced in tRNA molecules starting from day 1. 
On the contrary, if modified tRNA molecules would simply accumulate due to passive enrichment, the 
CH3/CD3 ratio should increase linearly with cell density and tRNA content (as modelled in section 
4.2.3). Therefore, we suggest that tRNA molecules after the diauxic shift might become more 
extensively modified and that the observed increase in modification content is not (exclusively) 
resulting from selective degradation of an unmodified tRNA subset. 
Active regulation of modification content might be linked to different aspects. On the one hand, 
increased modification might simply result from the long half-life of the tRNA molecules; on the other 
hand, it could be due to a variation in catalytic activity of tRNA modifying enzymes during entry into 
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stationary phase or to selective modification of previously hypomodified tRNA subsets. Interestingly, 
modulation of the enzymatic activity could be further coupled to tRNA transport in and out of the 
nucleus, as discussed later in this section. One aspect which cannot be resolved using this approach 
and that might be interesting to investigate in the future, is whether modifications are exclusively 
introduced in newly produced tRNA molecules, or whether previously generated tRNA molecules 
(e.g. labelled tRNAs) might also be further modified over time.  
However, from our study, we cannot exclude that tRNA degradation might play some role in 
enrichment of the tRNA population. In fact, investigation of the tRNA turnover was based only on 
methylated RNA nucleosides, excluding methylated uridines, and might therefore reflect the turnover 
rates of only a subset of tRNAs. In fact, although tRNA
Gly(UCC)
 and tRNA
Gly(CCC)
 are the only yeast 
tRNAs known to contain none of the methylated nucleosides investigated in this study,
[1b, 150]
 we 
cannot exclude that some tRNAs might be hypomodified at some point during cell growth. 
Hypomodified tRNAs might then be either further modified, leading to an increase in (unlabelled) 
modification content, or could on the contrary be selectively degraded, contributing to a higher 
modification content by passive enrichment without affecting the levels of labelled modification. In 
order to accurately establish the contribution of tRNA degradation to the modification increase, our 
study should be complemented by studies which independently assess the extent of tRNA turnover. 
This would allow to unambiguously determine the extent to which tRNA is further modified as 
opposed to simply enriched by selective tRNA degradation. 
Concerning the possible degradation pathways, tRNAs are known to be targeted by three different 
turnover mechanisms. Two of these pathways, the nuclear surveillance pathway involving the TRAMP 
complex, and the rapid tRNA decay (RTD) pathway, are known to generally degrade hypomodified or 
incorrectly processed tRNAs.
[4a, 34a]
 However, the third pathway involves mature tRNAs, which 
undergo endonucleolytic cleavage in response to a variety of stresses.
[42a, 43]
 In this case, Rny1, a 
member of the RNase T2 family, was shown to cleave tRNAs at the anticodon position in response to 
a variety of stress conditions, including growth into stationary phase.
[151]
 However, previous reports 
have pointed out that only a small portion of tRNAs undergo endonucleolytic cleavage and that full 
length tRNA levels do not decline significantly.
[42a, 43]
 Therefore, we can deduce that this is unlikely to 
be a major pathway for selective enrichment of the modified tRNA pool during entry into stationary 
phase, and that (hypomodified) tRNAs are more likely to be processed by alternative degradation 
pathways. However, one interesting implication of tRNA endonucleolytic cleavage in response to 
stress is the fact that, although yet unknown in yeast, there might be a RNA repair pathway similar to 
that observed in bacteria.
[152]
 More specifically, Chan et al. suggested that tRNA repair is more 
efficient if coupled to 2´-O-methylation at the repair site (in the anticodon loop), and that this 
modification stabilizes tRNA molecules against further cleavage. Hen1, which is responsible for the 
repair in bacteria when complexed with Pnkp, is also found in eukaryotes and it is known to perform 
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the same chemical reaction although on different RNA substrates.
[153]
 One interesting possibility is that 
the observed increase in Gm detailed in section 4.2.2 might be the result of a repair pathway aimed at 
stabilizing tRNA molecules against endonucleolytic cleavage during entry of yeast cell into 
quiescence. 
Another interesting aspect of growth into stationary phase is the fact that yeast cells have been shown 
to accumulate cytoplasmic tRNAs in the nucleus during glucose starvation, and transport was shown 
to be reversible once nutrients become again available.
[154]
 The exact role of retrograde tRNA transport 
is still unresolved but one of the main hypothesis put forward is that tRNAs are imported into the 
nucleus for storage or sequestration of the tRNA molecules from the translational apparatus during 
starvation.
[40]
 Furthermore, it has been suggested that transport into the nucleus might serve as a 
proofreading mechanism, allowing the cell to eliminate defective and possibly undermodified 
tRNA.
[40]
 Therefore, sequestration of tRNAs during growth of the cells into stationary phase by import 
into the nucleus could be a possible mechanism by which cells contribute to a selective enrichment of 
mature, fully modified tRNAs. This could either be linked to a regulated increase in modification of 
tRNA molecules to ensure tRNA retrograde transport into the nucleus, or, on the contrary, could be 
coupled to degradation of hypomodified tRNAs, leading in both cases to a more modified tRNA 
population.  
tRNA modifications as a tool to modulate efficient protein translation during stationary phase 
Yeast cells adapt their growth conditions depending on the nutrient availability in the surrounding 
environment. When grown to saturation in rich medium, the cells are known to enter quiescence, a 
resting state where cells stop proliferating and where they are able to survive for long periods of time 
under harsh conditions, while at the same time being able to rapidly proliferate again as soon as 
nutrients become available.
[155]
 Entry into quiescence is governed by a network of signalling pathways 
which lead to a coordinated down-regulation of the overall transcription and translation machinery. 
Ribosomal biosynthesis, which during exponential growth accounts for about 60 % of the total 
transcription and for 50 % of Pol II transcription, is strongly down-regulated in response to the 
decrease nutrient availability,
[156]
 overall transcription rates are about three to five times lower than in 
log-phase, and overall protein biosynthesis in stationary phase is reduced to about 0.3 % of that 
observed during exponential growth.
[155a]
 Nevertheless, despite the reduced expression of a large 
subset of genes, there is also a group of genes, particularly those involved in stress response,
[157]
 whose 
up-regulated expression is essential to ensure correct entry into quiescence and for proper life-span 
regulation.
[155]
 
tRNA modifications have been shown to enhance translational efficiency by modulating 
codon-anticodon interactions, as well as ensuring structural stabilization of the tRNA molecule and 
favouring cognate tRNA selection at the ribosome A site.
[11a, 11b, 18a]
 Furthermore, as detailed in chapter 
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3,
[158]
 a higher tRNA modification content was found to correlated with an increase protein translation 
efficiency. Therefore, in the case of yeast entering stationary phase, one possible explanation for an 
increase in the tRNA modification content might be the need to ensure optimal translation of essential 
genes in a state where the translational apparatus is relatively inert.
[157a, 159]
 In particular, previous 
studies have highlighted a role of tRNA modifications in modulation of the expression of genes 
involved in stress-response. In a recent publication, Chan et al. have shown that deletion of tRNA 
methyltransferase Trm4, responsible for generation of m
5
C in tRNA, confers hypersensitivity to 
oxidative stress.
[45]
 In fact, the increase in m
5
C at the anticodon position of tRNA
Leu(CAA)
 observed in 
yeast cells exposed to H2O2 was found to enhance the translation of stress-response proteins which are 
enriched in TTG codons.
[45]
 This would fit with the observed increase in m
5
C content detailed in this 
study, which is also in agreement with the observed increase in m
2
2G described in the original 
publication investigating the effect of H2O2 exposure on tRNA modifications.
[44a]
 In another study, 
Trm9 was found to modulate stress response upon exposure to methyl methanesulfonate (MMS) by 
generation of the modified uridine mcm
5
U and mcm
5
s
2
U. These are found at the wobble position of 
tRNA
Arg(UCU)
 and tRNA
Glu (UUC)
, and an increase in modification was found to be essential to enhance 
translation of stress-response proteins where specific arginine and glutamic acid codons were 
overrepresented.
[46]
 
Codon bias, which describes the different frequency with which synonymous codons are found in 
coding DNA, is known to vary strongly between species. However, variation in codon usage is also 
known within the same organism depending on the gene and it has been implicated in gene expression 
regulation.
[48, 160]
 In particular, it has been noted that functionally related genes tend to display similar 
codon bias patterns, and that variations in codon usage are exploited to selectively modulate 
expression of certain genes during cell cycle development. Codon usage is generally correlated with 
tRNA abundance (and to some extent with tRNA gene copy number);
[161]
 yet there is increasing 
evidence, as detailed in the previous paragraph, that tRNA modifications might contribute in the 
regulation of the composition of the proteome.
[45-46]
 In this way, selective modification of the 
anticodon loop might change the subset of ´preferred´ codons by modulating codon-anticodon 
interactions, therefore favouring translation of normally ´less preferred´ codons. In this case, the 
increase in tRNA modification observed in this study might constitute a mechanism to modulated 
selective expression of a subset of genes required for survival during stationary phase by favouring 
translation in the presence of different codon usage patterns. Alternatively, modulation of protein 
synthesis might be affected by altered aminoacylation. In fact, it has been reported that oxidative stress 
leads to an increase misacylation of methionine, resulting in altered protein composition synthesis as a 
protective measure against oxidative damage.
[44b]
 In relation to the current study, one possibility is that 
increased tRNA modifications might influence misacylation and lead to similar alterations in protein 
composition as part of a coordinated stress response mechanism, as previously suggested.
[44a]
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Alternatively, the higher modification content of tRNA molecules might play a role in exiting from 
stationary phase, where quiescent cells rapidly re-start transcription and translation in the presence of 
nutrients.
[155a, 162]
 In line with this argument, findings by Radonjic et al. have revealed that, despite the 
global transcription repression during quiescence, the transcription machinery is present in an inactive 
form, where RNA Pol II is poised upstream of hundreds of genes ready to rapidly initiate transcription 
as soon as required.
[163]
 Entry into stationary phase was also found to lead to an increase in EGP-
bodies, a set of cytoplasmic granules which are responsible for mRNA storage during periods of 
translational inactivity.
[164]
 These bodies are suggested to selectively preserve mRNA molecules which 
can then be rapidly translated upon new cell proliferation, allowing for more rapid changes in protein 
concentrations independently of the transcription machinery.
[165]
 In line with the argument that tRNA 
modifications allow for more efficient translation and might additionally favour specific patterns of 
codon usage, storage of highly modified tRNAs might therefore allow for more effective translational 
activity upon exit from stationary phase. Furthermore, the enhanced stability afforded by the increased 
modification content might ensure stabilization of tRNA molecules from degradation or 
endonucleolytic cleavage.
[4a, 4b]
 
The following table summarizes the aforementioned implications which might result from an increase 
in tRNA modification content. 
Roles of tRNA modifications 
 Implications of increase in tRNA  
modification levels during diauxic shift 
Known to enhance translational 
efficiency, modulate codon-anticodon 
interactions, reduce frameshift and 
misincorporation
[11a, 11b, 18a]
 
 
→ 
Ensure optimal translation of essential genes 
required during quiescence (e.g. genes 
involved  in stress response and life-span 
regulation) 
tRNA modification contribute to 
stabilization of tRNA molecules
[4a, 4b]
  
 
→ 
Stabilization and storage of tRNA during 
quiescence 
Loss of Trm4 leads to hypersensitivity to 
H2O2;
[44a, 45]
 loss of Trm9 leads to 
hypersensitivity to MMS
[46]
 
 
→ 
Ensure optimal translation of genes involved 
in stress response 
Specific modifications enhance translation 
of subset of genes enriched for a specific 
codon
[45-46]
 
 
→ 
Contribute to modulation of codon usage by 
modulation of wobble capacity of specific 
modifications 
Oxidative stress results in increased 
methionine misacylation as protection 
against oxidative damage
[44b]
 
 
→ 
Might contribute to alteration in 
aminoacylation 
Transcription machinery is present in 
poised state during quiescence;
[163]
 mRNA 
molecules are stored in EGP-bodies
[164]
 
 
→ 
Ensure effective translation upon exit from 
quiescence 
Summary Table: Overview of possible implications of increase tRNA modification content during growth into stationary 
phase. 
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In conclusion, this study confirms that yeast tRNAs become increasingly modified during entry into 
stationary phase. Using a simplified approach which relies on labelling of the modified tRNA 
nucleosides at the early phase of exponential growth, we were able to show that modified tRNAs have 
low turnover and that tRNA molecules are increasingly modified after diauxic shift. On the one hand, 
this suggests that modification content might increase over time due to the long permanence of tRNAs 
in the cell. On the other hand, we propose that, if there is some extent of tRNA turnover taking place, 
that it is mostly targeting hypomodified tRNAs, therefore leading to an enrichment of the modified 
tRNA pool. Further studies assessing the extent of tRNA turnover with respect to turnover of tRNA 
modifications will contribute to further elucidate the nature of the observed increase in tRNA 
modification levels. 
4.4 Materials and Methods 
4.4.1 Growth and handling of yeast  
Yeast S. cerevisiae (strain 70449) was obtained from the Deutsche Sammlung von Mikroorganismen 
und Zellkulturen, GmbH (DSMZ). Glycerol stocks were stored at -80 °C. Yeast was grown on 
YPD-Agar plates at 30 °C for 3 days and subsequently stored at 4 °C. For the labelling experiment, 
yeast cells were grown for two generations in labelled complete minimal medium (yeast nitrogen base 
– AA/AS, ammonium sulfate, 2 % dextrose and amino acid powder mix containing 
[methyl-D3]-L-methionine)
[166]
 and finally inoculated in 1 L of labelled medium. Cells were allowed to 
grow at 30 °C shaking vigorously (200 rpm in baffled flasks) to an optical density OD600 = 1, at which 
point they were briefly pelleted and resuspended in YPD. Cells were allowed to grow at 30 °C shaking 
for the following 7 days, and samples were collected at time points 0 h (prior to medium exchange) 
and 1, 2, 4, 20, 24, 48, 72, 96, 120, 144 and 168 h after resuspension in YPD.  
For sample collection, 25‒50 ml of yeast culture were removed, optical density was measured, and 
cells were pelleted at 4 °C, washed once in tRNA Extraction Buffer (10 mM Mg(OAc)2, 50 mM 
NaOAc, 150 mM NaCl, pH 4.5) and stored at -80 °C after freezing in liquid nitrogen.   
4.4.2 tRNA extraction 
tRNA extraction was performed as described previously with minor adaptations.
[142]
 Briefly, cells were 
resuspended in 5 mL of tRNA Extraction Buffer and mixed with 5 mL 80 % aq. phenol. The 
suspension was vortexed vigorously and incubated at 65 °C for 1 h, vortexing every 10 minutes. The 
two phases were separated by centrifugation (1 h, 4 °C, 4000 rpm), and the aqueous phase was again 
incubated with 5 mL of 80 % aq. phenol for 15 min at 65 °C. After centrifugation (30 min, 4 °C, 
4000 rpm), the aqueous phase was extracted twice with 2 mL of CHCl3, shaken vigorously and 
centrifuged to separated the two phases (10 min, 4000 rpm, 4 °C). The aqueous phase was mixed with 
20 % KOAc, pH 4.5 (0.1 vol) and with 12 M LiCl solution (0.2 vol). Samples were incubated for 4 h 
on ice to precipitate genomic DNA and long RNAs and finally centrifuged (30 min, 4 °C, 18000 rpm). 
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The supernatant was mixed with absolute EtOH (3 vol) and precipitated overnight at -20 °C. Finally, 
tRNA samples were precipitated by centrifugation (1 h, 4 °C, 12000 rpm), the supernatant discarded, 
and pellets were resuspended in 3 mL of DEAE Buffer I (100 mM Tris HCl, pH 7.5, 10 mM MgCl2).    
4.4.3 tRNA purification by ion-exchange chromatography 
Samples resuspended in DEAE Buffer I were further purified by anion exchange chromatography. All 
purification steps were performed at 4 °C. Crude tRNA samples were loaded on a DEAE Sepharose 
Fast Flow column (5 mL, GE Healthcare) using a ÄKTA purifier, and tRNA samples were eluted with 
a gradient from 0 % to 40 % DEAE Buffer II (100 mM Tris HCl, pH 7.5, 10 mM MgCl2, 1 M NaCl). 
Samples eluted between 0.2‒0.4 M NaCl, and showed a characteristic absorbance ration of 2:1 for 
absorbance at 254 nm with respect to 280 nm. Fractions were combined and precipitated by addition 
of absolute EtOH (3 vol) and incubation overnight at -20 °C. Purified tRNA was collected by 
centrifucation (1 h, 4 °C, 12000 rpm), pellets were air-dried and resuspended in 1 mL of ddH2O. 
Concentrations of the tRNA samples were evaluated by UV absorbance at 260  nm using a Nanodrop 
UV-spectrometer. 
4.4.4 Enzymatic digestion of tRNA samples 
Prior to enzymatic digestion, tRNA samples were denatured at 99 °C for 3 min and rapidly cooled on 
ice to prevent refolding. For each sample, 12 µg of tRNA (in 100 µL of ddH2O) were digested. After 
denaturation, samples were mixed with 10 µL of Digest Buffer A (300 mM ammonium acetate, 
100 mM CaCl2, 1 mM ZnSO4, pH 5.7) and digested with nuclease S1 (4 µL, 80 units, Aspergillus 
oryzae, Sigma Aldrich) for 3 h at 37 °C. Subsequently, samples were mixed with Digest Buffer B 
(12 µL, 500 mM Tris HCl, 1 mM EDTA, pH 8.0) and digested with Antarctic phosphatase (2 µL, 
10 units, New England Biolabs) and snake venom phosphodiesterdase I (2 µL, 0.2 units, Crotalus 
adamanteus venom, USB Corporation) for further 3 h at 37 °C. After enzymatic digest, labelled 
isotopes standards Ar, i
6
A and t
6
A were added to the mixture.
[142]
 Samples were centrifuged (15 min, 
13000 rpm), concentrated and analyzed by LC-MS. For each sample, three independent digestions 
were performed.   
4.4.5 HPLC-ESI-MS 
Digested samples were analyzed using a Dionex Ultimate 3000 HPLC system coupled to a Thermo 
Finnigan LTQ Orbitrap XL as detailed before.
[142, 158]
 The flow rate was set to 0.15 mL/min and the 
column was kept at a temperature of 30 °C. Buffer A (2 mM HCOONH4 in H2O (pH 5.5)) and Buffer 
B (2 mM HCOONH4 in H2O/MeCN 20/80 (pH 5.5)) were used for sample elution with the following 
gradient: 0 → 55 min, 0 % → 8 % Buffer B; 55 → 100 min, 8 % → 60 % Buffer B; 100 → 102 min, 
60 % → 100 % Buffer B; 102 → 120 min, 100 % Buffer B; 120 → 125 min, 100 → 0 % Buffer 
B; 125 → 135 min, 0 % Buffer B. Elution was monitored by UV absorbance at 260 nm. The eluent 
was injected into the ion source without prior splitting and ions were scanned using a positive polarity 
mode with a range of m/z 200-1000 with resolution of 30,000. The mass spectrometer was set with the 
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following parameters: sheath gas flow rate, 16 arb; auxiliary gas flow rate, 10 arb; sweep gas flow 
rate, 4 arb; spray voltage, 5.0 kV; capillary temperature, 200 °C; capillary voltage, 25 V; tube lens, 
60 V. 
4.4.6 Quantification of modified nucleosides and evaluation of light to heavy modification 
ratio 
Quantification of the modified nucleosides was performed using three different approaches depending 
on the nature of the modification. Nucleosides i
6
A, t
6
A and Ar were quantified by means of labelled 
isotope standards as previously described using a Qualbrowser program.
[142, 158]
 Quantification of m
1
A, 
m
1
G, m
2
G, m
5
C, Am and m
2
2G was based on absorbance at 260 nm. Calibration curves were 
generated by HPLC-ESI-MS using synthetic standards and integration of the corresponding UV 
absorbance signal (see Figure 20). The corresponding linear fits (obtained using ORIGIN
®
) were used 
to determine relative changes in modification content. Each technical replicate was analyzed in series 
for samples from time point 0 h to 168 h on three different days, and relative changes were calculated 
within each individual series. Quantification of nucleoside A was done by means of UV absorbance 
using the calibration curve previously measured by Dr. Veronika Reiter.
[167]
 Modifications Gm, Cm 
and m
7
G were quantified by comparison of the sums of the areas of labelled and unlabelled 
nucleosides (CH3- and CD3-, determined using Qualbrowser) with those of m
1
G (for Gm) and m
5
C 
(for Cm and m
7
G). The relative change was then normalized with respect to the relative changes of 
m
1
G and m
5
C as calculated from UV absorbance normalized to the absorbance of A (see Table 1). 
Irrespective of the quantification method, modification content was in all cases normalized to the A 
nucleoside content which was estimated from UV absorbance. For the evaluation of the CH3- and 
CD3-modification proportion in each sample, ratios of the CH3- to CD3-modification content were 
estimated by comparison of the areas of the labelled and unlabelled nucleosides using Qualbrowser. 
Formulae used in the analysis of CH3/CD3 ratios are listed in Table 1. 
 
Figure 20 Calibration curves for m1A, m1G, m2G, m22G, m
5C and Am based on absorbance at 260 nm. Linear fitting 
was performed using ORIGIN®. 
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Section Parameter to 
calculate 
Formulae 
4.2.2 Quantification of Gm 
with respect to m
1
G; 
similar procedure for 
Cm and m
7
G with 
respect to m
5
C 
 
= [MS(CH3-Gm + CD3-Gm) / MS(CH3-m
1
G + CD3-m
1
G)] * 
[UV(m
1
G) / UV(A)] 
4.2.3 
 
 
Expected CH3/CD3 
ratio based on OD600 
Expected CD3-content (1 h) = OD(1 h) / [CH3/CD3 (1 h, average 
experimental ratios) + 1] 
Expected CH3/CD3 ratio (x h) = [OD(x h) – CD3-content(1 h)] / 
(CD3-content(1 h))  
4.2.3 Expected CH3/CD3 
ratio based on OD600 
and tRNA content 
Expected CD3-content (1 h) = tRNA(1 h) / [CH3/CD3 (1 h, average 
experimental ratios) + 1] 
Expected CH3/CD3 ratio (x h) = [tRNA(x h) – CD3-content(1 h)] / 
(CD3-content(1 h)) 
4.2.4 Evaluation CH3- and 
CD3-modification 
content based on 
OD600 (e.g. m
1
A) 
CD3-m
1
A content (x h) = [m
1
A(UV, x h, n) / [CH3/CD3-m
1
A(x h) + 
1]] * OD(x h) x  
CH3-m
1
A content (x h) = [ m
1
A(UV, x h, n) - m
1
A(UV, x h, n) / 
[CH3/CD3-m
1
A(x h) + 1]] * OD(x h) 
4.2.4 Evaluation CH3- and 
CD3-modification 
content based on 
OD600 and tRNA 
content (e.g. m
1
A) 
CD3-m
1
A content (x h) = [m
1
A(UV, x h, n) / [CH3/CD3-m
1
A(x h) + 
1]] * OD(x h) * tRNA(x h, %) 
CH3-m
1
A content (x h) = [ m
1
A(UV, x h, n) - m
1
A(UV, x h, n) / 
[CH3/CD3-m
1
A(x h) + 1]] * OD(x h) * tRNA(x h, 
%) 
Table 1 Summary calculations. Table lists formulae used for evaluating CH3/CD3 ratios and CH3- and CD3-modification 
content as detailed in Sections 4.2.3 and 4.2.4. Parameters listed in the table: MS(x) = integral ion count; 
UV(a) = quantification of a based on UV absorbance; tRNA(x h) = tRNA content at time x; m1A(UV, x h, n) = m1A content 
at time x based on UV absorbance, normalized to time 1 h; CH3/CD3-m
1A(x h) = CH3/CD3 ratio for m
1A at time x. 
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4.5 Quantification data 
4.5.1 tRNA content per OD unit during growth of S. cerevisiae 
Time (h) OD600 
tRNA content 
per OD unit 
(%) 
St.Dev. for 
tRNA content 
St.Dev. for 
tRNA content 
% 
0 0.92 62.58 1.31 2.09 
1 1.32 68.38 3.13 4.57 
2 1.58 71.18 2.80 3.94 
4 2.46 100.00 0.00 0.00 
20 11.61 61.04 2.29 3.75 
24 12.18 63.27 1.97 3.12 
48 13.00 56.09 1.93 3.44 
72 15.96 47.45 2.43 5.11 
96 18.56 49.12 4.60 9.36 
120 21.09 45.38 5.97 13.15 
144 21.60 44.04 2.42 5.49 
168 20.52 42.27 3.26 7.72 
     
Table 2 Optical density and tRNA content per OD unit over time (see Figure 11). tRNA content was evaluated by two 
independent measurements using the Nanodrop UV-spectrometer prior and after ion-exchange purification, and measurement 
of the maximal absorbance at 260 nm during chromatographic purification of the tRNA samples. tRNA content was 
normalized to the highest value (time point 4 h). 
4.5.2 Quantification of modified nucleosides 
Time (h) 
Normalized 
m
1
G content 
St.Dev. St.Dev. % 
0 0.98 0.001 0.1 
1 1.00 0.000 0.0 
2 0.96 0.013 1.4 
4 0.88 0.008 0.9 
20 1.04 0.022 2.1 
24 1.06 0.010 0.9 
48 1.14 0.020 1.8 
72 1.14 0.031 2.7 
96 1.20 0.048 4.0 
120 1.23 0.028 2.3 
144 1.27 0.048 3.8 
168 1.28 0.050 4.0 
 
Table 3 Normalized content of m1G (see Figure 12). Relative change in m1G modification content. Quantification was 
performed by UV absorbance at 260 nm with respect to content of A nucleoside and normalized to time point 1 h. Values are 
averages of three independent digests and measurements. 
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Time (h) 
m
1
A 
change 
(%) 
St.Dev. 
m
1
G 
change 
(%) 
St.Dev. 
m
2
G 
change 
(%) 
St.Dev. 
m
5
C 
change 
(%) 
St.Dev. 
0 2.1 8.4 -2.0 0.1 5.0 9.4 -1.4 0.1 
1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
2 -4.4 1.5 -4.4 1.3 -0.8 2.5 -3.8 0.5 
4 -11.5 2.6 -11.7 0.8 -10.4 0.2 -11.7 0.7 
20 2.3 7.3 4.1 2.2 17.1 19.9 2.5 1.1 
24 1.7 1.3 5.7 1.0 6.3 2.2 3.9 0.4 
         
Time (h) 
i
6
A 
change 
(%) 
St.Dev. 
Ar 
change 
(%) 
St.Dev. 
t
6
A 
change 
(%) 
St.Dev. 
Am 
change 
(%) 
St.Dev. 
0 4.9 6.2 0.8 4.3 -27.4 2.1 -2.2 0.0 
1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
2 2.7 4.8 -2.1 4.9 4.9 1.7 10.9 1.3 
4 -0.6 1.4 -12.3 5.0 -7.0 1.2 34.8 0.6 
20 3.6 7.6 5.9 9.6 -8.4 3.7 -10.2 1.5 
24 3.9 4.5 3.7 7.7 -13.6 2.8 -7.4 9.4 
Table 4 Percental change in modification content during the first 24 h (see Figure 13). Quantification of absolute 
modification content per A nucleoside was performed by UV absorbance (m1A, m1G, m2G, m5C, Am) or by means of isotope 
labelled standards (i6A, t6A, Ar). Values are averages of three independent digests and measurements, and were normalized to 
time point 1 h. 
Time 
(h) 
m
1
A 
change 
(%)  
St.Dev. 
St.Dev. 
% 
i
6
A 
change 
(%)  
St.Dev. 
St.Dev. 
% 
Ar 
change 
(%)  
St.Dev. 
St.Dev. 
% 
first 24h 0 5,52   0 6,89   0 10,76 
 
48 12.19 1.87 15.36 5.79 2.74 47.31 28.47 2.69 9.44 
72 14.92 3.81 25.51 0.62 5.19 831.94 39.88 0.54 1.35 
96 18.19 4.52 24.87 3.90 2.87 73.65 57.93 4.62 7.98 
120 19.63 3.22 16.43 7.58 4.05 53.46 79.19 12.62 15.94 
144 28.47 5.02 17.63 8.62 3.54 40.99 75.63 12.43 16.43 
168 26.07 5.62 21.56 7.58 2.64 34.87 71.65 12.09 16.87 
          
Time 
(h) 
m
1
G 
change 
(%)  
St.Dev. 
St.Dev. 
% 
m
2
G 
change 
(%)  
St.Dev. 
St.Dev. 
% 
m
2
2G 
change 
(%)  
St.Dev. 
St.Dev. 
% 
first 24h 0.0 6.0   0.0 8.9   0.0 0.3 
 
48 15.1 1.4 9.4 10.6 4.1 38.6 4.3 1.6 35.9 
72 15.5 2.3 14.6 11.6 3.7 31.8 4.7 1.1 22.5 
96 21.6 3.7 17.1 23.1 10.7 46.3 5.5 0.1 2.5 
120 25.2 1.9 7.7 28.5 11.9 41.6 8.2 1.0 11.7 
144 28.4 3.7 13.0 31.8 11.4 35.9 10.9 0.5 4.7 
168 29.3 3.9 13.4 24.9 3.1 12.6 11.4 0.3 2.9 
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Time 
(h) 
t
6
A 
change 
(%)  
St.Dev. 
St.Dev. 
% 
m
5
C 
change 
(%)  
St.Dev. 
St.Dev. 
% 
Am 
change 
(%)  
St.Dev. 
St.Dev. 
% 
first 24h 0.0 8.1   0.0 5.4   0.0 15.3 
 
48 -8.7 3.3 -38.4 15.0 0.4 2.4 -22.9 0.3 -1.1 
72 -0.8 2.4 -297.7 20.4 0.5 2.5 -18.6 4.3 -22.9 
96 -5.0 4.2 -84.2 26.6 0.5 1.9 -21.5 1.6 -7.6 
120 14.5 3.3 22.9 31.5 0.8 2.5 -15.8 5.1 -32.1 
144 68.4 5.9 8.6 35.3 1.3 3.8 -14.5 5.8 -40.4 
168 97.9 11.2 11.4 35.9 1.3 3.5 -15.4 2.3 -14.8 
Table 5 Percental change in modification content with respect to day 1 (see Figure 14). Modification content during the 
first 24 h was averaged and used as reference for evaluation of the percental change starting from day 2. Quantification was 
performed by UV absorbance (m1A, m1G, m2G, m5C, Am) or by means of isotope labelled standards (i6A, t6A, Ar) and 
normalized to content of A nucleoside. Values are averages of three independent digests and measurements.  
 
Time (h) 
Gm change 
(%) based on 
m
1
G 
St.Dev. 
Cm change 
(%) based on 
m
5
C 
St.Dev. 
m
7
G change 
(%)  based on 
m
5
C 
St.Dev. 
0 -0.3 1.4 -8.4 2.4 -6.2 5.0 
1 0.0 0.0 0.0 0.0 0.0 0.0 
2 3.3 1.2 -9.7 7.4 -7.1 4.1 
4 -6.4 1.3 -12.9 4.2 -15.7 3.4 
20 6.6 8.1 -4.0 4.9 0.0 5.4 
24 2.4 11.2 -3.2 1.5 -7.0 3.5 
48 18.3 8.6 3.9 5.2 4.1 3.0 
72 30.5 6.9 8.5 5.4 8.4 6.3 
96 43.8 10.5 7.0 8.1 8.1 4.8 
120 55.8 7.3 22.3 2.2 17.7 3.1 
144 54.6 8.1 13.9 10.1 21.8 6.6 
168 52.3 9.5 16.6 8.9 18.1 5.0 
Table 6 Percental change of Gm, Cm and m7G (see Figure 15). Quantification of Gm, Cm and m7Gwas based on 
comparison of the total areas of labelled and unlabelled ion count signals with respect to that of m1G (for Gm) and m5C (for 
Cm and m7G). Values were then normalized based on m1G and m5C quantification by UV absorbance and total A nucleoside 
content. Values are averages of three independent digests and measurements. 
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4.5.3 Evaluation of CH3/CD3 ratio during entry into stationary phase 
Time 
(h) 
Average 
CH3/CD3 
all mod. 
St.Dev. 
St.Dev. 
% 
Expected 
CH3/CD3 
(OD) 
St.Dev. 
St.Dev. 
% 
Average 
CH3/CD3 
Am 
St.Dev. 
St.Dev. 
% 
0 1.80 0.11 6.24 - - -  2.04 0.11 5.22 
1 2.24 0.12 5.25 2.24 0.16 7.07 2.38 0.05 2.11 
2 2.84 0.12 4.12 2.87 0.20 7.07 2.82 0.08 2.81 
4 5.22 0.29 5.50 5.03 0.36 7.07 5.00 0.30 5.98 
20 28.13 2.48 8.82 27.46 1.94 7.07 15.85 1.88 11.88 
24 29.12 3.00 10.30 28.85 2.04 7.07 14.91 1.51 10.12 
48 37.12 3.33 8.96 30.86 2.18 7.07 20.60 2.31 11.22 
72 48.21 4.70 9.74 38.12 2.70 7.07 22.52 2.57 11.41 
96 56.74 6.29 11.09 44.49 3.15 7.07 25.64 3.53 13.77 
120 74.04 7.04 9.51 50.69 3.58 7.07 33.66 5.70 16.95 
144 71.28 7.86 11.03 51.94 3.67 7.07 35.96 9.85 27.39 
168 70.34 7.70 10.95 49.29 3.49 7.07 29.94 2.97 9.92 
Table 7 Comparison of measured and expected CH3/CD3-ratio based on optical density (see Figure 16). Average ratios 
for all modifications were obtained by averaging values for m1A, m1G, m2G, m7G, Gm, m22G (CD3-, CH3-labelled only), m
5C 
and Cm. Expected ratios were estimated on the assumption that CH3-modification content increased linearly with OD600 and 
were calculated starting from time point 0 h, with an initial CH3/CD3 ratio of 2.24 and OD600 = 1.32. Values are averages of 
three independent digests and measurements. 
Time 
(h) 
Average 
CH3/CD3 
all mod. 
St.Dev. 
St.Dev. 
% 
Expected 
CH3/CD3 
(OD and 
tRNA) 
St.Dev. 
St.Dev. 
% 
Average 
CH3/CD3 
Am 
St.Dev. 
St.Dev. 
% 
0 1.80 0.11 6.24 - -  - 2.04 0.11 5.22 
1 2.24 0.12 5.25 2.24 0.23 10.10 2.38 0.05 2.11 
2 2.84 0.12 4.12 3.03 0.27 9.01 2.82 0.08 2.81 
4 5.22 0.29 5.50 7.82 0.55 7.02 5.00 0.30 5.98 
20 28.13 2.48 8.82 24.40 1.95 7.99 15.85 1.88 11.88 
24 29.12 3.00 10.30 26.62 2.05 7.68 14.91 1.51 10.12 
48 37.12 3.33 8.96 25.14 1.97 7.84 20.60 2.31 11.22 
72 48.21 4.70 9.74 26.14 2.29 8.76 22.52 2.57 11.41 
96 56.74 6.29 11.09 31.68 3.77 11.91 25.64 3.53 13.77 
120 74.04 7.04 9.51 33.31 5.07 15.23 33.66 5.70 16.95 
144 71.28 7.86 11.03 33.09 2.97 8.98 35.96 9.85 27.39 
168 70.34 7.70 10.95 30.09 3.19 10.59 29.94 2.97 9.92 
Table 8 Comparison of measured and expected CH3/CD3-ratio based on optical density and tRNA content per OD600 
unit (see Figure 17). Average ratios for all modifications were obtained by averaging values for m1A, m1G, m2G, m7G, Gm, 
m22G (CD3-, CH3-labelled only), m
5C and Cm. Expected ratios were estimated on the assumption that CH3-modification 
content increased linearly with OD600 and with tRNA content, and were calculated starting from time point 0 h, with an initial 
CH3/d3 ratio of 2.24 and OD600 = 1.32 and tRNA content per OD unit of 68.38 %. Values are averages of three independent 
digests and measurements. 
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4.5.4 Evaluation of CH3- and CD3-modification content 
Time (h) 
Average   
CD3-
m
1
A 
St.Dev. 
Average   
CH3-
m
1
A 
St.Dev. 
Average   
CD3-
m
1
G 
St.Dev. 
Average   
CH3-
m
1
G 
St.Dev. 
1 0.405 0.004 0.915 0.00 0.420 0.006 0.900 0.006 
2 0.394 0.010 1.116 0.02 0.410 0.010 1.100 0.023 
4 0.357 0.011 1.820 0.06 0.372 0.014 1.800 0.024 
20 0.408 0.031 11.465 0.85 0.464 0.042 11.626 0.255 
24 0.409 0.012 11.973 0.16 0.471 0.036 12.401 0.125 
48 0.364 0.021 13.943 0.75 0.431 0.026 14.326 0.265 
72 0.359 0.026 17.637 1.24 0.425 0.025 17.761 0.500 
96 0.369 0.028 21.158 1.66 0.452 0.023 21.811 0.888 
120 0.312 0.043 23.978 1.08 0.403 0.041 25.640 0.588 
144 0.379 0.033 26.856 2.18 0.446 0.044 26.908 1.035 
168 0.352 0.033 25.040 2.18 0.426 0.028 25.745 1.036 
         
Time (h) 
Average   
CD3-
m
2
G 
St.Dev. 
Average   
CH3-
m
2
G 
St.Dev. 
Average   
CD3-
m
5
C 
St.Dev. 
Average   
CH3-
m
5
C 
St.Dev. 
1 0.401 0.008 0.919 0.008 0.388 0.006 0.932 0.006 
2 0.399 0.014 1.169 0.042 0.378 0.002 1.141 0.007 
4 0.346 0.008 1.860 0.010 0.332 0.005 1.839 0.018 
20 0.423 0.075 13.168 2.308 0.380 0.008 11.521 0.125 
24 0.394 0.016 12.548 0.263 0.390 0.010 12.262 0.049 
48 0.365 0.009 14.371 0.254 0.345 0.009 14.329 0.049 
72 0.344 0.018 17.911 0.555 0.339 0.004 18.531 0.030 
96 0.389 0.058 23.111 3.518 0.348 0.017 22.721 0.175 
120 0.349 0.055 27.551 4.383 0.327 0.007 26.899 0.272 
144 0.379 0.061 28.912 4.381 0.359 0.009 28.334 0.450 
168 0.336 0.016 25.320 0.976 0.336 0.016 27.041 0.402 
         
Time (h) 
Average   
CD3-Am 
St.Dev. 
Average   
CH3-Am 
St.Dev. 
    1 0.391 0.008 0.929 0.008 
    2 0.458 0.014 1.294 0.025 
    4 0.552 0.033 2.763 0.037 
    20 0.619 0.074 9.812 0.188 
    24 0.709 0.102 10.564 1.148 
    48 0.487 0.055 10.023 0.178 
    72 0.579 0.083 13.046 1.168 
    96 0.573 0.082 14.694 0.634 
    120 0.538 0.105 18.093 1.798 
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144 0.524 0.154 18.855 2.099 
    168 0.589 0.065 17.623 0.905 
    
Table 9 Evaluation of CD3- and CH3- modification content over time (see Figure 18). Evaluation of heavy and light 
modification content for m1A, m1G, m2G, m5C and Am was based on average ratios and normalized modification content, 
finally multiplied by the optical density to account for increasing cell amount. Values are averages of three independent 
digests and measurements. 
 
Average CH3- and CD3-modification content based on OD 
Time (h) 
Average   
CD3-m
1
A 
St.Dev. St.Dev. % 
Average   
CH3-m
1
A 
St.Dev. St.Dev. % 
1 0.405 0.004 0.9 0.915 0.00 0.39 
2 0.394 0.010 2.4 1.116 0.02 2.23 
4 0.357 0.011 2.9 1.820 0.06 3.50 
20 0.408 0.031 7.6 11.465 0.85 7.38 
24 0.409 0.012 2.9 11.973 0.16 1.35 
48 0.364 0.021 5.8 13.943 0.75 5.39 
72 0.359 0.026 7.1 17.637 1.24 7.02 
96 0.369 0.028 7.7 21.158 1.66 7.86 
120 0.312 0.043 13.9 23.978 1.08 4.49 
144 0.379 0.033 8.6 26.856 2.18 8.13 
168 0.352 0.033 9.4 25.040 2.18 8.69 
 
Average CH3- and CD3-modification content based on OD and tRNA content 
Time (h) 
Average   
CD3-m
1
A 
St.Dev. St.Dev. % 
Average   
CH3-m
1
A 
St.Dev. St.Dev. % 
1 0.277 0.013 4.7 0.626 0.029 4.6 
2 0.281 0.013 4.6 0.794 0.036 4.5 
4 0.357 0.011 2.9 1.820 0.064 3.5 
20 0.249 0.021 8.5 6.998 0.579 8.3 
24 0.259 0.011 4.3 7.575 0.257 3.4 
48 0.204 0.014 6.7 7.821 0.500 6.4 
72 0.170 0.015 8.8 8.368 0.727 8.7 
96 0.181 0.022 12.1 10.392 1.270 12.2 
120 0.141 0.027 19.1 10.882 1.512 13.9 
144 0.167 0.017 10.2 11.826 1.160 9.8 
168 0.149 0.018 12.1 10.584 1.230 11.6 
Table 10 Comparison of CD3- and CH3- content evaluation based on OD and tRNA content per OD unit (see Figure 
19). Evaluation of the absolute CH3- and CD3-modification content over time by accounting for the changes in optical density 
OD versus optical density and variable tRNA content. Units are not comparable between the different models. Values are 
averages of three independent digests and measurements. 
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5 Investigation of the structure-function relationships for the bifunctional 
tRNA-modifying enzyme MnmC in complex with substrate tRNA 
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5.1 Introduction  
tRNA molecules are the most highly modified RNA species. Modified nucleosides, which can range 
from simple methylations to hypermodified nucleosides, are found at various positions and play 
essential roles in structural stabilization
[4b]
 as well as modulation of codon-anticodon interaction.
[11b]
 
Post-transcriptional modifications are particularly frequent at position 34 of tRNA molecules, the so 
called wobble position in the anticodon, where 48 % of nucleosides are modified in E.coli tRNAs. In 
E.coli, U34 is either found as a 5-hydroxyuridine derivative (xo
5
U34) or as a 5-methyl(-2-thio)uridine 
derivative (xm
5
(s
2
)U34) (see Modomics database
[1b, 150]
). These two sets of modified uridines are 
responsible for different effects upon codon-anticodon pairing: the xo
5
U derivatives expand the 
wobble capacity to ensure efficient recognition of all four bases A, U, C and G opposite position 34, 
while xm
5
U modifications limit pairing to only purine-ending codons.
[14, 15b]
 One such modification is 
5-methylaminomethyl-2-thiouridine (mnm
5
s
2
U34), found at position 34 of E.coli tRNA
Glu
 and 
tRNA
Lys
 and the 5-methylaminomethyluridine (mnm
5
U34) of E.coli tRNA
Arg. 
The biosynthetic pathway of mnm
5
(s
2
)U34 is rather complex and it involves a variety of enzymes (see 
Figure 21A). Thiolation at position 2 of uridine, which can occur independently of modification at 
position 5,
[168]
 is catalyzed by MnmA and by the cysteine desulfurase IscS.
[169]
 Initial modification at 
position 5 is performed by MnmE and MnmG (which form a 22 heterotetramer), yielding the 
intermediate 5-carboxymethylaminomethyl(-2-thio)uridine (cmnm
5
(s
2
)U34).
[170]
 Subsequent C-N bond 
cleavage and methylation of cmnm
5
(s
2
)U34 to yield mnm
5
(s
2
)U34 is performed by the bifunctional 
enzyme MnmC.
[171]
 MnmC is composed of two domains: the C-terminal domain (MnmC1) is 
responsible for the initial FAD-dependent cleavage reaction on cmnm
5
(s
2
)U34 to yield the 
5-aminomethyluridine intermediate (nm
5
(s
2
)U34), while the N-terminal domain (MnmC2) performs 
the methylation reaction in the presence of cofactor S-adenosyl L-methionine (SAM) to give 
mnm
5
(s
2
)U34. 
MnmC is only found in bacteria (predominantly -proteobacteria), and knock-out of this protein leads 
to reduced growth rates,
[172]
 suggesting that incomplete modification of U34 results in impaired 
efficiency of protein translation. Furthermore, biochemical kinetic assays revealed that the catalytic 
machinery of this protein is probably tuned to yield only fully modified mnm
5
(s
2
)U34, given the 
tighter binding at MnmC2.
[172]
 The crystal structure of E.coli MnmC with bound FAD and SAM 
cofactors was solved only recently.
[173]
 Yet questions remain regarding the selective mode of RNA 
processing and the extent of cooperativity of the two modification reactions taking place at MnmC1 
and MnmC2.  
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Figure 21 A) Biosynthetic pathway of mnm
5
(s
2
)U and B) Summary of biosynthetic steps under 
investigation. In section A) R = RNA, X = O (for U) or S (for s
2
U). Modification at position 2 is shown in 
green, while at position 5 in red. B) Description of selectively undermodified tRNA
Glu
 (T1, T2) and fully 
modified tRNA
Glu
 T3, alongside the biosynthetic steps investigated with wild type (wt) and mutant MnmC.   
The main aim of the project was to obtain structural information of the MnmC-tRNA complex, in 
order to elucidate the biochemical and structural features which ensure selective modification of the 
uridine at position 34 of E.coli tRNA. Our study proceeded along two main lines of investigation: on 
the one hand characterization of the MnmC-T1 complex, which required prior design of mutant 
proteins for inhibition of the modification reaction, and on the other hand of the MnmC-T2 complex, 
where the reaction could be easily prevented in the absence of cofactor SAM (see Figure 21B). 
Biochemical and structural studies were carried out using selectively undermodified E.coli tRNA
Glu
 
which allowed for the investigation of the binding and activity of wild type and mutant MnmC in the 
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presence of substrate cmnm
5
s
2
U- and nm
5
s
2
U-containing tRNA
Glu
 (T1 and T2, see Figure 21B). The 
final aim was to obtain detailed snapshots of the sequential modification reactions.  
5.2 Results and discussion 
5.2.1 Purification of MnmC 
Purification of endogenous MnmC from Escherichia coli was initially described by Taya and 
Nishimura in 1973,
[174]
 followed by the subsequent purification of recombinant MnmC from E. coli 
published by Hagervall et al. in 1987.
[171a]
 The expression and purification protocol described in this 
work is an adaptation of a later procedure published by Bujnicki et al..
[171b]
 Two different expression 
vectors were used for recombinant expression of MnmC, pET-28a and pET-30a, both providing an 
N-terminal poly-histidine tag. The MnmC gene sequence was cloned in the expression vector pET-28a 
between the NdeI and BamHI restriction sites, yielding a protein with overall molecular weight of 
76.6 kDa. Cloning of this construct for wild type MnmC was originally performed by Dr. David 
Pearson. In the case of pET-30a, the construct was generated by PCR amplification of MnmC using 
primers that carried the KpnI site before the start codon and EcoRI site after the stop codon. The 
forward primer was designed to introduce a new sequence coding for an enterokinase cleavage site 
that would yield, after cleavage of the N-terminal tag, a final MnmC construct with no additional 
residues at its N-terminus (74.5 kDa), a feature that is ideal for crystallization studies. 
Both expression plasmids were transformed in E.coli strain BL21 and protein overexpression was 
performed as detailed in section 5.4.3. MnmC was purified by affinity chromatography using a 
HiScreen IMAC FF column charged with Ni
2+
, followed by ion-exchange chromatography on a 
MonoQ column and by a final purification step using a HiTrap Heparin HP column (see Figure 22). 
For MnmC constructs cloned in pET-30a, an additional tag-cleavage step was performed overnight 
prior to purification using a Heparin resin. Chromatographic purification of MnmC was monitored at 
the UV wavelengths 260 nm, 280 nm and 360 nm (this last one used to monitor the characteristic 
absorption of the FAD cofactor), followed by analysis by SDS-PAGE. 
The purified protein was concentrated (see section 5.4.3), aliquoted and stored at -80 °C. A yield of 
about 10 mg of pure protein was obtained per liter of E.coli culture.  
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Figure 22 Purification of MnmC (pET-30a construct). Chromatograms display UV absorbance at 280 nm 
(blue trace), 260 nm (red trace) and 360 nm (pink trace). The green trace indicates the gradient of the elution 
buffer. A) Affinity purification on HiScreen IMAC FF column. B) Ion-exchange chromatography on MonoQ. C) 
Purification on HiTrap Heparin HP. In all cases, elution fractions displaying absorption at 360 nm (characteristic 
of the FAD cofactor) were pooled for further purification. D) SDS-PAGE of sequential MnmC purification steps, 
lane 1: protein marker, lane 2: cell lysate, lane 3: pooled fractions after affinity purification, lane 4: pooled 
fractions after ion-exchange, lane 5: pure protein after enterokinase tag-cleavage and purification on Heparin 
column, lane 6: protein marker. 
5.2.2 Purification of undermodified E.coli tRNAGlu 
Cloning, expression and purification of undermodified tRNA
Glu
 was first established by Dr. David 
Pearson, who also derived the MnmC knockout MnmC T7 express E.coli strain.[172] The knockout 
strain was used for expression of undermodified tRNA
Glu
 containing cmnm
5
s
2
U at position 34 (T1, see 
Figure 21B). This protocol enabled us to isolate selectively undermodified tRNA
Glu
 which carries the 
characteristic , T and m2A modifications, alongside the cmnm5s2U34, therefore allowing to 
investigate binding and activity of MnmC on substrate tRNA with higher accuracy compared to in 
vitro transcribed tRNA molecules or crude tRNA samples from other species (see Figure 21B).
[172]  
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T1 was overexpressed in the knock-out E.coli strain and total tRNA was extracted and precipitated as 
described in section 5.4.4. The tRNA pellet (about 20 mg per liter of E.coli culture) was resuspended 
in tRNA Buffer A to an approximate concentration of 10 mg/mL, heated to 70 °C for complete 
deacylation and subsequently purified by anion exchange HPLC chromatography. The first 
purification of T1 was performed at pH 5.0, the second at pH 8.0, in both cases eluting with a gradient 
0‒500 mM NaCl (see Figure 23). In order to obtain nm5s2U-containing tRNAGlu (T2), purified T1 was 
reacted with MnmC (in the absence of SAM) for 1 h at 37 °C and subjected to further 
chromatographic purification at pH 8.0 as in the previous step. Purification and complete conversion 
of T1 to T2 prior to final purification was monitored by analytical HPLC. Purified tRNA
Glu
 T1 or T2 
(0.5 mg per liter of E.coli culture) was concentrated in tRNA Buffer A and stored at -80 °C. 
 
Figure 23 HPLC purification of selectively undermodified E.coli tRNA
Glu
 T1 and T2. In all cases 
purification was performed by ion-exchange chromatography. A) Purification of crude E.coli tRNA (tRNA 
Buffer B, pH 5.0). B) Second purification step to isolate T1 (tRNA Buffer A, pH 8.0). C) Reaction of T1 to T2 in 
the presence of MnmC in MnmC Reaction Buffer (R = RNA). D) Final purification of T2 (tRNA Buffer A, 
pH 8.0). Note the characteristic shift in retention time between T1 (about 25 min) and T2 (about 22.5 min) 
5.2.3 Characterization of the FAD-binding domain and design of inactive mutants for 
crystallization studies 
The C-terminal domain of MnmC (residues 255-668) is responsible for the FAD-dependent C-N bond 
cleavage of cmnm
5
s
2
U to the intermediate nm
5
s
2
U. This domain is characterized by a protein fold 
typical of the glutathione reductase 2 (GR2) family of FAD-binding proteins, and it is closely related to 
the D-amino acid oxidases (DAAO) superfamily,
[175]
 in particular to the glycine oxidase ThiO from 
Bacillus subtilis (PDB 1NG3), as well as to monomeric sarcosine oxidase (PDB 3M13).
[173a]
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Initial structural modelling studies of MnmC based on protein fold-recognition,
[175a]
 largely confirmed 
by later determination of the crystal structure of E.coli MnmC in complex with FAD (see Figure 24A 
and B, PDB 3AWI, PDB 3PS9),
[173]
 suggested that residues G271, G272 and G273 are involved in 
binding of the adenosine moiety of FAD, N306 interacts with the flavin, while residues R567, S617 
and R618 are responsible for binding of the substrate base cmnm
5
s
2
U and its conversion to 
nm
5
s
2
U.
[175a]
 The mechanism, suggested to largely resemble that of ThiO, is thought to proceed via a 
hydride transfer to the N5 of the flavin, facilitated by the nitrogen lone pair of the cmnm
5
 moiety.
[171b, 
176]
 A superposition model of MnmC and ThiO
[173a]
 reveals that R567 might be involved in hydrogen 
bonding to the carboxylate moiety of cmnm
5
U, a feature also observed in ThiO where Arg302 
coordinates the carboxylate oxygen atoms of N-acetylglycine and ensures correct orientation of the C 
atom with respect to the flavin moiety.
[176]
 From the same superposition model, R618 is suggested to 
be involved in binding of the tRNA anticodon loop.
[173a]
 
Mutational analysis of MnmC confirmed that R567A and R618A lead to partial inactivation of the 
C-N bond cleavage reaction, while no mutagenesis data support the role of S617.
[175a]
 However, 
enzymatic activity assays of these mutants were only performed with total tRNA from Bacillus subtilis 
(due to the natural occurrence of cmnm
5
s
2
U-containing tRNA in this organism and absence of nm
5
s
2
U 
or mnm
5
s
2
U) and no accurate data is yet available concerning their activity on substrate E.coli 
tRNA
Glu
. 
5.2.3.1 Cloning, purification and enzymatic activity assay of MnmC mutants R567A, S617A 
and R618A 
In order to design a MnmC mutant which would be suitable for structural characterization of the 
MnmC-T1 complex, we decided to investigate the extent of inactivation of the R567A, R618A and 
S617A mutants on conversion of E.coli T1 to T2. Protein mutants were generated for both pET-28a 
and pET-30a constructs using the Agilent Quick-change Lightning Site-directed Mutagenesis kit. 
Given the large plasmid, a different mutagenesis approach was used in order to avoid the potential 
problems which could arise from amplification of large targets. The method relies on a two-primer, 
two-stage PCR protocol which initially generates a megaprimer containing the desired mutation, 
followed by full plasmid amplification.
[177]
 Different mutagenic primers were used for the three 
desired mutants, while a single, non-mutagenic primer (not complementary to the first one) was used 
for megaprimer formation for all three constructs. After sequence verification, mutated plasmids were 
transformed in a BL21 E.coli expression strain and mutant proteins expression and purification was 
performed as detailed in section 5.2.1. 
Purified mutant proteins were subsequently tested for enzymatic activity on E.coli MnmC mutant-
derived crude tRNA to obtain a first estimate of the extent of inactivation. The assay was performed 
by incubating 20 µg of protein with 20 µg of crude tRNA contaning undermodified tRNA
Glu
 T1 as 
detailed in section 5.4.5, and samples were subsequently subjected to analytical ion-exchange 
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chromatography. Reaction progress was estimated by analysis of the peaks corresponding to T1 and 
T2.  
 
Figure 24 Activity assay of MnmC mutants R567A, R618A and S617A. A) Crystal structure of wild type 
E.coli MnmC bound to cofactors FAD and SAM (PDB 3ps9
[173b]
). B) Zoom into FAD active site (PDB 3ps9) 
highlighting residues which were mutated in the course of this study. Panels C-E display chromatograms 
monitoring the activity of wild type and mutant MnmC R567A, R618A and S617A on crude E.coli tRNA 
containing T1. C) Comparison of wild type, R567A and R618A MnmC. Wild type MnmC leads to conversion of 
T1 to T2 (large peak at 12.5 min). This conversion is largely suppressed in the case of the two mutant proteins. 
D) Comparison of wild type and S617A MnmC. Conversion of T1 to T2 is comparable for the two proteins, 
suggesting that the S617A mutation does not lead to inactivation (Note the slight shift in retention time, arising 
from small changes in salt concentration upon replenishing of elution buffer. Nevertheless, the two 
chromatographic profiles look very similar, indicating comparable conversion of T1 to T2). E) Control 
chromatogram displaying the two unreacted crude E.coli tRNA samples, one containing T1 and the other T2, for 
comparison of the expected profile and retention times for the two species. 
Shown in Figure 24 are the chromatograms of the reaction assays for the different mutant proteins. For 
comparison, unreacted crude tRNA (contaning T1) is presented in panel E alongside tRNA contaning 
T2, highlighting the expected difference in retention time between T1 (about 14 min) and T2 
(12.5 min), which allows to monitor the extent of reaction between the two differently modified tRNA 
species. As shown in Panel C, R567A and R618A mutant proteins display a large extent of 
inactivation of the conversion from T1 to T2, as evident from the small peak at retention time 12.5 min 
(T2) compared to the wild type enzyme and the correspondingly higher peak for T1 observed at 
14 min, confirming that both residues are essential for catalysis as previously shown by Roovers 
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et al..
[175a]
 On the contrary, mutant S617A (in Panel D) shows a chromatogram largely resembling that 
of the wild type enzyme, therefore suggesting that residue S617 is not essential for catalytic activity 
and that it might only play a minor role in binding of the target nucleobase in the enzyme active site. 
For each mutant protein a second set of reactivity tests was performed to verify that mutagenesis did 
not compromise the catalytic activity of the N-terminal methyltransferase domain. In all cases, 
conversion of T2 (nm
5
s
2
U-tRNA
Glu
) to T3 (mnm
5
s
2
U-tRNA
Glu
) in the presence of SAM was 
comparable to that of the wild type enzyme, in line with previous data published by Roovers et al. 
which highlighted the high degree of independence of the two domains in their catalytic activity.
[175a]
 
The results shown in Figure 24 therefore confirm that the alanine mutations of residues R567 and 
R618 can yield largely inactive proteins. In order to verify whether inactivation could be brought to 
completion upon lowering of the reaction temperature, a second activity test was performed at 4 °C at 
concentrations comparable to those used for crystallization (200 µM MnmC, 240 µM T1). Incubation 
overnight followed by analysis by HPLC showed that both R567A and R618A mutants retain partial 
activity at 4 °C, making these mutants unsuitable for structural characterization since the residual 
catalytic activity would not allow to obtain structural information on substrate binding to the C-
terminal domain. 
5.2.3.2 Cloning, purification and enzymatic activity assay of MnmC mutants Y312F, C500A, 
Y504F, Y521A and double mutant R567A/R618A 
Given that the first MnmC mutants proved unsuitable for crystallization studies, a second set of 
mutants was generated in an attempt to fully inactivate the protein and to further characterize residues 
in the active site which could be involved in substrate binding and catalysis. The following mutants 
were therefore generated: the double mutant R567A/R618A, to verify whether combining two 
inactivating mutations would lead to full suppression of the catalytic activity; Y504F, since Y504 is 
thought to coordinate the flavin ring through hydrogen bonding to its side chain;
[173a]
 Y312F, given 
that Y312 is placed adjacent to residue R618 and might be involved in coordination of the substrate in 
the active site, as previously observed for DAAO;
[178]
 C500A and Y521A, to investigate their potential 
role in substrate binding in the active site pocket. 
As described in Section 5.2.3.1, generation of the new mutants was performed using the Megaprimer 
PCR-based protocol, where the desired mutation was inserted by using different forward mutagenic 
primers for each individual mutant, together with a common reverse primer. The mutants for this 
second set were generated using the pET-30a plasmid construct, mutagenesis was verified by 
sequencing, and the plasmids were transformed in E.coli BL21 for subsequent protein expression and 
purification.  
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Activity assays for the newly designed MnmC mutants were performed using purified T1. Reactions 
were set up and analyzed by HPLC as described in section 5.2.3.1. The resulting chromatograms are 
shown in Figure 25. 
 
Figure 25 Activity assay of new set of MnmC mutants. Mutants Y312F, C500A, Y504F, Y521A, 
R567A/R618A were tested for conversion of T1 to T2. Previously generated mutants R567A, R618A and S617A 
(see Section 5.2.3.1) were also used in this assay for comparison. Conversion of T1 to T2 was monitored by ion-
exchange chromatography. A) Comparison of activity of wild type MnmC and mutants Y312F, C500A, Y521A, 
S617A and Y504F. In all cases, mutant proteins display the same activity as the wild type. B) Comparison of 
wild type MnmC and mutants R567A, R618A and the double mutant R567A/R618A. The double mutation leads 
to complete inactivation of the FAD-dependent reaction. C) Control chromatograms with unreacted T1, T2 and 
coinjection of the two species for comparison of the characteristic retention times. D) Summary of the relative 
activities of wild type and mutant MnmC analyzed in Panel B.  
As evident from Figure 25, Panel A, the majority of the newly designed mutants (Y312F, C500A, 
Y504F, Y521A) displayed the same chromatographic profile as the wild type enzyme, suggesting that 
conversion of T1 (retention time about 11 min) to T2 (retention time 10.5 min) is not affected by the 
mutation (note that S617A from the previous set of mutants was also tested in the same assay for 
comparison). On the contrary, comparison of the double mutant R567A/R618A with the wild type 
enzyme and with the single mutations R567A and R618A, shown in panel B, revealed that removal of 
both arginines in the active site leads to complete inactivation of the deacetylation reaction (a 
comparison of the relative activity of mutants shown in Figure 25B is summarized in Panel D). Panel 
C displays the control samples containing unreacted T1, T2 as well as the co-injection, for comparison 
of the retention times. We deduce that the key players in the catalytic conversion of cmnm
5
s
2
U to 
nm
5
s
2
U are R567 and R618, where R567 is suggested to coordinate the carboxylate group in the 
cmnm
5
-modification and R618 is thought to be involved in  binding of the target nucleobase.
[173a]
 The 
complete inactivation of the FAD-dependent reaction in R567A/R618A makes this mutant suitable for 
further crystallization studies aiming at the investigation of MnmC in complex with T1. 
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5.2.4 Circular dichroism studies of MnmC mutants 
In order to verify that the MnmC mutants display the same conformation as the wild type enzyme, 
circular dichroism studies were performed to compare the secondary and tertiary structures of the 
purified proteins. Circular dichroism is defined as the differential absorption of left- and right-handed 
circularly polarized light, and it is an excellent tool for studying the conformation and folding of 
proteins. More specifically, the far UV absorption (240 nm and below) arises from the peptide bond 
and provides information concerning the secondary structure, while spectra in the near UV region are 
mostly resulting from aromatic amino acids and organic cofactors (such as e.g. flavins) and inform 
about the tertiary structure of the protein under investigation. Wild type MnmC, as well as R567A, 
R618A and R567A/R618A were diluted to 1.6 µM (far UV) and 20 µM (near UV) in MnmC CD 
buffer and far and near spectra were measured using a 1 mm or 1 cm pathlength, respectively. The 
resulting spectra are shown in Figure 26. 
 
Figure 26 CD spectra of wild type and mutant MnmC. A) Far and B) near UV spectra of the mutant and wild 
type proteins show that there is no change in the secondary and tertiary structures upon mutation of the arginine 
residues in the active site. 
From Figure 26 it is evident that both the far (Panel A) and near (Panel B) UV spectra, corresponding 
to secondary and tertiary structure, respectively, display largely similar features in the wild type and 
mutant proteins, suggesting that loss of function in the arginine mutants is not due to unfolding of the 
MnmC C-terminal domain. Furthermore, the similar conformational features of the double mutant 
MnmC compared to the wild type confirm that this mutant is also a suitable candidate for structural 
characterization of the MnmC-T1 complex.  
5.2.5 Spectroscopic properties of MnmC and comparison with mutants 
The absorption spectrum of MnmC shows the characteristic features of a flavoprotein (Figure 27), 
with maximum absorption at 357 nm and 430 nm corresponding to the flavin cofactor, as originally 
described by Bujnicki et al., who also identified the flavin derivative as FAD.
[171b]
 Spectra of mutant 
MnmC proteins displayed similar features, suggesting that mutations did not lead to loss of the 
cofactor.  
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Figure 27 Absorption spectrum of wild type MnmC. 
5.2.6 Binding studies with T1 and T2 
In order to further characterize the protein-tRNA complex as well as to optimize the crystallization 
conditions, binding studies were performed with MnmC mutant and wild type proteins in complex 
with T1 and T2, respectively. Complexation was monitored using gel electrophoresis mobility shift 
assays (EMSA), where the free and bound tRNA could be monitored by SYBR Green II staining, and 
optimization of the experimental conditions was performed together with Dr. David Pearson. In order 
to derive the dissociation constant Kd, the tRNA concentration was optimized to ensure that free 
protein, free tRNA and complex would be present at equilibrium. As shown in Figure 28, different 
protein concentrations were incubated with a constant tRNA amount. In the case of MnmC 
R567A/R618A protein (Figure 28A) concentrations ranged from 0.1 µM to 20 µM with T1 set 
constant at 0.5 µM, while 1 µM T2 (Figure 28B) was incubated with wild type MnmC ranging from 
0.37 µM to 15.6 µM. 
In both cases, the dissociation constant was calculated by nonlinear least-squares fit to Equation 1 (see 
Section 5.4.8)
[179]
 which yields values for Kd assuming that there is a degree of receptor depletion. The 
Kd (T1) and the Kd (T2) are respectively 1.35 µM and 1.25 µM (see Figure 28). This is to some extent 
surprising given that previous kinetic studies suggest that the affinity of MnmC for T2 should be about 
ten-fold higher than for T1.
[172]
 However, the different binding affinity observed by gel shift assay 
might be due to the fact that complexation could be affected by the gel matrix, therefore disfavouring 
protein-RNA binding at lower concentrations and yielding an underestimation of the binding affinity 
for T2 (expected to be around 100 nM). 
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Figure 28 Binding studies of R567A/R618A and wild type MnmC with T1 and T2, respectively. A) EMSA 
binding study for R567A/R618A bound to T1 and corresponding binding isotherm plot used to calculate the 
Kd(T1). B) EMSA binding for wild type MnmC bound to T2 and corresponding binding isotherm plot. 
Most importantly, these binding studies confirm that incubation of MnmC with substrate tRNA at 
concentrations at least 10-fold above the obtained Kd result in full complexation, a feature which is 
essential for crystallization, and that could be used for later optimization of the crystallization 
conditions. 
Binding studies for MnmC in complex with T2 were also performed in the presence of Aza-SAM to 
investigate whether the AdoMet homologue could affect the binding affinity, but no significant effect 
was observed.  
Furthermore, in order to optimize the crystallization conditions, a stoichiometric titration of wild type 
MnmC with T2 was performed in order to determine the stoichiometry of the protein-tRNA complex. 
In fact, T2 should be bound at the N-terminus (where it is the preferred substrate) but could also bind 
at the C-terminus (where it is the product of the C-N bond cleavage reaction). For this purpose, T2 at 
concentrations at least 10-fold above the estimated Kd (in this case [T2] = 20 µM) was incubated with 
increasing concentrations of MnmC (up to 4-fold the tRNA concentration, 0‒80 µM). The expected 
pattern is a linear increase in the complex signal with increasing protein concentration, which reaches 
a plateau in correspondence of the protein equivalents yielding full tRNA complexation. However, as 
shown in Figure 29, stoichiometric curves present a few problems for the MnmC-tRNA complex: first 
of all, the large amounts of tRNA required for stoichiometric titrations result in signal cancellation 
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effects which make it impossible to quantify the tRNA vs complex signal intensity; second, the MnmC 
intrinsic fluorescence further distorts the signal intensity for the MnmC-tRNA complex; third, at these 
concentrations tRNA binding seems to be strongly affected by the gel matrix, possibly because of the 
small sample volumes used and the subsequently larger dilution effects resulting upon loading onto the 
gel (which could explain the observed smearing). However, from the stoichiometric binding curve 
presented in Figure 29 we can at least exclude a 2:1 tRNA to protein complex. More accurate 
evaluation of the stoichiometry of the complex could be investigated in the future by alternative 
methods such as, for example, capillary electrophoresis. 
 
Figure 29  Stoichiometric binding study with wild type MnmC and T2. Note the distorted fluorescence 
signal arising from large tRNA amounts. Smearing of the signal is most likely due to dilution effects upon 
loading of the sample on the gel.  
5.2.7 Preliminary crystallization screening of the MnmC-T2 complex 
One of the principal aims of the project was to investigate the structure-function relationships for the 
MnmC-tRNA complex to elucidate the specific features which ensure selective modification at the 
U34 position of E.coli tRNAs Glu, Lys and Arg. The structure of MnmC from E.coli was recently 
solved by two groups (PDB 3awi,
[173a]
  PDB 3ps9
[173b]
), but no crystal structure of the protein-tRNA 
complex is available yet.  
Given that the conversion reaction from T2 to T3 could easily be trapped in the absence of cofactor 
SAM, the majority of the crystallization tests were performed using wild type MnmC in complex with 
T2. Preliminary stability tests were performed incubating MnmC in crystallization buffer (see Section 
5.4.3) at 4 °C and 18 °C over three days and samples were analyzed by SDS-PAGE. In both cases, no 
protein degradation was observed. Similarly, MnmC was incubated at 4 °C and at 18 °C over three 
days and its tertiary structure evaluated by circular dichroism to verify whether the protein was 
unfolding during prolonged incubation in crystallization buffer. In both cases the tertiary structure was 
comparable to a control sample, suggesting that no protein unfolding was taking place.  
Crystallization screening was performed under a wide variety of conditions. High throughput 
screening using sitting drop was performed at the Max Planck Institute for Biochemistry (Conti Lab, 
Martinsried) as well as at the HT Crystallization Facility at the University of Zürich. Commercially 
available kits from Qiagen and Hampton  were used, as well as in-house designed crystallization 
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screenings. In addition, manual screening were performed in a 24-well hanging drop-format using 
crystallization conditions previously published for MnmC (PDB 3ps9, conditions taken from PDB 
prior to publication).
[173b]
  
Crystallization drops were generally set up using a 1:1 mixture of complex to reservoir, with a 1:1.2 
molar ratio of MnmC:T2 in crystallization buffer supplemented with 16 µM FAD and, occasionally, 
100 µM Aza-SAM. The complex was set up on ice prior to HT crystallization, and screening was 
performed both at 4 °C and at 18 °C. No crystals could be obtained so far.  
5.3 Conclusion 
Investigation focused on the two sequential biosynthetic steps that yield the modified mnm
5
s
2
U34 in 
E.coli tRNA
Glu
. Mutations of MnmC residues located in the FAD active site revealed that the main 
residues involved in catalysis are the two arginines R567 and R618, responsible for coordination of the 
cmnm
5
-moiety and binding of the substrate nucleobase,
[175a]
 while other residues might only play a 
minor role in coordination of the anticodon loop. Binding of the wild type and mutant MnmC to 
substrate tRNA species T1 and T2 lies in the low µM range, largely in agreement with previous kinetic 
studies,
[172]
 and the protein is likely to bind the tRNA substrates in a 1:1 complex. Furthermore, the 
fully inactive mutant R567A/R618A is a suitable candidate for crystallization screening in complex 
with substrate tRNA T1, given that it retains a similar secondary and tertiary structure to that of wild 
type MnmC as well as binding of the FAD cofactor. Further optimization of the crystallization 
conditions is required for both protein-tRNA complexes, and will provide insight into the selective 
recognition and modification of tRNA
Glu
 at the wobble position by MnmC. 
 
5.4 Materials and methods 
5.4.1 Cloning of pET-28a and pET-30a MnmC 
Cloning of wild type E.coli MnmC in pET-28a (Novagen) was performed by Dr. David Pearson 
according to Bujnicki et al..
[171b]
 Cloning of wild type MnmC in pET-30a (Novagen) was performed by 
PCR amplification of the MnmC gene from the pET-28a construct using the following primers:  
5´-GGATTAGCGAGGTACCGACGACGACGACAAGATGAAACACTACTCCATACAACCTGCC
AAC- 3´ 
5´-GCTACGGTCTGAATTCTCATTACCCCGCCTTAACCGCTTTACCCTTCAA- 3´ 
This primer pair yields a PCR product containing the KpnI and EcoRI restriction sites for cloning into 
pET-30a, as well as a newly designed Enterokinase cleavage site that, after incubation with the 
protease, results in complete removal of non-MnmC residues at the N-terminus of the purified protein. 
The PCR amplified gene was cloned in pET-30a between the KpnI and EcoRI restriction sites and 
correct amplification and cloning was verified by DNA sequencing. A similar cloning protocol was 
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also used to generate R567A and R618A pET-30a constructs using mutant pET-28a constructs 
(generated as detailed in the next section) as templates.  
5.4.2 Mutagenesis of pET-28a and pET-30a  
Mutations of the pET-28a MnmC construct were generated by initial megaprimer generation 
(introducing the desired mutation), followed by full plasmid amplification.
[177]
 Mutants R567A, S617A 
and R618A were generated from the wild-type MnmC-pET28a plasmid using the respective primers 
listed in Table 11, in combination with MnmCmid primer, yielding megaprimers of about 1200 bp (for 
R567A) and  1350 bp (for S617A and R618A).  
Primer Template 
plasmid 
Sequence 
MnmC R567A 
– rev 
pET-28a MnmC 
(wt) 
GATCGCGGGTGGCACAAGCCACACCGCAGCGCGCC 
(Roovers 2008) 
MnmC R618A 
– rev 
pET-28a MnmC 
(wt) 
GGCAGAACACAAACCGGCAGAACCTAAAGCCGC 
(Roovers 2008) 
MnmC S617A 
– rev 
pET-28a MnmC 
(wt) 
CAGAACACAAACCGCGAGCACCTAAAGCCGCAAAC 
MnmCmid  AGTAGATGCCTGGTTTCTGGACGG 
Table 11 Forward non-mutagenic (MnmCmid) and reverse primers carrying the R618A, R567A and S617A 
mutations used for mutagenesis of pET-28a MnmC.  
Mutagenesis by PCR amplification was performed using the Agilent Quick-change Lightning Site-
directed Mutagenesis Kit (Agilent) with the PCR program detailed in Table 12, followed by plasmid 
digestion using DpnI (New England Biolabs) and transformation in XL-10 Gold Ultracompetent cells 
(Stratagene). Correct mutagenesis was verified by DNA sequencing. 
Temperature 
(°C) 
Time 
(min) 
Number of 
cycles 
95 3   
95 0.5  
3 x 55 1  
72 1  
95 0.5 20 x 
68 8  
68 15   
4 hold  
Table 12 PCR program cycles for megaprimer-based mutagenesis. 
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A second set of mutants was generated by a similar protocol as detailed in the previous paragraph. 
Individual primers containing the desired mutation (Y312F, C500A, Y504F, Y521A, R567A, see 
Table 13) were used in combination with MnmCmid to generate megaprimers of pET-28a MnmC 
constructs (wild type or R618A) to yield single mutants and the double mutants R567A/R618A 
pET-28a construct. Correct mutagenesis was verified by sequencing. The generated pET-28a mutant 
constructs were subsequently digested with HindIII and NcoI restriction endonucleases and cloned in 
pET-30a MnmC constructs between the same sites, therefore yielding mutated pET-30a constructs 
Y312F, C500A, Y504F, Y521A and R567A/R618A.  
Primer Template 
plasmid 
Sequence 
MnmC Y312F- 
rev   
pET-28a 
MnmC (wt) 
GTTTGCTTAATAACGGAAACAGCGCCCCCTGGCG 
MnmC C500A 
– rev 
pET-28a 
MnmC (wt) 
GAGATAACCGTCATAGGCCAGCACCTGCTTCAGC 
MnmC Y504F 
– rev 
pET-28a 
MnmC (wt) 
CGGATTTTGTGGCGTGAGAAAACCGTCATAGCACAG 
MnmC Y521A 
– rev 
pET-28a 
MnmC (wt) 
CGCTGCCGCGATGAGCACTGGCACCAATACAATG  
MnmC R567A 
– rev 
pET-28a 
MnmC R618A 
GATCGCGGGTGGCACAAGCCACACCGCAGCGCGCC 
(Roovers 2008) 
MnmCmid 
primer 
 AGTAGATGCCTGGTTTCTGGACGG 
Table 13 Forward non-mutagenic (MnmCmid) and reverse primers carrying the C500A, Y504, Y312F, Y521 
and R567A mutations used for mutagenesis of pET-28a MnmC. Plasmids used as template for mutagenesis are 
listed in the section “Plasmid”. 
5.4.3 Protein expression and purification 
The protocol for protein expression and purification was adapted from Bujnicki et al..
[171b]
 Plasmids 
containing wild type or mutant MnmC were transformed in E.coli BL21 cells (New England Biolabs). 
Cells were grown in LB medium supplemented with 15 µg/mL kanamycin, at 37 °C, until a cell 
density OD600 = 0.7 was reached. Protein expression was induced by addition of IPTG (1 mM final 
concentration) and cells were grown for further 3 h at 37 °C and finally harvested. 
Cells were resuspended in cold MnmC Buffer A (50 mM Tris pH 8.0, 10 % glycerol, 10 mM MgCl2, 
200 mM KCl, 5 mM imidazole, 3 mM -mercaptoethanol) supplemented with a cocktail of protease 
inhibitors (Complete EDTA-free, Roche) and lysed using a French press. The lysate was cleared by 
centrifugation using a Sorvall SS-34 rotor (18000 rpm, 4 °C, 30 min) and applied onto a HiScreen 
IMAC FF column (GE Healthcare) at 4 °C. The protein was eluted by applying a gradient to MnmC 
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Buffer B (MnmC Buffer A + 0.5 M imidazole) and the eluted fractions pooled, concentrated using an 
Amicon Ultra centrifuge filter (Millipore, 30,000 MWCO), and buffer-exchanged to MnmC Buffer C 
(50 mM Tris pH 8.0, 10 % glycerol, 10 mM MgCl2, 3 mM -mercaptoethanol). The protein sample 
was then loaded onto a 1 mL MonoQ ion-exchange column (GE Healthcare) equilibrated with MnmC 
Buffer C. Protein was eluted by applying a linear gradient to MnmC Buffer D (MnmC Buffer C + 
0.5 M KCl), concentrated using an Amicon Ultra centrifuge filter (Millipore) and buffer exchanged to 
MnmC Buffer E (MnmC Buffer C + 50 mM KCl). Tag-cleavage of pET-30a constructs was performed 
by incubating the sample in MnmC Buffer E supplemented with 7.5 mM CaCl2 in the presence of 
Enterokinase light chain protease (New England Biolabs). The sample was incubated overnight at 
4 °C, and complete cleavage was monitored by SDS-PAGE. Finally, the sample was applied onto a 
1 mL HiTrap Heparin HP (GE Healthcare) and eluted by applying a gradient to MnmC Buffer D. 
Purified protein was stored in crystallization buffer MnmC Buffer F (50 mM Tris pH 8.0, 10 % 
glycerol, 1 mM MgCl2, 100 mM KCl, 3 mM -mercaptoethanol) at -80 °C.  
5.4.4 tRNA expression and purification 
Plasmid tRNA
Glu
-pSGAT2 was transformed in MnmC T7 express E.coli.[172] Transformed cells were 
grown in LB medium (with 100 µg/mL carbenicillin) at 37 °C until an OD600 of 0.5. tRNA expression 
was induced with 1 mM IPTG for 6 h at 30 °C. Subsequent tRNA extraction steps were performed at 
4 °C as described previously.
[142]
 Harvested cells were resuspended in 15 mL of tRNA extraction 
buffer (0.01 M Mg(OAc)2, 0.05 M NaOAc, 0.15 M NaCl, pH 4.5) and mixed with an equal volume of 
80 % aq. phenol. The suspension was shaken vigorously for 1 h at 4 °C and centrifuged for 30 min at 
3220 g. The aqueous layer was once again extracted with 15 mL of 80 % aq. phenol, followed by 
centrifugation (20 min, 3,220 g). The aqueous phase was extracted twice with chloroform (5 mL) and 
separated by centrifugation (10 min, 3,220 g). DNA and long RNAs were precipitated by addition to 
the aqueous phase of 0.1 vol of 20 % KOAc, pH 4.5 and LiCl to a final 2.0 M concentration, followed 
by incubation for 4 h at 4 °C and centrifugation (20 min, 38,724 g). The supernatant was combined 
with 3 vol of absolute EtOH and incubated overnight at -20 °C. The tRNA was pelleted by 
centrifugation (60 min, 24,336 g) and resuspended in tRNA Buffer A (100 mM Tris pH 8.0, 50 mM 
MgCl2). Subsequently, tRNA samples were subjected to anion exchange HPLC purification using a 
DNAPac PA100 22 x 250 mm column (Dionex) on a Merck Hitachi Lachrom system. Purification of 
cmnm
5
s
2
U-tRNA (T1) was performed once with tRNA Buffer B (100 mM NaOAc, pH 5.0, 50 mM 
MgCl2), followed by purification in tRNA Buffer A, in both cases eluting the tRNA samples by 
applying a gradient to 500 mM NaCl (T1 and T2 eluted at about 200‒250 mM NaCl). Purity and 
correct isolation of T1 was verified by incubation with purified MnmC and analysis by analytical 
HPLC on a DNAPac PA100 4 x 250 mm column (Dionex). Isolation of T2 required prior incubation of 
purified T1 with MnmC (1 h, 37 °C) in MnmC Reaction Buffer (50 mM Tris pH 8.0, 20 mM NH4Cl), 
followed by purification by anion exchange chromatography in tRNA Buffer A (elution with gradient 
to 500 mM NaCl). After each purification step, tRNA fractions were pooled, concentrated and buffer 
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exchanged using an Amicon Ultra centrifugal filter (10,000 MWCO, Millipore). Purified T1 and T2 
were stored in tRNA Buffer A at -80 °C.  
5.4.5 Mutant activity assay 
Mutant MnmC proteins were incubated either with crude E.coli tRNA containing undermodified 
tRNA
Glu
 or with purified T1 as detailed in sections 5.2.3.1 and 5.2.3.2. Assays were performed 
incubating wild type or mutant MnmC with substrate tRNA in MnmC Reaction buffer at 37 °C. For 
initial screening of R567A, S617A and R618A mutant activity, 20 µg of protein were incubated with 
20 µg of crude tRNA containing undermodified T1 (after ethanol precipitation, resuspended in tRNA 
Buffer A, see section 5.2.2) in a total 10 µL reaction volume, and incubated at 37 °C for 30 minutes. In 
the case of conversion of T2 to T3, the reaction with T2-containing crude E.coli tRNA was 
supplemented with 500 µM SAM. Activity tests of mutants described in section 5.2.3.2 were set up 
with 130 nM protein and 130 nM T1 in 60 µL total reaction volume. Reaction was incubated at 37 °C 
for 30 min. Reaction samples were quenched by addition of tRNA Buffer B (at least one vol) and 
analyzed on a DNAPac PA100 4 x 250 mm column (Dionex) using a Merck Hitachi Lachrom system. 
Elution was achieved by applying a gradient of 175‒225 mM NaCl. Reaction progress was estimated 
by analysis of the peaks corresponding to T1 and T2, each displaying a characteristic retention time. 
5.4.6 Circular dichroism  
Circular dichroism studies were performed using a Jasco Spectropolarimeter J-810. Protein samples 
were diluted in MnmC CD Buffer (20 mM Tris pH 8.0, 1 mM MgCl2, 5 % glycerol) to the 
concentrations detailed in Section 5.2.4, and spectra were recorded in triplica at 20 nm/min at 20 °C, 
using 1 mm and 1 cm pathlength for far and near UV, respectively. 
5.4.7 UV-Vis Spectroscopy 
Spectra were measured using a Jasco V-650 Spectrophotometer. Protein samples were diluted in 
MnmC UV Buffer (50 mM Tris pH 8.0, 10 mM MgCl2) at a concentration of 2 mg/mL. Spectra were 
measured in the range of 300‒500 nm using a 1 cm pathlength, at 20 °C. 
5.4.8 Electrophoretic mobility shift assay for the protein-tRNA complex 
Wild type and mutant MnmC protein stocks were prepared by serial dilutions in Binding buffer 
(50 mM Tris pH 8.0, 1 mM MgCl2, 20 mM NH4Cl, 1 mM -mercaptoethanol, 50 mM KCl, 10 % 
glycerol) and incubated with the appropriate amount of T1 or T2 in a final 10 µL (for equilibrium 
binding curves) and 4 µL (for stoichiometric curves). The complex was allowed to reach equilibrium 
for 1 hour at 4 °C and separated through a 8 % native polyacrylamide gel (8 % polyacrylamide, 2.5 % 
glycerol, 0.5 x TAE buffer) for 50 min at constant 100 V in 0.25 x TAE buffer at 4 °C. A 5 µL loading 
dye sample was loaded separately to monitor progress. The gel was subsequently incubated in 
0.25 x TAE buffer containing SYBR Green II (Sigma, 1:10,000 dilution) for 10 min. The tRNA and 
tRNA-MnmC bands were visualized using a Fuji LAS 3000 fluorescence imager, and band 
quantification was performed using AIDA software, and fitting to Equation 1
[179]
 was performed using 
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ORIGIN
®
. Samples containing T1 in complex with MnmC R567A/R618A were prepared in duplica, 
one aliquot loaded on a native polyacrylamide gel as detailed above, and one analyzed by analytical 
HPLC to confirm the absence of conversion of T1 to T2.  
Equation 1
[179]
   
   
                                  
               
 
 
where   Ltot = total ligand concentration (µM) 
  Ptot = total protein concentration (µM) 
  Kdis = dissociation constant 
  B = ligand bound (µM) 
 
5.4.9 Protein crystallization screening 
For co-crystallization, the MnmC-T2 complex was set up in a 1:1.2 molar ratio in crystallization 
buffer (50 mM Tris pH 8.0, 10 % glycerol, 1 mM MgCl2, 3 mM -mercaptoethanol, 20 mM NH4Cl, 
100 mM KCl) supplemented with 16 µM FAD and, depending on the screening, 100 µM Aza-SAM. 
Protein:tRNA concentrations were screened ranging from 10:4 mg/mL, to 30:12 mg/mL. The complex 
was set up on ice with freshly purified protein.   
High throughput screening was performed using a Phoenix nanodispenser robot (Art Robbins 
Instruments, drop size: 100 nL complex + 100 nL precipitant) in the research group of E. Conti (Max 
Planck Institute, Martinsried). The following screening kits were used: Qiagen JCSG+ kit, Qiagen 
MPDs kit, Qiagen PEGs kit, Hampton research Index kit, all commercially available, as well as 
additional screening kits designed by the Conti group (AJ1, AJ2, CP-PEGS-Salt screen kits). Plates 
were incubated either at 4 °C or at 18 °C.  
An additional robot screening was performed at the HT Crystallization facility at the University of 
Zürich using in-house designed crystallization screening kits. Plates were incubated at 20 °C. 
Finally, manual screenings were performed using a 24-well hanging drop-format with 1.2‒2.2 M tri-
ammonium citrate, pH 7.0, 0.1‒0.8 % ethyl acetate, at 20 °C (conditions used for PDB 3ps9).[173b]  
In all cases, no crystals could be obtained. In the best cases, drops showed fine crystalline precipitate 
or small spherulites. 
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6 Investigation of putative pathways of cytosine demethylation involving 
C-C bond cleavage or replication-coupled dilution 
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6.1 Introduction 
In eukaryotes, methylcytosine (mC) is thought to be a rather stable DNA modification and it plays an 
important role in a variety of processes such as modulation of gene expression, genomic imprinting 
and X-chromosome inactivation.
[180]
 However, methylation has also been observed to have a dynamic 
nature: on the one hand, de novo methylation taking place during development plays a crucial role in 
loss of pluripotency and in cellular specification;
[181]
 on the other hand, methylcytosine has also been 
reported to undergo depletion in both genome-wide and gene-specific demethylation events,
[122b]
 
where loss of the methylation pattern is thought to take place via active or passive mechanisms.
[122b]
 
For example, a rapid wave of genome-wide demethylation takes place in the male pronucleus after 
fertilization,
[182]
 resulting from genome-wide oxidation of mC,
[114]
 while gene-specific demethylation 
has been mainly observed in somatic cells,
[122b]
 such as activated T lymphocytes
[183]
 and neurons.
[127b]
 
While passive demethylation, where the methylation pattern is lost by dilution during replication, is 
broadly accepted, active demethylation remains a subject of controversy.
[122]
 Nevertheless, discovery 
of the oxidized cytosine derivatives 5-hydroxymethylcytosine (hmC), 5-formylcytosine (fC) and 
5-carboxycytosine (caC) has led to increasing interest in these modified nucleosides as possible 
intermediates in the demethylation process.
[98b, 100]
 Up to date, two main pathways of active 
demethylation have been proposed (see Figure 30). Demethylation might involve DNA glycosylases 
coupled to base excision repair (BER) while an alternative mechanism postulates direct C-C bond 
cleavage at the C5 position, yielding an unmodified cytosine without excision of the nucleobase. 
Two different BER-coupled demethylation mechanisms have been reported. On the one hand, thymine 
DNA glycosylase (TDG) was shown to efficiently excise fC and caC,
[100a]
 and these results were 
confirmed by various groups.
[126, 184]
 The second pathway is suggested to involve the activation-
induced cytidine deaminase (AID)/apolipo-protein B mRNA editing enzyme, catalytic polypeptide 
(APOBEC) family of enzymes.
[127b, 128]
 These are thought to deaminate mC and hmC to thymine and 
5-hydroxymethyluracil (hmU), respectively, followed by removal by the glycosylases TDG or single-
strand-selective monofunctional uracil DNA glycosylase 1 (SMUG1) and by processing via the BER 
machinery.
[125, 127b]
 However the involvement of deamination in the process of active demethylation 
remains controversial.
[129]
 In order to elucidate the nature of hmU generation and its relation to 
deamination of hmU, a more detailed study was undertaken in the course of this thesis and is discussed 
in Chapter 8. 
The second mechanism of active demethylation is thought to involve oxidation of methylcytosine to 
hmC, fC and ultimately caC, followed by decarboxylation via C-C bond cleavage (Figure 30),
[132]
 or to 
proceed directly from hmC or fC via a retro-Aldol-type chemistry. A similar decarboxylation reaction 
is known to occur in the thymidine salvage pathway, where a iso-orotate decarboxylase converts iso-
orotate (previously generated by a thymine 7-hydroxylase) to uracil,
[122b, 131]
 but no such protein has 
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yet been found to perform this reaction on cytosine derivatives. In a report published by Schiesser et 
al., incubation of [
15
N2]-caC-containing strands in mESC cell lysate followed by DNA re-isolation and 
HPLC-ESI-MS analysis revealed the presence of [
15
N2]-cytosine, suggesting that decarboxylation via 
C-C bond cleavage had taken place.
[132]
 However, there is yet no evidence available as to which 
protein or complex is responsible for this putative pathway of active demethylation. 
 
Figure 30 Pathways of active demethylation. Demethylation via C-C bond cleavage proceeds via elimination of 
formaldehyde from hmC, formic acid from fC and carbon dioxide from caC. An alternative mechanism involves removal of 
fC, caC and hmU (after deamination) by glycosylases TDG and SMUG1, followed by base excision repair (BER). 
Modifications at the C5 position are highlighted in red, while deamination is shown in blue. 
6.2 Results and discussion 
The investigation reported in this chapter aimed at the elucidation of pathways of active demethylation 
via C-C bond cleavage. Studies were performed using selectively labelled substrates incubated with 
nuclear extracts or with recombinant proteins. Additionally, recombinant mouse Dnmt1 was purified 
and used for in vitro assays aimed at assessing the interaction and enzymatic activity of this 
methyltransferase in the presence of oxidized cytosine derivatives. 
6.2.1 Substrates 
In order to investigate the possible pathways of active demethylation via direct C-C bond cleavage 
(Figure 30), selectively labelled substrates were designed to enable precise reaction monitoring. 
Nucleosides 5-hydroxymethylcytosine (hmC), 5-formylcytosine (fC) and 5-carboxycytosine (caC) 
were synthesized containing a double 
15
N-labelled nucleobase (see Figure 31). In the case of hmC two 
additional deuterium atoms were introduced at the 5-hydroxymethyl group. The labelled nucleosides 
were either generated as phosphoramidite reagents and subsequently incorporated in short 
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oligonucleotide strands,
[132]
 or, alternatively, they were synthesized as the corresponding triphosphates 
and used for generation of longer double-stranded DNA segments using a Polymerase Chain Reaction 
(PCR).
[185]
 For further details concerning the later method, see Chapter 7. In both cases, DNA 
substrates contained a biotin tag to facilitate isolation of the DNA strands. Synthesis of the labelled 
triphosphates and of the short, labelled oligonucleotides was performed by Stefan Schiesser and 
Barbara Steigenberger.  
 
Figure 31 Substrate DNA and schematic representation of experimental set up. A) Sequences for ODN1 and ODN2, 
both derived from the Ecat1 promoter,[132] alongside the forward sequence of the 150bp – Oct4 PCR fragment.[185] X and Y 
represent labelled oxidized cytosine derivatives, shown in the lower part of section A). B) Schematic representation of the 
experimental set up, taking [15N2]-caC-containing oligonucleotides as an example. 
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The two approaches used for oligonucleotide synthesis present different advantages and 
disadvantages: solid phase synthesis of labelled oligonucleotides allows for precise sequence control 
of the site of incorporation of the labelled nucleoside, but it is more labour intensive and, especially in 
the case of fC, it can be problematic if multiple fC-containing sites are required. On the contrary, 
synthesis of longer strands by PCR allows for a more rapid generation of the desired substrates 
containing multiple labelled nucleotides, but there is no control over the site of incorporation.  
The sequences adopted for our study were taken from the Ecat1 and Oct4 promoter sequences.
[132, 185]
 
The Ecat1 promoter (sequence shown in Figure 31), was chosen because this promoter is known to 
undergo dehydroxymethylation during stem cell differentiation,
[106]
 while the pluripotency-associated 
Oct4 promoter is characterized by low levels of methylation in undifferentiated cells, followed by 
increasing methylation during differentiation.
[186]
 
The labelled substrates were used in in vitro experiments by incubation of the labelled DNA with 
either cell nuclear extracts or specifically enriched protein samples. The DNA was subsequently re-
isolated, digested to single nucleosides and analyzed by high resolution HPLC-ESI-MS. Successful 
detection of [
15
N2]-labelled cytosine or methylcytosine in the analyte would confirm that the starting 
material (labelled-hmC, fC or caC) has been converted into cytosine or methylcytosine by direct C-C 
bond cleavage. Part of the experiments detailed in sections 6.2.2 and 6.2.3 were performed together 
with Benjamin Hackner. 
6.2.2 In vitro experiments using cell lysate samples 
To further investigate the possible pathways of active demethylation, various experiments were 
performed using cell nuclear extract samples based on the approach described by Schiesser et al..
[132]
 
In particular, this investigation extended the study presented in that publication to further elucidate 
which of the oxidized cytosine bases (hmC, fC or caC) is the most likely substrate for C-C bond 
cleavage, as well as to pinpoint specific cell types or conditions which could favour this pathway. 
In vitro incubation of labelled oligonucleotides was generally performed with undifferentiated mouse 
Embryonic Stem Cells (mESC), while HEK-293T cells served as negative control samples. Depending 
on the experiment, incubation was either performed with nuclear extracts or with intact nuclei, using 
substrates containing labelled hmC, fC or caC (see Section 6.4.1). Test incubations were also 
performed with mESC at different stages of differentiation (0, 4, 8 and 16 h) to investigate whether the 
previously observed peaking and decline of fC and caC during this time period would correlate with 
an enhanced decarboxylation activity (Section 6.4.1). However, neither [
15
N2]-C nor [
15
N2]-mC could 
be detected in any of the performed experiments, suggesting that there had been no removal of the C5-
functionality (hydroxymethyl-, formyl- or carboxyl-group) of the labelled substrate nucleoside. 
Problems of reproducibility of the decarboxylation reaction in stem cell nuclear extracts had also been 
previously reported by the author of the original study, Benjamin Hackner,
[132]
 and might be linked 
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either to a very sensitive decarboxylation protein/complex, or, alternatively, they might suggest that 
the previously reported decarboxylation is the result of an enzyme-independent reaction.
[132]
 
6.2.3 In vitro experiments using protein-enriched samples 
Experiments were also carried out using partially purified protein samples. GFP-tagged proteins were 
expressed in HEK-293T cells, purified on GBP-coated beads,
[187]
 and incubated with substrate DNA as 
described in section 6.4.2. Incubation experiments focused on the methyltransferases Dnmt1, Dnmt3a 
and Dnmt3b, and on the Tet proteins. 
The Dnmt enzymes were chosen based on the results reported by Schiesser et al.
[132]
 which showed 
that rapid decarboxylation takes place following saturation of the C5-C6 bond of caC. This mechanism 
mirrors the methylation mechanism adopted by the Dnmt proteins (see Chapter 1) and suggests that 
the methyltransferases might be putative candidates in this pathway of active demethylation. In 
support of this hypothesis, Dnmt3a and Dnmt3b were suggested to act as redox-dependent 
dehydroxymethylases
[133]
 and the same group further reported that all three Dnmts could perform mC 
demethylation in a Ca
2+
 ion- and redox state-dependent manner, though they could not exclude that 
these reactions might be linked to impurities in the protein samples.
[133]
 
On the other hand, the Tet proteins were found to oxidize mC to hmC, fC and caC,
[98b, 100a, 100b]
 
suggesting that there might be a pathway of active demethylation involving further oxidation of mC, 
and various studies have reported a Tet1-dependent, gene-specific regulation of the mC levels.
[188]
 
Incubation experiments were performed using all the Dnmt and Tet proteins individually isolated, or 
Tet1 in combination with the different Dnmts. Experiments investigated reactivity in the presence of 
labelled hmC, fC and caC. However, neither [
15
N2]-C nor the (re-)methylated [
15
N2]-mC could be 
detected by LC-MS analysis. This suggests that, under the condition tested, Dnmt and Tet proteins are 
not involved in C-C bond cleavage at the C5 position of the modified cytosine, or that demethylation 
activity might require some additional proteins or cofactor. 
6.2.4 Dnmt1 
Given that in vitro experiments using protein pull-down samples on beads did not yield any insight 
into the decarboxylation activity of the Dnmt enzymes, we next proceeded to purification of 
recombinant mouse Dnmt1 to test whether the purified enzyme could show enhanced activity on our 
substrate DNA. With the purified methyltransferase, a variety of studies were performed to investigate 
its interaction with the oxidized cytosine bases 5-formylcytosine and 5-carboxycytosine. Methylation 
activity and covalent trapping assays were performed together with Benjamin Hackner, while 
decarboxylation studies were carried out together with Stefan Schiesser. 
6.2.4.1 Purification of recombinant Dnmt1 
In order to investigate whether Dnmt1 could act as a potential decarboxylase, recombinant mouse 
Dnmt1 was overexpressed and purified. The mDnmt1(731‒1602) construct was kindly provided by 
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Dr. Jikui Song, and overexpression and purification was performed following the previously published 
protocol, with only minor variations.
[94]
 Briefly, the plasmid harbouring the mDnmt1 construct was 
transformed in E.coli strain Rosetta 2 (DE3) cells, and protein overexpression was performed as 
detailed in section 6.4.5. mDnmt1 was initially purified by affinity chromatography on a HisTrap HP 
column, followed by fractionation on a Heparin column and by final purification by size exclusion 
chromatography (see Figure 32). Fractions with more than 90 % purity were concentrated and stored 
at -80 °C. Note that in this study, removal of the His6-SUMO tag by ULP1 cleavage detailed in the 
original publication was not performed.
[94]
 
 
Figure 32 mDnmt1 structural overview and summary of purification of mDnmt1(731‒1602). A) Summary of domain 
structure of mDnmt1 and of mDnmt1(731‒1602) fragment. B) Affinity purification of HisTrap column. C) Affinity 
purification of HiTrap Heparin column. D) Final purification step by size exclusion chromatography. In graphs C) and D) 
peak corresponding to mDnmt1(731‒1602) is indicated with an arrow. Chromatographic purification was monitored by 
absorbance at 260 nm (red trace) and 280 nm (blue trace). E) SDS-PAGE gel of various purification steps. 1: protein marker; 
2: cell lysate; 3: fractions pooled after HisTrap column; 4: fractions pooled after HiTrap Heparin column; 5: pure 
mDnmt1(731‒1602) after size exclusion chromatography; 6: protein marker. 
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The purified mDnmt1(731-1602) construct, which includes the two bromo-adjacent homology (BAH) 
domains as well as the methyltransferase domain (see Figure 32), was reported to retain catalytic 
activity with both hemimethylated and non-methylated substrates.
[189]
 Additionally, the truncated 
mouse protein shares 85 % sequence homology with the human equivalent and can therefore provide 
useful insights in the enzymatic features of hDnmt1.
[94]
  
6.2.4.2 Methylation assay 
One of the first issues addressed with the recombinant mDnmt1(731-1602) was whether it could 
methylate cytosines opposite fC or caC in a CpG context. In fact, given that these oxidized cytosine 
derivatives are suggested to be intermediates in a pathway of demethylation (or 
dehydroxymethylation), it would be interesting to understand their potential for maintenance of the 
methylation pattern during DNA replication. Previous reports have in fact shown that in vitro 
maintenance methylation opposite hmC is reduced, suggesting that hmC might be involved in 
replication-coupled dilution of mC,
[123]
 but no information is currently available concerning the 
behaviour of fC and caC in this context. 
Purified mDnmt1 was incubated with double stranded DNA bearing a single, hemimodified CpG site 
containing either mC, hmC, fC or caC (annealed ODN3 + ODN4, see Figure 33). Experiments were 
performed in the presence of SAM, and control experiments were done in the absence of the methyl-
donor. As shown in Figure 33, mDnmt1 shows methylation activity opposite methylcytosine and 
hydroxymethylcytosine. Note that the experiment only assesses the ability of the protein to methylate 
opposite a modified cytosine-containing CpG site, no infomation can be deduced concerning the 
kinetics of methylation. The ability of mDnmt1 to methylate opposite hmC is in agreement with 
previous studies,
[123]
 although Hashimoto et al. reported a reduced activity compared to methylation 
opposite mC. Nevertheless, the result might stem from the extended incubation times of the 
experiment, and, more importantly, Dmnt1 activity might be further enhanced by the absence of the 
CXXC domain and the autoinhibitory CXXC-BAH1 linker in this protein construct.
[94]
 In fact, as 
described by Song et al., the CXXC and the autoinhibitory linker are essential in discrimination 
between unmethylated and hemimethylated DNA and might play a similar role in discrimination of 
hydroxymethylated CpG sites.
[94]
 
Interestingly, there is almost no methylation activity observed opposite formylcytosine and 
carboxycytosine (Figure 33). This observation suggests that these oxidized cytosine derivatives do not 
contribute to maintenance of the methylation pattern upon DNA replication. These results therefore 
support a possible role for these bases in the removal of methylation by replication-coupled dilution, 
where lack of methylation opposite fC and caC results in a gradual erasure of the methylation pattern 
during cell division. 
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Figure 33 Methylation activity assay for recombinant mDnmt1(731-1602). ODN3 and ODN4 were annealed and used for 
methylation activity assay. Plot details the percental change of the mC content per XpG site, where X = mC, hmC, fC or caC 
(shown on x-axis) with respect to control reaction (for exact values, see Table 16). 
6.2.4.3 Interaction with oxidised cytosine derivatives 
Additionally, we were interested in investigating whether mDnmt1 is able to generate a covalently 
bound intermediate with the oxidized cytosine derivatives. In fact, decarboxylation, as proposed by 
Schiesser et al., is thought to proceed via initial saturation of the C5‒C6 bond by nucleophilic attack at 
the C6 position.
[132]
. However, failure to remove the carboxyl- or formyl- group at the C5 position in 
the presence of a saturated C5-C6 bond would result in trapping of the mDnmt1-DNA adduct in a 
manner similar to aza-SAM. This in itself could provide a pathway for demethylation, since trapping 
of Dnmt1 would result in a suicide complex which would then be processed by the nucleotide excision 
repair (NER) machinery and lead to replacement by cytosine. 
Double-stranded, fluorescently-labelled oligonucleotides containing a hemi-modified CpG site with 
various cytosine derivatives (ODN5 + ODN6) were incubated in the presence of mDnmt1(731-1602) 
and subsequently analyzed by SDS-PAGE. Covalently bound oligonucleotides are expected to migrate 
at a molecular weight corresponding to about 115 kDa (i.e. the molecular weight of mDnmt1), while 
unbound DNA should migrate at a lower molecular weight.  
As it can be noted in Figure 34, in all cases most of the fluorescently-labelled DNA migrates at the 
bottom of the gel. In the case of cytosine, mC and hmC, both in the presence or absence of 
S-adenosyl-methionine (SAM), a faint band is also observed at high molecular weight, suggesting 
some extent of covalent trapping. This might reflect a rapid equilibrium of C5‒C6 bond saturation 
upon nucleophilic attack of the unmodified cytosine in the counterstrand prior to methylation, 
consistent with the results detailed in 6.2.4.2 showing methylation activity of mDnmt1 opposite these 
bases. Alternatively, it might result from erroneous attack at the C6 position of the modified 
nucleoside. In fact, since both strands are fluorescently-labelled, we cannot distinguish whether 
covalent trapping involves the modified strand or the unmodified counterstrand. 
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On the contrary, in the case of fC and caC no band is detected at higher molecular weight. This 
suggests that no nucleophilic attack is taking place at the C6 position of the modified nucleoside, and 
that most likely there is also no attack occurring at the C6 position of the unmodified CpG cytosine in 
the counterstrand. This is again in agreement with results reported in section 6.2.4.2, where no 
methylation activity is detected opposite fC and caC. However, from this study we cannot exclude that 
mDnmt1 might nevertheless interact with the fC and caC-containing CpG site. Presence of SAM did 
not show any effect on covalent trapping opposite these bases. 
 
Figure 34 Investigation of covalent trapping of mDnmt1. mDnmt1 was incubated with double stranded DNA containing a 
XpG site (X = C, mC, hmC, fC, caC). Top panels = fluorescence detection of DNA on SDS gel; bottom panels = protein 
detection by coomassie blue staining of SDS gel. 
In order to distinguish whether failure to detect a trapped intermediate for fC and caC is due to altered 
affinity of mDnmt1 or instead to lack of nucleophilic attack at the C6 position, binding studies of 
mDnmt1(731-1602) in the presence of fC or caC-containing double-stranded oligos were attempted by 
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Electrophoretic Mobility Shift Assay (EMSA). However, information concerning the binding affinity 
could not be obtained due to precipitation of the protein upon loading of the complex on the gel. 
Future studies could be performed by Fluorescence Polarization to avoid unwanted effects arising 
from interaction of the protein with the gel matrix. 
6.2.4.4 Decarboxylation and deformylation assays 
Purified mDnmt1 was also tested for any decarboxylation or deformylation activity. The purified 
methyltransferase was incubated with caC- or [
15
N2]-fC-containing oligonucleotides with or without 
SAM. The DNA was subsequently isolated and analyzed by LC-ESI-MS/MS or LC-ESI-MS, (for 
caC- or [
15
N2]-fC-containing oligonucleotides, respectively). In all cases, no conversion of caC or of 
[
15
N2]-fC to [
15
N2]-C or [
15
N2]-mC could be detected. This suggests that, if Dnmt1 is involved in the 
process of decarboxylation or deformylation, then the methyltransferase might require some additional 
protein or cofactor in order to perform this reaction. Previous studies have also reported that Dnmt1 is 
unable to act as a dehydroxymethylase, contrary to Dnmt3a and Dnmt3b.
[133]
 Therefore future studies 
should address whether Dnmt1 can indeed act as a deformylase or decarboxylase in combination with 
additional proteins or cofactors, or whether its contribution to demethylation is only through 
replication-coupled dilution. 
6.3 Conclusion 
The study presented in this chapter investigated the putative mechanism of active demethylation via 
direct C-C bond cleavage of the oxidized cytosine derivatives hmC, fC and caC. Selectively labelled 
substrates were generated for monitoring of the demethylation products. Incubation experiments 
performed with different cell nuclear extracts and protein samples did not reveal any product of C-C 
bond cleavage-dependent demethylation, hinting that, under the experimental conditions tested, this 
process is not taking place. This is to some extent not surprising, given that we are expecting the 
decarboxylase enzyme to be very tightly regulated in order to ensure correct demethylation, possibly 
linked to specific time points of cell growth and differentiation and/or in a sequence-specific manner. 
On the other hand, investigations performed with recombinant mouse Dnmt1 revealed that 
maintenance of DNA methylation during replication does not occur opposite fC and caC, supporting a 
role for this modified nucleosides in removal of the methylation pattern via replication-coupled 
dilution. 
6.4 Materials and methods 
6.4.1 In vitro experiments using cell lysate samples 
Preparation of the intact nuclei or nuclear lysate for in vitro studies was performed using an adapted 
Dignam protocol.
[190]
 All the steps were performed on ice or at 4 °C. The cells used in this study (wild 
type mESC J1 or HEK-293T) were provided by Udo Müller, from research group of Prof. H. 
Leonhardt (Department of Biology, LMU). Cell pellets were resuspended in 5 vol. of Lysate Buffer A 
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(10 mM HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT) supplemented with Complete-
EDTA free protease inhibitor cocktail (Roche). After 10 min incubation cells were gently pelleted 
(10 min, 2000 rpm) and resuspended in 2 vol. of Lysate Buffer A. Homogenization was performed 
using a douncer (20 strokes) and verified using trypan blue staining. Nuclei were pelleted (10 min, 
2000 rpm) and could be used directly for incubation with labelled DNA substrates. For nuclear extract 
preparation, the pelleted nuclei were resuspended in 2.5 vol. Lysate Buffer C (20 mM HEPES, pH 7.9, 
20 % glycerol, 1.5 mM MgCl2, 420 mM NaCl, 0.2 mM EDTA, 0.5 mM DTT, Complete EDTA-free 
protease inhibitor). The mixture was incubated for 30 min followed by centrifugation (15 min, 
13000 rpm). The nuclear extract (supernatant) was subsequently dialyzed for 2 h against 1 L of Lysate 
Buffer D (20 mM HEPES, pH 7.9, 25 % glycerol, 100 mM NaCl, 0.2 mM EDTA, 0.5 mM DTT) and 
subsequently used for incubation with labelled DNA substrates. 
Incubation with DNA substrates was performed in Lysate Buffer A (for intact nuclei) or in Lysate 
Buffer D (nuclear extracts). Samples were incubated at 37 °C for 1 h, shaking gently (300 rpm). 
Labelled substrates and amounts used for each experiment are listed in Table 14. 
Experiment Cell type 
Lysate 
preparation 
DNA substrate 
DNA substrate 
amount/exp. 
1 
HEK-293T vs 
HEK-293T 
overexpressing 
Dnmt3b1 
nuclear  
extract 
ODN1 + ODN2,  
[
15
N2]-caC (ds) 
0.3 nmol/exp 
2 
mESC vs  
HEK-293T 
intact  
nuclei 
ODN1 + ODN2,  
[
15
N2]-caC (ds), [
15
N2]-caC 
(mC), [
15
N2]-caC (C), 
[
15
N2]-fC (C) 
1 nmol/exp 
3 
mESC 
(differentiation time 
points 0, 4, 8, 16 h) 
intact  
nuclei 
ODN1 + ODN2,  
[
15
N2]-caC (ds) 
1 nmol/exp 
4 HEK-293T 
intact nuclei and 
nuclear extract 
150bp-Oct4,  
[D2,
15
N2]-hmC 
4 pmol/exp 
5 mESC 
nuclear extracts,  
anaerobic 
conditions 
150bp-Oct4,  
[D2,
15
N2]-hmC 
4 pmol/exp 
Table 14 Summary of in vitro experiments using cell extracts. ODN1 and ODN2 refer to oligonucleotides described in 
Figure 31. 150bp-Oct4 refers to PCR product containing labelled substrates.[185] Labelled nucleosides are listed under DNA 
substrates, in brackets is shown whether both strands contain the same modified nucleoside (ds), or whether the opposite CpG 
site contains a methylcytosine (mC) or cytosine (C).  
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Substrate DNA was subsequently isolated by extraction using Roti-Phenol/CHCl3/isoamylalcohol 
(Roth), precipitated with EtOH (3 vol), and purified using Streptavidin coated magnetic beads 
(Dynabeads M-270, Invitrogen) following the manufacturer´s procedure. Removal of the DNA from 
the beads was performed by applying a temperature gradient (20‒99 °C).[191] DNA samples were 
subsequently digested to nucleosides as detailed in section 6.4.3 and analyzed by HPLC-ESI-MS. 
6.4.2 In vitro experiments using protein pull-down samples 
Overexpression of GFP-tagged target proteins was performed in HEK-293T cells, followed by cell 
lysis and protein pull-down following previously published procedures.
[187]
 Protein pull-down samples 
were prepared by Udo Müller from the research group of Prof. H. Leonhardt (Department of Biology, 
LMU). Depending on the experiment, reactions were carried out in Buffer Pull down A (50 mM 
HEPES, pH 8.0, 100 µM ammonium iron (II) sulfate, 1 mM -ketoglutarate, 2 mM ascorbic acid, 
2.5 mM DTT, 100 mM NaCl, 1.2 mM ATP),
[118b]
 or in Buffer Pull down B (10 mM Tris-HCl, pH 7.4, 
50 mM NaCl, 1.5 mM MgCl2).
[133]
 Substrate DNA was hybridized (or simply resuspended) in 2x 
incubation buffer in half the reaction volume and added to the protein pull down sample (previously 
washed in 1x incubation buffer). Incubation condition, DNA substrates and protein samples are listed 
in Table 15. For every experiment, GFP protein (purified on beads as the other proteins) was used as a 
negative control. 
Experiment Protein tested DNA substrate Conditions 
1 
Tet1 (full length vs  
catalytic domain) 
ODN1 + ODN2, [
15
N2]-caC (ds), 
[
15
N2]-caC (C), [
15
N2]-fC (ds); 
ODN1, [
15
N2]-caC, [
15
N2]-fC; 
200 pmol/exp. 
Buffer Pull down A, 
reaction vol. 60 µL, 
37 °C, 1 h 
2 
Tet1, Tet2, Tet3;  
Dnmt1, Dnmt3a, Dnmt3b;  
Tet1 + Dnmt1, Tet1 + 
Dnmt3a, Tet1 + Dnmt3b 
ODN1 + ODN2, [
15
N2]-caC (ds), 
100 pmol/exp.; 150bp-Oct4, 
[D2,
15
N2]-hmC, 4 pmol/exp. 
Buffer Pull down A, 
SAM (160 µM), 
reaction vol. 60 µL, 
37 °C, 1 h 
3 Dnmt1 
ODN1 + ODN2, [
15
N2]-caC (ds), 
[
15
N2]-caC (mC), [
15
N2]-caC (C); 
100 pmol/exp. 
Buffer Pull down B, 
reaction vol. 100 µL, 
37 °C, 16 h 
4 Dnmt3a, Dnmt3b 
ODN1 + ODN2, [
15
N2]-caC (ds), 
[
15
N2]-caC (mC); 100 pmol/exp. 
Buffer Pull down B, 
reaction vol. 100 µL, 
37 °C, 16 h 
Table 15 Summary of in vitro experiments using protein pull-down samples. ODN1 and ODN2 are described in Figure 
31, while 150bp-Oct4 refers to labelled PCR product.[185] Description of DNA substrates is as noted in Table 14. 
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After incubation, DNA was isolated and processed as described in Section 6.4.1. The only difference 
was that digestion was performed directly after precipitation with EtOH, without further purification 
on streptavidin coated magnetic beads. 
6.4.3 Enzymatic digestion of DNA samples 
DNA samples isolated after in vitro experiments were resuspended in 25 µL H2O. The first digestion 
step was carried out in 100 µM ZnSO4 with 42 units Nuclease S1 (Aspergillus oryzae, Roche) and 
5 units antarctic phosphatase (New England Biolabs) and incubated at 37 °C for 3 h. The second 
digestion step was performed by addition of [Na]2-EDTA (final concentration 100 µM) and 0.2 units 
snake venom phosphodiesterase I (Crotalus adamanteus venom, UBS Corporation) and incubation at 
37 °C for 3 h. 
6.4.4 HPLC-ESI-MS analysis 
Digested samples were analyzed using a Thermo Finnigan LTQ Orbitrap XL coupled to a Dionex 
Ultimate 3000 HPLC system. Flow was set to 0.15 mL/min and chromatographic separation was 
performed using an Uptisphere 120-3HDO column (Interchim) at 30 °C. Elution buffer were Buffer A 
(0.01 % formic acid in H2O) and Buffer B (0.01 % formic acid in MeCN). The gradient used was the 
following: 0 → 12 min, 0 % → 1 % buffer B; 12 → 20 min, 1 % → 2 % buffer B; 20 → 30 min, 
2 % → 10 % buffer B; 30 → 35 min, 10 % → 80 % buffer B; 35 → 45 min, 80 % buffer B; 
45 → 50 min, 80 % → 0 % buffer B; 50 → 60 min, 0 % buffer B. Elution was monitored by 
absorbance at 260 nm. The eluted sample was directly injected into the ion source without prior 
splitting, and ions were scanned in positive mode using a scan range of m/z 100‒500. Parameters used 
were the following: sheath gas flow rate, 16 arb; auxiliary gas flow rate, 11 arb; sweep gas flow rate, 
4 arb; spray voltage, 5.0 kV; capillary temperature, 275 °C; capillary voltage, 35 V; tube lens, 65 V; 
resolution, 60000.
[132]
 
6.4.5 Overexpression and purification of mDnmt1 
The plasmid harbouring the mDnmt1(731‒1602) fragment was kindly provided by Dr. Jikui Song.[94] 
The plasmid was transformed in E.coli strain Rosetta 2(DE3) (Novagen) and cells were grown in LB 
medium in the presence of kanamycin (15 µg/mL) and chloramphenicol (34 µg/mL) to an 
OD600 = 0.6. Protein overexpression was induced with isopropyl--D-thiogalactopyranoside 
(0.4 mM) in the presence of ZnCl2 (0.1 mM final concentration), and cells were let grown overnight at 
20 °C. 
Cells were resuspended in cold Dnmt1 Buffer A (50 mM Tris HCl, pH 8.0, 1 M NaCl, 25 mM 
imidazole, approximately 20 mL per L of E.coli culture), and lysed using a French press. The 
suspension was supplemented with a cocktail of protease inhibitors (Complete EDTA-free, Roche), and 
the lysate was clarified using a Sorvall SS-34 rotor (18000 rpm, 4 °C, 1 h). The supernatant was 
loaded on a pre-equilibrated HisTrap HP 5 ml column (GE Healthcare) and the protein was eluted 
with Dnmt1 Buffer B (50 mM Tris HCl, pH 8.0, 1 M NaCl, 250 mM imidazole). Eluted protein 
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fractions were concentrated using an Amicon Ultra centrifuge filter (Millipore, 30,000 MWCO), the 
buffer was exchanged to Dnmt1 Buffer C (20 mM Tris HCl, pH 7.5, 50 mM NaCl, 5 mM DTT) and 
the protein sample was loaded on a HiTrap Heparin 5 mL column (GE Healthcare). Elution was 
performed by applying a gradient to Dnmt1 Buffer D (20 mM Tris HCl, pH 7.5, 1 M NaCl, 5 mM 
DTT), where mDnmt1 is expected to elute at about 0.4‒0.5 M NaCl. Fractions showing a significant 
level of purity were pooled, concentrated using an Amicon Ultra centrifuge filter (Millipore, 
30,000 MWCO), and buffer-exchanged to Dnmt1 Buffer E (20 mM Tris HCl, pH 7.5, 250 mM NaCl, 
5 mM DTT) and purified by size exclusion chromatography on a Superdex 16/60 HiLoad 200 (GE 
Healthcare). Fractions with > 90 % purity were pooled together, concentrated and stored at -80 °C. 
For all steps, chromatographic purification was monitored by UV absorbance at 260 nm and 280 nm 
and purity of the eluted protein fractions was verified by SDS-PAGE. 
6.4.6 Methylation assay 
Oligonucleotides (ODN3 + ODN4) bearing a single CpG site (modified or unmodified) where 
annealed by heating to 95 °C for 4 min followed by cooling to 4 °C over a period of 45 min. 
Methylation assay was performed in 1 x Dnmt1 Reaction Buffer (New England Biolabs), with double 
stranded DNA (1 µM), purified mDnmt1 (1 µM), Bovine Serum Albumin (0.1 mg/mL) and with or 
without SAM (160 µM). Experiments were performed in triplicate. The total reaction volume was 
20 µL. Samples were incubated at 37 °C for 3 h, followed by extraction using Roti-
Phenol/CHCl3/isoamylalcohol (Roth) and by desalting using ZipTip (Millipore). Purified 
oligonucleotides were subsequently digested to single nucleosides (as detailed in section 6.4.3) and 
analyzed by LC-ESI-MS/MS. Mass spectrometry analysis was performed by Toni Pfaffeneder. Data is 
presented in Table 16. 
XpG mC / XpG  (%) St.Dev. % 
mC 104,52 5,50 
hmC 106,07 5,43 
fC 8,55 10,72 
caC 4,08 14,58 
Table 16 Percental change of mC upon incubation with mDnmt1. Table lists the percental change in mC content between 
positive and negative controls (with or without SAM) per XpG site (X = mC, hmC fC or caC). Experiments were performed 
in triplicate. 
6.4.7 Covalent trapping of mDnmt1 in the presence of modified cytosine derivatives 
Fluorescently-labelled oligonucleotides containing a single CpG site with C, mC, hmC, fC or caC 
were annealed to unmodified CpG-containing counterstrands (also fluorescently-labelled). Annealed 
oligos (3 µM) were incubated in 1 x Dnmt1 Reaction Buffer (New England Biolabs) together with 
purified mDnmt1 (1 µM) and Bovine Serum Albumin (BSA, 0.1 mg/mL) in a total volume of 20 µL. 
Incubation was performed in the absence or presence of SAM (160 µM). Samples were incubated at 
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37 °C for 1 h, and subsequently denatured by addition of 0.2 vol. of 5 x SDS Loading Buffer 
(62.5 mM Tris, 4 % (w/v) SDS, 20 % (w/v) Glycerol, 5 % (w/v) -mercaptoethanol, pH 6.8) and 
heating to 90 °C for 5 min. Samples were subsequently electrophoresed under denaturing conditions 
through a 8 % polyacrylamide gel and fluorescence detection was performed using a Fuji LAS 3000 
(Raytest). 
6.4.8 Decarboxylation and deformylation assays 
Decarboxylation assays were performed in the presence of double- and single-stranded DNA. 
Oligonucleotides were annealed in different combinations to yield either fully carboxylated CpG sites 
(ODN7 + ODN8), hemi-carboxylated/hemi-methylated CpG sites (ODN7 + ODN9), or mismatch sites 
with a caCpG opposite a ApG site (ODN7 + ODN10). Single-stranded caC-containing 
oligonucleotides were also tested (ODN7). A positive control was performed with hemimethylated 
strands to verify the activity of purified mDnmt1 (ODN11 + ODN12). Oligonucleotides are listed in 
Table 17. 
Name Sequence Oligo 
ODN 7 5´-TTTTTTTcaCGTTTTTTTcaCGTTTTTTTcaCGTTTTTTT strand 
ODN 8 5´-AAAAAAAcaCGAAAAAAAcaCGAAAAAAAcaCGAAAAAAA counter-strand 
ODN 9 5´-AAAAAAAmCGAAAAAAAmCGAAAAAAAmCGAAAAAAA counter-strand 
ODN 10 5´-AAAAAAAAGAAAAAAAAGAAAAAAAAGAAAAAAA counter-strand 
   
ODN 11 5´-TTTTTTTmCGTTTTTTTmCGTTTTTTTmCGTTTTTTT strand 
ODN 12 5´-AAAAAAACGAAAAAAACGAAAAAAACGAAAAAAA counter-strand 
Table 17 Oligonucleotides used for decarboxylation experiments. 
Oligonucleotides (1.6 µM) were incubated with purified mDnmt1 (1 µM) in 1 x Dnmt1 Reaction 
Buffer (New England Biolabs), alongside BSA (0.1 mg/mL), with or without SAM (160 µM). The 
total reaction volume was 33.5 µL and each experiment was done in triplicates. Incubation was 
performed at 37 °C for 16 h. Samples were subsequently extracted with Roti-
Phenol/CHCl3/isoamylalcohol (Roth), precipitated with EtOH (3 vol), washed twice with ice-cold 
70 % EtOH and resuspended in ddH2O. The purified, desalted DNA was then digested to nucleosides 
and analyzed by ESI-LC-MS/MS as detailed in Section 6.4.6. Mass spectrometry analysis was 
performed by Toni Pfaffeneder. 
Deformylation experiments were performed using [
15
N2]-labeled fC-containing oligonucleotides (see 
Table 18). Strands were annealed either in the combination ODN13 + ODN14, or ODN13 + ODN15. 
Incubation of annealed oligonucleotides (1 µL) with mDnmt1 (1 µM) was done as described for the 
decarboxylation experiment, except for the final reaction volume which was 100 µL. Samples were 
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incubated at 37 °C for 3 h, followed by extraction using using Roti-Phenol/CHCl3/isoamylalcohol 
(Roth) and by desalting using ZipTip (Millipore). Samples were subsequently digested to single 
nucleosides and analyzed by high resolution HPLC-ESI-MS. 
Name Sequence Oligo 
ODN 13 5´ - GTA ATG fCGC TAG G [
15
N2]-fC 
ODN 14 5´- CCT AGC GCA TTA C C counter-strand 
ODN 15 5´- CCT AGmC GCA TTA C mC counter-strand 
 
Table 18 Oligonucleotides used for deformylation experiments 
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ABSTRACT
The synthesis of the triphosphates of 5-hydroxymethyl-, 5-formyl-, and 5-carboxycytidine and the incorporation of these building blocks into
long DNA fragments using the polymerase chain reaction (PCR) are reported. In this way DNA fragments containing multiple hmC, fC, and caC
nucleobases are readily accessible.
Recently three new nucleobases were discovered in
DNA isolated from mouse embryonic stem cells.14 The
three nucleobases are oxidation products of 5-methylcyto-
sine (mC), which is a base that regulates transcriptional
activity.5 The oxidation reaction of 5-methylcytosine to
5-hydroxymethylcytosine (hmC), 5-formylcytosine (fC),
and finally 5-carboxycytosine (caC) is now understood to
be performed by 10-11-translocon proteins (TET13).6
These enzymes are R-ketoglutarate dependent oxidases,
which directly utilize molecular oxygen for the oxidation
reaction.7 The three newnucleobases are currently thought
to be involved in epigenetic programming of cells,
and they could be intermediates of a long searched for
pathway of active demethylation.810 Recently new se-
quencingmethods that allow the genomewide localization
of hmC11,12 and fC13 in genomic DNA were reported.†These authors contributed equally.
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In the past couple of years phosphoramidite building
blocks of hmC, fC, and caC, which allow the solid phase
synthesis of oligonucleotides containing the new bases
at defined sites, were developed.1418 However, to search
for proteins that interactwith these new epigenetic bases, and
to decipher the biological/biochemical questions associated
with the new nucleobases, longer oligonucleotides contain-
ing multiple hmC, fC, and caC bases are required. In this
direction, we thought that using the corresponding triphos-
phates (Figure 1) in combination with the polymerase chain
reaction (PCR) would solve this chemical problem.1921
In such a PCR, onewould exchange the dCTP either com-
pletely or partially by the corresponding xdCTP (x = hm,
f or ca) so that these DNA fragments contain the new bases
hmC, fC, and caC at the corresponding dC positions.
While the triphosphate of hmC (hmdCTP) is already
commercially available and its incorporation via PCR is
established, the corresponding fdCTP and cadCTP com-
pounds were unknown at the beginning of this study. The
chemical synthesis of both building blocks was achieved
as outlined in Scheme 1. For fdCTP we started the synthesis
with the fC nucleoside 1, which was prepared as described
recently by us.22 This compound was converted into the
50-monophosphate 2, which was obtained afterHPLCpurifi-
cation in 29% yield. We subsequently employed the new
triphosphate method recently described by S. D. Taylor et al.
using sulfonyl imidazolium triflate as the activating reagent
and pyrophosphate.23 The procedure allowed us to access the
triphosphate from the monophosphate in 70% yield. The
triphosphate was best isolated by ion exchange chromatogra-
phy at 4 Cusing aDEAE-cellulose column24with a gradient
from 100% water to 0.5 M TEAB (pH 7.5). The crude
triphosphate product was further purified by FPLC (0.1 M
TEAB, 1 M TEAB; 0100% over 30 min) using a MonoQ
5/50 GL anion exchange column (GE). This two-step proce-
dure allowed us to generate the reactive aldehyde-containing
fC triphosphate in sufficient yield for all further studies.
Figure 1. Depiction of the canonical DNA base dC and of mC
as well as of the new epigenetic bases hmC, fC, and caC as
triphosphates.
Scheme 1. Synthesis of fdCTP and cadCTP
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The cadCTP compound was prepared from the TBS
protected caC methyl ester 3 which was also prepared as
described recently by us.17We first cleaved the TBS groups
to obtain compound 4. The methyl ester was subsequently
saponifiedwhichprovided theunprotected caCnucleoside5.
5 was next introduced into the one-step triphosphate
synthesis reported originally byEckstein et al.25Here the
yield could be improved to 7% if the conditions developed
by Huang et al. were employed.26
We recently reported the synthesis of hmC, fC, and caC
phosphoramidites and the incorporation of these building
blocks intoDNAstrands. Primer extension studies showed
that none of the newbases aremutagenic.17Herewe report
the development of PCR conditions for the incorporation
of fdCTP and cadCTP into long oligonucleotides. We
chose the oct4 promotor sequence (see Supporting Infor-
mation (SI)) as the DNA template. The primers for the
PCRwere designed to yield a 150 bp product containing 77
modified dCs (4 dC are present in the primer; these are not
exchanged). For this purpose the forward and reverse
primers were annealed to the template at 55 C. The
elongation of the primers was best performed at 75 C
(for fdCTP) and 72 C (for cadCTP). Different poly-
merases were screened. We discovered that the DNA
polymerase Vent (exo) (for fdCTP) and KOD XL poly-
merase for (cadCTP) provided the best results (see SI). To
ensure complete extension of the primer the elongation
time was lengthened compared to the time used for in-
corporation of dCTP. The experimental results of the
PCRs are described in Figure 2.
The PCR products obtained with cadCTP can only be
visualized when a 1  TBE buffer system is used for the
analysis. When other buffers such as TAE were used we
noted that the obtained oligonucleotide products did not
give a distinct band in the gel electrophoresis potentially
because of the additional carboxylic acid groupspresent on
caC. Rather a broad smear is detected due to the lower
buffer capacity. The TBE buffer system in contrast pro-
vides sharp bands for the caC containing DNA products.
As depicted in lanes 5 and 6, both triphosphates fdCTP
(lane 5) and cadCTP (lane 6) yielded PCR products with
the correct length (negative control lanes 1 and 2) if our
developed PCR methods are employed. In the shown
experiments we replaced the dCTP completely by the
corresponding xdCTP. Hence full length PCR product
can only be formed when the triphosphate is accepted, as
further shown by the negative control in lane 2. Further
proof for the correct incorporation of fC and caC using
PCR was obtained by LC-MS experiments. The PCR
products were to this end fully digested. For this purpose
the sugar phosphate backbone was first cleaved with
nuclease S1 and snake venom phosphodiesterase, giving
the 50-monophosphates. These were further hydrolyzed to
the nucleoside level by Antarctic phosphatase.3 Using this
procedure even the highly modified DNA prepared here
was fully digested. The resulting nucleoside mixture was
subsequently analyzed by LC-HRMS or LC-MS/MS. The
data obtained for incorporated fdCTP are shown in
Figure 2B (for cadCTP, see SI). Clearly evident is the
presence of dA, dT, and dG in addition to the fC-nucleo-
side. Our results show that both fC and caC can be
inserted as triphosphates into long DNA fragments
using PCR. The observation that formyl group contain-
ing nucleosides can be incorporated into PCR products
despite their high reactivity is in line with a recent report
by Hocek et al. This group reported the PCR based
synthesis of aldehyde containing DNA products.27,28
It is interesting that the polymerase tolerates also the
negative charge associated with the carboxylic acid
present in caC. For future quantification of fC and
caC in natural material we also prepared isotope labeled
fC and caC triphosphates and incorporated them into
DNA strands using basically the same PCR conditions
showing the broad applicability of the here reported
technology (see SI).
We next turned our attention to the hmCbase.Here, the
corresponding triphosphate is generated from the mono-
phosphate, which is directly isolated from natural sources.
A chemical synthesis of the hmC triphosphate was not
Figure 2. (A)Depiction of the results of the PCR analyzed by gel
electrophoresis. Lane 1: without template. Lane 2: without any
dCderivative. Lane 3: dCTP.Lane 4: protectedD2,
15N2-hmdCTP.
Lane 5: fdCTP.Lane 6: cadCTP. (B)UV trace (left) andmass trace
of fC (right) of a fully digested PCR mixture with fdCTP.
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performed so far, which limits our ability to create DNA
fragments with modified hmC, e.g. with isotopically la-
beled compounds as needed for mass spectrometry based
quantification and proteomics studies. The synthetic chal-
lenge associated with the synthesis of hmdCTP is the
benzylic hydroxyl group of the hmC heterocycle which is
more reactive than the primary 50-OH group. This makes
it difficult to access the 50-monophosphate directly from
hmC. To circumvent this problem and to enable the PCR
incorporation of modified hmC building blocks, we in-
vestigated the ability to insert a protected hmC derivative
by PCR followed by deprotection. The synthesis of the
protected hmdCTP building block and the results of the
PCR study are shown in Figure 3.
To exemplify the possibilities associated with the chemi-
cal method, we prepared for this study the unnatural 2 
[15N] and 2Dmodified hmC (SI). The starting point for
the synthesis is theTBSprotected iodouracil 6,29whichwas
carbonylated to 7 and reduced to 8. Compound 8 was
protected as the carbamate 9, and the TBS groups were
cleaved to obtain 10. We utilized the optimized one-pot
triphosphate synthesis described above to obtain the la-
beled hmdCTP 11. Subsequent PCR based incorporation
studies showed that the reaction is best performedwith the
KOD XL polymerase with again slightly prolonged elon-
gation times (30 s instead of 15 s). The PCR product was
subsequently deprotected with 0.1 M NaOH in water/
methanol 1:4 for 1 h at rt. The DNA was finally purified
using a silica membrane (see SI). The agarose gel of the
deprotected and purified DNA fragment is depicted in
Figure 2A, lane 4. Again a clean PCR product is observed.
The results of the total digest performed under the opti-
mized conditions reported above are shown in Figure 3B.
Again next to dA, dG, and dT as well as small amounts of
residual dC from theprimers, an additional signal is observed
with the correct retention timeandexactmolecularweight for
D2,
15N2-hmC.Most importantly we do not observe a signal
forun-deprotectedhmCshowing that full deprotectionof the
carbamate protecting group present on our hmdCTP build-
ing block was achieved. In summary we report here the first
chemical synthesis of the three triphosphates hmdCTP,
fdCTP, and cadCTP of the new epigenetic bases hmC, fC,
and caC and describe PCR conditions which enable the
incorporation of these building blocks into long DNA frag-
ments. The chemical synthesis allows even the synthesis and
incorporationof isotopologuesof thenewbases,whichshould
facilitate mass spectrometry based quantification methods.
We believe that the reported synthetic methodologies
disclosed herewill strongly advance our ability to study the
biology andbiochemistry of the new epigenetic bases hmC,
fC and caC.
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Figure 3. (A) Synthesis of the protected D2,
15N2-hmdCTP. (B)
UV trace (top) and D2,
15N2-hmCmass trace (bottom) of a fully
digested PCR mixture.
(29) Schiesser, S.; Hackner, B.; Pfaffeneder, T.;M€uller,M.;Hagemeier,
C.; Truss, M.; Carell, T. Angew. Chem., Int. Ed. 2012, 51, 6516.
The authors declare no competing financial interest.
7. Results – Modified DNA nucleosides 
 
96 
  
8. Results - Modified DNA nucleosides 
 
101 
 
 
 
 
 
 
 
 
 
 
 
8 Tet oxidizes thymine to 5-hydroxymethyluracil in mouse embryonic 
stem cell DNA 
 
  
574  nature chemical biology | vol 10 | july 2014 | www.nature.com/naturechemicalbiology
article
published online: 18 may 2014 | doi: 10.1038/nchembio.1532
Methylcytosine is an epigenetically important nucleobase associated with the control of transcriptional activity, genomic imprinting, X-chromosome inactivation and 
suppression of transposable elements1. Controlled formation and 
removal of mC at specific genomic loci is critical for correct genome 
programming or reprogramming during cellular differentiation2. 
Recently, it was discovered that Tet proteins (Tet1–3) oxidize mC 
to give the oxidized C-derived nucleobases hmC3, 5-formylcytosine 
(fC)4,5 and 5-carboxycytosine (caC)5,6, whose biological functions 
are still yet unclear (Fig. 1a)7. As fC and caC are both removed 
by thymine DNA glycosylase (Tdg)6,8, it is currently assumed that 
they serve as intermediates of an active DNA demethylation pro-
cess involving base excision repair. In addition to these oxidized 
C derivatives, cells also contain oxidized T nucleobases such as hmU 
and fU. These compounds are currently known as oxidative lesions 
that are thought to form upon the reaction of T with reactive oxygen 
species (ROS)9,10. It was recently suggested that hmU might also be 
produced by deamination of hmC, a hypothesis that remains con-
troversial11–14. Deamination of hmC, situated in a base pair with G 
(hmC:G), would give rise to hmU:G mismatches, which are known 
substrates for the DNA glycosylases Tdg, Smug1, Mbd4, Ung2 
(ref. 15), Neil1 and Nthl1 (ref. 16). Deamination of hmC:G to 
hmU:G followed by mismatch repair would therefore establish an 
alternative pathway to active demethylation (Fig. 1a).
To unravel the origin of oxidized nucleobases, and of hmU 
in particular, in DNA from mESCs, we performed isotope trac-
ing and quantitative MS studies using the chemically synthesized 
isotopologs of mC, hmC, fC, caC, hmU and fU as internal standards 
(Fig. 1b and Supplementary Results, Supplementary Fig. 1). For 
the assessment of oxidation products that are formed by the action 
of ROS, we additionally quantified 8-oxo-G because 8-oxo-G is a 
well-established ROS reaction product formed from G17,18. We show 
here that hmU is generated enzymatically from thymidine during 
stem cell differentiation by the action of the Tet enzymes. A pro-
teomic analysis provides new insight into how genomic hmU can 
influence the binding of chromatin remodeling proteins and tran-
scription factors.
RESULTS
hmU is present at elevated levels in mESCs
We first created an inventory of the named nucleosides 
(Supplementary Fig. 1) in mESCs (Fig. 1c) and adult cortex tissue 
(Fig. 1d). In mESCs, we observed that hmC is, as expected, the most 
abundant oxidized pyrimidine (10% relative to mC), followed by fC 
(~1–2% of hmC). The ROS marker 8-oxo-G was detected at simi-
lar levels (~45% of fC), showing that nonenzymatic, ROS-induced 
oxidations of nucleobases are important processes, as expected. We 
also found relatively high levels of fU (22% of fC). Clearly detect-
able were also caC and hmU. hmU, which is at the center of this 
study, was unequivocally detected, as shown by its retention time 
and its specific fragmentation pattern, which were found to be iden-
tical with that of the internal standard [D2]hmU (Fig. 1e). Notably, 
both caC and hmU were present in comparable amounts (5% 
of fC). In adult mouse cortex DNA (Fig. 1d; for other tissues see 
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Ten eleven translocation (Tet) enzymes oxidize the epigenetically important DNA base 5-methylcytosine (mC) stepwise 
to 5-hydroxymethylcytosine (hmC), 5-formylcytosine and 5-carboxycytosine. It is currently unknown whether Tet-induced 
oxidation is limited to cytosine-derived nucleobases or whether other nucleobases are oxidized as well. We synthesized 
isotopologs of all major oxidized pyrimidine and purine bases and performed quantitative MS to show that Tet-induced 
oxidation is not limited to mC but that thymine is also a substrate that gives 5-hydroxymethyluracil (hmU) in mouse 
embryonic stem cells (mESCs). Using MS-based isotope tracing, we show that deamination of hmC does not contribute to the 
steady-state levels of hmU in mESCs. Protein pull-down experiments in combination with peptide tracing identifies hmU as a 
base that influences binding of chromatin remodeling proteins and transcription factors, suggesting that hmU has a specific 
function in stem cells besides triggering DNA repair. 
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Supplementary Fig. 2), the hmC levels are very high (13% rela-
tive to mC), as previously reported19–21. In contrast, fC was detected 
only in very small amounts (0.03% relative to hmC), and caC was 
not observed at all22. The detected amounts of 8-oxo-G and fU are 
comparable. Notably, the detected levels of hmU in the cortex were 
significantly lower compared to that in mESCs (27%; P = 2.2 × 10−4 
by Student’s t-test). Because the detected levels of 8-oxo-G were 
similar in the cortex (Fig. 1d) and in mESCs (Fig. 1c), the elevated 
hmU levels in mESCs cannot be explained by greater ROS-induced 
damage in mESCs and must have a different origin.
We next investigated this in more detail and quantified the levels 
of hmU in three different mESC lines (WT01, J1 and R1) and in 
a variety of tissues (Fig. 2a). Clearly, the hmU levels were higher 
in mESCs than in somatic tissues by factors of 2–15. The detected 
hmU levels correspond roughly to 500–1,700 hmU bases per 
genome in tissue and 2,900–7,800 in mESCs (Fig. 2a) depending on 
the cell type and growth conditions. We cannot explain these differ-
ences by elevated oxidative stress levels in mESCs (Supplementary 
Fig. 3). We next analyzed the levels of C, mC and the oxidized 
pyrimidines hmC, fC, hmU and fU as well as 8-oxo-G in somatic 
tissues (Supplementary Fig. 2) and performed a correlation and 
cluster analysis to reveal relationships of the modification levels 
(Fig. 2b). The data analysis confirmed that the low levels of hmU 
in somatic tissues correlate strongly (significant on a level <0.001) 
with the levels of fU and 8-oxo-G within a separated cluster. 
This result showed that in somatic cells, hmU and fU are ROS-
induced reaction products. If we assume that in somatic tissues 
hmU is exclusively formed by ROS, the data showed that in mESCs, 
70–80% of the detected hmU is produced by ROS-independent 
processes (Supplementary Fig. 3).
hmU formation by oxidation of T
To analyze the origin of the oxidized nucleobases in mESCs, we per-
formed isotope tracing experiments (Fig. 3a–c and Supplementary 
Fig. 4). Substitution of L-methionine with [methyl-13CD3]L- 
methionine ([13CD3]L-Met) in the growth medium is known to give 
the labeled S-adenosylmethionine cofactor, which is needed for the 
conversion of C to mC. Replacement of L-Met by [13CD3]L-Met for 5 d 
(2 passages) in the medium at a concentration of 0.2 mM furnished 
89% labeled [13CD3]mC, 88% labeled [hydroxymethyl-13CD2]hmC 
and 93% labeled [formyl-13CD]fC (Fig. 3b and Supplementary 
Fig. 4). Within the detection limit (7 and 50 molecules per 108  
nucleosides, respectively), no incorporation of the isotopes 13C and 
D into hmU and fU was observed, showing that hmC is not the pre-
cursor of hmU. We next added isotope-labeled [13C,15N2]thymidine 
([13C,15N2]T) to the growth medium and observed ~76% of label 
incorporation into T, hmU and fU (Fig. 3a, Supplementary Fig. 4  
and Supplementary Table 1). The combined data showed that 
hmU is not generated by deamination of hmC but by oxidation of 
T (T → hmU; Fig. 3c). Consequently, all of the detected hmU 
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(and also fU) resides in an A base pair context (hmU:A). In this 
base pair, hmU is repaired by Smug1 but not Tdg12. This was con-
firmed by siRNA-mediated knockdown of Smug1 in mESC cells 
and HEK-293T cells. Indeed, the hmU level increased in these cells 
(Supplementary Fig. 5).
The fact that we were unable to detect hmU derived from 
hmC deamination, which would be situated in a base pair with G 
(hmU:G), could also be explained by very fast repair. If repair of the 
hmU:G base pair is extremely efficient, for example, because deami-
nation and glycosylase-based repair occurs in a tight complex of the 
involved enzymes, we would be unable to detect this type of hmU 
because of low steady state levels. Indeed, it was proposed that hmC 
deamination and hmU excision requires a complex of the cytidine 
deaminase Aid and the glycosylase Tdg12. To assess this possibility, 
we performed isotope tracing experiments using [13CD3]L-Met in 
Tdg−/− mESCs stably complemented with either empty vector (con-
trol) or a minigene expressing a catalytically incompetent Tdg at 
near-endogenous levels. These cells are able to form the Aid–Tdg 
complex, but the Tdg is inactive, which should give elevated hmU 
levels if deamination occurs. In both cell lines, we detected high 
levels of labeled hmC. In the control cells, [hydroxymethyl-13CD2]
hmU was not detected. However, in the cell line complemented 
with inactive Tdg, some labeled [hydroxymethyl-13CD2]hmU was 
indeed observed, albeit only in small amounts (~7% of total hmU 
and ~0.06% of total hmC; Supplementary Fig. 6). Thus, the Tdg 
protein is required for deamination of hmC to hmU. In wild-type 
(WT) mESCs, the hmU:G mismatches are obviously repaired so 
quickly that they do not contribute to steady state levels of hmU. 
All of the detected hmU was derived from T oxidation and resided 
in hmU:A base pairs.
Tet enzymes form hmU in correlation with mC oxidation
We next investigated whether enzymatic oxidation or ROS-
dependent processes are responsible for the observed oxidation of 
T to hmU. To this end, we studied mESCs with genetic or func-
tional depletions of Tet or DNA methyltransferase (Dnmt) 
enzymes (Fig. 4). Although hmU levels were maintained at nor-
mal levels in the severely hypomethylated, Dnmt-depleted cell 
lines, they were substantially reduced upon knockdown of Tet1 
and Tet2. As the levels of fU and 8-oxo-G remained unaffected, 
the data establish that, though both hmU and fU are generated by 
T oxidation, their formation must occur by two independent pro-
cesses in mESCs. The data supported the idea that fU is a ROS-
created lesion similar to 8-oxo-G9,10,17,18, whereas most hmU is 
generated by Tet-induced oxidation of T.
In support of enzymatic T oxidation by Tet proteins, ectopic 
expression of the catalytic domain of Tet1 (Tet1cd) in HEK-293T 
cells led to a 65-fold increase for both hmC and hmU levels. This was 
not observed when a catalytic mutant of Tet1 (Tet1cm) was expressed 
(Supplementary Fig. 7a). To determine whether under these condi-
tions hmU is generated by deamination, as previously suggested11,12, 
we again replaced natural L-Met with [13CD3]L-Met in the medium, 
but we did not detect incorporation of heavy isotopes into hmU, 
providing evidence that the elevated hmU levels do not originate 
from hmC deamination (Supplementary Table 1). Finally, we con-
firmed enzymatic generation of hmU in vitro by incubating recom-
binant Tet1cd with a plasmid that was premethylated by bacterial 
methyltransferase M.SssI. In addition to oxidation of mC to hmC, 
fC and caC, we detected hmU at a prominent level of 9% relative to 
hmC (Supplementary Fig. 7b), showing that the catalytic center of 
the Tet enzymes clearly has the capacity to oxidize T to hmU.
To further confirm that hmU is formed in mESCs in the process 
of epigenetic reprogramming, we analyzed the dynamic changes of 
mC and all of the oxidized pyrimidines plus 8-oxo-G during dif-
ferentiation. It was recently shown that mC and hmC levels sharply 
increase when mESCs maintained in the naive state are shifted to a 
primed state in serum-containing medium23–25. To investigate global 
kinetics of all of the Tet-generated oxidation products under more 
physiologically relevant priming conditions, we used established 
protocols based on serum-free N2B27 medium for differentiation 
of naive mESCs into states resembling that of post-implantation 
epiblasts26,27. mESCs were first grown for several passages in the 
presence of MEK and GSK3 inhibitors (dual inhibition or 2i condi-
tions) and LIF to induce a hypomethylated state resembling that of 
the naive epiblast23–25. The data in Figure 5a are averaged from three 
independent differentiation experiments, each performed with two 
cell lines in the absence of growth factors. First, we observed that 
the fU and 8-oxo-G levels stayed constant (Fig. 5a), in line with the 
idea that both are ROS-derived products. In contrast, fC and caC 
levels peaked at about 8 h. Both hmU and hmC also peak between 
8 h and 16 h. Isotope tracing with [13CD3]L-Met under these condi-
tions provided no evidence for switched-on deamination of hmC to 
hmU (Supplementary Table 1). At these peak levels, we estimated 
that mESCs contain roughly 110,000 fC bases, 4,400 caC bases and 
Figure 2 | hmU is present at elevated levels in mESCs compared to tissue. 
(a) hmu levels per genome in mESCs (nWT01 = 7 replicates, nj1 = 2, nR1 = 3) 
and mouse tissue (3-month-old individuals, n = 3). levels per genome 
were obtained considering a mouse genome size of 2.7 × 109 base pairs. 
Depicted are mean values ± s.d. The differences between mESCs and 
mouse tissues are significant (P = 2.9 × 10−5 to 3.6 × 10−2; unpaired  
two-tailed t-test) except for WT01 and hippocampus (P = 0.292) or 
heart (P = 0.069). These exceptions are due to higher hmu levels in the 
hippocampus and heart caused by higher background oxidation (higher 
8-oxo-G levels). hmu levels normalized to oxidative background (8-oxo-G) 
levels are in Supplementary Figure 3. NS, not significant. (b) unsupervised 
clustering analysis of Pearson correlation coefficients of 24 data sets of 
selected mouse organs at a defined time point (3-month-old individuals: 
cortex, hippocampus, cerebellum, heart, liver and kidney). Discussed 
correlations are strong to very strong (Pearson coefficient >0.7) and 
significant on a level <0.001.
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14,000 hmU bases per genome, showing that, at its peak level, hmU 
is three times more abundant than caC. The dynamic peaking data 
allowed us to estimate half-life times for fC (7 h), caC (5 h) and hmU 
(4 h) during the differentiation process (Supplementary Fig. 8). 
Using the dynamic quantitative data, we performed a correlation 
and cluster analysis of the DNA modification levels (Fig. 5b). Three 
independent clusters were obtained. One cluster involves members 
of cytosine methylation (and demethylation) dynamics, including 
C, mC, fC and caC, but, to our surprise, not hmC. Instead, hmC 
groups with hmU. We therefore concluded that the formation 
of these modifications is tightly coupled by the action of the Tet 
enzymes. The ROS-induced lesions fU and 8-oxo-G form the third, 
well-separated cluster. Notably, hmU does not correlate with the 
ROS lesions.
Recently, it was shown that exposure of naive mESCs to fibro-
blast growth factor 2 (FGF-2) and activin A (ActA) for 48 h under 
similar conditions as those described above gives a homogeneous 
cell population whose transcriptome closely resembles that of the 
post-implantation epiblast26. Under these conditions, mC levels 
increased more rapidly, approaching somatic levels within a time 
frame closely reflecting that observed during embryonic develop-
ment (Supplementary Fig. 9a). Levels of hmC rose steadily 
throughout the 48-h time course. Whereas fC peaked at 36 h, hmU 
reached its maximum at 24 h (Supplementary Fig. 9b). qPCR data 
showed a robust induction of Dnmt3b that is 
most likely responsible for the increasing mC 
levels (Supplementary Fig. 9a). A transient 
peak of Tet1 expression at 24 h went in hand 
with rising hmU and fC levels, whereas Tet3 
expression started rising slowly from the same 
time point and may drive further accumulation 
of hmC and fC (Supplementary Fig. 9b). Tdg 
was progressively upregulated together with the 
onset of methylation activity, whereas Smug1 
showed little, if any, change (Supplementary 
Fig. 10). These data supported our view that 
hmU peaking is not caused by downregulation 
of the repair pathway.
Thus, the kinetic data showed a com-
plex interplay between methylation and two 
oxidation reactions during differentiation, 
which depends on the exact conditions. Most 
important is the fact that hmU showed a time-
 dependent occurrence similar to the other oxi-
dized bases hmC, fC and caC independently 
of the conditions investigated, confirming its 
formation during epigenetic reprogramming.
hmU attracts specific readers
To obtain initial insight into a potential biologi-
cal function of hmU in comparison to hmC, we 
screened for specific readers associating with 
hmU:A as well as with hmC:G and hmU:G 
using protein pulldown and relative quantifica-
tion by LC/MS/MS. In previous stable isotope 
labeling by amino acids in cell culture (SILAC)-
based proteomics studies with hmC, fC and 
caC containing oligonucleotides, we and oth-
ers observed a high number of specific protein 
readers, arguing that the new bases influence a 
variety of different processes28,29. For this hmU 
study, we further developed this approach for 
the detection of proteins that directly interact 
with the modified bases hmU (as well as hmC 
for comparison) to get a more direct insight into 
their function (Fig. 6a). For the study, we not 
only included into the biotinylated DNA duplexes (24mers) an hmU 
(hmC) base but also equipped the counter strand with a polyethylene 
glycol–based linker carrying a reactive N-hydroxysuccinimide 
(NHS) ester moiety and a reductively cleavable disulfide bond in 
the middle. This reactive linker cannot be inserted into the DNA 
strand using solid phase synthesis. In addition, the NHS ester does 
not survive hybridization conditions. We therefore attached the 
linker as its azide derivative, using Cu(I)-catalyzed click chem-
istry, to an alkyne-bearing base present in the DNA duplex30,31. 
These DNA duplexes were subsequently incubated with nuclear 
extracts from mESCs. The DNA-bound protein complexes were 
isolated using streptavidin-coated magnetic beads (Fig. 6a)32. 
DNA duplexes with the canonical base pairs A:T and C:G at the 
respective positions served as reference strands. The NHS linker has 
two functions in the experiment: First, it will covalently trap the 
reader proteins specifically at the ε-amino groups of lysines, which 
allows the identification of transiently binding proteins as well. 
Second, because the linker is cleavable, it will tag the trapped lysine 
residues, leaving a defined label on those proteins that bind in close 
proximity to the modified bases hmC and hmU. This allowed us to 
distinguish protein readers that bound close to hmC and hmU from 
proteins that are secondary members of the complexes. The cova-
lently trapped proteins were next tryptically digested and labeled 
with tandem mass tagging (TMT) isobaric tags to allow protein 
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identification and quantification by MS32,33. Only proteins that were 
enriched in both the forward and the reverse TMT experiment were 
considered to be specific hmU (hmC) readers (Fig. 6). All of the 
readers were subsequently divided into two groups. Proteins that 
were enriched relative to the control strands are termed specific 
readers (sRs). Of those, the proteins that were identified with a pep-
tide containing the tag are termed direct-specific readers (dsRs).
The scatter plot (Fig. 6b and Supplementary Fig. 11a) revealed 
over 250 sRs recognizing the hmU:A base pair (relative to T:A). 
Of those proteins, 99 were identified with tagged peptides. These 
proteins were therefore designated dsRs. A gene ontology analysis 
showed that 64 proteins of the 250 sRs are nucleotide bind-
ers, and 25 proteins are involved in chromatin organization 
(Supplementary Fig. 11b).
Among the dsRs we identified were the regulatory proteins Uhrf2, 
transcription factor HIVEP3 or the poly [ADP-ribose]  polymerase 14 
(Parp14), which showed that these proteins interacted directly with 
hmU. We also detected several H2A and H2B histone proteins among 
the dsRs and the sRs. Notably, in the group of the sRs, we observed 
also Dnmt3a and Dnmt3b, which are involved in gene expression 
regulation. Methyl CpG-binding protein 2 (MeCP2) was identified 
as well, but it showed only low enrichment. We also detected sev-
eral transcriptional regulators, such as bromodomain PHD finger 
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Figure 4 | Tet1 and Tet2 generate hmU in mESCs. Effect of Tet and Dnmt 
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WT (j1, n = 2), Dnmt1−/− (j1, n = 2) and Dnmt3a/b−/− (j1, n = 6).
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Figure 5 | hmU is produced during mESC differentiation. (a) Time course 
of DNA modification levels during early differentiation (0−40 h) of naive 
mESCs in the absence of growth factors. Box plot of relative modification 
changes for hmC, fC, caC and hmu averaged from six independent 
experiments using two different mESC lines. In the four upper plots, colored 
diamonds reflect mean values of technical triplicate measurements, open 
squares reflect mean values of biological replicates, boxes represent the 
s.e.m., and whiskers represent the the s.d. of the biological replicates;  
*P < 0.05, **P < 0.01 and ***P < 0.005 by unpaired two-tailed t-test. In 
the two lower plots, the relative modification changes of mC, hmu, fu and 
8-oxo-G are depicted as biological mean values ± s.e.m. (b) unsupervised 
clustering analysis of Pearson correlation coefficients of 22 data sets 
obtained from the differentiation experiments depicted in a. Discussed 
correlations are strong to very strong (Pearson coefficient >0.7) and 
significant on a level <0.001.
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transcription factor (Bptf), transcription factor E2F6 and mediator of 
RNA polymerase II transcription subunit 12 (Med12). Moreover, we 
identified hmU-binding E3 ubiquitin-protein ligases such as Uhrf1, 
Trim37 and Huwe1 and finally the chromodomain helicase DNA-
binding proteins 1 and 9 (Chd1 and Chd9) among the hmU readers, 
which are chromatin remodeling factors and regulate polymerase I 
and II transcription. To exclude bias by sequence-specific binding, 
we repeated the experiment with hmU in a different sequence con-
text. Indeed, 78% of the identified protein readers are also observed 
in this control experiment, and included among them were all of 
the proteins discussed above, with the notable exception of Uhrf1, 
which was not observed in this experiment (Supplementary Data 
Set 1). The data show that hmU:A recruits specific proteins that are 
involved in chromatin biochemistry in a broad sense.
As a first validation of the MS-identified readers, we focused on 
Uhrf1 and Uhrf2. Uhrf1 is a known mC and hmC binder34, whereas 
we recently identified the homolog Uhrf2 as a specific binder of 
hmC29. The MS data for hmU obtained in this study showed an 
enrichment of Uhrf1 and Uhrf2. In addition, Uhrf2 was identified 
as a direct binder. To validate the MS findings, we overexpressed 
Uhrf1 or Uhrf2 together with Tet1cd in 
HEK-293T29 and measured the levels of mC, 
hmC, fC, caC and also hmU. Indeed, we 
observed increased levels of hmU, proving a 
functional relation between hmU levels and 
Uhrf1 and Uhrf2 (Supplementary Fig. 12). 
As Uhrf2 is known to interact with Dnmt3a 
and Dnmt3b35 and these two proteins are 
also identified as sRs of hmU, our initial data 
provide a consistent picture.
Analysis of the specific hmU readers 
showed that 49 of the identified proteins were 
also enriched with an hmC-modified strand. 
Among these proteins were, for instance, 
 bromodomain PHD finger transcription factor 
(Bptf), MeCP2 and 19 other nucleotide- binding 
proteins. The obtained list of specifically bind-
ing proteins is in good agreement with our 
recently published data set29, which further 
supports the validity of the covalent trapping 
method. Finally, we compared the results 
of the hmU:A pulldown with a pulldown of 
hmU:G, which would be the product of hmC 
deamination. We found 69 of 280 sRs in both 
experiments. We identified transcription regu-
lators as sRs as well in the hmU:G pulldown. 
However, we also found several DNA repair 
proteins, such as DNA repair protein comple-
menting XP-C cells homolog (XPC), DNA 
repair protein Rad50 and five helicases, among 
others (Supplementary Data Set 1).
DISCUSSIoN
This work aimed to analyze the origin of hmU 
in mESCs. Although hmU as well as fU are 
both well-characterized oxidation products of 
thymidine9,10, hmU in particular was recently 
discussed as an intermediate in active demeth-
ylation by deamination of hmC11,12. We used sta-
ble isotopologs of the main oxidation products 
hmC, fC, caC, hmU, fU and 8-oxo-G in com-
bination with quantitative MS to show that the 
levels of hmU are strongly elevated in stem 
cells in comparison to somatic tissue. Notably, 
we did not observe equally elevated levels of 
fU and 8-oxo-G, both of which are formed by 
the reaction of DNA with ROS. This analysis suggests that hmU in 
stem cells is not only formed by ROS. The quantitative data allowed 
us to estimate that in WT stem cells, about 70–80% of the found 
hmU is not formed by ROS but is derived from a different process. 
Isotope tracing studies with labeled [13CD3]L-Met and [13C,15N2] 
thymidine showed that the detected hmU originates exclusively from 
T. Previous studies already proposed a connection between Tet activ-
ity and hmU levels, but these studies did not address the origin of 
hmU, which led to the hypothesis that hmU could form by deamina-
tion of hmC11,22. To investigate the involvement of deamination11–14, 
we studied Tdg−/− stem cells reconstituted with a catalytically inac-
tive Tdg. In these cells, the putative deamination–repair complex12 
of Tdg and Aid could form, and we expected to see elevated hmU 
levels. Indeed, in this experiment, we were able to detect labeled 
hmU, showing that deamination of hmC does occur, but the levels 
were low. Most notably, special conditions were required to detect 
this deamination. In WT cells, all of the detected hmU is clearly 
derived from T oxidation. As such, the detected hmU is situated in 
a base pair with A (hmU:A). In conclusion, the majority of hmU in 
mESCs is produced independently of both ROS and deamination. 
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Figure 6 | Identification of hmU:A readers. (a) Workflow of pulldown experiments with hmu:A–
containing oligonucleotides. DNA oligomers with the modified base Z containing an alkyne group 
for click reaction and biotin for the pulldown are hybridized with DNA oligomers containing hmu 
(X = hmu and y = A). After the click reaction with the DNA-protein cross-linker (red), which has 
an NHS ester as a lysine-specific reactive group (RG), the dsDNA oligomers are incubated with 
a nuclear extract from mESCs, and specific binders are covalently linked to the DNA. After three 
washing steps, the linker is reductively cleaved, and the proteins are enzymatically digested  
and labeled with TMT2plex reagents. The same dsDNA oligomer without hmu modification  
(X = T and y = A) was used as a control sample. Specifically enriched proteins are mixed with the 
control sample before lC/MS analysis. The same workflow was used for experiments with hmu:G 
or hmC:G and C:G as a control. (b) Magnified view of proteins enriched with hmu:A–containing 
oligomer. Specific readers in the forward and reverse experiment are marked in blue. Direct-specific 
readers are identified by the presence of the DNA-protein cross-linker and marked in red. Black 
dots are considered unspecific binders. A full-scale representation is shown in Supplementary 
Figure 11. (c) venn diagram showing overlap of specific binders for hmu:A, hmu:G and hmC:G.
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Using a combination of functional knockdown in mESCs, ecto-
pic expression of Tet1 catalytic domain in HEK-293T cells and 
in vitro studies with recombinant Tet protein, we showed that the 
Tet enzymes, known to oxidize mC to hmC, are also responsible 
for oxidation from T to hmU. A kinetic study in which the tempo-
ral changes of all of the oxidized pyrimidines were observed under 
two different differentiation kinetics showed finally that hmU is 
formed in processes that also generate hmC and fC. Together with 
the observed peak levels of hmU of about 14,000 bases per genome, 
this suggests that hmU could have an epigenetic function similar 
to hmC. It is conceivable that the Tet enzymes introduce a small 
amount of hmU during the hmC manufacturing process to trigger 
faster demethylation by induction of DNA repair. It is known that 
hmC is not a substrate for repair8,12, whereas hmU is efficiently rec-
ognized and repaired36, for example, by the repair glycosylase Smug1 
(refs. 37,38). Sporadic introduction of hmU could therefore allow 
recruitment of repair factors, for example, for long patch repair, as 
recently suggested39. Alternatively, hmU might influence transcrip-
tion factor binding, which is known to be a hallmark of epigenetic 
reprogramming40. To study the proteins that closely interact with 
hmU, a new pulldown experiment was devised in which we inserted 
a trapping linker into the oligonucleotide. This linker is able to react 
covalently with proteins that assemble on the DNA duplex close to 
the hmU base. Because the linker is reductively cleavable, it leaves 
a tag on the respective lysine residues, which is detected in subse-
quent MS-based proteomics measurements. Using this technology, 
we observed that hmU:A recruits transcription factors and proteins 
that are involved in chromatin biochemistry, including Uhrf1 and 
Uhrf2. This result is in line with the recent observation that oxida-
tive lesions in DNA can change the binding affinity of the transcrip-
tion factor CREB when they are present in the respective cognate 
sequence41. A further analysis in HEK-293T revealed that the hmU 
readers Uhrf1 and Uhrf2 are able to modulate the levels of all of 
the oxidized mC bases and of hmU. It is interesting to note that the 
observed level increases of hmC were small, whereas they were sub-
stantial for hmU and also for the further oxidized bases fC and caC. 
As Uhrf1 and Uhrf2 are proteins known to be involved in numer-
ous epigenetic processes, our data supported the hypothesis that 
Tet-induced oxidation of T to hmU may have an epigenetic func-
tion. Even in the case that hmU is formed just as a side product 
of Tet-induced hmC formation, it is now clear that the oxidation 
chemistry performed by the Tet enzymes has to go in hand with 
effective DNA repair. 
received 15 December 2013; accepted 17 april 2014; 
published online 18 May 2014
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Methods and any associated references are available in the online 
version of the paper.
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General materials and methods. Chemicals were purchased from Sigma-
Aldrich, Fluka, ABCR or Acros Organics and used without further purifica-
tion. Acetonitrile of LC/MS grade was purchased from Carl Roth GmbH + Co., 
KG. Formic acid, p.a. for MS, was purchased from Fluka, and water was puri-
fied with a Milli-Q Plus system from Merck Millipore.
The MS standards 5-methyl-2′-deoxycytidine (mC), 5-trideuteromethyl-
2′-deoxycytidine ([D3]mC), 5-hydroxymethyl-2′-deoxycytidine (hmC), 
5-dideuterohydroxymethyl-2′-deoxy-(N1,N3–15N2)-cytidine ([15N2,D2]
hmC), 5-formyl-2′-deoxycytidine (fC), 5-formyl-2′-deoxy-(N1,N3–15N2)-
cytidine ([15N2]fC), 5-carboxy-2′-deoxycytidine (caC), 5-carboxy-2′-deoxy-
(N1,N3–15N2)-cytidine ([15N2]caC), 5-hydroxymethyl-2′-deoxyuridine (hmU), 
5-(dideuterohydroxymethyl)-2′-deoxyuridine ([D2]hmU), 5-formyl-2′-
deoxyuridine (fU) and 5-formyl-2′-deoxy-(N1,N3–15N2)-uridine ([15N2]fU) were 
synthesized according to earlier published work19,21,42. All of the synthesized 
compounds were characterized and purity confirmed by 1H-NMR, 13C-NMR 
and ESI-MS, and some were additionally validated by 15N-NMR. 8-hydroxy-2′-
deoxy-(15N5)-guanosine ([15N5]8-oxo-G) (99 atom% 15N) was purchased from 
Cambridge Isotope Laboratories; 8-hydroxy-2′-deoxyguanosine (8-oxo-G) was 
from BIOLOG; 2′-deoxyguanosine (G) and 2′-deoxycytidine (C) were from 
ChemGenes. (methyl-13C,D3)-L-Met (99 atom% D and 13C) was purchased from 
Sigma-Aldrich, and 2′-deoxy-(C2–13C, N1,N3–15N2)-thymidine (99 atom% 13C 
and 15N) from Hartmann Analytic. Aqueous stock solutions of these com-
pounds were stored at −20 °C and warmed up to RT before usage.
Oligonucleotide synthesis. Oligonucleotide synthesis was performed on an 
ABI 394 DNA/RNA synthesizer (Applied Biosystems) using standard DNA 
synthesis conditions (DMT off) and acetyl-protected dC. Phosphoramidites 
(including the 5-hydroxymethyl-dU-CE phosphoramidite and the 5′-biotin 
phosphoramidite) and polystyrene carriers were obtained from Glen Research. 
5-octadinyl-dU (Z) phosphoramidite was synthesized according to litera-
ture and characterized by 1H-NMR, 13C-NMR, 31P-NMR and ESI-MS43. The 
crude oligonucleotide was cleaved from the resin and deprotected in 30% (v/v) 
ammonium hydroxide and 40% (v/v) methylamine (1:1) at 65 °C for 10 min 
and purified by preparative and analytical HPLC (Waters Breeze and Alliance, 
respectively). Separation was performed by applying a VP 250/10 Nucleosil 
100-7 C18 column (flow: 5 ml/min) from Macherey-Nagel with a gradient 
of buffer A (0.1 M NHEt3OAc in water) and buffer B (0.1 M NHEt3OAc in 
80% MeCN). DNA-containing fractions were characterized by MALDI-TOF 
(Bruker Autoflex II) and analytical HPLC, combined, and desalted by C18-
Sep-Pak cartridges (Waters). For analytical HPLC, separation was performed 
by applying a CC 250/4 Nucleosil 120-3 C18 column from Macherey-Nagel 
(flow: 0.5 ml/min) with the aforementioned buffer system.
For the protein pulldown studies, an hmU-containing oligonucleotide was 
hybridized with a DNA strand modified with a 5′-biotin and a 5-octadienyl- 
dU. The sequences of the DNA strands are summarized in Supplementary 
Table 3. To 10 nmol of the dsDNA, 0.5 μl of a 200 mM solution of the cross- 
linking azide-PEG3-S-S-NHS ester (C18H29N5O8S2, Jena Bioscience, 
Jena, Germany) in DMSO was added. In a separate tube, CuBr was dis-
solved in a TBTA solution (DMSO/tBuOH 3:1, 100 mM) resulting in a 1:1 
Cu(I):TBTA ratio. This solution was immediately added to the DNA/azide 
mixture. Furthermore, 45 μl of DMSO/tBuOH (3:1) were added, the mixture 
was shaken at 37 °C for 3 h, and the resulting product was purified by 
ethanol precipitation.
LC/MS analysis of DNA samples. Quantitative LC/UV-ESI-MS/MS analysis of 
digested DNA samples was performed using an Agilent 1290 UHPLC system 
equipped with a UV detector and an Agilent 6490 triple quadrupole mass 
spectrometer coupled with the stable isotope dilution technique. An improved 
method, based on earlier published work29,42,44,45, was developed, which allowed 
the concurrent analysis of all nucleosides in one single analytical run. The 
source-dependent parameters were as follows: gas temperature 50 °C, gas 
flow 15 l/min (N2), nebulizer 30 psi, sheath gas heater 275 °C, sheath gas flow 
11 l/min (N2), capillary voltage 2,500 V in the positive ion mode, capillary volt-
age −2,250 V in the negative ion mode and nozzle voltage 500 V. The fragmentor 
voltage was 380 V. Delta EMV was set to 500 (positive mode) and 800 (negative 
mode). Compound-dependent parameters are summarized in Supplementary 
Tables 4 and 5. Chromatography was performed by a Poroshell 120 SB-C8 
column (Agilent, 2.7 μm, 2.1 mm × 150 mm) at 30 °C using a gradient of water 
and MeCN, each containing 0.0085% (v/v) formic acid, at a flow rate of 
0.35 ml/min: 0 → 5 min; 0 → 3.5% (v/v) MeCN; 5 → 6.9 min; 3.5 → 5% MeCN; 
6.9 → 7.2 min; 5 → 80% MeCN; 7.2 → 10.5 min; 80% MeCN; 10.5 → 11.3 min; 
80 → 0% MeCN; 11.3 → 13 min; 0% MeCN. The effluent up to 1.5 min and after 
9 min was diverted to waste by a Valco valve. The autosampler was cooled to 
10 °C. The injection volume was amounted to 29 μl. Calibration curves, method 
validation and data processing are in Supplementary Note 2. A complete 
compilation of LC/MS quantifications results see Supplementary Note 3.
DNA digestion. 5–25 μg of genomic DNA in 25 μl H2O were digested as follows: 
An aqueous solution (7.5 μl) of 480 μM ZnSO4, containing 42 U nuclease S1 
(Aspergillus oryzae, Sigma-Aldrich), 5 U Antarctic phosphatase (New England 
BioLabs) and specific amounts of labeled internal standards (Supplementary 
Note 2) were added, and the mixture was incubated at 37 °C for 3 h. After 
addition of 7.5 μl of a 520 μM [Na]2-EDTA solution, containing 0.2 U snake 
venom phosphodiesterase I (Crotalus adamanteus, USB corporation), the sam-
ple was incubated for another 3 h at 37 °C and then stored at −20 °C. Prior to 
LC/MS/MS analysis, samples with up to 15 μg DNA, for which the quantifica-
tion of low amounts of caC was aspired, were filtered by using an AcroPrep 
Advance 96 filter plate 0.2 μm Supor (Pall Life Sciences). In contrast, samples 
with 15–25 μg DNA (isotope-tracing experiments) were filtered by using an 
AcroPrep Advance 96 filter plate 10K Omega (Pall Life Sciences).
Genomic DNA isolation. Tissues of female WT mice (C57-BL6/N) were 
dissected at postnatal day 90 and prepared as earlier described19,21. Genomic 
DNA was extracted using the Qiagen Blood and Cell Culture DNA Midi Kit 
except for mESC samples differentiated in the presence of growth factors 
(see below). Extraction was performed following the manufacturer’s instruc-
tions for genomic DNA isolation from cell culture samples or tissue samples, 
respectively. All buffers until loading of the sample on Genomic-tip 100/G 
were additionally supplemented with antioxidants 3,5-di-tert-butyl-4- 
hydroxytoluene. (BHT, 200 μM) and deferoxamine mesylate salt (desferal, 
200 μM) as well as the deaminase inhibitor tetrahydrouridine (THU, 200 μM), 
according to published methods, to reduce background oxidation or deamina-
tion18. Elution buffer QF was supplemented with 200 μM BHT. Following elu-
tion, all steps were performed on ice. DNA was then precipitated with NaOAc 
(0.3 M final) and 0.7 volumes iPrOH. DNA pellets from cultured cells were 
washed twice with ice-cold 70% EtOH and resuspended in H2O containing 
20 μM BHT using a Qiagen TissueLyser (30 Hz, 2 min). DNA pellets from 
mouse tissues were resuspended in PBS buffer and additionally extracted with 
phenol/CHCl3, precipitated, washed and resuspended as described above.
R1 mESC samples differentiated in the presence of growth factors or trans-
fected with Smug1 esiRNAs were lysed directly in the plates with RLT buffer 
(Qiagen) supplemented with BHT and desferal as described above. DNA was 
isolated using the Zymo Quick gDNA Midi Kit according to the manufacturer’s 
instruction, except that elution was repeated four times with 100 μl of elu-
tion buffer supplemented with BHT (200 μM). Eluted DNA was precipitated 
with 2 M ammonium acetate and two volumes of absolute ethanol and finally 
resuspended in H2O containing 20 μM BHT. The flow-through from the spin 
columns was used to isolate RNA (see real-time PCR analysis).
mESC cell culture. Feeder independent WT01 mESCs (C57BL/6 strain)46 were 
cultured in the presence of serum and LIF as previously described4. Tdg+/− and 
Tdg−/− mESCs were described previously47. Tdg−/− mESCs were complemented 
by random integration of either empty vector (hereafter referred to as Tdg−/− 
mESCs) or a minigene expressing catalytically inactive Tdg (N151A)47. Clonal 
mESC lines with targeted Tdg alleles, R1 cells (strain 129/Sv)48, J1 cell lines 
(strain 129S4/SvJae)49 and a mESC line derived from C57Bl/6/129 mixed 
background50 were routinely maintained on gelatinized plates in DMEM 
(PAA or Sigma) supplemented with 10% FBS, 1× MEM-nonessential amino 
acids (NEAA), 0.2 mM L-alanyl-L-glutamine, 100 U/ml penicillin, 100 μg/ml 
strepto mycin (all from PAA), 0.1 mM β-mercaptoethanol, 20 ng/ml 
(≥1 ×103 U/ml) mouse recombinant LIF (ORF Genetics), 1 μM PD 0325901 and 
3 μM CHIR 99021 (2i; both from Axon Medchem). In these conditions, the glo-
bal levels of genomic mC were very low (and, as a consequence, the levels of its 
oxidized derivatives were even lower; data not shown). Before DNA isolation, 
2i cultures were passaged twice (over 5 d) in DMEM supplemented with FBS 
and LIF as above but lacking 2i. With this strategy, primed mESC cultures were 
obtained with no sign of overt differentiation and modified genomic cytosines 
reached reproducibly higher and stable levels. For isotope tracing with heavy 
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thymidine in serum-primed mESCs 2i cultures of R1, cells were passaged 
twice (5 d) in the same serum-containing medium lacking 2i and simultane-
ously supplemented with 100 μM [13C,15N2]T. For isotope tracing with heavy 
methionine in serum-primed mESCs, 2i cultures of R1 cells and mESC lines 
with targeted Tdg alleles were passaged twice (over 5 d) without 2i in L-Met-
free DMEM (Life Technology) supplemented as above and with 0.2 mM of 
either [methyl-13C,D3]L-Met or natural L-Met. For mESC differentiation with-
out growth factors, R1 cells and the C57Bl/6/129 mixed background cell line 
were first plated at 1 × 105 cells/cm2 on gelatin-coated plates in N2B27 medium 
containing 1,000 U/ml LIF to favor attachment and initial survival51. After 12 h, 
the medium was replaced without addition of LIF (defined as time point 0 h). 
The medium was replaced once more at 24 h. For isotope tracing with [methyl-
13C,D3]L-Met during mESC differentiation, R1 cells were cultured for two pas-
sages in L-Met-free N2B27 medium supplemented with LIF, 2i and 0.2 mM 
of either [methyl-13C,D3]L-Met or natural L-Met. Differentiation of R1 cells 
in the presence of FGF-2 and ActA was as described26, with minor modifi-
cations. Briefly, mESCs were cultured in N2B27 medium containing 2i and 
1,000 U/ml LIF for several passages and then seeded at 2.2 × 105 cells/cm2 in N2B27 
medium containing 1% KnockOut Serum Replacement (Life Technologies), 
12 ng/ml FGF-2 (PeproTech) and 20 ng/ml ActA (ORF Genetics) on 
plates coated with a thin layer of Geltrex extracellular matrix preparation 
(Life Technologies). The medium was exchanged after 24 h.
Knockdown experiments in mESCs. shRNA expression vectors targeting 
Tet1 and Tet2 were generated by cloning synthetic oligonucleotides in pLKO.1 
(ref. 52). Recombinant lentiviruses were produced by cotransfecting pLKO.1 
shRNA expression vectors and packaging plasmids in HEK-293 cells. 48 h after 
transduction in the presence of 8 μg/ml polybrene, shRNA-expressing mESCs 
were selected with 4 μg/ml puromycin. Cell pools were continuously cultured 
in the presence of puromycin. shRNA target sequences were as follows: SCR 
(control), 5′-CCT AAG GTT AAG TCG CCC TCG-3′ (ref. 52); Tet1, 5′-TGT 
AGA CCA TCA CTG TTC GAC-3′ (see ref. 52), Tet2: 5′-TTC GGA GGA 
GAA GGG TCA TAA-3′. esiRNAs for Smug1 knockdown were generated as 
described53. The cDNA template for in vitro transcription was generated by 
PCR using following primers: forward, 5′- CGT AAT ACG ACT CAC TAT 
AGG GAG CCC GTG GGT G-3′, and reverse, 5′-CGT AAT ACG ACT CAC 
TAT AGG GGT TTC GTC CAC TGG G-3′. R1 mESCs were weaned from 
2i for two passages in FBS- and LIF-containing medium as described above. 
Upon plating the second passage, the cells were transfected in a p60 plate with 
6 μg of Smug1 esiRNAs (34.5 nM) and 20 μl of Lipofectamine RNAi MAX 
(Life Technologies) according to the manufacturer’s instructions and were 
lysed 72 h after transfection.
Culture and transfection procedures for HEK-293T cells. All transfections 
were performed using jetPRIME transfection reagent (PEQLAB Biotechnologie 
GmbH) according to the manufacturer’s instructions. HEK-293T cells were 
seeded 24 h before transfection at a density of 2.5 × 106 cells per 75 cm2 flask and 
incubated in 10 ml of medium. The transfection solution (500 μl of jetPRIME 
buffer, a specific amount of plasmid DNA (Supplementary Note 4) and 20 μl 
of jetPRIME reagent) was added to the medium, and the cells were incub-
ated for 48 h, with an additional medium exchange 24 h after transfection. 
When cotransfection of esiRNA was performed, a second transfection step 
(500 μl of jetPRIME buffer, 5 μg of esiRNA and 20 μl of jetPRIME reagent) was 
carried out 4 h after transfection of plasmid DNA. esiRNAs were purchased 
from Sigma (human TDG esiRNA EHU038971; human SMUG1 esiRNA 
EHU098861; human CDK5RAP1 esiRNAEHU079221). Supplementary 
Note 4 summarizes the overexpression and knockdown procedures.
Isotope tracing with [13C,15N2]thymidine or [13C,D3]L-Met in HEK-293T cells 
transfected with Tet1cd. 24 h before transfection, 2.5 × 106 cells were seeded 
in a 75-cm2 flask containing 10 ml either of (for [13C,15N2]thymidine) DMEM 
medium supplemented with 50 μM [13C,15N2]T or (for [13C,D3]L-Met) DMEM 
medium lacking L-Met, L-cystine and pyruvate, which was supplemented with 
10% dialyzed FBS, 2 mM [13C,D3]L-Met and 0.2 mM L-cystine. Transfection 
was performed as described above using labeled medium.
Real-time PCR analysis of mRNA expression. For analysis of Tet1 and Tet2 
knockdown in mESC total RNA was prepared with Trizol (Invitrogen), cDNA 
synthesis was performed with Quantitect reverse transcription kit from 
Qiagen, and real-time PCR was performed with the Power Sybr Green PCR 
master mix from Applied Biosystems on an Applied Biosystems 7500 Fast 
system. Knockdown efficiencies relative to control samples transfected with 
SCR esiRNAs were 79% and 70% for Tet1 and Tet2, respectively. The primers 
used to estimate them are listed in Supplementary Note 4. For analysis of Smug1 
knockdown in mESCs and EpiLC differentiation samples, total RNA was pre-
pared with RNeasy spin columns (Qiagen), followed by DNase treatment using 
TURBO DNA-free (Ambion, Life Technologies); cDNA synthesis was carried 
out using iScript cDNA Synthesis kit (Bio-Rad); real-time PCR was performed 
with SsoFast EvaGreen Supermix (Bio-Rad). Smug1 knockdown efficiency rel-
ative to control samples transfected with esiRNAs targeting GFP was estimated 
to be 60%. Quantification of Tet, Dnmt, Tdg and Smug1 transcripts during 
EpiLC differentiation and Smug1 knockdown samples was performed using 
the primers listed in Supplementary Note 4. Expression levels were quanti-
fied with respect to the housekeeping gene Gapdh and normalized to time 
point 0 h.
Tet in vitro assay. A plasmid was prepared from dam−/dcm− competent E. coli 
strain (New England BioLabs) and methylated with M.SssI (New England 
BioLabs). 1.5 μg of plasmid DNA were then treated with recombinant Tet1 
from the 5hmC TAB-Seq Kit (Wisegene) corresponding to ref. 54. After 3 h 
incubation at 37 °C and proteinase K treatment, the oxidized plasmids were 
purified with GeneJET PCR Purification Kit from Thermo Scientific and 
eluted in 25 μl water. Samples were then subjected to LC/MS/MS analysis as 
described42. The results are compiled in Supplementary Note 3.
Correlation and cluster analyses. Statistical data analysis was performed using 
IBM SPSS Statistics 19. Results of bivariate correlation analyses are summarized 
in Supplementary Note 5. Unsupervised clustering of species with respect to 
its correlation coefficients was applied by average linkage hierarchical cluster-
ing using a squared Euclidean distance measure.
Pulldown assay. For the pulldown assay, 250 μg (50 μl) of the crude nuclear 
protein extracts were filled up to 500 μl with 50 mM TEAB and 1 mM MgCl2. 
The binding conditions were 45 mM TEAB, 1.1 mM MgCl2, 2 mM HEPES, 
42 mM NaCl and 20 μM EDTA. Complete Protease Inhibitor Cocktail Tablets 
were used from Roche Diagnostics (Indianapolis, IN, USA). The DNA oligo-
mers with DNA-protein cross-linker were dissolved in neat DMSO, and 1 nmol 
was added to the protein lysate and incubated for 20 min at room temperature. 
Streptavidin-coated magnetic particles (Roche Diagnostics, Indianapolis, IN, 
USA) were washed three times with binding buffer (100 mM NaCl, 10 mM 
Tris, 1 mM EDTA, pH 7.4) before 200 μl of the bead slurry (equal to 2 mg 
beads) were added to the sample. Following 2 h incubation at room tempera-
ture under constant rotating, the beads were washed three times with 50 mM 
TEAB and 1 mM MgCl2. The beads were reconstituted in 50 mM TEAB and 
1 mM MgCl2. Disulfide bonds of the cross linker were cleaved and alkylated in 
the process of enzymatic digestion, and the magnetic particles were removed 
before adding trypsin (described below).
Protein sample preparation. Cell lysis of mouse embryonic stem cells was per-
formed as described in ref. 29. For each lysis, approximately 7.5 × 107 cells were 
used. Protein concentration was determined by Bradford assay. For each exper-
iment 250 μg (50 μl) of the crude nuclear protein extract were used. Protein 
samples for MS analysis were reduced by adding 100 mM TCEP and by incu-
bating on a shaker at 650 r.p.m. for 1 h at 60 °C and subsequently alkylated with 
200 mM iodoacetamide in the dark for 30 min at 25 °C. Protein samples were 
digested with 0.5 μg trypsin (Promega, Madison, MA, USA) for 16 h at 37 °C. 
The reaction was stopped using 1 mM phenylmethylsulphonylfluoride. After 
tryptic digestion, peptide labeling with the TMT2plex reagents (Thermo Fisher 
Scientific, Waltham, MA, USA) was performed according to the manufacturer’s 
instructions. TMT2plex reagents 126 and 127 were used to label the samples. 
When the sample (proteins enriched with hmU- or hmC-containing DNA 
strands) was labeled with TMT126, the control sample (proteins enriched with 
no modified DNA-bases) was labeled with the TMT127 reagent and vice versa. 
Subsequent to the labeling, both sample and control, were combined. This way, 
each experiment was performed twice as a so-called label swap experiment. 
Organic solvent was removed by vacuum centrifugation, and the sample was 
finally reconstituted in 1% (v/v) formic acid for MS analysis.
LC/MS analysis of protein samples. The samples were analyzed using an 
UltiMate 3000 nano liquid chromatography system (Dionex, Fisher Scientific, 
Waltham, MA, USA) coupled to an LTQ-Orbitrap XL (Thermo Fisher 
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proteins, the only proteins considered as ‘specific readers’ were enriched in 
both the forward and the reverse experiment.
Scientific, Waltham, MA, USA). Of each eluate, 15 μl were injected for the 
analysis. The samples were desalted and concentrated on a μ-precolumn 
cartridge (PepMap100, C18, 5 μM, 100 Å, size 300 μm i.d. x 5 mm) and fur-
ther processed on a custom-made analytical column (ReproSil-Pur, C18, 3 μM, 
120 Å, packed into a 75 μm i.d. x 150 mm and 8 μm picotip emitter). A 57-min 
multistep analytical separation was performed at a flow rate of 300 nl/min. 
In the first 50 min, a linear gradient was ramped up from 5% (v/v) solvent B 
(acetonitrile containing 0.1% formic acid and 5% DMSO) and 95% solvent A 
(water containing 0.1% formic acid and 5% DMSO) to 95% solvent B. This level 
was held for 5 min and then ramped down again to 5% solvent B within 2 min. 
Mass spectrometric analyses were performed starting with a full mass scan in 
the mass range between m/z 300 and m/z 1,650. This survey scan was followed 
by three MS/MS scans using the FTMS mass analyzer and high normalized 
collision energy of 70 in the HCD cell and three additional scans using the ion 
trap mass analyzer and a normalized collision energy of 35.
Protein identification and relative quantification method. The Thermo 
Proteome Discoverer 1.1 software (Thermo Fisher Scientific, Waltham, MA, 
USA) was used for protein identification and for relative quantification. The 
Sequest (Thermo Fisher Scientific, Waltham, MA, USA) search engine was 
used in combination with a Uniprot database (Mus musculus; date of download, 
04/2013). As a limit of detection, a ratio of threefold signal over the noise filter 
was applied. A maximum of two missed cleavage sites was allowed. The mass 
tolerances were 10 p.p.m. for the precursor mass and 0.5 Da for the fragment 
ion mass. Carbamidocysteine was set as static modification. Dynamic modi-
fications were: cation, Na (D, E); the residue of the DNA-protein crosslinker 
(+146.028 Da; K, Y); Oxidation (M) as well as TMT2plex (N-term. and K). 
Identified, nonredundant peptides, which were labeled with the TMT2 reagent, 
were used for relative quantification. The integration window tolerance was 
20 p.p.m., and the integration method was set to ‘most confident centroid’. The 
signals of the TMT2 reporter ions 126 and 127 were used to calculate ratios and 
monitor either preferred or nonpreferred binding of the identified proteins to the 
modified DNA bases in comparison to the control strand. From the identified 
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9 Outlook 
The investigation of modified tRNA nucleosides in higher eukaryotes presented in this work reveals 
that modification levels differ between mammalian tissues. This difference is proposed to depend on 
variations in protein synthesis needs. Additionally, S. cerevisiae was found to increasingly modify its 
tRNA population upon entry into stationary phase, a feature which is suggested to facilitate protein 
translation during quiescence and to ensure rapid start of the translational machinery upon exit from 
stationary phase. These findings suggest a regulation of the tRNA modification levels to ensure a 
dynamic adaptation to the translational requirements of the cell. As a next step it would be interesting 
to further elucidate how this regulation is established, whether it is dependent on the levels of tRNA 
modifying proteins or whether it derives from selective maintenance of a pool of hypomodified tRNA 
molecules which can be targeted for modification depending on protein synthesis needs. Furthermore, 
investigation using double-labelling of the tRNA will allow to elucidate whether tRNA modification 
turnover is coupled to overall tRNA turnover and this result will help to accurately determine the 
contribution of tRNA degradation to the increase in RNA modifications observed in S. cerevisiae. In 
addition, it would be interesting to determine at which point of development the tissue-dependent 
distribution of tRNA modifications is established, for example by monitoring the tRNA modification 
levels during differentiation of mouse embryonic stem cells to different cell lineages. 
Further studies should additionally focus on the modifications discovered in other RNA species and 
their role and impact on RNA function. Quantification of these modifications and their variation in 
response to various environmental cues will certainly prove essential for their further characterization. 
Particularly helpful will also be the development of RNA modification mapping/sequencing methods 
which will then allow to specifically locate modified nucleosides in the various RNA molecules. 
The involvement of the oxidized cytosines hmC, fC and caC as epigenetic markers or as intermediates 
in different pathways of active demethylation is still the focus of ongoing investigation. Results 
presented in this work showed that fC and caC might be involved in replication-coupled dilution (i.e. 
erasure) of the methylation pattern, possibly complementing the previously discovered TDG-
dependent mechanism of fC and caC removal. Further studies should continue the search for a C-C 
cleavage-dependent demethylation pathway, which to date remains elusive. In particular, it would be 
beneficial to perform these studies in living cells, testing a range of cells as well as various 
differentiation time points. Furthermore, the generation of plasmid DNA using labelled cytosine 
triphosphate derivatives via the Polymerase Chain Reaction could be exploited to produce labelled 
substrates for a putative demethylase which can be transfected into cells. The enhanced stability of 
these DNA constructs would allow for the unambiguous identification of possible demethylation 
products.  
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Furthermore, the role of fC and caC as epigenetic markers with a specific function in modulation of 
gene expression is still unclear. Future studies should address this issue by establishing the influence 
of these modifications on the rate of gene transcription, as well as on recruitment of specific chromatin 
remodelling proteins. 
The discovery of hmU as a product of Tet1 enzymatic activity suggests that hmU might play a more 
complex role compared to a simple oxidative lesion. It would therefore be interesting to characterize 
the specific binders of hmU as determined by proteome analysis. Further information could be gained 
by sequencing of this base in the mammalian genome. This might reveal specific loci where hmU is 
enriched, and therefore contribute to our understanding of its function as a product of Tet1 enzymatic 
activity. 
The observation that hmU is largely generated by Tet1-dependent oxidation of T rather than by 
deamination of hmC also raises the question of whether deamination of hmC is at all involved in 
active demethylation. Further studies should monitor whether deamination of hmC can be detected 
during specific stages of cell differentiation and whether it is restricted to specific cell types. It would 
in fact be interesting to clarify the contribution of this pathway to the demethylation process and how 
it is eventually regulated. Similarly, the high sensitivity of UPLC-MS/MS-based quantification 
methods should be exploited to address the process of deamination of mC to generate T, which again 
would provide important insights into the process of active demethylation. 
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12 Abbreviations 
 
A  Adenosine 
A-site  Aminoacyl tRNA binding site 
AID  Activation-induced deaminase 
Am   2´-O-Methyladenosine 
Ar  2´-O-Ribosyladenosine 
ASL  Anticodon stem and loop 
BER  Base excision repair 
bp  Base pair 
BSA  Bovine serum albumine 
C  Cytosine 
caC  5-Carboxycytosine 
Cm  2´-O-Methylcytosine 
CpG  dC-dG dinucleotide 
DEAE  Diethylaminoethylcellulose 
DMEM  Dulbecco´s Modified Eagle´s Medium 
DNA  Deoxyribonucleic acid 
ds  Double stranded 
DSL  Dihydrouridine stem and loop 
DTT  Dithiothreitol 
E.coli  Escherichia coli 
EDTA  Ethylendiamine tetraacetate 
ES cells Embryonic stem cells 
ESI  Electrospray Ionisation 
EtOH  Ethanol 
FAD  Flavin adenine dinucleotide 
fC  5-formylcytosine 
Gm  2´-O-Methylguanosine 
h  Hour 
hmC  5-Hydroxymethylcytosine 
hmU  5-Hydroxymethyluracil 
HPLC  High performance liquid chromatography 
I  Inosine 
i
6
A  N
6
-isopentenyladenosine 
IPTG  Isopropylthiogalactoside 
m
1
A  1-Methyladenosine 
m
1
G  1-Methylguanosine 
m
2
A  2-Methyladenosine 
m
2
G  N
2
-Methylguanosine 
m
2
2G  N
2
,N
2
-Dimethylguanosine 
m
7
G  7-Methylguanosine 
mC  5-Methylcytosine 
mcm
5
s
2
U 5-Methoxycarbonylmethyl-2-thiouridine 
MeCN  acetonitrile 
min  Minutes 
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mnm
5
s
2
U 5-Methylaminomethyl-2-thiouridine 
MS  Mass spectrometry 
ms
2
i
6
A  2-Methylthio-N
6
-isopentenyladenosine 
OD  Optical density 
OHyW  Hydroxywybutosine 
P-site  Peptidyl tRNA binding site 
PCR  Polymerase chain reaction 
PDB   Protein Data Bank 
Q  Queuosine 
RNA  Ribonucleic acid 
rpm  Rotation per minute 
RS  tRNA synthase 
S. cerevisiae Saccharomyces cerevisiae 
SAM  S-Adenosylmethionine 
SDS  Sodium dodecylsulfate 
SMUG1 Single-strand-selective monofunctional uracil-DNA glycosylase 1 
t
6
A  N
6
-THeronylcarbamoyladenosine 
Tet  Ten-eleven translocation 
Tris  Tris(-hydroxymethyl)-aminomethane 
tRNA  Transfer ribonucleic acid 
TSL  Thymidine stem and loop 
U  Uridine 
UV  Ultraviolet 
vol.  Volume 
  Pseudouridine 
yW  Wybutosine  
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Supplementary Materials and Methods 
Porcine and murine tissue samples. Pork tissue was obtained from a slaughterhouse 
immediately after sacrifice and processed within 4 h. Prolonged waiting times were observed 
to result in impaired results. Heart, kidneys, liver and spleen were briefly washed with 
demineralized water. Cerebellum, cerebrum, spinal cord and lung were washed rigorously and 
superficial blood vessels were removed. Each organ was sampled at three different positions 
from two animals to give 6 samples in total. Tissue samples were cut out omitting surface 
areas. Mouse organs were prepared from C57BL/6N mice (5 weeks old) and frozen in liquid 
nitrogen. The organs were kept at –80°C until tRNA extraction was performed. 
 
tRNA extraction. All extraction steps were performed on ice or at 4 °C. All extraction, 
desalting, and chromatography steps were performed with minor changes as described 
previously [1]. Pork tissue samples (5 g) or whole cerebellums, buffer 1 (15 mL, 0.01 M 
Mg(OAc)2, 0.05 M NaOAc, 0.15 M NaCl, pH 4.5) and ice were placed into a Waring 
Blender. The mixture was homogenized and transferred to a 50 mL Falcon tube and extracted 
three times with phenol. A similar lysis protocol was used for whole mouse organs. The final 
purified dry tRNA pellet was dissolved in MilliQ water (200-1000 µL) for enzymatic 
digestion. In case the resulting tRNA concentration proved to be too low for the subsequent 
digestion (<140 ng/µl) another EtOH precipitation step was conducted. Purity of the tRNA 
samples was proven by gel electrophorsis (Fig. S10). 
 
Enzymatic digestion. The enzymatic digestion was performed in a two step procedure as 
described previously [1]. All labeled nucleosides were added, followed by centrifugation of the 
sample (12100 g, 15 min). The supernatant was lyophilized to a total volume of 105 µL. Each 
pork and mouse tissue experiment was performed at least in triplicate with three independent 
concentrations of the appropriate labeled nucleosides. The concentrations of standard 
solutions were chosen to be in the expected range of the sample nucleoside concentration. 
 
LC-ESI-MS. The samples (100 µL injection volume) were analyzed by LC-ESI-MS on a 
Thermo Finnigan LTQ Orbitrap XL and were chromatographed by a Dionex Ultimate 3000 
HPLC system with a flow of 0.15 mL/min over an Uptisphere120-3HDO column from 
Interchim. The column temperature was maintained at 30 °C. Eluting buffers were buffer C 
(2 mM HCOONH4 in H2O (pH 5.5)) and buffer D (2 mM HCOONH4 in H2O/MeCN 20/80 
(pH 5.5)). The gradient was 0 → 41.25 min; 0 % → 6 % buffer D; 41.25 → 80 min; 8 % → 
60 % buffer D; 80 → 82 min; 60 % → 100 % buffer D; 82 → 100 min; 100 % buffer D; 100 
→ 105 min; 100 → 0 % buffer D; 105 → 115 min; 0 % buffer D. The elution was monitored 
at 260 nm (Dionex Ultimate 3000 Diode Array Detector). The chromatographic eluent was 
directly injected into the ion source without prior splitting. Ions were scanned by use of a 
positive polarity mode over a full-scan range of m/z 200-1000 with a resolution of 30000. 
Parameters of the mass spectrometer were tuned with a freshly mixed solution of adenosine 
(5 µM) in buffer C. The parameters used in this section were sheath gas flow rate, 16 arb; 
auxiliary gas flow rate, 10 arb; sweep gas flow rate, 4 arb; spray voltage, 5.0 kV; capillary 
temperature, 200 °C; capillary voltage, 25 V, tube lens 60 V. 
 
LC-MS of RNase A digests. RNase A digests were performed by incubation of tRNA 
(10 µg) with RNase A (1 or 10 µg, Fermentas) in 100 mM ammonium acetate buffer at a total 
volume of 100 µL at 37 ºC for 2 h. Whole digested samples were analyzed by the same LC-
ESI-MS system as for the quantitative analysis with a flow of 0.15 mL/min (Thermo Finnigan 
LTQ Orbitrap XL; Dionex Ultimate 3000 HPLC system; Uptisphere120-3HDO column from 
Interchim). The column temperature was maintained at 30 °C. We used the same eluting 
buffers C and D. The gradient was 0 min → 10 min; 0 % buffer D; 10 → 20 min; 0 % → 
10 % buffer D; 20 min → 42 min; 10 % → 40 % buffer D; 42 min → 50 min; 40 % → 
100 %; 50 min → 60 min; 100 % buffer D; 60 min → 70 min; 100 % → 0 % buffer D; 
70 min → 80 min; 0 % buffer D. The parameters used in this section were sheath gas flow 
rate, 30 arb; auxiliary gas flow rate, 10 arb; sweep gas flow rate, 4 arb; spray voltage, 2.3 kV; 
capillary temperature, 200 °C; capillary voltage, -20 V, tube lens -93 V. Ions were scanned by 
use of a negative polarity mode over a full-scan range of m/z 200-1500 with a resolution of 
30000. Parameters of the mass spectrometer were tuned with a solution of the RNA 7-mer 
AUUCCCG (5 µM) in buffer C. 
 
Separation of mitochondria and cytosol. Isolation of mitochondria from porcine organs was 
done by fractionated centrifugation at low and high speed according to the Mitochondria 
Isolation Kit from Sigma-Aldrich.[2]  
 
Cytochrome C oxidase assay. The respiratory activity of mitochondria in whole cell lysates 
and in enriched fractions of pork tissue was measured using the cytochrome C oxidase Assay 
Kit of Sigma-Aldrich.[3]  
 
In vitro translation assay. For in vitro translation activity measurements we used the 
combined transcription and translation reticulocyte assay kit from Promega (TNT Coupled 
Reticulocyte Lysate System). tRNAs present in the reticulocyte lysate were removed by 
chromatography using an ethyanolamine-Sepharose column according a previous report [4]. 
The chromatographic step was performed at 4 °C and collected fractions were frozen at -
80 °C. Briefly, we supplemented the lysate with 20 µM hemin, 50 mM KCl, and 0.5 mM 
MgCl2 prior to chromatography. The column was equilibrated with buffer H (75 mM KCl, 
1.6 mM MgCl2, 10 mM NaCl, 0.1 mM EDTA, 1 mM DTT, 10 mM HEPES pH = 7.2). The 
supplemented extract (700 µL) was loaded on the column and eluted with 1.0 mL of buffer H. 
Fractions of 50 µL were collected and assayed for tRNA dependent translational activity 
before usage. The column was regenerated between different filtration steps with buffer I 
(500 mM KCl, 1,6 mM MgCl2, 10 mM NaCl, 0,1 mM EDTA, 1 mM DTT, 10 mM HEPES 
pH = 7.2) and stored at 4 °C. The collected tRNA-depleted fractions were used for in vitro 
translation experiments and stored at -80 °C.  
For the in vitro translation assay, we used the non-radioactive luciferase control reaction with 
TNT RNA Polymerase T7 and Luciferase control DNA as described in the Promega Kit with 
minor changes. Each assay contained TNT reaction buffer (0.5 µL), T7 TNT RNA 
Polymerase (0.25 µL), amino acid mixture minus leucine (1 mM), amino acid mixture minus 
methionine (1mM), RNasin ribonuclease inhibitor (10 U), Luciferase T7 control DNA 
(0.25 µg). Afterwards the appropriate tRNA (12.5 ng) and RNase-free water were added to a 
total assay volume of 6.25 µL, followed by addition of tRNA-depleted lysate (6.25 µL). 
These translation reactions were incubated at 30 °C and a 1 µL aliquot was removed every 2-
3 min from each fraction starting at 12 min. This sample was transferred into a 96 well plate, 
mixed well with 25 µL of Luciferase Assay substrate and analyzed immediately. 
Luminescence was measured with a TECAN Microplate Reader Genios Pro in 10 cycles for 
100 ms each cycle. Reproducible luminescence slopes were obtained after normalization to 
the liver value and the results are shown in Fig S7. The data were averaged and plotted 
against time. A linear fit of each initial slope was performed and normalized to the highest 
value (usually liver). Every measurement was repeated at least in triplicate and every value 
represents mean value with s.d. Care was taken to use different tRNA-depleted fractions. 
 
Calibration curves. Mass calibration curves of the labeled and corresponding unlabeled 
synthesized nucleosides were obtained at five different concentration ratios. For each 
concentration an average value of three independent measurements was determined (Fig. S2). 
Each labeled nucleoside solution was mixed with three different concentrations of the 
corresponding unlabeled nucleosides. The areas of labeled and unlabeled nucleosides from 
LC-MS measurements were determined using the Qualbrowser program by extraction of the 
accurate mass range with a mass filter (Table S1) from the total ion current (TIC). The linear 
fits of the determined area ratios with the amount ratios gave R2-values of minimum 0.9992. 
The linear fit equations were used for calculation of the exact nucleoside contents in bulk 
tRNA samples. Synthetic labeled nucleosides were added to the digest solutions and the areas 
of labeled and unlabeled nucleosides were determined as described above. The amount of 
each nucleoside (Table S2-7) was calculated from the obtained area ratios and the linear fit 
equations of the calibration curves. 
Ψ calibration curves (see Fig. S3) were obtained by addition of three different known amounts 
of non labeled Ψ standard to three of four liver tRNA extract samples previously digested as 
described above. The samples were measured by HPLC-ESI-MS together with the non-spiked 
liver tRNA extract sample. The ion current area of the non-spiked sample was subtracted 
from the ion current areas of the spiked samples and the resulting values were plotted against 
the amount of Ψ added. The derived linear fit equation was used for quantification of Ψ in the 
investigated samples. 
 
Intra- and Inter-assay tests. The intra-assay test was performed for representative 
nucleosides m1A, i6A, ms2i6A, and m1G. The determined values of labeled to unlabeled 
nucleosides using the calibration curves of a sample after enzymatic digestion showed good 
reproducibility for each nucleoside (N=5); 2.5% for m1A, 0.4% for i6A, 0.7% for ms2i6A, and 
2.6% for m1G. The single area values of each labeled or unlabeled nucleoside in the intra-
assay test resulted in an average value of 4.1%. The inter-assay test gave an area ratio 
reproducibility (N=6) of 6.3% for m1A, 1.0% for i6A, 1.8% for ms2i6A, and 4.3% for m1G on 
six subsequent days. The determined single area values for each nucleoside resulted in strong 
variations and large average error of 34.5%. Using the area ratio with the calibration curves 
we gained perfect reproducibility (Table S10). No memory effect was observed during blank 
LC/MS experiments performed after several measurements of a sample. The blank analyses 
were not contaminated by carry-over. 
 
Quantification of the Ψ nucleoside in murine and porcine tissues. Biological samples from 
different murine and porcine tissues were analyzed by HPLC-ESI-MS without addition of 
standards and quantification of Ψ was obtained from the ion current area of the unlabeled Ψ in 
each sample (accurate mass range is given in Table S1) and the linear fit equation of the 
calibration curve (see Fig.S3). The HPLC-ESI-MS protocol used was similar to that used for 
quantification by isotope-dilution (see above). Care was taken to perform all the 
measurements and the data collection for the calibration curve during the same day so to 
avoid variations in the mass detection accuracy. 
 
Influence of codon bias on the in vitro translation activity experiment. Observed 
differences in translation activity could be attributed both to a variable composition of 
isoacceptor tRNAs and differences in tRNA modification levels. A tissue-specific codon bias 
has in fact been statistically proven in mammals by Plotkin et al.,[5] but they also show that 
the same tissues of evolutionary closely related species feature the same codon usage. From 
our analysis of the tRNA ensembles of cerebrum and spleen we can deduce that in our 
experiments codon bias only plays a minor role. As shown in our data, the porcine spleen 
tRNA set shows a higher level of modification than the cerebrum tRNAs. This is in good 
accordance with our observation that the in vitro translation activity of porcine spleen tRNA 
is higher than that of cerebrum. In the case of mouse we observe the opposite behavior. The 
murine spleen tRNA set is less modified than its cerebrum tRNAs, which goes in line with a 
lower translation activity of murine spleen tRNA in vitro compared to cerebrum. 
If codon usage strongly biased the in vitro translation results presented here, we would expect 
similar outcomes for both organisms regarding the translational activity in a certain tissue. 
This is not the case. 
 
Supplementary Figures 
 
 
Fig. S1. Illustration of the isotope dilution method used to quantify modified tRNA 
nucleosides. A) The general method used, starting with homogenization of different tissue 
samples and ending with LC-MS analysis. The red colour letters represent the added isotope-
labeled derivatives. B) Example of the two ion currents obtained for the natural 
monomethylated adenosines m1A, Am and m6A and the corresponding labeled nucleosides 
d3-m1A, d3-Am and d3-m6A.  
 
 
 Fig. S2. Calibration curves for the nucleosides synthesized and used for quantification: m6t6A, 
i6A, t6A, m1A, m1G, ms2i6A, m22G, m2G, Q, OHyW, m6A, and Am, with an average R2 value 
of 0.9995. Quantitative data for the modification m6A are not presented due to rearrangement 
from m1A to m6A. Inter-and intra-assays proved constant values of m1A and varying values of 
m6A. The modifications m1G and Gm were quantified with d3-m1G because of overlapping 
UV and mass signals. 
 Fig. S3. Calibration curve for the tRNA nucleoside Ψ with a R2 value of 0.9989 (for details, 
see above). Care was taken to perform data collection for the calibration curve and the 
measurements of the biological samples during the same day so to avoid variations in the 
mass detection accuracy. 
 
Fig. S4. Quantitative data for the tRNA nucleosides m1G, m5C and Ψ in various 
representative murine (A) and porcine (B) tissues. All tRNA nucleoside values are given per 
1000 tRNA molecules (‰). These data reveal a similar, tissue-dependent extent of 
modification for the investigated modified nucleosides, corresponding to the trend shown in 
the main paper. The Ψ values were determined by the method described above without 
addition of an isotope-labeled derivative. A separate quantification of m1G for porcine tissues 
(B) was possible using the optimized LC-method. Color codes in (A) and (B) are based on 
quantile calculations; red: highest value, yellow: 50% quantile, green: lowest value. For 
intermediate values appropriate shades of color were calculated, standard deviations are listed 
in Tables S6-S7. 
 Fig. S5. Correlation of in vivo protein synthesis rates with normalized nucleoside levels. This 
correlation shows a high significance with P = 0.011 [6].  
 
 
 
Fig. S6. Cytochrome C oxidase activity after separation of mitochondria and cytosol in 
porcine tissues. Activity of cytochrome C oxidase was taken as a measure of the 
mitochondrial content in each fraction. Values for the activity are increased in mitochondrial 
fractions and decreased in cytosolic fractions for the two representative tissues heart and liver, 
therefore providing evidence for an enrichment of mitochondria in mitochondrial fractions 
and suggesting an almost mitochondria-free cytosolic fraction.  
 
Fig. S7. (A) Representative in vitro translation experiment read out of pork cytosolic tRNAs 
(liver, kidney, cerebrum, spleen, heart) and mouse total tRNAs (cerebrum, liver, lung and 
spleen). Mouse tissues were selected based on low mitochondrial content, as shown by the 
relatively low content of ms2i6A modification (see (B)), which is known to only occur in 
mitochondrial tRNA.[3] Heart is listed to provide a comparison with a tissue known to contain 
a high proportion of mitochondrial tRNA. This experiment was performed at least in 
triplicate. Initial rates were calculated in the range of 17-25 min and normalized to liver in the 
case of pork samples. For mouse tRNA ensembles, rates were calculated from data points 
between 12-16 minutes and normalized to cerebrum. 
 
 
 
Fig. S8. Translational activity of tRNA sets from pork tissues. Average normalized 
nucleoside levels of pork liver, cerebellum, spleen, kidney, cerebrum, and heart (calculated 
from LC-MS data presented in Fig. 2B) and relative in vitro translation activities of cytosolic 
and total tRNA. All values are normalized to the highest value. Standard deviations (mean ± 
s.d.) are given for the other tissues. Note: while the error values here are relatively large, these 
represent the variation over all modified nucleosides. The measurements for each nucleoside 
have low errors (~5%), and they show the same relationship as the averaged set. 
 
 
 Fig. S9. Translational activity of tRNA sets from mouse tissues. (A) Average normalized 
nucleoside levels of mouse liver, cerebrum, lung and spleen (calculated from LC-MS data 
presented in Fig. 2A) and corresponding in vitro translation rates for each replicate. (B) Linear 
fit of normalized in vitro translational acitivity of total murine tRNAs and normalized 
nucleoside levels showing a considerable correlation (r = 0.723, P = 0.011). Each data set was 
normalized to its corresponding highest value. 
 
Fig. S10. RNA PAGE gel for mouse tRNA extracts from different tissues. a) Marker, b) 
Liver, c) Cerebrum, d) Cerebellum, e) Brain stem, f) Lung, g) Spleen, h) Kidney. As 
previously reported by others, there is a small but constant contamination of 5S rRNA. This 
contamination is observed for all tissues and therefore does not bias the results reported in this 
publication [7]. 
Supplementary Tables 
 
Nucleoside Nucleosides 
mass range m/z 
Labeled nucleosides 
mass range m/z 
Am, m1A 282.1142-282.1262 285.1335-285.1435 
t6A 413.1315-413.1475 418.1420-418.1580 
i6A 336.1606-336.1716 338.1740-338.1840 
ms2i6A 382.1484-382.1594 385.1679-385.1789 
m22G 312.1248-312.1368 315.1441-315.1561 
m2G, m1G, Gm 298.1076-298.1196 301.1276-301.1396 
Q 410.1640-410.1730 413.1778-413.1898 
m6t6A 427.1532-427.1622 430.1707-430.1807 
OHyW 525.1879-525.2029 528.2065-528.2195 
m5C 258.1034-258.1134 261.1223-261.1323 
Ψ 245.0708-245.0828 - 
 
Table S1. High resolution mass ranges of natural and corresponding labeled nucleosides used 
for quantification. Modifications 3'-adjacent to the anticodon loop: hydroxywybutosine 
(OHyW), N6-isopentenyladenosine (i6A), N6-methyl-N6-threonylcarbamoyladenosine (m6t6A), 
N6-threonylcarbamoyladenosine (t6A), and 1-methylguanosine (m1G). Modifications in the 
wobble position: queuosine (Q) and 2'-O-methylguanosine (Gm). Modifications in other 
positions: 1-methyladenosine (m1A), 2'-O-methyladenosine (Am), m1G, N2-methylguanosine 
(m2G), N2,N2-dimethylguanosine (m22G), 5-methylcytosine (m5C), pseudouridine (Ψ) and 
Gm. 
 
 
Mouse Tissues  Am t6A i6A m22G m2G Q OHyW m1G m6t6A m1A 
Kidney Mean value 21.0 202.7 36.0 389.5 779.7 70.8 22.5 517.9 19.8 715.7 
 Standard deviation 3.6 5.8 0.9 12.3 40.3 6.2 4.3 23.0 1.3 66.0 
 Standard deviation in % 17.2 2.9 2.5 3.2 5.2 8.8 19.3 4.4 6.7 9.2 
            
Lung Mean value 28.7 271.7 45.0 495.2 946.2 81.3 21.7 640.0 24.8 876.5 
 Standard deviation 18.2 18.3 1.9 30.5 48.1 7.4 3.4 21.5 1.8 54.2 
 Standard deviation in % 63.2 6.7 4.3 6.2 5.1 9.2 15.9 3.4 7.3 6.2 
            
Spleen Mean value 47.8 210.3 30.6 397.0 754.3 47.7 26.9 487.0 20.9 653.6 
 Standard deviation 1.4 7.8 2.1 3.2 43.9 17.4 11.4 26.3 0.9 60.1 
 Standard deviation in % 2.9 3.7 6.8 0.8 5.8 36.5 42.4 5.4 4.3 9.2 
            
Liver Mean value 18.9 304.0 49.8 614.6 1102.7 62.5 37.7 735.0 30.2 1016.7 
 Standard deviation 9.6 7.5 1.0 14.2 34.8 7.7 9.1 14.2 0.7 150.2 
 Standard deviation in % 50.7 2.5 2.1 2.3 3.2 12.3 24.3 1.9 2.3 14.8 
            
Cerebrum Mean value 23.6 290.3 50.6 555.8 1104.0 109.7 27.6 694.1 24.2 972.4 
 Standard deviation 1.7 10.8 3.0 23.0 33.8 11.9 2.4 24.2 0.6 39.9 
 Standard deviation in % 7.4 3.7 5.9 4.1 3.1 10.9 8.6 3.5 2.5 4.1 
            
Cerebellum Mean value 20.7 274.8 41.1 524.4 1026.3 95.0 18.6 646.6 24.4 1011.0 
 Standard deviation 1.4 14.9 1.7 18.1 67.7 9.1 3.3 35.3 0.9 118.9 
 Standard deviation in % 6.6 5.4 4.2 3.5 6.6 9.6 17.6 5.5 3.5 11.8 
            
Heart Mean value 26.4 241.2 36.4 419.8 801.6 83.4 12.8 526.8 17.5 800.7 
 Standard deviation 9.5 26.6 5.3 44.9 108.1 13.6 2.7 61.1 2.7 113.2 
 Standard deviation in % 35.9 11.0 14.4 10.7 13.5 16.3 20.8 11.6 15.4 14.1 
Mouse Tissues  Am t6A i6A m22G m2G Q OHyW m1G m6t6A m1A 
Brain stem Mean value 19.3 262.5 40.4 514.5 1025.7 93.5 16.9 644.3 23.2 944.3 
 Standard deviation 3.6 9.5 2.7 23.4 72.1 6.7 3.4 39.2 0.7 111.0 
 Standard deviation in % 18.7 3.6 6.6 4.5 7.0 7.2 20.5 6.1 3.1 11.8 
 
Table S2. Modification numbers per 1000 tRNAs in different murine tissues. The table lists the average values calculated from the modification 
content of two sets of five animals. For each sample at least three independent digests and measurements were performed. 10,3 % mean standard 
deviation was obtained for all nucleosides excluding Am. 22,3 % mean standard deviation was obtained for Am. As noted in the Table S3, the 
overall mean standard deviation across nucleosides and tissues for the two individual sample sets is below 5%. 
 
 
 
 
 
 
 
 
 
 
 
Mouse Tissues  Am t6A i6A m22G m2G Q OHyW m1G m6t6A m1A 
Lung A Mean value 49.6 255.8 43.0 479.9 938.6 90.1 23.9 634.8 24.4 852.3 
 Standard deviation 0.6 15.5 0.8 27.9 62.0 1.2 3.1 30.3 2.0 59.1 
 Standard deviation in % 1.3 6.1 1.8 5.8 6.6 1.3 13.0 4.8 8.2 6.9 
            
Lung B Mean value 13.1 283.6 46.5 506.6 951.9 75.3 20.0 643.9 25.2 900.0 
 Standard deviation 2.1 8.5 0.9 27.2 33.0 2.0 2.6 9.1 1.6 39.4 
 Standard deviation in % 16.1 3.0 1.9 5.4 3.5 2.6 13.0 1.4 6.2 4.4 
            
Spleen A Mean value 47.2 217.4 32.2 397.8 797.7 67.7 37.7 508.6 21.5 646.3 
 Standard deviation 0.2 4.7 0.4 3.7 8.5 0.7 2.2 18.7 0.8 30.2 
 Standard deviation in % 0.4 2.1 1.4 0.9 1.1 1.0 5.7 3.7 3.5 4.7 
            
Spleen B Mean value 48.3 203.2 29.1 396.5 711.0 32.7 16.1 465.5 20.3 660.9 
 Standard deviation 1.8 0.9 1.9 2.6 6.0 1.7 4.8 10.4 0.6 78.7 
 Standard deviation in % 3.7 0.5 6.6 0.7 0.8 5.2 29.7 2.2 3.0 11.9 
            
Liver A Mean value 28.4 310.6 50.1 612.6 1107.8 68.8 45.7 744.1 30.4 895.9 
 Standard deviation 0.7 4.4 0.4 3.2 39.5 0.7 2.0 13.6 0.9 9.1 
 Standard deviation in % 2.5 1.4 0.8 0.5 3.6 1.0 4.3 1.8 2.9 1.0 
            
Liver B Mean value 9.4 297.4 49.5 616.5 1097.7 54.2 29.7 725.8 30.0 1137.6 
 Standard deviation 1.9 2.7 1.4 19.7 28.6 3.7 5.9 7.1 0.3 125.8 
 Standard deviation in % 20.0 0.9 2.7 3.2 2.6 6.8 20.0 1.0 0.8 11.1 
            
Cerebrum A Mean value 22.2 298.6 52.8 572.2 1131.5 113.8 28.8 713.0 24.3 963.2 
 Standard deviation 0.9 5.0 1.2 8.4 15.3 4.8 1.7 9.3 0.7 46.4 
 Standard deviation in % 3.9 1.7 2.2 1.5 1.4 4.3 6.0 1.3 2.7 4.8 
Mouse Tissues  Am t6A i6A m22G m2G Q OHyW m1G m6t6A m1A 
Cerebrum B Mean value 25.3 279.2 47.7 533.9 1067.3 104.2 25.2 668.9 23.9 984.6 
 Standard deviation 0.7 5.2 1.8 17.4 2.7 15.8 1.4 11.6 0.4 24.2 
 Standard deviation in % 2.9 1.8 3.9 3.3 0.2 15.1 5.7 1.7 1.6 2.5 
            
Cerebellum A Mean value 19.3 291.2 42.8 544.7 1096.1 102.7 20.7 684.4 25.2 1082.0 
 Standard deviation 0.6 6.3 0.5 5.1 23.3 6.6 2.8 19.5 0.4 129.9 
 Standard deviation in % 3.0 2.2 1.3 0.9 2.1 6.4 13.3 2.9 1.8 12.0 
            
Cerebellum B Mean value 21.8 262.6 39.9 509.2 974.0 87.3 17.0 618.2 23.8 957.8 
 Standard deviation 0.7 3.0 1.2 3.8 35.1 2.2 2.6 3.8 0.5 74.0 
 Standard deviation in % 3.1 1.1 3.0 0.8 3.6 2.5 15.5 0.6 2.0 7.7 
            
Heart A Mean value 17.0 266.2 41.1 461.9 905.8 93.9 15.7 584.3 20.1 891.9 
 Standard deviation 0.6 8.0 2.4 12.8 30.2 7.7 0.3 21.7 0.9 82.1 
 Standard deviation in % 3.5 3.0 5.8 2.8 3.3 8.2 1.7 3.7 4.4 9.2 
            
Heart B Mean value 35.7 216.3 31.6 377.6 697.4 69.4 10.7 469.4 14.9 709.4 
 Standard deviation 2.3 10.4 2.0 17.8 27.1 3.4 1.2 20.1 0.6 47.1 
 Standard deviation in % 6.6 4.8 6.3 4.7 3.9 4.9 11.7 4.3 3.7 6.6 
            
Brain stem A Mean value 14.5 274.8 43.5 543.1 1091.9 87.0 20.9 692.7 23.8 1023.2 
 Standard deviation 1.2 3.6 1.5 0.4 32.1 - 1.0 3.3 0.9 40.7 
 Standard deviation in % 8.6 1.3 3.4 0.1 2.9 - 5.0 0.5 3.6 4.0 
            
Brain stem B Mean value 21.7 256.4 38.9 500.2 992.5 95.1 14.8 620.2 22.8 904.8 
 Standard deviation 1.3 4.0 1.6 14.3 63.2 6.6 2.2 23.4 0.4 113.9 
 Standard deviation in % 5.9 1.6 4.2 2.8 6.4 6.9 14.8 3.8 1.5 12.6 
Mouse Tissues  Am t6A i6A m22G m2G Q OHyW m1G m6t6A m1A 
Kidney A Mean value 24.6 204.2 36.4 376.3 810.6 74.4 25.9 540.1 20.7 770.0 
 Standard deviation 0.6 7.6 0.6 2.9 26.6 4.5 0.5 5.0 0.9 9.8 
 Standard deviation in % 2.3 3.7 1.7 0.8 3.3 6.0 2.1 0.9 4.4 1.3 
            
Kidney B Mean value 17.5 201.1 35.6 399.4 748.8 66.3 19.1 495.7 18.6 675.0 
 Standard deviation 0.9 2.4 1.0 5.5 25.0 5.3 3.8 6.3 0.6 60.6 
 Standard deviation in % 5.2 1.2 2.7 1.4 3.3 7.9 19.8 1.3 3.2 9.0 
 
Table S3. Modification numbers per 1000 tRNAs in different murine tissues. The table lists the average values calculated from the modification 
content of each individual set of five animals. For each sample at least three independent digests and measurements were performed. 4,8 % mean 
standard deviation was obtained for all nucleosides excluding Am. 5,0 % mean standard deviation was obtained for Am. 
 
 
 
 
 
 
 
 
 
Pork Tissues  Am t6A i6A m22G m2G Q OHyW m1G+Gm m6t6A m1A 
Heart Mean value 45.9 175.4 29.0 372.9 673.1 29.6 12.0 638.2 11.0 810.9 
 Standard deviation 3.3 8.2 2.7 22.7 61.3 0.0 0.0 3.0 0.4 19.1 
 Standard deviation in % 7.2 4.7 9.4 6.1 9.1 0.0 0.3 0.5 3.5 2.4 
            
Liver Mean value 20.5 214.6 39.6 562.7 1,176.5 55.2 33.6 1,059.6 21.9 941.6 
 Standard deviation 4.8 6.4 2.7 26.1 54.7 4.6 2.9 43.6 1.8 23.6 
 Standard deviation in % 23.2 3.0 6.8 4.6 4.7 8.4 8.7 4.1 8.0 2.5 
            
Kidney Mean value 68.4 177.8 30.7 451.5 896.0 32.3 21.1 816.3 15.8 871.6 
 Standard deviation 19.1 7.7 0.5 25.4 55.0 13.8 4.7 40.3 1.5 35.5 
 Standard deviation in % 28.0 4.3 1.8 5.6 6.1 42.8 22.3 4.9 9.5 4.1 
            
Spleen Mean value 80.4 182.1 30.7 464.3 793.6 42.7 26.1 690.5 13.9 833.6 
 Standard deviation 12.6 8.9 1.0 19.6 29.5 5.9 2.2 13.4 0.4 45.2 
 Standard deviation in % 15.6 4.9 3.2 4.2 3.7 13.8 8.4 1.9 2.9 5.4 
            
Lung Mean value 58.5 184.1 33.6 427.2 879.3 33.9 21.7 793.6 13.9 876.3 
 Standard deviation 16.3 8.5 2.9 27.0 45.4 11.3 1.5 28.2 1.1 16.1 
 Standard deviation in % 27.8 4.6 8.5 6.3 5.2 33.3 7.0 3.6 7.9 1.8 
            
Spine marrow Mean value 61.8 198.6 36.0 457.0 970.7 50.8 26.0 799.5 11.8 911.0 
 Standard deviation 1.7 2.7 0.1 2.8 13.1 0.3 0.1 1.5 0.1 11.4 
 Standard deviation in % 2.7 1.4 0.3 0.6 1.3 0.6 0.3 0.2 1.0 1.2 
            
Cerebellum Mean value 67.8 237.3 41.7 566.8 1,036.4 83.5 29.0 829.4 17.5 1,102.8 
 Standard deviation 6.1 0.6 0.3 1.2 1.2 4.8 1.9 13.8 0.0 6.7 
 Standard deviation in % 9.0 0.2 0.6 0.2 0.1 5.7 6.5 1.7 0.2 0.6 
Pork Tissues  Am t6A i6A m22G m2G Q OHyW m1G+Gm m6t6A m1A 
Cerebrum Mean value 139.9 165.8 26.1 406.2 682.2 57.2 20.3 586.8 10.5 732.6 
 Standard deviation 15.9 2.8 1.5 7.3 34.6 3.8 1.2 0.1 0.6 26.3 
 Standard deviation in % 11.3 1.7 5.9 1.8 5.1 6.6 5.7 0.0 5.9 3.6 
 
Table S4. Modification numbers per 1000 tRNAs in different porcine tissues. The table lists the average values calculated from the modification 
content of two different animals. From each animal at least two independent samples were investigated. For each sample at least three 
independent digests and measurements were performed. 5.9 % mean standard deviation was obtained for all nucleosides excluding Am. 14.7 % 
mean standard deviation was obtained for Am. 
 
 
 
 
 
 
 
 
 
 
 
Pork Tissues  Am t
6A i6A m22G m2G Q OHyW m1G+Gm m6t6A m1A 
Heart 1 Mean value 48.2 169.6 30.9 356.8 629.8 29.6 12.0 636.0 11.2 797.4 
 Standard deviation 9.7 6.1 1.1 4.0 18.3 1.1 0.5 34.6 0.5 10.4 
 Standard deviation in % 20.1 3.6 3.7 1.1 2.9 3.9 3.8 5.4 4.2 1.3 
            
Heart 2 Mean value 43.5 181.3 27.1 389.0 716.5 29.6 12.1 640.3 10.7 824.5 
 Standard deviation 12.1 7.1 3.0 40.7 85.2 0.9 1.1 38.8 1.1 28.5 
 Standard deviation in % 27.8 3.9 11.0 10.5 11.9 3.1 9.0 6.1 10.5 3.5 
            
Liver 1 Mean value 23.8 210.1 37.7 544.2 1,137.8 58.5 35.7 1,028.7 20.6 958.3 
 Standard deviation 2.2 2.2 0.4 18.1 0.8 4.6 1.6 7.7 0.8 39.4 
 Standard deviation in % 9.4 1.0 1.1 3.3 0.1 7.9 4.6 0.8 3.7 4.1 
            
Liver 2 Mean value 17.1 219.1 41.5 581.1 1,215.2 51.9 31.5 1,090.4 23.1 925.0 
 Standard deviation 1.2 12.1 1.9 39.5 86.9 1.9 3.4 39.5 0.9 30.0 
 Standard deviation in % 6.8 5.5 4.6 6.8 7.2 3.7 10.9 3.6 3.9 3.2 
            
Kidney 1 Mean value 81.9 172.4 30.3 433.5 857.1 22.5 17.8 787.9 14.8 846.5 
 Standard deviation 23.7 19.1 2.8 30.1 89.1 2.1 2.1 43.0 2.0 25.5 
 Standard deviation in % 28.9 11.1 9.4 6.9 10.4 9.4 11.6 5.5 13.3 3.0 
            
Kidney 2 Mean value 54.8 183.3 31.1 469.5 934.9 42.1 24.5 844.8 16.9 896.7 
 Standard deviation 15.8 2.9 2.9 3.7 10.7 0.1 3.8 3.8 0.4 40.4 
 Standard deviation in % 28.8 1.6 9.2 0.8 1.1 0.2 15.4 0.4 2.5 4.5 
            
Spleen 1 Mean value 89.3 175.8 30.0 450.4 772.8 38.6 24.5 681.0 13.6 801.7 
 Standard deviation 6.7 2.6 0.0 14.4 16.6 0.7 2.2 1.6 0.4 6.6 
 Standard deviation in % 7.5 1.5 0.1 3.2 2.1 1.7 9.1 0.2 3.0 0.8 
Pork Tissues  Am t
6A i6A m22G m2G Q OHyW m1G+Gm m6t6A m1A 
Spleen 2 Mean value 71.5 188.4 31.4 478.2 814.5 46.9 27.6 699.9 14.2 865.5 
 Standard deviation 11.2 9.7 1.9 30.7 76.0 0.7 0.3 87.3 1.5 102.8 
 Standard deviation in % 15.6 5.1 5.9 6.4 9.3 1.5 1.0 12.5 10.5 11.9 
            
Lung 1 Mean value 47.0 178.1 31.6 408.0 847.2 25.9 20.7 773.7 13.2 864.9 
 Standard deviation 1.2 4.3 0.1 5.3 3.2 4.6 0.7 0.1 1.2 3.7 
 Standard deviation in % 2.5 2.4 0.3 1.3 0.4 17.6 3.5 0.0 8.8 0.4 
            
Lung 2 Mean value 70.0 190.1 35.7 446.3 911.3 41.9 22.8 813.6 14.7 887.7 
 Standard deviation 5.0 5.0 2.2 19.5 32.7 0.5 0.6 24.6 0.2 25.3 
 Standard deviation in % 7.2 2.6 6.3 4.4 3.6 1.3 2.5 3.0 1.3 2.8 
            
Spine marrow 1 Mean value 63.0 200.5 36.1 459.0 961.4 51.0 26.1 798.5 11.9 919.1 
 Standard deviation 7.6 4.3 1.3 8.3 28.4 3.1 1.1 17.2 0.8 56.6 
 Standard deviation in % 12.1 2.1 3.5 1.8 3.0 6.1 4.2 2.2 7.1 6.2 
            
Spine marrow 2 Mean value 60.7 196.7 35.9 454.9 979.9 50.6 26.0 800.6 11.7 903.0 
 Standard deviation 17.5 2.8 1.4 14.3 20.1 2.2 2.0 2.8 0.6 25.5 
 Standard deviation in % 28.9 1.4 3.8 3.2 2.1 4.3 7.6 0.3 5.4 2.8 
            
Cerebellum 1 Mean value 72.1 237.7 41.9 567.6 1,035.6 86.8 30.3 839.1 17.6 1,098.1 
            
Cerebellum 2 Mean value 63.5 236.9 41.5 566.0 1,037.2 80.1 27.6 819.6 17.5 1,107.5 
            
Cerebrum 1 Mean value 151.1 163.8 25.0 401.0 657.7 59.9 21.2 586.9 10.1 714.1 
 Standard deviation 27.9 10.8 1.7 30.5 44.2 5.1 1.0 22.3 0.8 61.6 
 Standard deviation in % 18.5 6.6 6.7 7.6 6.7 8.6 4.7 3.8 8.2 8.6 
Pork Tissues  Am t
6A i6A m22G m2G Q OHyW m1G+Gm m6t6A m1A 
Cerebrum 2 Mean value 128.7 167.8 27.2 411.3 706.7 54.6 19.5 586.7 11.0 751.2 
 Standard deviation 0.1 7.8 0.7 6.1 19.0 1.5 0.7 18.7 0.4 38.1 
 Standard deviation in % 0.1 4.6 2.5 1.5 2.7 2.8 3.8 3.2 3.8 5.1 
 
Table S5. Modification numbers per 1000 tRNAs in different porcine tissues. The table lists the average values calculated from the modification 
content of at least two independent samples from one animal (with the exception of cerebellum, for which only one sample was analyzed). For 
each sample at least three independent digests and measurements were performed. 6.7 % mean standard deviation was obtained for all 
nucleosides excluding Am. 17.0 % mean standard deviation was obtained for Am. 
 
 Mouse Tissues  m5C Ψ 
Liver Mean value 1888.0 1986.9 
 Standard deviation 68.3 49.4 
 Standard deviation in % 3.6 2.5 
    
Cerebrum Mean value 1831.5 1639.2 
 Standard deviation 84.2 61.8 
 Standard deviation in % 4.6 3.8 
    
Lung Mean value 1747.8 1436.9 
 Standard deviation 237.6 - 
 Standard deviation in % 13.6 - 
    
Kidney Mean value 1316.5 924.5 
 Standard deviation 81.8 65.6 
 Standard deviation in % 6.2 7.1 
    
Spleen Mean value 1368.5 1284.7 
 Standard deviation 98.1 2.7 
 Standard deviation in % 7.2 0.2 
 
Table S6. Modification numbers per 1000 tRNAs in different murine tissues. The table lists the average values calculated from the modification 
content of two sets of five animals (with the exception of cerebrum Ψ). For each sample at least two independent digests and measurements were 
performed. 5.4 % mean standard deviation was obtained for the two nucleosides. As noted in the Table S3, the overall mean standard deviation 
across nucleosides and tissues for the two individual sample sets is below 5 %. 
Pork Tissues  m1G m5C Ψ 
Liver Mean value 746.7 2742.5 2263.1 
 Standard deviation 3.2 253.6 347.0 
 Standard deviation in % 0.4 9.2 15.3 
     
Spleen Mean value 627.1 2687.5 2146.1 
 Standard deviation 7.8 182.1 161.5 
 Standard deviation in % 1.2 6.8 7.5 
     
Kidney Mean value 628.8 2764.5 1886.8 
 Standard deviation 10.6 217.0 270.2 
 Standard deviation in % 1.7 7.9 14.3 
     
Lung Mean value 575.8 2452.7 1907.6 
 Standard deviation 8.8 307.1 163.9 
 Standard deviation in % 1.5 12.5 8.6 
     
Heart Mean value 535.1 2138.1 1776.1 
 Standard deviation 3.1 269.5 203.0 
 Standard deviation in % 0.6 12.6 11.4 
     
Cerebrum Mean value 448.5 1936.4 1330.4 
  2.6 318.4 48.0 
  0.6 16.4 3.6 
 
Table S7. Modification numbers per 1000 tRNAs in different porcine tissues. The table lists the average values calculated from at least two 
independent digests and measurements. 7.3 % mean standard deviation was obtained for the three nucleosides. As noted in the Table S5, the 
overall mean standard deviation across nucleosides and tissues for individual sample sets is around 7 %. 
 
Table S8. Color-coded table listing the average modification levels and Am content in 
porcine and murine tissues. Values for each modification (listed in Fig. 2A and 2B) were 
normalized for the highest value across both organisms. The average modification level was 
calculated by averaging the normalized modification values. 
   
 Number tRNA fragments 
Liver 
(modified/unmo
dified) 
Heart 
(modified/unmodified)
1 A-m2G-Cp 1.00 0.62 
2 G-m2G-Up 0.49 0.41 
3 m1G-m2G-Cp 0.59 0.35 
4 t6A-ACp 1.28 0.85 
5 A-m1A-AUp 20.3 3.69 
6 G-m1A-AACp 6.01 2.20 
7 A-i6A-ACp 1.07 0.14 
8 G-m1A-GCp 0.25 0.24 
9 G-m1A-Up 0.27 0.28 
10 A-ms2i6A-AGCp Traces (<0.1) 0.33 
 
Table S9. Representative modified tRNA fragments analyzed after RNase A digestion of 
porcine tRNA, calculated using Sprinzl tRNA database [8] sequences and the Mongo Oligo 
Mass Calculator program (http://library.med.utah.edu/masspec/mongo.htm). The mass area 
ratios of modified to unmodified fragments from total tRNA of liver and heart are shown 
using the z=-2 peak. Analyzed fragments 1-7 clearly represent higher modification in liver 
than in heart. Fragments 8 and 9 have similar modified to unmodified ratios. Fragment 10 
represents a mitochondrial tRNA fragment containing m2i6A, which is present in heart and 
only in traces in liver. These relative non-quantitative data are in strict accordance to the 
quantitative values described in Fig. 2. 
 Table S10. Intra- and Inter-assay test of representative nucleosides m1A, i6A, ms2i6A and 
m1G. 
Intra-assay A(m1A) A([D3]m1A) m1A         
/1000 tRNAs
A(i6A) A([D2]i6A) i6A          
/1000 tRNAs
1 4,910,905 3,228,128 231.7 20,679,891 24,434,161 81.5 
2 4,610,522 3,000,111 234.1 22,055,338 26,075,813 81.5 
3 4,519,200 2,977,821 231.1 22,851,651 26,747,503 82.3 
4 4,296,971 2,795,390 234.1 22,336,638 26,299,470 81.8 
5 4,256,358 2,959,025 218.9 23,127,819 27,224,872 81.8 
Mean value 4,518,791 2,992,095 230.0 22,210,267 26,156,364 81.8 
RSD % 5.2 4.6 2.5 3.8 3.6 0.4 
       
Intra-assay A(ms2i6A) A([D3]ms2i6A) ms2i6A       
/1000 tRNAs
A(m1G) A([D3]m1G) m1G         
/1000 tRNAs
1 7,565,152 6,021,535 34.4 1,555,016 1,882,259 135.5 
2 8,516,277 6,814,035 34.2 1,629,176 1,901,322 140.8 
3 8,736,921 6,919,317 34.6 1,564,160 1,880,098 136.5 
4 8,595,797 6,922,770 34.0 1,530,903 1,860,304 134.9 
5 9,057,064 7,301,879 34.0 1,614,978 1,842,588 144.2 
Mean value 8,494,242 6,795,907 34.3 1,578,847 1,873,314 138.4 
RSD % 5.9 6.2 0.7 2.4 1.1 2.6 
       
Inter-assay A(m1A) A([D3]m1A) m1A         
/1000 tRNAs
A(i6A) A([D2]i6A) i6A          
/1000 tRNAs
1 5,203,410 3,331,919 237.9 14,545,585 17,095,570 82.0 
2 2,987,553 1,958,336 232.3 12,575,227 14,579,015 83.2 
3 3,225,581 2,095,535 234.4 12,151,803 14,540,493 80.4 
4 1,951,525 1,265,851 234.8 10,028,667 11,761,222 82.2 
5 4,256,358 2,959,025 218.9 23,127,819 27,224,872 81.8 
6 3,249,988 2,223,235 222.5 21,114,201 24,952,572 81.5 
Mean value 3,479,069 2,305,650 230.1 15,590,550 18,358,957 81.8 
RSD % 29.4 29.3 6.3 31.0 31.1 1.0 
       
Inter-assay A(ms2i6A) A([D3]ms2i6A) ms2i6A       
/1000 tRNAs
A(m1G) A([D3]m1G) m1G         
/1000 tRNAs
1 5,974,676 4,846,268 33.7 926,498 1,054,171 144.6 
2 5,461,095 4,327,040 34.6 705,140 894,683 128.9 
3 3,881,613 3,101,702 34.3 641,656 776,294 135.5 
4 3,758,364 2,908,332 35.5 439,096 544,671 132.0 
5 9,057,064 7,301,879 34.0 1,614,978 1,842,588 144.2 
6 8,707,594 6,786,037 35.2 1,452,283 1,713,325 139.2 
Mean value 6,140,068 4,878,543 34.5 963,275 1,137,622 137.4 
RSD % 34.1 34.4 1.8 44.7 42.1 4.3 
 
 
Data set Mean Standard 
deviation 
n Shapiro 
Wilk W 
Shapiro Wilk 
significance 
Normalized murine nucleosides 0.87 0.15 4 0.90 0.46 
Normalized porcine nucleosides 0.75 0.13 6 0.85 0.15 
Protein synthesis rate  
(this study, all murine tRNA) 
0.38 0.29 11 0.94 0.52 
Protein synthesis rate (this study, 
cytosolic porcine tRNA) 
0.75 0.24 6 0.93 0.57 
Protein synthesis rate  
(this study, all porcine tRNA) 
0.84 0.13 6 0.96 0.82 
Protein synthesis rate (this study, all 
porcine tRNA excluding heart) 
0.83 0.15 5 0.95 0.70 
Protein Synthesis rate (Suryawan, %/d) 35.5 20.5 5 0.878 0.26 
 
Table S11: Descriptive Statistics. All calculations were carried out using the SPSS or 
Statistica statistics programs. Correlations are calculated as Pearson’s r coefficients with 2-
tailed significance values. This test was chosen as the data sets used in correlations appear to 
be parametric as evidenced by non-significant scores in the Shapiro-Wilk test. The small 
sample sizes are recognized as a possible source of error and correspondingly it cannot be 
excluded that more complex relationships than simple linear correlations may be present. 
 
 
 
 
Protein synthesis rate r  Significance 
(P value) 
n 
This study (cytosolic porcine tRNA) 0.861* 0.028 6 
This study (all porcine tissues, total tRNA) 0.672 0.143 6 
This study (all porcine tissues except heart, 
total tRNA) 
0.965** 0.008 5 
This study (all murine tissues, total tRNA) 0.723* 0.011 11 
Suryawan 0.956* 0.011 5 
 
Table S12. Correlations of normalized nucleoside levels (excluding ms2i6A) with protein 
synthesis rates. * significant to 5 % level, ** significant to 1 % level. 
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General methods: 
All non-aqueous reactions were performed using flame- or oven-dried glassware under an atmosphere 
of dry nitrogen. Commercial reagents from Sigma-Aldrich or Acros were used as received unless 
otherwise noted. Non-aqueous reagents were transferred under nitrogen with a syringe or cannula. 
Solutions were concentrated in vacuo on a Heidolph rotary evaporator with a Vario PC2001 diphragm 
pump by Vacuubrand. Chromatographic purification of products was accomplished using flash column 
chromatography on Merck Geduran Si 60 (40–63 µm) silica gel (normal phase). Thin layer 
chromatography (TLC) was performed on Merck 60 (silica gel F254) plates. Visualization of the 
developed chromatogram was performed using fluorescence quenching or anisaldehyde staining. 1H-, 
13C- and 15N-NMR spectra were recorded in deuterated solvents on Bruker ARX 300, Varian VXR400S, 
Varian Inova 400 and Bruker AMX 600 spectrometers and calibrated to the residual solvent peak. High-
resolution ESI spectra were obtained on the mass spectrometer Thermo Finnigan LTQ FT-ICR. IR 
measurements were performed on a Perkin Elmer Spectrum BX FT-IR spectrometer (Perkin Elmer) with 
a diamond-ATR (Attenuated Total Reflection) setup. Melting points were determined with a Büchi 
Melting Point B540. The concentration of the purified DNA was determined with a NanoDrop ND-1000 
spectrophotometer (Peqlab). Extinction coefficients at 260 nm were calculated by addition of the 
extinction coefficients of the individual nucleobases. These are dA 15.0 L/mmol⋅cm, dC 
7.1 L/mmol⋅cm, dG 12.0 L/mmol⋅cm and dT 8.4 L/mmol⋅cm. For the dC derivatives, the dC value was 
used. Nuclease S1 (Aspergillus oryzae) was obtained from Roche, snake venom phosphodiesterase I 
(Crotalus adamanteus) from USB corporation and antarctic phosphatase from New England Biolabs.  
 
High performance liquid chromatography: 
HPLC was performed on Waters or Merck-Hitachi units. These were in detail: analytical HPLC: Waters 
Alliance (2695 Separation Module, 2996 Photodiode Array Detector), Merck analytical (L-7400 UV 
detector, L-7100 pump), preparative HPLC: Waters Breeze (2487 Dual λ Array Detector, 1525 Binary 
HPLC Pump), Merck preparative (L-7150 pump, L-7420 UV detector, Rheodyne P/N 77 25i injection 
valve, ERC-3415 solvent degasser). For analytical HPLC Nucleosil 120-3 C18 from Macherey Nagel 
were used, for preparative HPLC Nucleosil 100-7 C18, VP 250/10 C18 and VP 250/32 C18 also from 
Macherey Nagel were used. 
Buffer systems:  Buffer A: 0.1 M triethylammonium acetate 
   Buffer B: 0.1 M triethylammonium acetate in 80% MeCN 
Buffer system for HPLC-MS and UPLC-MS/MS:  Buffer A: 0.01% formic acid in H2O 
                                                   Buffer B: 0.01% formic acid in MeCN 
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Polymerase chain reaction: 
The PGL3_pOct4_eGFP template was a generous gift of H. Leonhart.[3] The primers were obtained 
from Metabion and had the following sequences, which resulted in a 150 bp fragment: 
Forward Primer: 5´-TCCCGTCCTAAGGGTTGTCCTGTC-3´ 
Reverse Primer: 5´-ACCCTCTAGCCTTGACCTCTGGC-3´ 
Thermostable pyrophosphatase and natural triphosphates were obtained from New England Biolabs. 
KOD XL-polymerase was obtained from Novagen, and Vent (exo-) from New England Biolabs. PCRs 
were carried out on Eppendorf realplex4 thermocycler and analyzed by 1–1.5% agarose gels that were 
run with a horizontal cell (Sub-Cell Bio-Rad) at 110 V using ethidium bromide for staining. 
The protected D2,15N2-hmC containing DNA fragments were deprotected by shaking in 0.1 M NaOH in 
a water/methanol 1:4 mixture at room temperature for 1 h. 
Prior to analysis the reactions were cleaned up using Nucleo Spin® clean up Kits obtained from 
Macherey Nagel. 
A typical PCR in a total volume of 50 µl contained 5 ng of template, 0.25 µM of each Primer, 2.5 U 
KOD XL-polymerase for cadCTP and D2,15N2-hmC, respectively, 2.0 U Vent (exo-) for fdCTP, 2.0 U of 
thermostable pyrophosphatase and 200 µM of each dNTP (corresponding natural dNTP substituted by 
modified triphosphates) and was incubated according to the following protocols. 
 
Table S1. PCR program for amplification with D2,15N2-hmC: 
Step duration Temperature 
initial denaturation 2 min 95°C 
30 cycles 
denaturation 15 s 95 °C 
annealing 15 s 56 °C 
extension 30 s 72 °C 
final extension 5 min 72 °C 
 
Table S2. PCR program for amplification with dfCTP: 
Step duration Temperature 
initial denaturation 2 min 95 °C 
30 cycles 
denaturation 15 s 95 °C 
annealing 15 s 55 °C 
extension 15 s 75 °C 
final extension 5min 75 °C 
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Table S3. PCR program for amplification with cadCTP 
Step duration Temperature 
initial denaturation 2 min 95 °C 
31 cycles 
denaturation 30 s 95 °C 
annealing 20 s 55 °C 
extension 15 s 72 °C 
final extension 5 min 72 °C 
 
LC-MS analysis of PCR products: 
Three independent PCRs were carried out with each modified dNTP and analyzed by LC-MS based on a 
further development, for which we are currently finishing a manuscript.1,2 In the following we shortly 
summarize the parameters of the method. 
LC-MS/MS analysis was performed on an Agilent 6490 triple quadrupol mass spectrometer coupled to 
an Agilent 1290 UHPLC system with UV-detection. The transitions of the nucleosides were analyzed in 
the positive ion selected reaction monitoring mode (SRM) operating under unit mass resolution 
conditions (Table S4). 
 
Table S4. Compound-dependent parameters for LC-MS/MS. 
Compound Precursor Ion Product Ion
5-caC 272.09 156.04 
5-fC 256.09 140.05 
 
For the analysis of biological samples, we used a C8 column from Agilent (1.8 µm, 2.1 mm × 150 mm). 
The compounds were separated by a gradient using water and acetonitrile with 0.0075% formic acid. 
The column temperature was maintained at 30 °C. The flow rate was 400 μL min−1 and the injection 
volume 29 μL. 
 
LC-HRMS-analysis with isotope labeled triphosphates were carried out using a Thermo Finnigan LTQ 
Orbitrap XL and chromatographed by a Dionex Ultimate 3000 HPLC system. The flow was set to 
0.15 mL/min over an Uptisphere120-3HDO (3 µm, 2.1 mm × 15 mm) column from Interchim. 
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Results of LC-HRMS analysis: 
 
 
Figure S1: UV 260 nm and mass traces of the total digests of the 15N2-labeled xdCTP measured with 
HRMS. Positive control with dCTP (black), D2,15N2-hmdCTP (blue), 15N2-fdCTP (green) and 
15N2-cadCTP (red). 
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 Figure S2: UV 260 nm and mass traces of the total digests of the cadCTP measured with HRMS. 
 
 
Synthesis of hmC, fC and caC-triphosphates: 
 
5-Formyl-2´-deoxy-cytidine-5´-monophosphate triethylammonium salt (2) 
 
5-Formyl-2´-deoxy-cytidine (1) (13 mg, 0.051 mmol, 1.0 eq.), and proton sponge (16.4 mg, 
0.076 mmol, 1.5 eq.) were dissolved in dry trimethylphosphite (1 mL). The solution was cooled to 0 °C 
and phosphorus oxychloride (5.4 L, 0.061 mmol, 1.2 eq.) was added. After stirring for 3 h the reaction 
was quenched by addition of triethylammonium bicarbonate buffer (3 mL, pH 8). RP-HPLC purification 
(0%  20% B in 45 min) gave 2 as a colorless solid (6.4 mg, 0.014 mmol, 29 %). 
1H-NMR (200 MHz, D2O): δ (ppm) = 9.49 (s, 1H, CHO), 8.79 (s, 1H, N-CH=C), 6.17 (t, J=6.1 Hz, 1H, 
O-CH-N), 4.39–4.42 (m, 1H, CH-O), 4.10–4.12 (m, 1H, CH-CH2-O), 3.71–3.87 (m, 2H, CH2-O), 2.24–
2.61 (m, 1H, N-CH-CH2), 2.39–2.46 (m, 1H, N-CH-CH2); 31P-NMR (162 MHz, D2O): δ (ppm) = 0.2 
(s); HRMS (ESI-): calc. for C10H13O8N3P- [M-H+]-: 334.0446, found: 334.0449. 
 
 
 
 
 
S7 
 
5-Formyl-2´-deoxy-cytidine-5´-triphosphate triethylammonium salt (fdCTP) 
O
OH
O
N
N
NH2
O
H
O
PO
O
O
POPHO
O
O
O
O
NHEt3 NHEt3 NHEt3
 
Dry tributylamine (13 L, 56 mol, 4.7 eq.) and 1-Methyl-3-benzenesulfonylimidazolium triflate 
(5.3 mg, 14 mol, 1.2 eq.) was added to a stirred solution of 5-formyl-2´-deoxy-cytidine-5´-
monophosphate 2 (4 mg, 12.0 mol, 1.0 eq) in dry DMF (0.45 mL) at 0 °C. The resulting colorless 
solution was added to pyrophosphate (8.7 mg, 24 mol, 2.0 eq.) in dry DMF (0.45 mL). The ice bath 
was removed and the reaction mixture stirred at room temperature for 3 h. The mixture was quenched 
by addition of triethylammonium acetate buffer (1 M) and the solvent was removed in vacuo. The 
triphosphate was isolated by ion exchange chromatography at 4 °C unsing a DEAE-cellulose column 
with a gradient from 100% water to 0.5 M TEAB (pH 7.5). Further purification was achieved by FPLC 
(0.1 M, 1 M TEAB, 0-100% TEAB over 30 min) by using a MonoQ 5/50 GL anion exchange column 
(GE) gave fdCTP as a colorless solid (6.9 mg, 8.4 µmol, 70 %). 
1H-NMR (400 MHz, D2O): δ (ppm) = 9.53 (s, 1H, CHO), 8.74 (s, 1H, N-CH=C), 6.11 (t, J=5.9 Hz, 1H, 
O-CH-N), 4.48–4.58 (m, 1H, O-CH), 4.13–4.19 (m, 3H, O-CH-CH-CH2-O), 2.26–2.46 (m, 2H, O-CH-
CH2-CH-N); 31P-NMR (162 MHz, D2O, ppm): δ = -10.5 (m, P), -11.7 (d, J=19.8 Hz, P), -23.3 (t, 
J=16.4 Hz, P); HRMS (ESI+): calc. for C11H15N3P3O14 [M-H+]-: 493.9927, found: 493.9920.  
 
 
5-Carboxylmethyl-2´-deoxy-cytidine (4) 
 
In a polypropylene tube 5-carboxylmethyl-3´,5´-(tert-butyl-dimethylsilyl)-2´-deoxy-cytidine (3) 
(266 mg, 0.52 mmol, 1.0 eq.) was dissolved in 30 mL EtOAc and HF-pyridine (70% HF, 270 μL, 
7.8 mmol, 5.7 eq.) was added. After stirring the reaction mixture for 14 h at room temperature, 
additional HF-pyridine (100 μL, 1.1 mmol, 2 eq.) was added and the reaction mixture was stirred for 5 h 
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at room temperature. The reaction was quenched by addition of methoxytrimethylsilane (2.0 mL, 
14 mmol, 27 eq.). After stirring for 30 min, the precipitate was collected by centrifugation (4500 rpm, 
20 min). The crude product was purified by column chromatography (CH2Cl2/MeOH, 10:1  4:1) to 
yield 5-carboxylmethyl-2´-deoxy-cytidine 4 as a colorless solid (109 mg, 0.38 mmol, 73%). 
1H-NMR (400 MHz, CD3OD) δ = 9.13 (s, 1H, N-CH=C), 6.19 (t, J=5.9 Hz, 1H, N-CH-O),  
4.36– 4.39 (m, 1H, CH-OH), 4.06 (q, J=6.8 Hz, CH-CH2-O), 3.92–3.88 (m, 5H, CH2-OH, OCH3), 
2.44–2.49 (m, 1H, N-CH-CH2), 2.18–2.25 (m, 1H, N-CH-CH2);13C-NMR (100 MHz, CD3OD) δ = 
166.6 (COO), 165.2 (C-NH2), 156.5 (N-CO-N), 149.9 (CH=C), 96.9 (C-CO), 89.2 (N-CH-CH2), 88.5 
(CH-CH2-O), 71.2 (CH-OH), 62.28 (CH2-OH), 52.4 (OCH3), 42.6 (O-CH-CH2); HRMS (ESI+): calc. 
for C11H16N2O6, [M+H]+: 286.1034, found: 286.1032; Melting range: 160–170 °C; IR (cm-1): ν = 3402 
(m), 2924 (m), 1712 (s), 1632 (ss), 1501 (s), 1438 (s), 1319 (s), 1256 (s), 1191 (s), 1092 (ss), 1059 (ss), 
991 (s), 991 (s), 870 (m), 790 (ss), 721 (s), 693 (s). 
 
 
5-Carboxyl-2´-deoxycytidine (5) 
O
OH
HO
N
N
NH2
O
HO
O
 
5-Carboxylmethyl-2´-deoxy-cytidine (4) (139 mg, 487.0 mmol, 1.0 eq.) was dissolved in a mixture of 
water (7.2 mL) and MeCN (38.0 mL). Then LiOH (139 mg, 5.8 mmol, 12.0 eq.) was added and the 
mixture was stirred at room temperature for 19 h. After adjusting to pH 4.0 with 2 M hydrochloric acid, 
5 precipitated as a colorless solid (58 mg, 0.214 μmol, 44%). 
 
1H-NMR (400 MHz, D2O): δ (ppm) = 8.81 (s, 1H, N-CH=C), 6.30 (t, J=6.2 Hz, 1H, N-CH-O),  
4.51–4.53 (m, 1H, CH-OH), 4.18–4.15 (m, 1H, CH-CH2-O), 3.92 (dd, J=12.7 Hz, 3.4 Hz, 2H, CH2-
OH), 2.60–2.40 (m, 2H, N-CH-CH2); 13C-NMR (100 MHz, D2O): δ =167.9 (CO-O), 159.6 (C-NH2), 
149.7 (C=O-N), 148.2 (CH=C), 101.2 (C=CO), 87.2 (CH-CH2-O), 86.9 (N-CH-CH2), 70.1 (CH-OH), 
60.8 (CH2-OH), 39.5 (O-CH-CH2); HRMS (ESI-): calc. for C10H12N3O6 [M-H+]-: 270.0732, found: 
270.0732; melting range: > 250 °C decomposition; IR (cm-1): ν = 3254 (m), 2934 (m), 1718 (s), 1653 
(m), 1540 (m), 1437 (s), 1363 (s), 1279 (s), 1235 (m), 1198 (s), 1090 (s), 1050 (ss), 995 (s), 869 (m), 
783 (s), 758 (s), 732 (s), 684 (ss). 
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5-Carboxyl-2´-deoxy-cytidine-5´-triphosphate triethylammonium salt (cadCTP) 
 
Tributylammonium pyrophosphate (37.5 mg, 0.08 mmol, 2.0 eq.) was dissolved in DMF (0.10 mL) and 
tributylamine (0.15 mL) was added. The resulting mixture was added to 2-chloro-1,3,2-
benzodioxaphosphorin-4-one (16 mg, 0.08 mmol, 2.0 eq.) in DMF (0.11 mL). After 30 min at room 
temperature the stirred solution was added to 5-Carboxyl-2´-deoxycytidine (5) (10.5 mg, 38.4 mol, 
1.0eq.). After stirring at room temperature for 2.5 h a solution of 3 % iodine in a pyridine/water mixture 
(9:1, 0.3 mL) was added and stirred at room temperature for 1.5 h. The crude product was precipitated 
by addition of a 3 M sodium chloride solution (0.8 mL) and ethanol (15 mL) at -80 °C for 14 h. RP-
HPLC purification (0%  15% B in 75 min) gave cadCTP as a colorless solid (2.69 mg, 2.7 mol, 
8%). 
1H-NMR (400 MHz, D2O): δ (ppm) = 8.32 (s, 1H, N-CH=C), 6.11 (t, J=5.6 Hz, 1H, O-CH-N), 4.46–
4.47 (m, 1H, CH-O), 4.29–4.23 (m, 3H, CH-CH-CH2-O), 2.52–2.39 (m, 2H, N-CH-CH2). 31P-NMR 
(162 MHz, D2O): δ (ppm) = -10.1 (d, J=19.6 Hz), -11.4 (d, J=19.8 Hz), -23.4 (t, J=19.8 Hz, P); HRMS 
(ESI+): calc. for C10H17N3P3O15 [M+H+]+: 511.9867, found: 511.9861. 
 
 
5-Deuteroformyl-3´,5´-(tert-butyl-dimethylsilyl)-2´-deoxy-(N1,N3-15N)-cytidine (7) 
 
5´-Iodo-3´,5´-(tert-butyl-dimethylsilyl)-2´-deoxy-(N1,N3-15N)-cytidine (6)3 (0.20 g, 0.34 mmol, 1.0 eq.), 
Pd2(dba)3·CHCl3 (56.0 mg, 0.05 mmol, 0.2 eq.) and triphenylphosphine (85.0 mg, 0.32 mmol, 0.9 eq.) 
were dissolved in d8-toluene (7.8 mL) in a high pressure glas autoclave. The autoclave was flushed with 
CO to remove residual air and after heating to 60 °C, the CO pressure was set to 3.5 bar. Tributyltin 
deuteride (0.18 mL, 0.68 mmol, 2.0 eq.) in d8-toluene (0.82 mL) were added within 10 h and the 
reaction was stirred for additional 14 h at 60 °C and 3.5 bar CO pressure. After evaporation to dryness, 
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the product was purified by silica gel column chromatography (iHex/EtOAc 1:1) to give product 7 as an 
orange solid (106 mg, 0.22 mmol, 64%). 1H-NMR (300 MHz, CDCl3, ppm): δ = 8.52 (s, 1H, N-CH=C), 
8.16 (s br, 1H, NH2), 6.32 (s br, 1H, NH2), 6.19 (dt, J=6.2, 0.9 Hz, 1H, N-CH-O), 4.35–4.31 (m, 1H, 
CH-O-Si), 4.03 (dd, J=5.9, 2.6 Hz, 1H, CH-CH2-O), 3.94 (dd, J=11.6, 2.6 Hz, 1H, CH2-O-Si), 3.76 (dd, 
J=11.6, 2.5 Hz, 1H, CH2-O-Si), 2.64–2.56 (m, 1H, N-CH-CH2), 2.10–2.01 (m, 1H, N-CH-CH2), 0.88 
(s, 9H, Si-C-CH3), 0.87 (s, 9H, Si-C-CH3), 0.08 (s, 3H, Si-CH3), 0.07 (s, 3H, Si-CH3), 0.06 (s, 3H, Si-
CH3), 0.05 (s, 3H, Si-CH3). 13C-NMR (151 MHz, CDCl3, ppm): δ = 187.1 (t, J=26.6 Hz, COD), 162.9 
(d, J=5.9 Hz, C-NH2), 153.5 (dd, J=9.4, 7.2 Hz, N-C=O), 153.1 (d, J=14.1 Hz, CH=C), 105.1 (C-CO), 
88.8 (O-CH-CH2-O), 88.0 (d, J=9.5 Hz, N-CH-O), 71.8 (CH-O-Si), 62.8 (CH2-O-Si), 43.2 (N-CH-
CH2), 26.2 (Si-C-CH3), 25.9 (Si-C-CH3), 18.7 (Si-C), 18.2 (Si-C), -4.3 (Si-CH3), -4.7 (Si-CH3), -5.0 
(Si-CH3), -5.1 (Si-CH3). 15N-NMR (40 MHz, CDCl3, ppm): δ =-172.7, -207.3. HRMS (ESI+): calc. for 
C22H41DN15N2O5Si2 [M+H+]+: 487.2660, found: 487.2661. Melting range: 137–139 °C. IR (cm-1): ν= 
3366 (w), 2954 (m), 2927 (m), 2857 (m), 1639 (s), 1504 (m), 1471 (m), 1462 (m), 1251 (m), 1084 (s), 
829 (s), 775 (s). 
 
 
5-Dideuterohydroxymethyl-3´,5´-(tert-butyl-dimethylsilyl)-2´-deoxy-(N1,N3-15N)-cytidine (8) 
 
To 5-deuteroformyl-3´,5´-(tert-butyl-dimethylsilyl)-2´-deoxy-(N1,N3-15N)-cytidine (7) (77.0 mg, 
0.16 mmol, 1.0 eq.) in CD3OD (5.3 mL) were added sodium borodeuteride (7.5 mg, 0.18 mmol, 1.1 eq.) 
and cerium(III) chloride (0.12 g, 0.49 mmol, 3.0 eq.). The resulting orange solution was stirred at room 
temperature for 25 min and then quenched with a saturated ammonium chloride solution (53 mL). The 
aqueous phase was extracted with EtOAc (53 mL), the resulting organic phase was washed with a 
saturated ammonium chloride solution (2 × 53 mL) and dried over magnesium sulfate. The solvent was 
evaporated to dryness and the product purified by silica gel column chromatography (DCM/MeOH 
20:1) to obtain 8 as a colorless solid (31.0 mg, 0.06 mmol, 40%). 1H-NMR (600 MHz, CDCl3, ppm): δ 
= 7.57 (d, J=1.1 Hz, 1H, N-CH=C), 6.10 (t, J=6.4 Hz, 1H, N-CH-O), 4.28 (dt, J=6.6, 3.5 Hz, 1H, CH-
O-Si), 3.89 (q, J=3.1 Hz, 1H, CH-CH2-O), 3.80 (dd, J=11.2, 3.2 Hz, 1H, CH2-O-Si), 3.70 (dd, J=11.2, 
3.0 Hz, 1H, CH2-O-Si), 2.38–2.33 (m, 1H, N-CH-CH2), 1.97–1.89 (m, 1H, N-CH-CH2), 0.87 (s, 9H, Si-
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C-CH3), 0.85 (s, 9H, Si-C-CH3), 0.06 (s, 3H, Si-CH3), 0.05 (s, 3H, Si-CH3), 0.03 (s, 3H, Si-CH3), 0.03 
(s, 3H, Si-CH3). 13C-NMR (151 MHz, CDCl3, ppm): δ = 165.5 (dd, J=6.1, 1.4 Hz, C-NH2), 156.5 (dd, 
J=12.6, 8.1 Hz, N-C=O), 138.8 (d, J=13.2 Hz, CH=C), 106.1 (d, J=0.7 Hz, C-CD2), 88.0 (O-CH-CH2-
O), 86.5 (d, J=11.2 Hz, N-CH-O), 71.9 (CH-O-Si), 62.9 (CH2-O-Si), 59.1 (s br, CD2), 42.4 (N-CH-
CH2), 26.1 (Si-C-CH3), 26.0 (Si-C-CH3), 18.6 (Si-C), 18.2 (Si-C), -4.3 (Si-CH3), -4.7 (Si-CH3), -5.1 
(Si-CH3), -5.2 (Si-CH3). 15N-NMR (40 MHz, CDCl3, ppm): δ =-173.6, -223.3. HRMS (ESI+): calc. for 
C22H42D2N15N2O5Si2 [M+H+]+: 490.2880, found: 490.2878. Melting range: 95–97 °C. IR (cm-1): ν= 
3202 (w), 2928 (w), 2856 (w), 1657 (m), 1604 (m), 1471 (m), 1253 (m), 1075 (m), 1029 (m), 832 (s), 
775 (s). 
 
 
5-Dideutero-3´,5´-(tert-butyl-dimethylsilyl)-4,5-(1,3-[3H,6H]oxazin-2-one)-2´-deoxy-(N1,N3-15N)-
cytidine (9) 
 
To a solution of 5-dideuterohydroxymethyl-3´,5´-(tert-butyl-dimethylsilyl)-2´-deoxy-(N1,N3-15N)-
cytidine (8) (23 mg, 46.96 mol, 1.0 eq.) in THF (9.3 mL) were added 4-Nitrophenylchloroformate 
(10.6 mg, 52.59 mol, 1.12 eq.) and DIPEA (16.5 L, 111.3 mol, 2.4 eq.). After stirring for 17 h at 
room temperature additional 4-Nitrophenylchloroformate (2.1 mg, 10.42 mol, 0.2 eq.) and DIPEA 
(3.4 L, 22.90 mol, 0.49 eq.) were added. After stirring at room temperature for additional 4 h, the 
solvent was removed in vacuo. Purification by silica gel column chromatography (DCM/MeOH 100:1 
 80:1) gave 9 as a colorless solid (18 mg, 34.90 mol, 74%). 1H-NMR (200 MHz, CDCl3, ppm): δ = 
8.16 (s, 1H, N-CH=C), 6.20 (t, J=5.9 Hz, 1H, N-CH-O), 4.35–4.29 (m, 1H, CH-O-Si), 3.99–3.89 (m, 
2H, CH-CH2-O, CH2-O-Si), 3.75 (dd, J=11.3, 1.7 Hz, 1H, CH2-O-Si), 2.61–2.48 (m, 1H, N-CH-CH2), 
2.10–1.96 (m, 1H, N-CH-CH2), 0.89 (s, 9H, Si-C-CH3), 0.86 (s, 9H, Si-C-CH3), 0.09 (s, 3H, Si-CH3), 
0.08 (s, 3H, Si-CH3), 0.05 (s, 3H, Si-CH3), 0.04 (s, 3H, Si-CH3). 13C-NMR (100 MHz, CDCl3, ppm): δ 
= 159.7 (dd, J=6.9, 1.0 Hz, C-NH), 154.6 (dd, J=11.9, 6.2 Hz, N-C=O), 149.9 (d, J=2.8 Hz, O-C=O), 
138.7 (d, J=13.6 Hz, CH=C), 96.1 (C-CD2), 88.5 (O-CH-CH2-O), 87.7 (d, J=9.8 Hz, N-CH-O), 71.4 
(CH-O-Si), 64.5 (qi, J=23.3 Hz, CD2), 62.6 (CH2-O-Si), 42.8 (N-CH-CH2), 26.1 (Si-C-CH3), 25.9 (Si-
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C-CH3), 18.6 (Si-C), 18.3 (Si-C), -4.3 (Si-CH3), -4.7 (Si-CH3), -5.1 (Si-CH3), -5.2 (Si-CH3). 15N-NMR 
(40 MHz, CDCl3, ppm): δ =-152.7, -210.2. HRMS (ESI+): calc. for C23H40D2N15N2O6Si2 [M+H+]+: 
516.2671, found: 516.2668. Melting range: 92–94 °C. IR (cm-1): ν= 2952 (w), 2928 (w), 2855 (w), 
1757 (m), 1658 (m), 1553 (m), 1471 (m), 1253 (m), 1112 (m), 1064 (m), 1028 (m), 832 (s), 774 (s). 
 
 
5-Dideutero-4,5-(1,3-[3H,6H]oxazin-2-one)-2´-deoxy-(N1,N3-15N)-cytidine (10) 
 
To a solution of 5-dideutero-3´,5´-(tert-butyl-dimethylsilyl)-4,5-(1,3-[3H,6H]oxazin-2-one)-2´-deoxy-
(N1,N3-15N)-cytidine (9) (299 mg, 0.58 mmol, 1.0 eq.) in EtOAc (19 mL) were added pyridine (226 L, 
2.79 mmol, 4.8 eq.) and 70% HF-pyridine (234 L, 8.70 mmol, 15.0 eq.). After stirring at room 
temperature for 19 h additional pyridine (226 L, 2.79 mmol, 4.8 eq.) and 70% HF-pyridine (234 L, 
8.70 mmol, 15.0 eq.) were added. After stirring for additional 20 h the reaction was quenched by 
addition of methoxytrimethylsilane (6.3 mL, 45.70 mmol, 78.8 eq.) and stirring was continued for 
30 min. After evaporation to dryness the crude product was purified by silica gel column 
chromatography (DCM/MeOH 10:1  5:1) to obtain 10 as a colorless solid (151 mg, 0.53 mmol, 91%). 
1H-NMR (200 MHz, CD3OD, ppm): δ = 8.39 (s, 1H, N-CH=C), 6.20 (dt, J=6.2, 1.3 Hz, 1H, N-CH-O), 
4.36 (dt, J=6.2, 3.9 Hz, 1H, CH-OH), 4.03–3.97 (m, 1H, CH-CH2-O), 3.89–3.70 (m, 2H, CH2-OH), 
2.56–2.43 (m, 1H, N-CH-CH2), 2.23–2.09 (m, 1H, N-CH-CH2). 13C-NMR (151 MHz, d6-DMSO, 
ppm): δ = 160.1 (dd, J=6.8, 1.7 Hz, C-NH), 154.3 (dd, J=11.3, 5.5 Hz, N-C=O), 150.6 (d, J=3.1 Hz, O-
C=O), 138.8 (d, J=13.2 Hz, CH=C), 96.7 (C-CD2), 87.9 (CH-CH-CH2-O), 86.1 (d, J=10.3 Hz, N-CH-
O), 70.0 (O-CH), 63.7 (qi, J=23.1 Hz, CD2), 61.0 (CH2-OH), 40.7 (N-CH-CH2). 15N-NMR (40 MHz, 
d6-DMSO, ppm): δ =-153.0, -213.0. HRMS (ESI-): calc. for C11H10D2N15N2O6 [M-H+]-: 286.0796, 
found: 286.0800. Melting range: >200 °C (decomposition). IR (cm-1): ν= 3361 (w), 3270 (w), 3161 
(w), 1749 (m), 1667 (s), 1627 (s), 1557 (m), 1476 (m), 1282 (s), 1268 (s), 1101 (s), 1082 (s), 1067 (s), 
1060 (s), 794 (s), 775 (s). 
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5-Dideutero-4,5-(1,3-[3H,6H]oxazin-2-one)-2´-deoxy-(N1,N3-15N)-cytidine-5´-triphosphate 
triethylammonium salt (11) 
 
A solution of tributylammonium pyrophosphate (146.0 mg, 0.27 mmol, 2.7 eq.) in DMF (0.52 mL) and 
tributylamine (0.67 mL) was added to 2-chloro-1,3,2-benzodioxaphosphorin-4-one (53.6 mg, 
0.26 mmol, 2.6 eq.) in DMF (0.37 mL). After stirring for 30 min at room temperature this solution was 
added to 5-dideutero-4,5-(1,3-[3H,6H]oxazin-2-one)-2´-deoxy-(N1,N3-15N)-cytidine (10) (30 mg, 
0.10 mmol, 1.0 eq.). After stirring at room temperature for 3 d iodine (69.5 mg, 0.27 mmol, 2.7 eq.) in a 
pyridine (2.16 mL) water (0.24 mL) mixture was added and stirred at room temperature for 2 h. The 
crude product was precipitated by addition of a 3 M sodium acetate solution (1.37 mL) and ethanol 
(26 mL) at -80 °C over night. RP-HPLC purification (0%  19% buffer B in 45 min) gave 11 as a 
colorless solid (0.58 mg, 0.70 mol, 1%). 1H-NMR (400 MHz, D2O, ppm): δ = 8.44 (d, J=0.9 Hz, 1H, 
N-CH=C), 6.29 (t, J=6.3 Hz, 1H, N-CH-O), 4.70–4.66 (m, 1H, CH-OH), 4.32–4.25 (m, 3H, CH-CH2-
O), 2.62–2.55 (m, 1H, N-CH-CH2), 2.43–2.36 (m, 1H, N-CH-CH2).31P-NMR (162 MHz, D2O, ppm): δ 
= -7.5 (br), -11.6 (d, J=20.1 Hz), -22.6 (t, J=20.4 Hz, P). 15N-NMR (40 MHz, D2O, ppm): δ =-160.5, -
210.3. HRMS (ESI-): calc. for C11H13D2N15N2P3O15 [M-H+]-: 525.9786, found: 525.9789.  
 
 
5-Formyl-(tert-butyl-dimethylsilyl)-2´-deoxy-(N1,N3-15N)-cytidine (12) 
 
5´-Iodo-3´,5´-(tert-butyl-dimethylsilyl)-2´-deoxy-(N1,N3-15N)-cytidine (6)1 (1.4 g, 2.4 mmol, 1.0 eq.), 
Pd2(dba)3·CHCl3 (0.245 mg, 0.24 mmol, 0.1 eq.) and triphenylphosphine (0.373 mg, 1.42 mmol, 
0.6 eq.) were dissolved in toluene (40 mL) in a high pressure glas autoclave. The autoclave was flushed 
with CO to remove residual air and after heating to 60 °C, the CO pressure was set to 3.5 bar. 
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Tributyltin hydride (0.83 mL, 2.8 mmol, 1.2 eq.) was added within 4 h and the reaction was stirred for 
additional 14 h at 60 °C and 3.5 bar CO pressure. After evaporation to dryness, the product was purified 
by silica gel column chromatography (iHex/EtOAc 4:1  1:1) to give 12 as an orange solid (864 mg, 
1.78 mmol, 74%). 
1H-NMR (200 MHz, CDCl3, ppm): δ = 9.47 (s, 1H, CHO), 8.53 (s, 1H, N-CH=C), 6.19 (t, J=5.9 Hz, 
1H, N-CH-O), 4.35–4.32 (m, 1H, CH-O-Si), 4.02–4.03 (m, 1H, CH-CH2-O), 3.94 (dd, J=11.6, 2.6 Hz, 
1H, CH2-O-Si), 3.77 (dd, J=11.6, 2.6 Hz, 1H, CH2-O-Si), 2.62–2.58 (m, 1H, N-CH-CH2), 2.07–2.02 
(m, 1H, N-CH-CH2), 0.89 (s, 9H, Si-C-CH3), 0.87 (s, 9H, Si-C-CH3), 0.08 (s, 3H, Si-CH3), 0.07 (s, 3H, 
Si-CH3), 0.06 (s, 3H, Si-CH3), 0.05 (s, 3H, Si-CH3). 13C-NMR (100 MHz, CDCl3, ppm): δ = 162.5 (d, 
J=6.8 Hz, C-NH), 152.3 (d, J=14.3 Hz, N-C=O), 132.1 (d, J=9.9 Hz, O-C=O), 138.7 (d, J=12.1 Hz, 
CH=C), 104.9 (C-CH2), 88.6 (O-CH-CH2-O), 87.7 (d, J=9.6 Hz, N-CH-O), 71.5 (CH-O-Si), 62.5 
(CH2-O-Si), 42.9 (N-CH-CH2), 25.9 (Si-C-CH3), 25.7 (Si-C-CH3), 18.4 (Si-C), 17.9 (Si-C), -4.6 (Si-
CH3), -4.9 (Si-CH3), -5.3 (Si-CH3), -5.4 (Si-CH3). HRMS (ESI+): calc. for C22H42N215N2O6Si2 
[M+H+]+: 486.2599, found: 486.2600. Melting range: 150–152 °C. IR (cm-1): ν= 2952 (w), 2928 (w), 
2855 (w), 1757 (m), 1658 (m), 1553 (m), 1471 (m), 1253 (m), 1112 (m), 1064 (m), 1028 (m), 832 (s), 
774 (s). 
 
 
5-Formyl-2´-deoxy-(N1,N3-15N)-cytidine (13) 
 
In a polypropylene tube 5-Formyl-(tert-butyl-dimethylsilyl)-2´-deoxy-(N1,N3-15N)-cytidine (12) 
(493 mg, 0.84 mmol, 1.0 eq.) was dissolved in 20 mL EtOAc and 70% HF-pyridine (325 μL, 3.6 mmol, 
4.2 eq.) was added. The reaction was stirred for 17 h at room temperature and was quenched by addition 
of methoxytrimethylsilane (2.0 mL, 14.5 mmol, 17 eq.). After stirring for 30 min, the precipitate was 
collected by centrifugation (4500 rpm, 20 min). The crude product was purified by RP-HPLC (0%  
20% buffer B in 45 min) to yield 13 as a colorless solid (190 mg, 0.52 mmol, 63%). 
1H-NMR (200 MHz, D2O, ppm): δ = 9.58 (d, J=0.4 Hz, 1H, CHO), 8.87 (s, 1H, N-CH=C), 6.26 (t, 
J=6.1 Hz, 1H, N-CH-O), 4.49 (dd, J=11.2, 4.7 Hz, 1H, CH-OH), 4.20 (dd, J=8.7, 4.3 Hz, 1H, CH-CH2-
O), 3.97 (dd, J=12.6, 3.3 Hz, 1H, CH2-OH), 3.85 (dd, J=12.6, 4.9 Hz, 1H, CH2-OH), 2.66–2.60 (m, 1H, 
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N-CH-CH2), 2.47–2.40 (m, 1H, N-CH-CH2). 13C-NMR (100 MHz, D2O, ppm): δ = 190.4 (d, J=2.0 Hz, 
C-NH), 162.3 (d, J=1.4 Hz, C-NH2), 154.5 (d, J=6.4 Hz, N-CO-N), 105.6 (CH=C), 87.4 (C-CO), 87.3 
(N-CH-CH2), 86.1 (CH-CH2-O), 69.7 (CH-OH), 60.6 (CH2-OH), 40.0 (O-CH-CH2); HRMS (ESI+): 
calc. for C10H14N215N2O5 [M+H+]+: 258.0869, found: 48258.0867;. Melting range: 150–152 °C. IR 
(cm-1): ν= 2952 (w), 2928 (w), 2855 (w), 1757 (m), 1658 (m), 1553 (m), 1471 (m), 1253 (m), 1112 (m), 
1064 (m), 1028 (m), 832 (s), 774 (s). 
 
 
5-Formyl-2´-deoxy-(N1,N3-15N)-cytidine-5´-triphosphate triethylammonium salt (14) 
 
 
A solution of tributylammonium pyrophosphate (42 mg, 77.46 mol, 2.0 eq.) in DMF (0.15 mL) and 
tributylamine (0.20 mL) was added to 2-chloro-1,3,2-benzodioxaphosphorin-4-one (15.7 mg, 
77.5 mol, 2.0 eq.) in DMF (0.11 mL). After stirring for 30 min at room temperature this solution was 
added to 5-Formyl-2´-deoxy-(N1,N3-15N)-cytidine (13) (10 mg, 38.8 mol, 1.0eq.). After stirring at 
room temperature for 3.5 h a solution of 3 % iodine in a pyridine/water mixture (9:1, 0.5 mL) was added 
and stirred at room temperature for 1.5 h. The crude product was precipitated by addition of a 3 M 
sodium chloride solution (0.8 mL) and ethanol (15 mL) at -80 °C for 14 h. The triphosphate was 
isolated by ion exchange chromatography at 4 °C unsing a DEAE-cellulose column with a gradient from 
100% water to 0.5 M TEAB (pH 7.5). Further purification was achieved by FPLC (0.1 M, 1 M TEAB, 0-
100% TEAB over 30 min) by using a MonoQ 5/50 GL anion exchange column (GE) and gave 14 as a 
colorless solid (2.06 mg, 2.5 mol, 12%). 
1H-NMR (400 MHz, D2O): δ (ppm) = 9.69 (s, 1H, CHO), 8.90 (s, 1H, N-CH=C), 6.27 (t, J=6.3 Hz, 1H, 
N-CH-O), 4.66–4.69 (m, 1H, CH-O), 4.29–4.37 (m, 3H, CH-CH2-O), 2.42–2.64 (m, 2H, N-CH-CH2); 
31P-NMR (162 MHz, D2O), δ (ppm)= -10.3 (m, P), -11.7 (d, J=20.2.8 Hz, P), -23.3 (t, J=19.3 Hz, P); 
HRMS (ESI+): calc. for C10H17N3P3O15 [M-H+]-: 495.9713, found: 493.9713. 
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5-Carboxylmethyl-2´-deoxy-(N1,N3-15N)-cytidine (15) 
 
A solution of 3´,5´-(tert-butyl-dimethylsilyl)-5-carboxylmethyl-2´-deoxy-(N1,N3-15N)-cytidine1 
(170 mg, 0.33 mmol, 1.0 eq.), 70% HF-pyridine (0.13 mL, 4.94 mmol, 15.0 eq.) and pyridine (0.13 mL, 
1.60 mmol, 4.8 eq.) in EtOAc (10.7 mL) was stirred at room temperature for 21 h. Then additional 70% 
HF-pyridine (0.09 mL, 3.42 mmol, 10.4 eq.) and pyridine (0.09 mL, 1.11 mmol, 3.4 eq.) were added 
and the reaction mixture was stirred for additional 26 h. The reaction was quenched with 
methoxytrimethylsilane (2.7 mL, 19.59 mmol, 59.4 eq.) and stirred for 30 min. After evaporation to 
dryness and purification by silica gel column chromatography (DCM:MeOH 50:1  5:1) product 15 
was obtained as a colorless solid (30 mg, 0.10 mmol, 30%). 1H-NMR (200 MHz, D2O, ppm): δ = 8.96 
(s, 1H, N-CH=C), 6.16 (t, J=5.8 Hz, 1H, N-CH-O), 4.45–4.36 (m, 1H, CH-OH), 4.08–4.02 (m, 1H, 
CH-CH2-O), 3.94–3.71 (m, 2H, CH2-OH), 3.83 (s, 3H, OCH3), 2.58–2.43 (m, 1H, O-CH-CH2), 2.39–
2.25 (m, 1H, N-CH-CH2). 13C-NMR (100 MHz, D2O, ppm): δ = 166.0 (d, J=1.6 Hz, COO), 163.5 (dd, 
J=6.2, 1.4 Hz, C-NH2), 155.8 (dd, J=11.8, 8.3 Hz, N-CO-N), 148.8 (d, J=14.0 Hz, CH=C), 96.8 (d, 
J=1.0 Hz, C-CO), 86.9 (d, J=9.7 Hz, N-CH-CH2), 86.7 (CH-CH2-O), 69.2 (CH-OH), 60.1 (CH2-OH), 
52.3 (OCH3), 39.9 (O-CH-CH2). 15N-NMR (40 MHz, D2O, ppm): δ =-179.7, -212.2. HRMS (ESI+): 
calc. for C11H16N15N2O6 [M+H]+: 288.0974, found: 288.0977. Melting range: 169–171 °C. IR (cm-1): 
ν= 1713 (m), 1635 (s), 1480 (s), 1321 (s), 1097 (s), 1062 (s), 786 (s). 
 
 
5-Carboxyl-2´-deoxy-(N1,N3-15N)-cytidine (16) 
 
A solution of 5-Carboxylmethyl-2´-deoxy-(N1,N3-15N)-cytidine (15) (25 mg, 87.0 mol, 1.0 eq.) and 
LiOH (25 mg, 1.04 mmol, 12.0 eq.) in a water (1.3 mL) MeCN (7.0 mL) mixture was stirred at room 
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temperature for 19 h. After adjusting the pH to 4.0 with 2 M hydrochloric acid (0.5 mL) the colorless 
precipitate was filtered and washed with water to obtain 16 (11 mg, 40.26 mol, 46%). 
1H-NMR (400 MHz, D2O): δ (ppm) = 8.79 (s, 1H, N-CH=C), 6.29 (dt, J=6.5, 1.3 Hz, 1H, N-CH-O), 
4.53–4.49 (m, 1H, CH-OH), 4.16 (dd, J=8.1, 4.2 Hz, 1H, CH-CH2-O), 3.92 (dd, J=12.4, 3.5 Hz, 1H, 
CH2-O), 3.83 (dd, J=12.5, 5.3 Hz, 1H, CH2-O), 2.59–2.53 (m, 1H, N-CH-CH2), 2.46–2.38 (m, 1H, N-
CH-CH2). 13C-NMR (101 MHz, D2O, ppm): δ =168.0 (CO-O), 159.8 (d, J=13.3 Hz, C-NH2), 150.0 (N-
C=O), 148.0 (d, J=13.1 Hz, CH=C), 101.3 (C-CO), 87.2 (CH-CH2-O), 86.9 (d, J=10.2 Hz, N-CH-CH2), 
70.1 (CH-OH), 60.8 (CH2-OH), 39.5 (O-CH-CH2). 15N-NMR (41 MHz, d6-DMSO, ppm): δ = -171.6, -
212.1. HRMS (ESI+): calc. for C10H14N15N2O6+ [M+H+]+: 274.0818, found: 274.0818. Melting range: 
>250 °C (decomposition). IR (cm-1): v= 3402 (m), 3274 (br, m), 1661 (s), 1627 (m), 1448 (m), 1291 
(m), 1202 (m), 1093 (s), 1003 (s), 816 (m). 
 
 
5-Carboxyl-2´-deoxy-(N1,N3-15N)-cytidine-5´-triphosphate triethylammonium salt (17) 
 
A solution of tributylammonium pyrophosphate (42.5 mg, 77.46 mol, 2.0 eq.) in DMF (0.15 mL) and 
tributylamine (0.20 mL) was added to 2-chloro-1,3,2-benzodioxaphosphorin-4-one (15.7 mg, 
77.5 mol, 2.0 eq.) in DMF (0.11 mL). After stirring for 30 min at room temperature this solution was 
added to 5-carboxyl-2´-deoxy-(N1,N3-15N)-cytidine (16) (10.5 mg, 38.4 mol, 1.0 eq.). After stirring at 
room temperature for 20 h iodine (34.8 mg, 0.14 mmol, 3.6 eq.) in a pyridine (1.08 mL) water 
(0.12 mL) mixture was added and stirred at room temperature for 2 h. The crude product was 
precipitated by addition of a 3 M sodium acetate solution (0.65 mL) and ethanol (12 mL) at -80 °C for 
1 h. RP-HPLC purification (0%  6% buffer B in 45 min) gave 17 as a colorless solid (2.28 mg, 
2.5 mol, 7%). 1H-NMR (400 MHz, D2O): δ (ppm) = 8.44 (t, J=1.3 Hz, 1H, N-CH=C), 6.29 (t, 
J=6.7 Hz, 1H, N-CH-O), 4.65–4.61 (m, 1H, CH-OH), 4.29–4.20 (m, 3H, CH-CH2-O), 2.51–2.36 (m, 
2H, N-CH-CH2). 31P-NMR (162 MHz, D2O, ppm): δ = -11.0 (d, J=19.8 Hz), -11.0 (d, J=19.8 Hz), -23.4 
(t, J=19.8 Hz, P). HRMS (ESI+): calc. for C10H15N15N2O15P3+ [M+H+]+: 511.9662, found: 511.9661. 
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Supplementary Results 
 
 
Supplementary Figure 1. Isotopically labeled nucleosides used as internal standards for quantitative LC-MS/MS 
analysis (dR = -2´-deoxyribose). 
 
 
Supplementary Figure 2. DNA modification levels per nucleoside (N) of different murine tissues from 3 month 
old individuals (n = 3). Depicted are biological mean values ±SD. 
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Supplementary Figure 3. hmU-levels normalized to the oxidative background marker 8-oxo-G in mESCs (nWT01 
= 7; nJ1 = 2, nR1 = 2) and murine tissues (n = 3, 3 month old individuals) in order to dissect ROS dependent and 
ROS independent processes. Normalization was necessary to take deviating background oxidation of DNA sample 
preparation into account. The light grey area reflect the hmU-level fractions, which are generated by ROS 
dependent processes. The green area reflect the hmU-level fractions, which are generated by ROS independent 
processes. The assignment is based on the assumption, that hmU-levels in somatic tissue are exclusively ROS 
created lesions (derived from the cluster analysis in Fig. 2b). The dark grey area reflect the mean value ±SD of 
hmU/8-oxo-G ratios of the tissue data. The difference between the height of the hmU/8-oxo-G ratios of mESCs 
and the mean of the tissue data give the hmU-fraction which is formed by ROS-independent processes. In WT01, 
J1 and R1 cells about 67%, 83% and 74%, respectively, of the global hmU-levels are estimated to be created by 
ROS independent processes. Bars reflect biological mean values ±SD. The differences between mESCs (WT01, 
J1) and murine tissues are significant (P = 9.3x10-5–5.0x10-3; unpaired two-tailed t-test) except for mESCs (WT01, 
J1) and liver (P = 0.081, 0.15). 
 
Supplementary Figure 4. Schematic representation of isotope tracing experiments with [13C,15N2]-T (left; blue) 
and [13C,D3]-methionine (right; red) and exchange rates of derived genomic isotopologues. Small negligible 
deviations in the exchange rates are due to differential noise sources. LOD = limit of detection. wt = wild type 
mESCs; Tdg cm = Tdg /  mESCs complemented with catalytic inactive Tdg (see Supplementary Fig. 6). 
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Supplementary Figure 5. (a) Effect of Smug1 depletion on modification levels in mESCs (R1). Effect of SMUG1 
(b) and TDG (c) depletion on modification levels in HEK-293T cells overexpressing Tet1cd. Shown is the percent 
change in modification content per nucleoside in cells co-transfected with esiRNAs targeting TDG or SMUG1 
relative to co-transfection with control esiRNA. Depicted are technical mean values ± SD. 
 
Supplementary Figure 6. Isotope tracing experiments with Tdg+/-, Tdg-/- mESCs as well as Tdg-/- mESCs 
complemented with a catalytic mutant of Tdg (Tdg cm) grown in the presence of [13C,D3]-methionine (200 µM). 
The catalytic mutant of Tdg is not completely inactive (fC levels are between Tdg +/- and Tdg -/- cells, left). Only 
in case of Tdg-/- cells complemented with a catalytic inactive Tdg (Tdg cm) labeled hmU was detected, which 
originated from the deamination of labeled hmC. ~7% [13C,D2]-hmU over total hmU was observed. This 
corresponds to ~0.06% deamination of hmC to hmU under these conditions (2.5x10-4 total hmC / N; 2.2x10-6 total 
hmU / N). Labeled fU was not observed. Depicted fC-levels represent technical mean values ±SD. 
 
Supplementary Figure 7. Tet1 and Tet2 generate hmU in HEK-293T and in vitro (a) Effect of Tet1 
overexpression on modified pyrimidines in HEK-293T cells. Modification levels in cells overexpressing wt and 
catalytic mutant versions of Tet1 catalytic domain (Tet1cd, blue bars and Tet1cm, gray bars, respectively), or a 
control construct (white bars). Depicted are mean values ±SD of technical triplicates on a logarithmic scale. (b) 
Pyrimidine modification levels in methylated plasmid DNA after treatment in vitro with Tet1cd. Depicted are 
mean values ±SD of technical duplicates. Note the logarithmic scale. 
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Supplementary Figure 8. Exponential models for fitting the decay curve of fC, caC and hmU in combined data 
sets from differentiation of R1 and C57Bl6/129-derived mESCs (6 biological independent experiments). In a 
simplified approach a single exponential decay model (y = y0 + A*exp(-x/t0)) was plotted using ORIGIN®. The 
parameters y0 (offset), t0 (time constant) and A (amplitude) of each decay function were iteratively optimized until 
the minimum of the Chi2 value of the fitting was reached. Half-life times (t1/2= t0*ln2) for fC, caC and hmU were 
7.2±1.2, 5.1±1.1 and 4.1 h, respectively. 
 
Supplementary Figure 9. Normalized transcript levels of Dnmts (c), Tet1–3 (d) and normalized modification 
levels of mC (c), hmC, fC and hmU (d) during differentiation of naïve mESCs in the presence of FGF-2 and ActA.  
 
 
Supplementary Figure 10. Expression level analysis of Tdg and Smug1 during differentiation of mESCs in the 
presence of FGF-2 and ActA. Expression levels were quantified with respect to the housekeeping gene Gapdh and 
normalized to time point 0 h. Depicted are technical mean values ± SD. 
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Supplementary Figure 11. (a) Scatterplot of proteins enriched with the hmU:A containing oligomer. Ratios of a 
forward and a reverse experiment are plotted. Specific readers in the forward and reverse experiment are marked 
in blue. Direct-specific readers are identified by the presence of the DNA-protein cross linker and marked in red. 
Gray dots are considered unspecific binders. See Fig. 6 for detailed view. (b) Gene Ontology Analysis performed 
with DAVID Bioinformatics Resources 6.74 
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Supplementary Figure 12. Effect on modified pyrimidines in HEK-293T cells upon Tet1cd and Uhrf1 (light gray 
bars) or Uhrf2 (gray bars) co-overexpression. Depicted are mean values ±SD of technical triplicates on a 
logarithmic scale. 
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Supplementary Table 1. Isotope tracing experiments by supplementing the growth medium of mES cells (LIF), 
differentiating mESCs (R1, without growth factors) and HEK-293T cells with either [13C,15N2]-T (50 or 100 µM) 
or [13C,D3]-methionine (0.2 mM). Small deviations in the exchange yields are due to differential noise sources and 
are negligible. LOD = Limit of detection. In case of [13C,D1]-fU no difference was observed compared to the 
natural control. 
cell type growth medium [
13C,15N2]-T /
T [%] 
[13C,15N2]-hmU /
hmU [%] 
[13C,15N2]-fU / 
fU [%]  
mESC (2i) 100 µM natural T 0.1 < LOD < LOD  
mESC (2i) 100 µM [13C,15N2]-T 76.0 78.2 74.6  
HEK + Tet1cd (72h) 50 µM [13C,15N2]-T 73.8 74.2 71.0  
      
cell type growth medium [
13C,D3]-mC /
mC [%] 
[13C,D2]-hmC / 
hmC [%] 
[13C,D2]-hmU / 
hmU [%] 
[13C,D1]-fU /
fU [%] 
mESC (LIF) natural methionine 0.1 < LOD < LOD 3.3 
mESC (LIF; 0 h) [13C,D3]-methionine 88.9 87.6 < LOD 3.0 
diff. mESC (12 h) [13C,D3]-methionine 89.3 88.4 < LOD 3.1 
diff. mESC (24 h) [13C,D3]-methionine 90.1 89.3 < LOD 3.2 
diff. mESC (48 h) [13C,D3]-methionine 90.4 90.5 < LOD 3.5 
mESC Tdg+/- [13C,D3]-methionine 88.0 87.6 < LOD 3.7 
mESC Tdg-/- [13C,D3]-methionine 87.4 87.2 < LOD < LOD 
mESC Tdg-/- + Tdg cm [13C,D3]-methionine 86.9 86.7 7.4 2.2 
HEK + Tet1cd (72h) [13C,D3]-methionine 87.4 83.4 < LOD < LOD 
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Supplementary Table 2. Assessment of ROS dependent hmU and fU product ratio of T-oxidation in HEK-293T 
wild type cells where TET activity is lowest (related to Fig. 3c). Modified nucleosides / N are given as mean values 
plus SD of three independent technical replicates. When T is oxidized by ROS about 9.8% hmU and 90.2% fU is 
generated. 
n 
mC / N hmC / N fC / N caC / N  
techn. 
mean SD 
techn. 
mean SD 
techn. 
mean SD 
techn. 
mean  
1 6.14E-03 1.97E-04 2.92E-05 9.90E-08 2.56E-07 2.59E-09 n.d.  
2 6.21E-03 1.32E-05 2.95E-05 2.21E-09 3.10E-07 2.06E-08 n.d.  
3 5.76E-03 4.36E-05 3.32E-05 6.55E-07 2.86E-07 2.95E-09 n.d.  
4 9.01E-03 2.87E-04 5.23E-05 5.01E-07 3.50E-07 5.00E-09 n.d.  
5 8.80E-03 9.62E-05 3.39E-05 5.44E-07 2.43E-07 2.41E-09 n.d.  
6 8.55E-03 7.69E-05 3.70E-05 2.17E-07 2.14E-07 1.30E-08 n.d.  
biol. mean 7.41E-03  3.59E-05  2.76E-07    
biol. SD 1.52E-03  8.56E-06  4.90E-08    
         
n 
hmU / N fU / N hmU/ (hmU+fU) 
fU/ 
(hmU+fU) 8-oxo-G / N 
techn. 
mean SD 
techn. 
mean SD [%] [%] 
techn. 
mean SD 
1 2.66E-07 5.54E-08 5.15E-06 1.59E-07 4.9 95.1 8.49E-06 1.30E-07 
2 1.21E-06 1.62E-07 8.02E-06 6.66E-07 13.1 86.9 1.00E-05 1.98E-07 
3 3.65E-08 7.35E-09 9.76E-07 8.75E-09 3.6 96.4 3.02E-06 7.02E-08 
4 6.31E-07 9.10E-10 3.51E-06 3.28E-08 15.3 84.7 7.43E-06 1.34E-07 
5 7.21E-07 5.93E-08 4.89E-06 1.59E-07 12.8 87.2 1.06E-05 1.14E-07 
6 3.58E-07 4.95E-08 3.56E-06 9.64E-09 9.1 90.9 7.22E-06 1.15E-08 
biol. mean 5.37E-07  4.35E-06  9.8 90.2 7.80E-06  
biol. SD 4.13E-07  2.33E-06  4.8 4.8 2.70E-06  
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Supplementary Note 1: oligonucleotide sequences for protein pull-down 
assays 
Supplementary Table 3. DNA oligonucleotides used in protein pull-down studies. 
ODN Sequence (5´ 3´) Modifications 
1 Biotin-GCA-TCC-GGT-CAY-CGT-TCC-TTC-GGA Y = 5-octadienyl-U 
2 Biotin-GCA-TCC-GGT-CAY-CAT-TCC-TTC-GGA Y = 5-octadienyl-U 
3 
TCC-GAA-GGA-AXG-ATG-ACC-GGA-TGC 
X= T 
4 X= hmU 
5 X= C 
6 X= hmC 
7 Biotin-GCT-CAC-GCT-AGY-CGA-CTC-CGT-GCA Y = 5-octadienyl-U 
8 TGC-ACG-GAG-TXG-ACT-AGC-GTG-AGC X = T 
9 Y = hmU 
 
Hybridization scheme: 
Pull-down 1: hmU:A vs. T:A : ODN4/2 vs. ODN3/2 
Pull-down 2: hmU:G vs. C:G = ODN4/1 vs. ODN5/1 
Pull-down 3: hmC:G vs. C:G = ODN6/1 vs. ODN5/1 
Pull-down 4 (scrambled sequence): hmU:A vs. T:A = ODN9/7 vs. ODN8/7 
 
Supplementary Note 2: LC-UV-ESI-MS/MS analysis of DNA 
Supplementary Table 4. Compound-dependent LC-MS/MS-parameters used for the analysis of genomic DNA. 
CE: collision energy; CAV: collision cell accelerator voltage; EMV: electron multiplier voltage. The nucleosides 
were analyzed in the positive ([M+H]+ species) as well as in the negative ([M-H]- species) ion selected reaction 
monitoring mode (SRM). 
compound Precursor Ion (m/z) 
MS1 
Resolution 
Product 
Ion (m/z) 
MS2 
Resolution 
Dwell 
time 
[ms] 
CE 
(V) 
CAV 
(V) Polarity 
time segment 1.5–4.0 min 
[15N2]-caC 274.08 Wide 158.03 Wide 170 5 5 Positive 
caC 272.09 Wide 156.04 Wide 170 5 5 Positive 
[15N2,D2]-hmC 262.12 enhanced 146.07 enhanced 40 27 1 Positive 
hmC 258.11 enhanced 142.06 enhanced 40 27 1 Positive 
[D3]-mC 245.13 enhanced 129.09 enhanced 30 60 1 Positive 
mC 242.11 enhanced 126.07 enhanced 30 60 1 Positive 
C 228.1 enhanced 112.05 enhanced 1 1 0 Positive 
time segment 4.0–6.0 min 
[D2]-hmU 259.09 Wide 216.08 Wide 48 7 5 Negative 
[D2]-hmU 259.09 Wide 126.05 Wide 48 7 5 Negative 
hmU 257.08 Wide 214.07 Wide 48 7 5 Negative 
hmU 257.08 Wide 124.04 Wide 48 7 5 Negative 
[15N2]-fU 257.06 Wide 213.05 Wide 48 6 5 Negative 
fU 255.06 Wide 212.06 Wide 48 6 5 Negative 
time segment 6.0–9.0 min 
[15N5]-8-oxo-G 289.08 Wide 173.04 Wide 120 9 7 Positive 
8-oxo-G 284.1 Wide 168.05 Wide 120 9 7 Positive 
[15N2]-fC 258.09 Wide 142.04 Wide 120 5 5 Positive 
fC 256.09 Wide 140.05 Wide 120 5 5 Positive 
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Supplementary Table 5. Compound-dependent LC-MS/MS-parameters used for the analysis of genomic DNA 
obtained from cells which were grown in medium supplemented with labeled thymidine ([13C,15N2]-T). CE: 
collision energy; CAV: collision cell accelerator voltage; EMV: electron multiplier voltage. The nucleosides were 
analyzed in the positive ([M+H]+ species) as well as in the negative ([M-H]- species) ion selected reaction 
monitoring mode (SRM). 
compound Precursor Ion (m/z) 
MS1 
Resolution 
Product 
Ion (m/z) MS2 Resolution 
Dwell 
time 
[ms] 
CE 
(V) 
CAV 
(V) Polarity 
time segment 1.5–4.0 min 
[13C,15N2]-caC 275.09 wide 159.04 wide 65 5 5 Positive 
caC 272.09 wide 156.04 wide 65 5 5 Positive 
[13C,15N2]-hmC 261.11 enhanced 145.06 enhanced 40 27 1 Positive 
hmC 258.11 enhanced 142.06 enhanced 40 27 1 Positive 
[13C,15N2]-mC 245.13 enhanced 129.09 enhanced 30 60 1 Positive 
mC 242.11 enhanced 126.07 enhanced 30 60 1 Positive 
[13C,15N2]-C 231.1 enhanced 115.05 enhanced 40 1 3 Positive 
C 228.1 enhanced 112.1 enhanced 40 1 3 Positive 
time segment 4.0–6.0 min 
[13C,15N2]-hmU 260.08 wide 215.07 wide 50 7 5 Negative 
hmU 257.08 wide 214.07 wide 50 7 5 Negative 
[13C,15N2]-fU 258.06 wide 213.05 wide 50 6 5 Negative 
fU 255.06 wide 212.06 wide 50 6 5 Negative 
time segment 6.0–9.0 min 
[15N5]-8-oxo-G 289.08 wide 173.04 wide 80 9 7 Positive 
8-oxo-G 284.1 wide 168.05 wide 80 9 7 Positive 
[13C,15N2]-fC 259.09 wide 143.04 wide 80 5 5 Positive 
fC 256.09 wide 140.05 wide 80 5 5 Positive 
[13C,15N2]-T 246.1 enhanced 130.05 enhanced 30 40 3 Positive 
T 243.1 enhanced 127.05 enhanced 30 40 3 Positive 
 
Supplementary Table 6. Compound-dependent LC-MS/MS-parameters used for the analysis of genomic DNA 
obtained from cells which were grown in medium supplemented with labeled (methyl-13C,D3)-methionine.CE: 
collision energy; CAV: collision cell accelerator voltage; EMV: electron multiplier voltage. The nucleosides were 
analyzed in the positive ([M+H]+ species) as well as in the negative ([M-H]- species) ion selected reaction 
monitoring mode (SRM). 
compound Precursor Ion (m/z) 
MS1 
Resolution 
Product 
Ion (m/z) MS2 Resolution 
Dwell 
time 
[ms] 
CE 
(V) 
CAV 
(V) Polarity 
time segment 1.5–4.0 min 
[13C]-caC 273.09 wide 157.04 wide 65 5 5 Positive 
caC 272.09 wide 156.04 wide 65 5 5 Positive 
[13C,D2]-hmC 261.12 enhanced 145.08 enhanced 40 27 1 Positive 
hmC 258.11 enhanced 142.06 enhanced 40 27 1 Positive 
[13C,D3]-mC 246.14 enhanced 130.09 enhanced 30 60 1 Positive 
mC 242.11 enhanced 126.07 enhanced 30 60 1 Positive 
C-dN 228.1 enhanced 112.1 enhanced 40 1 3 Positive 
time segment 4.0–6.0 min 
[13C,D2]-hmU 260.09 wide 217.09 wide 60 7 5 Negative 
hmU 257.08 wide 214.07 wide 60 7 5 Negative 
[13C,D]-fU 257.07 wide 214.07 wide 60 6 5 Negative 
fU 255.06 wide 212.06 wide 60 6 5 Negative 
time segment 6.0–9.0 min 
[15N5]-8-oxo-G 289.08 wide 173.04 wide 80 9 7 Positive 
8-oxo-G 284.1 wide 168.05 wide 80 9 7 Positive 
[13C,D]-fC 258.1 wide 142.06 wide 80 5 5 Positive 
fC 256.09 wide 140.05 wide 80 5 5 Positive 
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Spiking amounts of labeled internal standards for quantitative LC-MS/MS analysis 
The quantification of nucleosides of genomic DNA isolated from mESC or mouse tissue was carried 
out with the following amounts of internal standards: 51.03 pmol [D3]-mC, 7.655 pmol [15N2,D2]-hmC, 
45.6 fmol [15N2]-fC, 43.0 fmol [15N2]-caC, 108.9 fmol [15N5]-8-oxo-G; 160.1 fmol [D2]-hmU and 
180.0 fmol [15N2]-fU. The quantification of nucleosides of genomic DNA isolated from HEK293 cells 
overexpressing Tet was carried out with the following amounts of internal standards: 34.02 pmol [D3]-
mC, 5.103 pmol [15N2,D2]-hmC, 303.8 fmol [15N2]-fC, 215.1 fmol [15N2]-caC, 108.9 fmol [15N5]-8-oxo-
G; 160.1 fmol [D2]-hmU and 180.0 fmol [15N2]-fU. Genomic DNA samples isolated from cells grown 
in media supplemented with either [13C,15N2]-T or [13C,D3]-methionine were not spiked with internal 
standards except [15N5]-8-oxo-G. 
Validation of the LC-UV-MS/MS quantification method: 
Method validation, in particular linearity, precision, and accuracy (i.e. determined from matrix samples 
spiked with isotopically labeled internal standards) of the established method were investigated. 
Validation for the established LC-UV-ESI-MS/MS quantification method was based on three different 
series (i.e., calibration functions and quality control samples) accomplished on different days. Each 
calibration standard (5-8 standard concentrations) was analyzed five times. Each validation experiment 
was complemented by matrix blanks (analyzed in triplicates) to ensure selectivity and specificity of the 
method. Linear regression was applied by Origin® 6.0 (Microcal™) to obtain calibration curves. 
Therefore, the ratio of the area under the curve (A/A*) of the unlabeled nucleoside to the internal 
standard (*) was plotted against the ratio of the amount of substance (n/n*) of the unlabeled nucleoside 
to the internal standard (*) (see Supplementary Fig. 13). Calibration functions were calculated without 
weighting. Additionally, acceptable accuracy (80–120%) as well as precision (<20% RSD) was 
required. Accuracy was proven by computing the amount of substance n from the obtained A/A* ratios 
of the calibration standards using the respective calibration function. Here, accuracy was defined as the 
ratio of the used amount of substance to the calculated amount of substance in percent and had to be 
between 80–120% for each standard concentration. Precision was defined as follows: technical 
replicates of A/A* ratios for each calibration standard had to have relative standard deviations (RSD) 
smaller than 20%. The lower limit of quantification (LLOQ) was defined as the lowest concentration 
fulfilling the requirements of accuracy and precision and achieving a response of at least three times the 
response compared with the blank response. A compilation of absolute and relative LLOQs is shown in 
Supplementary Table 7. 
Quality control samples to evaluate intra-batch precision (see below) were investigated using a 
biological sample spiked with internal standards. Long-term stability of aqueous solutions of the labeled 
and unlabeled nucleosides at a storage temperature of −20 °C was investigated over two months 
including several freeze and thaw cycles by analyzing the MS/MS-responses with each batch. 
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Supplementary Table 7. Compilation of absolute lower limits of quantification [fmol] (LLOQ; see 
Supplementary Fig. 13) and relative LLOQs [per N] depending on the amount of DNA, which is digested. The 
relative LLOQs were computed by generating ratios of the absolute LLOQ [pmol] to the total amount of 
nucleosides (N; [pmol]) in the respective amount of DNA [µg]. The total amount of nucleosides was obtained by 
using the average molar mass of 308.91 g mol-1 for the monomeric DNA entity by taking the GC-content (21% C 
or G) in mouse into account. 
 
absolute
LLOQ  
[fmol] 
relative
LLOQ  
[per N] 
relative
LLOQ  
[per N] 
relative
LLOQ  
[per N] 
DNA amount  5 µg 10 µg 25 µg 
mC 104.5 6.5E-06 3.2E-06 1.3E-06 
hmC 100.8 6.2E-06 3.1E-06 1.2E-06 
fC 2.1 1.3E-07 6.5E-08 2.6E-08 
caC 2.0 1.2E-07 6.2E-08 2.5E-08 
8-oxo-G 2.0 1.2E-07 6.2E-08 2.5E-08 
dU 14.1 8.7E-07 4.4E-07 1.7E-07 
hmU 6.4 4.0E-07 2.0E-07 7.9E-08 
fU 5.7 3.5E-07 1.8E-07 7.0E-08 
 
 
Intra-batch assay and quantification data processing: 
In order to evaluate intra-batch precision (see below) quality samples were investigated using a 
biological sample spiked with internal standards. The intra-batch-assay was performed for the LC-ESI-
MS/MS analysis of the nucleosides G, C, mC, hmC, fC, caC, hmU, fU and 8-oxo-G. For this, a 
representative mESC DNA sample was analyzed. Technical replicates (n=5; each 4 µg DNA) were 
independently prepared using the below described digestion protocol. For data processing MassHunter 
Quantitative Analysis from Agilent was used. The area under the curve (A) was determined by LC-
MS/MS for mC, hmC, fC, caC, hmU, fU, 8-oxo-G and for the corresponding labeled internal standards 
(A*); the area under the curve (AUV) for G and C was determined by LC-UV. The amount of substance 
(n; pmol) of each nucleoside was computed by using the calibration curves (see Supplementary Fig. 
13). The total sample volume was 40 µL, the injection volume after sample filtration was 29 µL. 
Therefore, the obtained values of G and C by LC-UV quantification were corrected by the factor given 
by the ratio of 40 µL/29 µL. Careful monitoring of the exact pipetting and injection volumes was 
therefore necessary. The obtained absolute amounts (pmol) of the DNA modifications (X= C, mC, fC, 
caC, hmU, fU, 8-oxo-G) were then related to the amount of G (pmol) giving ratios of X / G in %. The 
sum of X / G was defined as 100%. These values were then transferred in X / N values, considering that 
the G content is 21% in mouse.  
The determined A/A* ratios of the DNA nucleosides to the labeled internal standards (see 
Supplementary Table 8) showed a high precision (RSD = 3.9-18%) for each nucleoside. The necessity 
in using labeled internal standards for quantification is shown by comparing these results with the 
relative standard deviation (RSD = 7.6-49.5%) of the uncorrected mass signal (A) of the respective DNA 
modification. Moreover, in order to gain precision between sample batches measured on different days 
(data not shown), it is even more important to use internal standards. No memory effect was observed 
during blank experiments performed after several measurements of a sample. The blank analyses were 
not contaminated by carry-over. 
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Supplementary Figure 13. UV and LC-MS/MS calibration curves and representative chromatograms of C (UV), 
G (UV), mC/[D3]-mC, hmC/[15N2,D2]-hmC, fC/[15N2]-fC, caC/[15N2]-caC, 8-oxo-G/[15N5]8-oxo-G, U/[15N2]-U, 
hmU/[D2]-hmU, fU/[15N2]-fU. These were obtained by applying the compound-dependent parameters summarized 
in Supplementary Table 4. For hmU the MS/MS transition 257→214 was used. Depicted are the means of five 
technical replicates of one sample batch. Error bars reflect SD. Linearity was given across the following compound 
amounts in 29 µL injection volume: 10.63–7751 pmol C; 19.11–4892 pmol G; 104.5 fmol–228.6 pmol mC; 
100.8 fmol–73.45 pmol hmC; 2.1–515.0 fmol fC; 2.0–496.6 fmol caC; 2.0–475.7 fmol 8-oxo-G; 6.4–519.3 fmol 
hmU; 5.7–459.6 fmol fU. The amounts of the labeled internal standards in 29 µL injection volume were as follows: 
51.03 pmol [D3]-mC; 7.655 pmol [15N2,D2]-hmC; 45.6 fmol [15N2]-fC; 43.0 fmol [15N2]-caC; 108.9 fmol [15N5]-8-
oxo-G; 96.1 fmol [D2]-hmU; 135.0 fmol [15N2]-fU. 
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Supplementary Table 8. Intra-batch-assay and quantification data processing. 
 AUV(G) n(G) [pmol] AUV(C) n(C) [pmol] C / G [%] C / N 
techn. replicate 1 956 2431 485 2341 96.3 2.02E-01 
techn. replicate 2 980 2493 495 2391 95.9 2.01E-01 
techn. replicate 3 1043 2654 531 2566 96.7 2.03E-01 
techn. replicate 4 979 2492 498 2406 96.5 2.03E-01 
techn. replicate 5 982 2498 498 2406 96.3 2.02E-01 
techn. mean value 988 2513 501 2422 96.4 2.02E-01 
SD 33 83 18 85 0.3 6.29E-04 
RSD [%] 3.3 3.3 3.5 3.5 0.3 0.3 
       
 A(mC) A([D3]-mC) A(mC)/ A([D3]-mC n(mC) [pmol] mC / G [%] mC / N 
techn. replicate 1 636358 510501 1.247 91.9 3.78 7.94E-03 
techn. replicate 2 678284 512180 1.324 97.7 3.92 8.23E-03 
techn. replicate 3 565889 447103 1.266 93.4 3.52 7.39E-03 
techn. replicate 4 664238 546597 1.215 89.6 3.60 7.56E-03 
techn. replicate 5 719777 570445 1.262 93.1 3.73 7.82E-03 
techn. mean value 652909 517365 1.263 93.1 3.71 7.79E-03 
SD 57206 46591 0.040 2.9 0.16 3.30E-04 
RSD [%] 8.8 9.0 3.1 3.1 4.2 4.2 
       
 A(hmC) A([D2,15N2]-hmC) 
A(hmC)/ 
A([D2,15N2]-
hmC) 
n(hmC) [pmol] hmC / G [%] hmC / N 
techn. replicate 1 80754 84338 0.958 8.51 0.350 7.35E-04 
techn. replicate 2 115869 108774 1.065 9.46 0.380 7.97E-04 
techn. replicate 3 264594 269496 0.982 8.72 0.329 6.90E-04 
techn. replicate 4 139093 133830 1.039 9.23 0.371 7.78E-04 
techn. replicate 5 116163 106074 1.095 9.73 0.389 8.18E-04 
techn. mean value 143295 140502 1.028 9.13 0.364 7.64E-04 
SD 70941 74213 0.057 0.51 0.024 5.12E-05 
RSD [%] 49.5 52.8 5.6 5.6 6.7 6.7 
       
 A(fC) A([15N2]-fC) A(fC)/ A([15N2]-fC) n(fC) [pmol] fC / G [%] fC / N 
techn. replicate 1 163427 31747 5.148 0.199 8.18E-03 1.72E-05 
techn. replicate 2 178366 32585 5.474 0.211 8.48E-03 1.78E-05 
techn. replicate 3 196827 35504 5.544 0.214 8.07E-03 1.69E-05 
techn. replicate 4 193392 33755 5.729 0.221 8.88E-03 1.86E-05 
techn. replicate 5 193493 35959 5.381 0.208 8.32E-03 1.75E-05 
techn. mean value 185101 33910 5.455 0.211 8.38E-03 1.76E-05 
SD 14070 1816 0.214 0.008 3.17E-04 6.66E-07 
RSD [%] 7.6 5.4 3.9 3.9 3.8 3.8 
 A(caC) A([15N2]-caC) A(caC)/ A([15N2]-caC) n(caC) [pmol] caC / G [%] caC / N 
techn. replicate 1 1444 6666 0.217 0.0104 4.28E-04 8.99E-07 
techn. replicate 2 1735 8205 0.211 0.0102 4.08E-04 8.57E-07 
techn. replicate 3 2111 9709 0.217 0.0104 3.93E-04 8.26E-07 
techn. replicate 4 1985 8301 0.239 0.0114 4.59E-04 9.63E-07 
techn. replicate 5 1927 8581 0.225 0.0108 4.31E-04 9.05E-07 
techn. mean value 1840 8292 0.222 0.0106 4.24E-04 8.90E-07 
SD 260 1089 0.011 0.0005 2.48E-05 5.20E-08 
RSD [%] 14.1 13.1 4.8 4.6 5.8 5.8 
       
 A(hmU) A([D2]-hmU) A(hmU)/ A([D2]-hmU) n(hmU) [pmol] hmU / G [%] hmU / N 
techn. replicate 1 894 5799 0.154 0.0090 3.69E-04 7.74E-07 
techn. replicate 2 1278 6368 0.201 0.0130 5.23E-04 1.10E-06 
techn. replicate 3 1561 7679 0.203 0.0133 5.00E-04 1.05E-06 
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techn. replicate 4 1695 8148 0.208 0.0137 5.49E-04 1.15E-06 
techn. replicate 5 1236 9010 0.137 0.0075 3.00E-04 6.29E-07 
techn. mean value 1333 7401 0.181 0.0113 4.48E-04 9.41E-07 
SD 312 1309 0.033 0.0029 1.08E-04 2.27E-07 
RSD [%] 23.4 17.7 18.1 25.3 24.2 24.2 
       
 A(fU) A([15N2]-fU) A(fU)/ A([15N2]-fU) n(fU) [pmol] fU / G [%] fU / N 
techn. replicate 1 7527 19661 0.383 0.0553 2.27E-03 4.78E-06 
techn. replicate 2 8672 22769 0.381 0.0550 2.21E-03 4.63E-06 
techn. replicate 3 11884 23930 0.497 0.0711 2.68E-03 5.63E-06 
techn. replicate 4 10143 27784 0.365 0.0528 2.12E-03 4.45E-06 
techn. replicate 5 14349 30152 0.476 0.0682 2.73E-03 5.73E-06 
techn. mean value 10515 24859 0.420 0.0605 2.40E-03 5.04E-06 
SD 2695 4148 0.061 0.0085 2.82E-04 5.93E-07 
RSD [%] 25.6 16.7 14.5 14.0 11.7 11.7 
       
 A(8oxo-G) A([15N5]-8oxo-G) 
A(8oxo-G)/
A([15N5]-
8oxo-G) 
n(8oxo-G) [pmol] 8oxo-G / G [%] 8oxoG / N
techn. replicate 1 237655 245919 0.966 0.113 4.63E-03 9.73E-06 
techn. replicate 2 256991 266182 0.965 0.113 4.51E-03 9.48E-06 
techn. replicate 3 310924 294412 1.056 0.123 4.64E-03 9.74E-06 
techn. replicate 4 282245 299479 0.942 0.110 4.41E-03 9.26E-06 
techn. replicate 5 327930 305105 1.075 0.125 5.01E-03 1.05E-05 
techn. mean value 283149 282219 1.001 0.117 4.64E-03 9.75E-06 
SD 37187 25225 0.060 0.007 2.28E-04 4.79E-07 
RSD [%] 13.1 8.9 6.0 6.0 4.9 4.9 
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Supplementary Note 3: LC-MS/MS quantification results of genomic DNA 
Supplementary Table 9. LC-MS/MS quantification results of mESC (WT01, J1 and R1) wild type, knock down 
(KD) and knock out cells (related to Fig. 1c,, 2a and 4a). The results of independent biological replicates are shown, 
the biological mean values / N and the biological standard deviation (SD). n.d. = not detected. 
biol. replicate C / N mC / N hmC / N fC / N caC / N hmU / N fU / N 8-oxo-G / N 
mESC (WT01) 1 2.01E-01 8.08E-03 6.53E-04 9.35E-06 6.01E-07 6.94E-07 3.51E-06 6.75E-06 
mESC (WT01) 2 2.02E-01 7.71E-03 6.41E-04 9.81E-06 5.90E-07 7.04E-07 2.52E-06 5.95E-06 
mESC (WT01) 3 2.02E-01 7.78E-03 6.82E-04 9.26E-06 5.24E-07 4.81E-07 1.60E-06 4.02E-06 
mESC (WT01) 4 2.01E-01 8.17E-03 6.92E-04 1.03E-05 6.44E-07 4.73E-07 2.17E-06 4.90E-06 
mESC (WT01) 5 2.02E-01 6.72E-03 8.63E-04 1.36E-05 7.25E-07 3.83E-07 4.34E-06 5.76E-06 
mESC (WT01) 6 2.03E-01 6.43E-03 7.70E-04 1.32E-05 3.81E-07 5.14E-07 1.30E-06 3.17E-06 
mESC (WT01) 7 2.03E-01 6.10E-03 8.18E-04 1.08E-05 6.77E-07 4.78E-07 1.03E-06 3.47E-06 
biol. mean value 2.02E-01 7.28E-03 7.31E-04 1.09E-05 5.92E-07 5.32E-07 2.35E-06 4.86E-06 
SD 7.75E-04 8.48E-04 8.63E-05 1.81E-06 1.13E-07 1.21E-07 1.21E-06 1.36E-06 
 
biol. replicate C / N mC / N hmC / N fC / N caC / N hmU / N fU / N 8-oxo-G / N 
Tet1 KD  (WT01) 1 2.01E-01 8.99E-03 2.76E-04 3.31E-06 2.21E-07 1.42E-07 7.98E-07 3.21E-06 
Tet1 KD  (WT01) 2 2.02E-01 7.77E-03 1.39E-04 2.53E-06 2.20E-07 6.44E-08 2.00E-06 3.73E-06 
Tet1 KD  (WT01) 3 2.03E-01 6.37E-03 2.36E-04 6.51E-06 2.07E-07 3.07E-07 4.13E-06 7.08E-06 
biol. mean value 2.02E-01 7.71E-03 2.17E-04 4.11E-06 2.16E-07 1.71E-07 2.31E-06 4.67E-06 
SD 1.33E-03 1.31E-03 7.03E-05 2.11E-06 7.87E-09 1.24E-07 1.69E-06 2.10E-06 
 
biol. replicate C / N mC / N hmC / N fC / N caC / N hmU / N fU / N 8-oxo-G / N 
Tet2 KD (WT01) 1 2.00E-01 9.41E-03 4.45E-04 6.12E-06 2.38E-07 9.51E-08 5.18E-07 2.82E-06 
Tet2 KD (WT01) 2 2.02E-01 7.25E-03 3.38E-04 4.52E-06 9.02E-08 3.23E-07 6.01E-07 1.78E-06 
Tet2 KD (WT01) 3 2.02E-01 7.36E-03 3.98E-04 6.25E-06 3.36E-07 1.21E-07 2.50E-06 5.21E-06 
Tet2 KD (WT01) 4 2.02E-01 7.69E-03 3.90E-04 6.78E-06 3.37E-07 n.d. 1.16E-06 6.52E-06 
biol. mean value 2.02E-01 7.93E-03 3.93E-04 5.92E-06 2.50E-07 1.80E-07 1.20E-06 4.08E-06 
SD 1.04E-03 1.01E-03 4.36E-05 9.73E-07 1.16E-07 1.25E-07 9.16E-07 2.17E-06 
 
biol. replicate C / N mC / N hmC / N fC / N caC / N hmU / N fU / N 8-oxo-G / N 
mESC (J1) 1 2.04E-01 5.53E-03 3.61E-04 2.18E-06 7.95E-07 1.48E-06 3.98E-06 6.68E-06 
mESC (J1) 2 2.04E-01 5.63E-03 3.32E-04 2.17E-06 9.30E-07 1.41E-06 4.19E-06 6.64E-06 
biol. mean value 2.04E-01 5.58E-03 3.47E-04 2.17E-06 8.62E-07 1.44E-06 4.08E-06 6.66E-06 
SD 4.96E-05 6.97E-05 2.06E-05 8.94E-09 9.55E-08 4.91E-08 1.51E-07 2.93E-08 
 
biol. replicate C / N mC / N hmC / N fC / N caC / N hmU / N fU / N 8-oxo-G / N 
DNMT1 -/- (J1) 1 2.07E-01 2.72E-03 1.80E-04 1.36E-06 3.10E-07 1.68E-06 4.56E-06 7.22E-06 
DNMT1 -/- (J1) 2 2.07E-01 2.71E-03 1.77E-04 1.55E-06 2.94E-07 1.56E-06 3.90E-06 6.73E-06 
biol. mean value 2.07E-01 2.72E-03 1.79E-04 1.46E-06 3.02E-07 1.62E-06 4.23E-06 6.97E-06 
SD 5.80E-06 3.35E-06 2.28E-06 1.31E-07 1.11E-08 8.47E-08 4.73E-07 3.45E-07 
 
biol. replicate C / N mC / N hmC / N fC / N caC / N hmU / N fU / N 8-oxo-G / N 
DNMT3ab -/- (J1) 1 2.10E-01 4.12E-04 3.01E-05 2.46E-07 n.d. 8.02E-07 6.25E-07 2.68E-06 
DNMT3ab -/- (J1) 2 2.10E-01 3.76E-04 3.54E-05 5.67E-07 n.d. 2.60E-06 7.86E-07 5.73E-06 
DNMT3ab -/- (J1) 3 2.10E-01 3.81E-04 3.03E-05 3.71E-07 n.d. 2.27E-06 3.94E-07 2.32E-06 
DNMT3ab -/- (J1) 4 2.10E-01 2.67E-04 2.67E-05 4.52E-07 n.d. 1.71E-06 4.50E-07 1.79E-06 
DNMT3ab -/- (J1) 5 2.10E-01 2.50E-04 1.07E-05 3.78E-07 n.d. 7.41E-07 4.51E-06 7.68E-06 
DNMT3ab -/- (J1) 6 2.10E-01 2.32E-04 1.60E-05 2.64E-07 n.d. 5.28E-07 2.87E-06 5.50E-06 
biol. mean value 2.10E-01 3.20E-04 2.48E-05 3.80E-07  1.44E-06 1.61E-06 4.28E-06 
SD 9.60E-05 7.83E-05 9.51E-06 1.19E-07  8.76E-07 1.70E-06 2.35E-06 
 
biol. replicate C / N mC / N hmC / N fC / N caC / N hmU / N fU / N 8-oxo-G / N 
mESC (R1) 1 2.01E-01 8.37E-03 2.00E-04 1.04E-06 n.d. 1.52E-06 2.56E-06 1.21E-05 
mESC (R1) 2 2.03E-01 6.76E-03 3.30E-04 2.00E-06 3.03E-07 9.23E-07 1.20E-06 n.d. 
mESC (R1) 3 2.01E-01 8.68E-03 2.70E-04 2.12E-06 n.d. 1.77E-06 4.67E-06 1.05E-05 
biol. mean value 2.02E-01 7.94E-03 2.67E-04 1.72E-06 3.03E-07 1.40E-06 2.81E-06 8.42E-06 
SD 9.92E-04 1.03E-03 6.52E-05 5.91E-07  4.35E-07 1.75E-06 5.00E-06 
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Supplementary Table 10. LC-MS/MS quantification results of different murine organs of 3 months old wild type 
individuals (n) (related to Fig. 1d, 2 and Supplementary Fig. 2). Compiled are mean values / N obtained from three 
independent technical replicates and the standard deviation (SD).  
n organ DNA isolation C / N mC / N hmC / N fC / N 
      techn. mean SD 
techn. 
mean SD 
techn. 
mean SD 
techn. 
mean SD 
1 cerebellum   2.01E-01 2.30E-04 8.06E-03 2.40E-04 6.59E-04 1.08E-05 3.45E-07 3.14E-08 
1 cerebellum BHT, + Desf., 2.01E-01 2.67E-04 8.27E-03 2.59E-04 7.37E-04 1.76E-05 2.86E-07 1.30E-08 
1 cerebellum BHT, + Desf., +THU 2.01E-01 3.66E-04 8.52E-03 3.45E-04 7.29E-04 2.14E-05 2.97E-07 2.03E-08 
2 cerebellum BHT, + Desf., +THU 2.00E-01 3.92E-04 9.81E-03 2.80E-04 6.37E-04 4.00E-05 2.73E-07 1.16E-08 
3 cerebellum BHT, + Desf., +THU 2.00E-01 3.95E-04 8.95E-03 3.45E-04 6.90E-04 2.91E-05 2.61E-07 1.57E-08 
4 cerebellum BHT, + Desf., +THU 2.00E-01 4.55E-04 9.46E-03 3.60E-04 6.69E-04 2.45E-05 2.59E-07 3.89E-09 
                      
1 kidney   2.01E-01 1.72E-04 8.13E-03 1.59E-04 4.37E-04 2.79E-05 2.27E-07 1.10E-08 
1 kidney BHT, + Desf. 2.02E-01 3.38E-04 7.79E-03 3.29E-04 4.33E-04 8.84E-06 2.25E-07 2.75E-08 
1 kidney BHT, + Desf., +THU 2.02E-01 1.70E-04 7.71E-03 1.76E-04 4.27E-04 2.15E-05 2.11E-07 1.19E-08 
2 kidney BHT, + Desf., +THU 2.01E-01 4.44E-04 8.59E-03 3.75E-04 3.78E-04 1.35E-05 1.86E-07 1.43E-08 
3 kidney BHT, + Desf., +THU 2.01E-01 1.46E-04 8.20E-03 1.02E-04 3.73E-04 1.67E-05 1.88E-07 8.82E-09 
4 kidney BHT, + Desf., +THU 2.01E-01 3.17E-04 8.30E-03 2.45E-04 3.79E-04 2.06E-05 1.94E-07 2.45E-08 
                      
1 cortex BHT, + Desf., +THU 2.00E-01 4.48E-04 9.06E-03 3.37E-04 1.12E-03 7.21E-05 4.09E-07 4.17E-08 
2 cortex BHT, + Desf., +THU 1.99E-01 2.05E-04 9.29E-03 1.48E-04 1.37E-03 2.05E-05 4.34E-07 1.14E-08 
3 cortex BHT, + Desf., +THU 2.00E-01 4.65E-04 9.23E-03 3.73E-04 1.14E-03 7.48E-06 4.24E-07 1.92E-08 
                      
1 hippocampus BHT, + Desf., +THU 1.98E-01 1.88E-04 1.08E-02 2.11E-04 1.56E-03 6.83E-05 4.49E-07 2.82E-08 
2 hippocampus BHT, + Desf., +THU 1.98E-01 2.13E-04 1.08E-02 1.73E-04 1.55E-03 3.08E-05 7.08E-07 4.67E-08 
3 hippocampus BHT, + Desf., +THU 1.97E-01 1.78E-04 1.09E-02 1.44E-04 1.71E-03 2.66E-05 3.89E-07 2.66E-08 
                      
1 heart BHT, + Desf., +THU 2.02E-01 3.25E-04 7.96E-03 2.87E-04 4.08E-04 3.32E-05 1.85E-07 1.66E-08 
2 heart BHT, + Desf., +THU 2.02E-01 1.68E-04 7.87E-03 1.31E-04 3.84E-04 2.30E-05 1.48E-07 2.64E-09 
3 heart BHT, + Desf., +THU 2.01E-01 4.25E-04 8.07E-03 3.42E-04 4.56E-04 4.39E-05 1.41E-07 1.35E-08 
                      
1 liver BHT, + Desf., +THU 2.01E-01 2.32E-04 8.35E-03 1.92E-04 2.44E-04 3.24E-06 1.66E-07 2.23E-08 
2 liver BHT, + Desf., +THU 2.02E-01 3.16E-04 8.10E-03 2.61E-04 2.73E-04 8.57E-06 1.78E-07 2.26E-08 
3 liver BHT, + Desf., +THU 2.01E-01 3.04E-04 8.42E-03 2.39E-04 2.82E-04 3.44E-05 1.81E-07 2.91E-08 
           
n organ DNA isolation hmU / N fU / N 8-oxo-G / N  
      
techn. 
mean SD 
techn. 
mean SD 
techn. 
mean SD   
1 cerebellum   7.27E-08   2.03E-06 2.29E-07 5.09E-06 1.92E-07   
1 cerebellum BHT, + Desf., n.d.   6.89E-07 2.65E-08 2.96E-06 6.04E-08   
1 cerebellum BHT, + Desf., +THU n.d.   8.05E-07 7.34E-08 3.30E-06 3.79E-08   
2 cerebellum BHT, + Desf., +THU 1.30E-07 7.94E-08 1.02E-06 4.83E-08 3.86E-06 2.70E-07   
3 cerebellum BHT, + Desf., +THU 6.01E-08 3.67E-08 9.33E-07 9.52E-08 3.66E-06 2.26E-07   
4 cerebellum BHT, + Desf., +THU 1.07E-07 7.00E-08 1.03E-06 8.63E-08 4.67E-06 5.69E-07   
                    
1 kidney   n.d.   7.58E-07 7.38E-08 3.66E-06 2.63E-07   
1 kidney BHT, + Desf. n.d.   7.00E-07 5.30E-08 3.24E-06 3.73E-07   
1 kidney BHT, + Desf., +THU n.d.   7.16E-07 1.73E-08 3.48E-06 2.63E-07   
2 kidney BHT, + Desf., +THU 1.08E-07 7.89E-08 1.08E-06 1.45E-07 3.73E-06 1.42E-07   
3 kidney BHT, + Desf., +THU 1.29E-07 9.06E-08 1.17E-06 1.67E-07 3.91E-06 5.99E-08   
4 kidney BHT, + Desf., +THU n.d.   9.34E-07 6.36E-08 3.65E-06 1.57E-07   
                    
1 cortex BHT, + Desf., +THU 1.46E-07 6.19E-09 1.28E-06 1.22E-07 2.51E-06 3.74E-08   
2 cortex BHT, + Desf., +THU 8.24E-08 2.81E-08 1.30E-06 7.35E-08 3.13E-06 1.16E-07   
3 cortex BHT, + Desf., +THU 2.05E-07 5.83E-08 1.43E-06 3.72E-08 3.58E-06 2.83E-07   
                    
1 hippocampus BHT, + Desf., +THU 2.74E-07 6.06E-08 2.18E-06 1.29E-07 6.30E-06 2.17E-07   
2 hippocampus BHT, + Desf., +THU 6.00E-07 5.50E-08 3.20E-06 3.46E-07 1.31E-05 7.69E-07   
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3 hippocampus BHT, + Desf., +THU 4.68E-08 1.85E-08 9.85E-07 2.26E-07 5.03E-06 8.96E-08   
                    
1 heart BHT, + Desf., +THU 4.14E-07 7.28E-08 1.97E-06 3.46E-07 7.85E-06 1.69E-06   
2 heart BHT, + Desf., +THU 9.81E-08 4.23E-09 1.15E-06 7.63E-08 2.48E-06 1.18E-07   
3 heart BHT, + Desf., +THU 1.04E-07 3.36E-08 1.55E-06 7.55E-08 3.14E-06 2.27E-07   
                    
1 liver BHT, + Desf., +THU n.d.   1.13E-06 9.97E-08 2.69E-06 3.93E-07   
2 liver BHT, + Desf., +THU 1.48E-07 8.67E-08 1.09E-06 1.96E-07 2.43E-06 9.41E-08   
3 liver BHT, + Desf., +THU 2.34E-08   1.05E-06 1.18E-07 2.39E-06 4.69E-08   
 
Supplementary Table 11. LC-MS/MS quantification results of n = 6 independent mESC differentiation 
experiments without growth factors (related to Fig. 5a,b). Compiled are mean values / N obtained from three 
independent technical measurements and their standard deviation (SD). K = C57Bl6/129 derived mES cell line. 
n Sample C / N mC / N hmC / N fC / N caC / N 
 mESC diff. time 
techn. 
mean SD 
techn. 
mean SD 
techn. 
mean SD 
techn. 
mean SD 
techn. 
mean SD 
1 K, t= 0h 2.06E-01 1.47E-04 3.79E-03 1.52E-04 4.25E-04 8.84E-06 1.68E-05 9.20E-07 1.21E-06 5.80E-08 
1 K, t= 8h 2.06E-01 9.23E-05 3.43E-03 9.96E-05 5.33E-04 1.27E-05 1.71E-05 7.46E-07 1.09E-06 2.97E-08 
1 K, t= 16h 2.06E-01 1.07E-04 3.88E-03 1.15E-04 4.93E-04 9.98E-06 6.69E-06 2.33E-07 3.92E-07 4.81E-08 
                       
2 R1, t= 0h 2.08E-01 1.38E-04 1.87E-03 1.05E-04 3.89E-04 3.33E-05 2.17E-05 5.00E-07 1.52E-06 6.10E-08 
2 R1, t= 8h 2.08E-01 2.55E-05 1.60E-03 1.73E-05 5.50E-04 1.14E-05 2.91E-05 1.12E-06 1.91E-06 3.30E-08 
2 R1, t= 16h 2.08E-01 7.54E-05 1.74E-03 7.53E-05 5.87E-04 1.28E-05 1.89E-05 4.48E-07 1.04E-06 2.38E-08 
                       
3 K, t= 0h 2.05E-01 6.83E-05 4.24E-03 6.36E-05 3.84E-04 6.03E-06 9.95E-06 1.46E-07 1.74E-07 1.70E-08 
3 K, t= 8h 2.05E-01 7.08E-05 4.08E-03 7.14E-05 4.85E-04 5.17E-06 1.47E-05 7.35E-07 2.60E-07 1.84E-08 
3 K, t= 24h 2.05E-01 5.00E-05 4.65E-03 5.74E-05 4.48E-04 7.86E-06 4.00E-06 1.67E-07 8.74E-08 2.02E-08 
                       
4 R1, t= 0h 2.07E-01 6.37E-05 2.49E-03 5.86E-05 4.61E-04 1.43E-05 1.71E-05 4.28E-07 3.25E-07 4.80E-08 
4 R1, t= 8h 2.07E-01 5.45E-05 2.27E-03 4.25E-05 5.53E-04 1.69E-05 2.63E-05 8.05E-07 5.71E-07 2.45E-08 
4 R1, t= 24h 2.06E-01 5.12E-05 3.00E-03 5.28E-05 5.93E-04 7.13E-06 8.39E-06 2.73E-07 1.74E-07 2.04E-08 
                       
5 K, t=0 h 2.04E-01 1.02E-04 5.38E-03 1.04E-04 3.89E-04 4.27E-06 7.66E-06 2.13E-07 2.29E-07 1.73E-08 
5 K, t=8 h 2.04E-01 1.74E-04 5.10E-03 1.72E-04 4.65E-04 4.64E-06 1.01E-05 5.36E-07 2.37E-07 8.38E-10 
5 K, t=16 h 2.04E-01 2.04E-04 5.88E-03 2.09E-04 5.22E-04 9.13E-06 4.40E-06 2.13E-07 1.92E-07 1.34E-08 
5 K, t=24 h 2.04E-01 1.84E-04 5.40E-03 1.79E-04 4.01E-04 6.47E-06 2.06E-06 1.87E-07 1.00E-07 1.16E-08 
5 K, t=40 h 2.04E-01 1.71E-04 5.72E-03 1.71E-04 3.00E-04 1.20E-06 1.20E-06 5.32E-08 7.93E-08   
                       
6 R1, t=0 h 2.06E-01 2.16E-05 3.56E-03 3.01E-05 5.85E-04 1.80E-05 2.08E-05 4.72E-07 5.49E-07 5.15E-08 
6 R1, t=8 h 2.05E-01 9.98E-05 3.83E-03 8.48E-05 7.63E-04 1.51E-05 2.05E-05 5.32E-07 8.74E-07 9.94E-09 
6 R1, t=16 h 2.06E-01 4.53E-05 3.44E-03 3.95E-05 6.89E-04 7.42E-06 1.20E-05 5.65E-07 3.03E-07 8.59E-09 
6 R1, t=24 h 2.06E-01 1.19E-04 3.57E-03 8.65E-05 6.16E-04 3.52E-05 7.18E-06 2.03E-07 1.55E-07 2.87E-08 
6 R1, t=40 h 2.05E-01 6.38E-06 4.95E-03 1.56E-05 4.42E-04 1.11E-05 1.97E-06 4.48E-08 9.46E-08 1.84E-08 
            
n Sample hmU / N fU / N 8-oxo-G / N    
 mESC diff. time 
techn. 
mean SD 
techn. 
mean SD 
techn. 
mean SD     
1 K, t= 0h 3.75E-07 1.67E-09 3.89E-06 2.73E-07 6.66E-06 2.74E-07     
1 K, t= 8h 1.08E-06 1.57E-07 4.83E-06 3.45E-07 7.79E-06 3.05E-07     
1 K, t= 16h 1.01E-06 1.76E-07 5.11E-06 5.69E-07 8.07E-06 5.57E-07     
                   
2 R1, t= 0h 1.14E-06 3.65E-07 3.82E-06 4.10E-07 6.70E-06 1.72E-07     
2 R1, t= 8h 2.97E-06 4.13E-07 5.23E-06 9.97E-08 9.08E-06 5.89E-07     
2 R1, t= 16h 3.75E-06 6.55E-07 5.15E-06 5.72E-07 8.81E-06 5.37E-07     
                   
3 K, t= 0h 8.76E-07 2.02E-08 8.86E-06 9.44E-07 1.35E-05 9.84E-07     
3 K, t= 8h 1.29E-06 1.76E-07 6.90E-06 9.81E-07 1.00E-05 6.53E-07     
3 K, t= 24h 6.55E-07 5.89E-08 6.72E-06 7.12E-07 9.73E-06 5.55E-07     
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4 R1, t= 0h 1.22E-06 1.58E-07 8.62E-06 7.83E-07 1.26E-05 8.90E-08     
4 R1, t= 8h 1.91E-06 2.69E-07 6.02E-06 4.56E-07 8.05E-06 2.35E-07     
4 R1, t= 24h 1.82E-06 3.67E-07 6.60E-06 6.25E-07 1.06E-05 6.27E-07     
                   
5 K, t=0 h 9.98E-07 2.95E-07 7.04E-06 1.35E-06 9.98E-06 9.08E-07     
5 K, t=8 h 2.97E-06 2.62E-07 6.89E-06 5.67E-07 9.64E-06 5.85E-07     
5 K, t=16 h 1.43E-06 3.46E-07 2.71E-06 1.92E-07 3.82E-06 3.04E-07     
5 K, t=24 h 8.01E-07 2.16E-07 6.60E-06 5.93E-07 9.72E-06 1.33E-07     
5 K, t=40 h 8.30E-07 3.44E-08 7.78E-06 1.31E-07 1.13E-05 3.07E-07     
                   
6 R1, t=0 h 1.85E-06 3.00E-07 8.62E-06 1.94E-07 1.12E-05 7.13E-07     
6 R1, t=8 h 3.77E-06 6.22E-07 4.01E-06 7.44E-07 6.02E-06 1.41E-06     
6 R1, t=16 h 3.94E-06 8.01E-08 5.93E-06 3.24E-07 7.61E-06 2.01E-07     
6 R1, t=24 h 3.84E-06 3.90E-07 8.92E-06 1.03E-06 1.23E-05 2.83E-07     
6 R1, t=40 h 1.84E-06 9.73E-08 8.44E-06 2.94E-07 1.26E-05 1.02E-06     
 
Supplementary Table 12. Relative modification levels of combined data sets from differentiation (0–40 h) of R1 
and C57Bl6/129-derived mESCs without growth factors (related to Fig. 5a and Supplementary Fig. 8). In order to 
obtain these, the absolute modification levels of t = 0 h time points compiled in Supplementary Table 11 were set 
as 1 and the modification levels of later time points respectively related to these. Summarized are the biological 
mean values at each differentiation time point and the standard deviation (SD). 
  relative C / N relative mC / N relative hmC / N 
time biol. mean SD biol. mean SD biol. mean SD 
t = 0 h 1.00000E+00  1.000E+00  1.000E+00  
t = 8 h 1.00024E+00 1.2480E-03 9.435E-01 7.579E-02 1.270E+00 8.082E-02 
t = 16 h 9.98952E-01 1.4308E-03 1.004E+00 7.157E-02 1.296E+00 1.629E-01 
t = 24 h 9.98556E-01 1.4742E-03 1.077E+00 9.513E-02 1.133E+00 1.176E-01 
t = 40 h 9.96347E-01 3.4067E-03 1.228E+00 2.314E-01 7.634E-01 1.034E-02 
       
  relative fC / N relative caC / N  
time biol. mean SD biol. mean SD   
t = 0 h 1.000E+00  1.000E+00    
t = 8 h 1.280E+00 2.318E-01 1.339E+00 3.329E-01   
t = 16 h 6.051E-01 1.980E-01 5.991E-01 2.175E-01   
t = 24 h 3.769E-01 9.373E-02 4.393E-01 1.122E-01   
t = 40 h 1.255E-01 4.352E-02 2.589E-01 1.225E-01   
       
  relative hmU / N relative fU / N relative 8-oxo-G / N 
time biol. mean SD biol. mean SD biol. mean SD 
t = 0 h 1.000E+00  1.000E+00  1.000E+00  
t = 8 h 2.258E+00 6.597E-01 9.221E-01 3.417E-01 9.024E-01 3.178E-01 
t = 16 h 2.390E+00 8.012E-01 9.337E-01 4.755E-01 8.978E-01 4.410E-01 
t = 24 h 1.278E+00 6.283E-01 8.742E-01 1.357E-01 9.086E-01 1.623E-01 
t = 40 h 9.129E-01 1.155E-01 1.043E+00 8.856E-02 1.129E+00 3.665E-04 
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Supplementary Table 13. LC-MS/MS quantification results of mESC differentiation with the growth factors 
FGF-2 and ActA (related to Supplementary Fig. 9). Modified nucleosides / N are given as mean values plus SD 
of three independent technical replicates. 
Sample C / N mC / N hmC / N fC / N 
EpiLC diff. time techn. mean SD 
techn. 
mean SD 
techn. 
mean SD 
techn. 
mean SD 
t= 0h 2.096E-01 1.40E-05 3.92E-04 1.35E-05 4.57E-05 6.48E-07 2.88E-07 4.52E-09 
t= 12h 2.093E-01 1.01E-05 5.80E-04 4.94E-06 6.85E-05 5.47E-06 1.65E-06 1.34E-07 
t= 24h 2.074E-01 1.17E-04 2.29E-03 1.02E-04 2.60E-04 1.41E-05 4.45E-06 6.30E-09 
t= 36h 2.044E-01 9.71E-05 4.96E-03 7.38E-05 5.81E-04 2.30E-05 6.16E-06 5.27E-08 
t= 48h 2.020E-01 8.85E-05 7.23E-03 8.83E-05 7.53E-04 8.90E-07 4.92E-06 1.31E-07 
 
Sample hmU / N fU / N 8-oxo-G / N 
EpiLC diff. time techn. mean SD 
techn. 
mean 
techn. 
mean SD 
techn. 
mean 
t= 0h 4.76E-07 7.05E-08 1.87E-06 9.10E-08 4.00E-06 1.10E-07 
t= 12h 2.01E-06 1.90E-07 3.91E-06 7.84E-07 9.80E-06 3.07E-07 
t= 24h 2.78E-06 7.20E-07 2.42E-06 3.65E-07 5.19E-06 1.45E-07 
t= 36h 2.10E-06 5.82E-07 2.20E-06 1.51E-07 5.42E-06 4.12E-07 
t= 48h 1.90E-06 1.03E-07 3.74E-06 3.74E-07 6.69E-06 3.08E-07 
 
Supplementary Table 14. HEK-293T wild type vs. HEK + Tet1cm vs. HEK + Tet1cd (related to Supplementary 
Fig. 7a). Modified nucleosides / N are given as mean values of three independent technical replicates. 
  HEK-293T wild type  HEK + Tet1cm  HEK + Tet1cd  
Nucleosides techn. mean SD techn. mean SD techn. mean SD 
C / N 2.01E-01 9.67E-05 2.02E-01 1.09E-04 2.03E-01 3.91E-04 
mC / N 8.80E-03 9.62E-05 8.04E-03 1.09E-04 4.18E-03 3.93E-05 
hmC / N 3.39E-05 5.44E-07 4.95E-05 1.04E-06 2.21E-03 9.42E-05 
fC / N 2.43E-07 2.41E-09 2.18E-07 1.17E-08 2.48E-04 5.96E-06 
caC / N n.d.  n.d.  1.29E-04 3.35E-06 
hmU / N 7.21E-07 5.93E-08 1.51E-07 9.07E-09 4.24E-05 2.51E-06 
fU / N 4.89E-06 1.59E-07 1.42E-06 6.66E-08 8.79E-06 1.07E-07 
8-oxo-G / N 1.06E-05 1.14E-07 6.83E-06 1.47E-07 8.31E-06 9.03E-07 
 
Supplementary Table 15. DNA modification levels of Tet1 in vitro assay (related to Supplementary Fig. 7b). 
Plasmid DNA with full CpG methylation was treated with commercially available Tet1. 
 plasmid mC / N hmC / N fC / N caC / N hmU / N fU / N 8-oxo-G / N 
untreated 4.8E-02 n.d. n.d. n.d. n.d. 4.4E-06 8.6E-06 
untreated 4.6E-02 n.d. n.d. n.d. n.d. 4.0E-06 9.4E-06 
+Tet1 7.6E-04 4.8E-03 5.0E-03 9.0E-03 3.8E-04 1.5E-04 4.0E-05 
+Tet1 6.5E-04 4.7E-03 4.8E-03 9.3E-03 4.4E-04 1.6E-04 3.7E-05 
-Tet1 4.8E-02 n.d. 3.5E-05 n.d. 1.6E-05 2.5E-04 4.0E-05 
-Tet1 4.7E-02 n.d. 3.5E-05 n.d. 1.2E-05 2.3E-04 4.5E-05 
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Supplementary Table 16. Effect of Smug1 depletion on modification levels in mESCs (R1) and effect of TDG 
and SMUG1 depletion on modification levels in HEK-293T cells overexpressing Tet1cd (related to Supplementary 
Fig. 5). Percent change values for modified nucleosides of cells treated with esiRNA (targeting Smug1/SMUG1 
or TDG) with respect to unrelated control esiRNA. The absolute modification content of HEK-293T cells was 
normalized based on Tet1cd expression levels (determined by TECAN reading). The percent change is given as a 
mean value of three independent technical replicates. 
  mESC  Smug1 KD HEK-293T + Tet1cd / TDG KD HEK-293T + Tet1cd / SMUG1 KD 
Nucleosides Percent change SD Percent change SD Percent change SD 
hmC -0.15 4.07 -2.22 2.61 -3.43 2.24 
fC -1.26 3.29 38.15 1.25 0.77 2.05 
caC 14.04 29.24 33.51 2.72 6.59 3.24 
hmU 37.14 9.47 -10.41 4.74 46.46 5.65 
fU 71.00 15.73 -4.36 2.34 22.66 1.91 
8-oxo-G 17.27 14.26 -5.36 2.04 -6.97 1.77 
 
Supplementary Table 17. HEK-293T wild type, HEK with Tet1cd-overexpression, Tet1cd/Uhrf1 co-
overexpression or Tet1cd/Uhrf2 co-overexpression (related to Supplementary Fig. 12). Modified nucleosides / N 
are given as mean values of three independent technical replicates. 
 HEK-293T wt  
HEK 
+ Tet1cd  
HEK 
+ Tet1cd 
+ Uhrf1
 
HEK 
+ Tet1cd 
+ Uhrf2 
 
Nucleosides techn. mean SD 
techn. 
mean SD 
techn. 
mean SD 
techn. 
mean SD 
C / N 2.04E-01 2.97E-05 2.04E-01 1.24E-04 2.05E-01 8.32E-05 2.04E-01 1.15E-04 
mC / N 6.01E-03 2.74E-05 5.29E-03 1.22E-04 4.63E-03 8.93E-05 5.11E-03 1.15E-04 
hmC / N 2.86E-05 1.57E-06 4.29E-04 1.85E-05 3.31E-04 1.93E-05 5.13E-04 9.85E-06 
fC / N 4.51E-07 5.21E-08 5.97E-05 3.43E-06 7.21E-05 4.24E-06 1.39E-04 5.61E-06 
caC / N 1.77E-07 2.67E-09 2.32E-05 8.50E-07 2.23E-04 1.84E-05 1.66E-04 1.21E-06 
hmU / N 8.18E-07 8.89E-08 2.55E-06 6.26E-08 1.27E-05 4.30E-07 6.74E-06 1.59E-06 
fU / N 7.60E-06 3.39E-07 5.40E-06 5.26E-07 5.64E-06 8.42E-07 1.22E-05 2.10E-06 
8-oxo-G / N 1.27E-05 7.08E-07 9.23E-06 3.22E-07 6.93E-06 1.09E-06 1.62E-05 8.43E-07 
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Supplementary Note 4: materials in cell culture 
 
Supplementary Table 18. Overexpression plasmids and esiRNAs used in HEK-293T cell experiments. 
Figure Experiment Sample Plasmid DNA esiRNA 
S7a HEK-293T +/- Tet1xx 
HEK + Tet1cd GFP-Tet1cd (7.5 µg) x 
HEK + Tet1cm mCh-Tet1cm (7.5 µg) x 
Wild type pCMV6-Cdk5Rap1-v2 (7.5 µg) x 
S5b,S5c Tet1cd with TDG or SMUG1 KD 
HEK + Tet1cd GFP-Tet1cd (10 µg) 
CDK5RAP1 esiRNA 
(5 µg) 
HEK + Tet1cd 
with TDG KD 
GFP-Tet1cd 
(10 µg) 
TDG esiRNA 
(5 µg) 
HEK + Tet1cd 
with SMUG1 KD 
GFP-Tet1cd 
(10 µg) 
SMUG1 esiRNA 
(5 µg) 
 HEK-293T Tet1cd GFP-Tet1cd (6 µg) x 
S12 HEK-293T Tet1cd + Uhrf1 GFP-Tet1cd, GFP-Uhrf1
1 
(each 6 µg) x 
 HEK-293T Tet1cd + Uhrf2 GFP-Tet1cd, GFP-Uhrf2
1 
(each 6 µg) x 
 
Supplementary Table 19. Knockdown (KD) efficiencies by Tet relative to SCR shRNAs. 
  FWD REV Reference 
Tet1 GAGCCTGTTCCTCGATGTGG  CAAACCCACCTGAGGCTGTT Ito et. al.2 
Tet2 TGTTGTTGTCAGGGTGAGAATC  TCTTGCTTCTGGCAAACTTACA Ito et. al.2 
actin AAGGCCAACCGTGAAAAGAT GTGGTACGACCAGAGGCATAC This work 
 
 
Supplementary Table 20. Primers for qPCR analysis of Tet, Dnmt, Tdg and Smug1 of EpiLC differentiation and 
Smug1 knockdown samples. 
  FWD REV Reference 
Gapdh CATGGCCTTCCGTGTTCCTA CTTCACCACCTTCTTGATGTCATC Szwagierzcak et al.3 
Tet1 CCAGGAAGAGGCGACTACGTT TTAGTGTTGTGTGAACCTGATTTATTGT Szwagierzcak et al.3 
Tet2 ACTTCTCTGCTCATTCCCACAGA TTAGCTCCGACTTCTCGATTGTC Szwagierzcak et al.3 
Tet3 GAGCACGCCAGAGAAGATCAA CAGGCTTTGCTGGGACAATC Szwagierzcak et al.3 
Dnmt1 CCTAGTTCCGTGGCTACGAGGAG TCTCTCTCCTCTGCAGCCGACTC This work 
Dnmt3a GCTTTCTTCTCAGCCTCCCT CCATGCCAAGACTCACCTTC This work 
Dnmt3b CTGGCACCCTCTTCTTCATT ATCCATAGTGCCTTGGGACC This work 
Tdg GTCTGTTCATGTCGGGGCTGAGTGAG CTGCAGTTTCTGCACCAGGATGCGC This work 
Smug1 CACTGGGGCCTACCCATGA CTCCCAAGCATAATCCACCG This work 
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Supplementary Note 5: correlation analysis results of modification levels 
 
Supplementary Table 21. Correlation analysis of DNA modification levels comparing murine tissues from three 
months old individuals (cortex, hippocampus, cerebellum, heart, liver and kidney). Pearson coefficients (p) and 
significance values (s) are summarized. n=24 independent DNA samples (see Supplementary Table 10). 
Highlighted in gray are strong to very strong correlations (│p│> 0.7) with significance levels (s) lower than 0.001 
(marked with *). Additionally, moderate correlations (0.7 > │p│> 0.6) with significance level lower than 0.001 
are highlighted in light gray.  
 C mC hmC fC 8-oxo-G hmU fU 
C 
p 1.000 -0.986* -0.935* -0.832* -0.534 -0.466 -0.479 
s  0.000 0.000 0.000 0.007 0.022 0.018 
mC p 
-0.986* 1.000 0.863* 0.769* 0.534 0.464 0.460 
s 0.000  0.000 0.000 0.007 0.022 0.024 
hmC p 
-0.935* 0.863* 1.000 0.887* 0.481 0.420 0.472 
s 0.000 0.000  0.000 0.017 0.041 0.020 
fC p 
-0.832* 0.769* 0.887* 1.000 0.663* 0.586 0.649* 
s 0.000 0.000 0.000  0.000 0.003 0.001 
8-oxo-G p 
-0.534 0.534 0.481 0.663* 1.000 0.837* 0.835* 
s 0.007 0.007 0.017 0.000  0.000 0.000 
hmU p 
-0.466 0.464 0.420 0.586 0.837* 1.000 0.871* 
s 0.022 0.022 0.041 0.003 0.000  0.000 
fU 
p -0.479 0.460 0.472 0.649* 0.835* 0.871* 1.000 
s 0.018 0.024 0.020 0.001 0.000 0.000  
 
Supplementary Table 22. Correlation analysis of DNA modification levels during early mESC differentiation (0-
40 h). Pearson coefficients (p) and significance values (s) are summarized. n=22 independent DNA samples (see 
Supplementary Table 11). Highlighted in gray are strong to very strong correlations (│p│> 0.7) with significance 
levels (s) lower than 0.001 (marked with *). Additionally, weak correlations of hmC/hmU with mC/C are 
highlighted in pale pink.  
 C mC hmC fC caC 8-oxo-G hmU fU 
C p 
1 -0.997* 0.324 0.806* 0.699* -0.032 0.299 -0.145 
s  0.000 0.141 0.000 0.000 0.889 0.176 0.518 
mC p 
-0.997* 1 -0.399 -0.815* -0.693* 0.057 -0.356 0.160 
s 0.000  0.066 0.000 0.000 0.801 0.104 0.476 
hmC p 
0.324 -0.399 1 0.404 0.182 -0.312 0.783* -0.227 
s 0.141 0.066  0.062 0.417 0.157 0.000 0.309 
fC p 
0.806* -0.815* 0.404 1 0.797* -0.266 0.303 -0.299 
s 0.000 0.000 0.062  0.000 0.232 0.170 0.177 
caC p 
0.699* -0.693* 0.182 0.797* 1 -0.435 0.165 -0.567 
s 0.000 0.000 0.417 0.000  0.043 0.463 0.006 
8-oxo-G p 
-0.032 0.057 -0.312 -0.266 -0.435 1 -0.080 0.959* 
s 0.889 0.801 0.157 0.232 0.043  0.723 0.000 
hmU p 
0.299 -0.356 0.783* 0.303 0.165 -0.080 1 -0.022 
s 0.176 0.104 0.000 0.170 0.463 0.723  0.921 
fU 
p -0.145 0.160 -0.227 -0.299 -0.567 0.959* -0.022 1 
s 0.518 0.476 0.309 0.177 0.006 0.000 0.921  
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